abmt_10k.htm

0001354488-15-000348.txt : 20150129 0001354488-15-000348.hdr.sgml : 20150129 20150129121909 ACCESSION NUMBER: 0001354488-15-000348 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20141031 FILED AS OF DATE: 20150129 DATE AS OF CHANGE: 20150129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advanced Biomedical Technologies Inc. CENTRAL INDEX KEY: 0001385799 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 980516589 STATE OF INCORPORATION: NV FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53051 FILM NUMBER: 15557627 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVE., 59TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (718) 766-7898 MAIL ADDRESS: STREET 1: 350 FIFTH AVE., 59TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Geostar Mineral CORP DATE OF NAME CHANGE: 20070110 10-K 1 abmt_10k.htm ANNUAL REPORT abmt_10k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-K

þ	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the fiscal year ended October 31, 2014

	OR

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53051

Advanced Biomedical Technologies, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

Empire State Building

350 Fifth Ave, 59th Floor

New York, NY 10118

(Address of principal executive offices, including zip code.)

(718) 766-7898

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.00001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES þ NO o

Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES þ NO o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨		Accelerated filer	¨
Non-accelerated filer	¨		Smaller reporting company	þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No þ

There was no active public trading market as of the last business day of the Company’s year-end.

The aggregate market value of common stock held by non-affiliates of the registrant, computed by reference to the price at which the common equity was last sold being $0.60 on April 30, 2014 which is the last trading day of the second quarter, was approximately $8,436,210 as of April 30, 2014 (the last business day of the registrant’s most recently completed second quarter), assuming solely for the purpose of this calculation that all directors, officers and more than 10% stockholders of the registrant are affiliates. The determination of affiliate status for this purpose is not necessarily conclusive for any other purpose.

As of January 29, 2015, there are 56,874,850 shares of common stock outstanding.

TABLE OF CONTENTS

		Page

Special Note Regarding Forward Looking Statements		3
PART I
Item 1.	Business	4
Item 1A.	Risk Factors	11
Item 1B.	Unresolved Staff Comments	11
Item 2.	Properties	11
Item 3.	Legal Proceedings	11
Item 4.	Mine Safety Disclosures	12

PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	12
Item 6.	Selected Financial Data	13
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	20
Item 8.	Financial Statements and Supplementary Data	21
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	22
Item 9A.	Controls and Procedures	22
Item 9B.	Other Information	22

PART III
Item 10.	Directors, Executive Officers and Corporate Governance	23
Item 11.	Executive Compensation	25
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	26
Item 13.	Certain Relationships and Related Transactions, and Director Independence	27
Item 14.	Principal Accounting Fees and Services	28
Item 15.	Exhibits, Financial Statement Schedules	29

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

Investors are cautioned that certain statements contained in this document, as well as some statements in periodic press releases and some oral statements of Advanced Biomedical Technologies, Inc. (“ABMT”) officials during presentations about ABMT, are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” or similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future ABMT actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements are based on current expectations and projections about future events and are subject to risks, uncertainties, and assumptions about ABMT, economic and market factors and the industries in which ABMT does business, among other things. These statements are not guaranties of future performance and we have no specific intention to update these statements.

Actual events and results may differ materially from those expressed or forecasted in forward-looking statements due to a number of factors. Although forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in the forward-looking statements, and Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K.

ITEM 1. BUSINESS

Organizational History

Advanced Biomedical Technologies, Inc. has one direct wholly owned subsidiary, Masterise Holdings Ltd., a limited liability company organized under the laws of British Virgin Islands (“Masterise”). Masterise, owns seventy percent (70%) of the issued and outstanding equity or voting interests in Shenzhen Changhua, a company formed under the laws of the People’s Republic of China. (ABMT, Masterise, and Shenzhen Changhua are collectively referred to throughout this document as “We, “Us,” “Our” (and similar pronouns), “ABMT” and the “Company”).

We were incorporated in the State of Nevada on September 12, 2006. We maintain our statutory registered agent's office at The Corporation Trust Company of Nevada, 311 S Division Street, Carson City, Nevada 89703, and our business office is located at 350 Fifth Avenue, 59th Floor, New York, NY 10118. We have not been subject to any bankruptcy, receivership, or similar proceeding, or any material reclassification or consolidation.

Our primary business is carried out by Masterise through Shenzhen Changhua, as set forth in the following diagram:

Shenzhen Changhua has no subsidiaries.

Organizational History of Masterise and Shenzhen Changhua

Masterise is a wholly owned subsidiary of Advanced Biomedical Technologies, Inc.

Masterise is a limited liability company which was organized under the laws of British Virgin Islands (“BVI”) on May 31, 2007, and owns 70% of the capital stock of Shenzhen Changhua.

Shenzhen Changhua is a limited liability company which was organized under the laws of PRC on September 25, 2002.

Since their founding, Shenzhen Changhua has been involved in the development of self-reinforced, absorbable degradable screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending approval of its products by the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC.

Primary Products

Our primary products include Absorbable PA Osteosynthesis Devices made of a proprietary polyamide material. These advanced materials are used in surgical screws, binding wires, rods and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, and reconstructive dental procedures. Our devices are Self-Reinforced, Bio-absorbable, Brady-degradable internal fixation devices. At this time, ABMT is the sole patent holder of PA technologies in China, as well as the only company currently engaged in clinical trials and marketing submission for PA devices in the PRC. Our PA Screws have completed clinical trials and are pending approval by the China Food and Drug Administration of China (“CFDA”); and our PA Binding Wires are under clinical trials; and our PA Mini-Screws are under animal test.

Product Characteristics:

The theory of Brady-degradable PA absorbable material is based on water dissolution, that is, the material is broken down by body fluids in a predictable and carefully engineered fashion. As a bone fracture heals, the supporting implant is designed to degrade from the outer to the inner layers, inducing new bone generation in the gap left by the degrading material. Eventually, new bone is formed to occupy all of the space left by the degraded implant.

Brady-degradable PA absorbable materials consist of enhanced fiber and high molecular polymers. It has high tensile, bending, and shear strengths, and is particularly suitable for patients with severe conditions, high tensile, bending, and shear strengths, and is particularly suitable for patients with severe conditions, such as fractures with light osteoporosis, severe soft tissue injury or bad blood supply, and so forth. This innovative material provides several benefits:

1. Reduces costs on all patient medical care,

2. Helps avoid the necessity for secondary surgery,

3. Enhances the performance of components constructed from these materials,

4. Improves the biological activity of components employing these materials,

5. Effectively controls the degeneration speed of the temporary support component.

The Company has developed six proprietary re-absorbable polymer fixation implant product lines, including screws, pins, tacks, rods and binding wires, which provide an alternative to metal implants and overcome the limitations of first generation re-absorbable fixation devices. The Company’s product range will ultimately cover the full gamut of components featuring self-reinforced, re-absorbable, biodegradable PA macromolecule polymer materials for implantation, including human orthopedic and dental applications, as well as veterinary applications.

Industry Development

The fracture fixation industry has developed through three generations of materials science:

The first generation internal-fracture fixation material:

The first generation internal-fracture-fixer components are usually made of stainless steel, titanium and alloy. Due to their high intensity, low costs and easy machining character, these components have achieved huge success in fracture treatment and remain the most widely used internal-fracture-fixer material. However, their prominent flaws are the huge difference between metal’s elasticity co-efficient, easily causing second-time bone fracture. The metallic ion can also cause tissue inflammation, and the need of a secondary surgery to have them taken out. These flaws stimulated the development of the degradable macromolecule material.

The second generation fracture fixation material:

The second generation bone-fracture-fixed components are made of degradable macromolecule material, such as PLLA, PGA and PDS, etc. The disadvantage of these components is rapid self-degeneration in early stages after the initial implant. For example, the strength of SR-PLLA decreases to 10-20Mpa after 4 weeks of implantation. Therefore, the second generation bone-fracture-fixed components can be only used to treat substantial spongiosa bone fractures.

The third generation fracture fixation material:

The third generation fracture fixation material, biodegradable fracture fixation components are currently under research by developed countries. There are many technical challenges to research in the third generation fracture fixation material field; for example, the materials must have a high degree of bio-compatibility and mechanical compatibility. They also must be of high biological activity, self-absorbable, and degeneration controllable.

Product Development

After careful deliberation, we selected the biodegradable screw as our first product to market. In order to replace the widely-used metal components, the new materials must meet multiple bio-consistency and mechanical-consistency requirements. Furthermore, they must also exhibit specific properties with respect to bio-activities, degradability, and controllable degradation speed. Although many macromolecule materials are degradable inside human body, relatively few provide the physical characters required for fracture fixation.

Development began with selection of macromolecule materials that exhibited the desired physical characters, leading, ultimately, to our selection of polyamide. In order to achieve the desired mechanical performance and degrading speed, various chemical and physical techniques were employed to modify the bio-degradable polyamide so as to synthesize the required new bio-degradable material. This phase of our research also entailed the selection of monomer class, polymerization conditions, the mensuration of polymer molecular weight, hydrophile capability, crystal capability, the mensuration and controlled degrading speed of the polymer, the mensuration and control of the mechanical performance of the polymer, and numerous other critical considerations.

Our next challenge was to identify a suitable bio-active inorganic material, and to optimize the compound and associated production conditions. It was critical that we could predict and control the bio-activities of the implanted fixture material, and to this end we used high grade and mature phosphate type bio-active materials, taking into account the preparation characteristics of the compound material, and the surface character requirements of the finished products. We also improved current technical parameters by modifying the surface character, thereby achieving critical control over the desired grain size and surface activities.

The third technological hurdle involved the actual preparation and utilization of the engineered compound in conjunction with a bio-active material. Hydronium bombardment of the surface, with spread and cover techniques, was employed during this critical step in the process. This had the effect of creating a well-knit bio-active membrane on the degradable polymer’s surface, and embedding a bio-active core inside the degradable polymer stick, so as to form the bio-active degradable compound material.

The final step entailed strengthening and shaping the processed compound by using directional extrusion and molding. Degradable acantha inoculators, fixation screws, orthopedics stuffing, enlace strings, and anti-conglutination membrane can all be manufactured, as needed, using this same technique.

Our company has studied and researched Polyamide, changing its chemical and physical properties to meet the above requirements. As a result of our research we have:

1.	Increased mechanical strength to 170Mpa.

2.	Increased biological activities to accelerate bone cell substitution.

3.	Extended the degeneration period during the implant. While the PA is degenerating layer by layer, the bone cells grow and take its place.

Product Analysis

Our Company is researching and currently developing the capability of manufacturing several different kinds of human implant products including Artificial Lumber Disc, Mini-Screws, Suture Anchors, reconstructive dental devices and other PA products. Currently the company has two production lines certified by the GMP regulations.

Our Company is constantly analyzing the market needs to develop suitable products. One of the company’s products is currently pending CFDA approval and two products are under clinical tests.

Overview of PA Devices and Market in the US, China and Worldwide

Fractures are among the most common orthopaedic problems. There are estimated 1.5 million fracture cases each year in the United States alone (Riggs and Melton 1995), and the average citizen in a developed country can expect to sustain two fractures over the course of their lifetime. Fractures occur at an annual rate of 2.4 per 100 population. Men are more likely to experience fractures (2.8 per 100 population) than women (2.0 per 100). In 1998, over 10.7 million fractures were seen by physicians in office-based practice (this included visits for follow-up care). Of these, approximately 8.6 million visits for fracture care (79.6%) were made to orthopaedic surgeons. When a fracture was referred to another physician, approximately 90.6% were referred to orthopaedic surgeons. (Data Source: National Ambulatory Medical Care Survey & American Academy of Orthopaedic).

Hip fracture rates are increasing throughout urban Asia. A landmark study from Beijing 2002–2006 indicates the hip fracture incidence in those aged over 50 years to be 229/100,000 per year in women and 129/100,000 per year in men. This study found the rates of age-specific hip fractures in those aged over 50 years increased by 58% in women and by 49% in men. The same study also compared hip fractures that occurred from 2002-2006 with those that had occurred previously from 1990-1992, and it was found that the adjusted age-specific rates of hip fracture over age 50 years increased 2.76-fold in women and 1.61-fold in men. The increasing rate of hip fractures is serious since they are associated with increased mortality. In Mainland China, 1.8 million new osteoporotic vertebral fractures occurred in 2006. Since the number of people aged older than 60 years is expected to approach 438 million by 2050, it can be projected that the number of Chinese in this age group with osteoporotic vertebral fractures could reach 36.7 million and 48.5 million in 2020 and 2050, respectively. (Data Source: International Osteoporosis Foundation).

The demand for medical device equipment has rapidly increased during the last decade. Total market sales have increased more than 15% each year. The figures show that about 4 million bone bolts/screws are needed each year. Between 2005 and 2009, the total world-wide sales of clinical equipment and materials are over USD 2 trillion, and more than 50% of the sales are related to bio-materials.

China’s Market for PA Devices

China’s market for PA devices depends on 3 major conditions:

- patients

- advanced technology level

- performance and price of the materials.

In the first 50 years of the 21st century, China will have a growing aging population, while the total population in China will continually increase. New and improved medical technologies will be rapidly developed and utilized throughout hospitals in China, and material optimization and product pricing is expected to directly stimulate increased sales.

Competitive Analysis

Our Company is the only patent holder of PA technologies in China, as well as the only company carrying out Clinical Trials on PA products in China. At this time there are no similar products in this market (bio-degradable internal fixation devices that degrade without acids or other non-naturally occurring substances). Moreover, due to the nature of the regulatory environment, and the requirements and logistics of mounting a clinical trial, we esitimate that it would take any new competitor a minimum of three years to catch up to our lead in this area alone. Factoring in our established relationships with key customers, distributors, and regulators, as well as our ready-to-run production facilities, and our actual advantage is considerable longer than the 3 year regulatory advantage. This represents an invaluable window in which to firmly entrench our company as the preferred purveyor of self-reinforced, absorbable biodegradable PA components in the Chinese health care environment.

To reiterate, our company and product line offer several critical competitive advantages, specifically:

●	There are no similar patent registrations in China.

●	Our initial product, the PA Screw, has completed 100% of the required clinical trials, with a 100% success rate, and now await the formality of CFDA approval.

●	We are the only company qualified and permitted to conduct clinical trials of other PA products by China’s CFDA.

●	We have a timing advantage over other companies in China, which would have to go through the preclinical testing before they could even apply for a permit to conduct actual clinical trials.

●	Under existing regulation structure, it will take at least 3 years for any competitor’s clinical trials to be completed, and total of 7 or more years to reach the point where we are now.

Specific Competition

Competition in the medical implant device industry is intense both in China and in global markets. In orthopedics, ABMT’s principal competitors are the numerous companies that sell metal implants. ABMT competes with the manufacturers and marketers of metal implants by emphasizing the ease of implantation of the Company’s Self-Reinforced, Bio-absorbable, Brady-degradable implants, the cost effectiveness of such products, and the elimination of risks associated with the necessity of performing removal surgeries frequently required with less modern products.

Within the resorbable implant market, ABMT is competing with other manufacturers of resorbable internal fixation devices primarily on the basis of the physiological strength of ABMT’s polymers and the length of the strength retention time demonstrated by ABMT’s formulations. In order to replace the widely-used metal components, the new materials must meet numerous bioconsistency and mechanical-consistency requirements. Furthermore, they must also exhibit specific properties with respect to bio-activities, degradability, and controllable degradation speed. Although many macromolecule materials are degradable inside human body, relatively few provide the physical characters required for fracture fixation.

Our primary competition will be the generation-one and generation-two counterparts, which, despite their functional inferiority, enjoy the benefit of familiarity and an established manufacturing and marketing base. This competition comes from a number of entrenched players worldwide, including Acumed, Biomet, Inc., Conmed Corp., Encore Orthopedics, Exactech, Inc., Johnson & Johnson, DePuy, Inc., Medtronic Sofamor Danek, Inc., Orthofix International N.V., Smith and Nephew Plc, Stryker Corp., Synthes, Inion, Ltd. and others. Although many of these competitors have substantially greater resources upon which to draw, we are confident that the technological superiority of the more forward-looking product will ultimately equalize the playing field by orthopaedic innovation.

For the past 20 years, titanium has been the most widely used, and the most expensive material for fixing fractures (in both elective and emergency surgery). Although metal exhibits the desired strength and rigidity to allow the healing process to begin, there are a number of issues associated with using permanent titanium systems. Biodegradable plating systems deliver many of the benefits of their metal counterparts, without the disadvantages.

There are a number of marketers and manufacturers of PLA and PLLA--the first generation of Self-degradable, absorbable, orthopedic internal fixation devices in China. (Note: Titanium screws cost as much as $2200.)

Competing products and prices in China (screw)
Producer	Origin	Brand	Price (USD/PC)
Arthrex	Germany/USA	Arthrex	$	554.74
Conmed	USA	Linvatec	$	554.74
Bionx	Finland	Biofix	$	554.74
Gunze	Japan	Grandfix	$	416.06
Takiron	Japan	Fixsorb	$	408.76
Dikang	China	PDLLA	$	321.17
ABMT	China	ABMT	$	300.00

Other foreign companies that produce PLA, PLLA or titanium, stainless products, but have less marketing in China are:

● DePuy (Johnson & Johnson)

● Medtronic

● Stryker

● Zimmer

● Smith & Nephew

● Biomet

● Conmed

● Inion

Product advantage and Market Opportunity:

- There are no similar patent registrations in China.

- We are the only company qualified and permitted to take clinical trials by China CFDA.

- We have a timing advantage over other companies in China which would have to go through the preclinical testing for the CFDA permit on Clinical Trials.

- Under existing regulation by CFDA, it will take at least 3-5 years to complete clinical trials for a new product similar to the Company’s PA Screw, which has

finished all required clinical trials.

Product Comparisons

Among many other advantages, a main advantage of ABMT’s proprietary PA technology is the elimination of the need for secondary surgery to remove an implantation device. Implant removal belongs to the most common elective orthopaedic procedures in industrial countries. In children, implant removal may be necessary to remove implants early to avoid disturbances to the growing skeleton, to prevent their bony immuring making later removal technically difficult or impossible, and to allow for planned reconstructive surgery after skeletal maturation (e.g., in case of hip dysplasia). In adults, pain, soft tissue irritation, the resumption of strenuous activities or contact sports after fracture healing, and the patient's demand are typical indications for implant removal in clinical practice. However, implant removal requires a second surgical procedure in scarred tissue, and poses a risk for nerve damage and re-fractures. (cite: Hanson et al. BMC Musculoskeletal Disorders 2008)

PHYSICAL COMPARISON
	Metal	PLLA	ABMT’s PA devices
Strength	Excellent	Weak	Superior to PLLA
Unit Cost	High	Low	Lowest
Processability	Good	Good	Good
Modulus of Elasticity	Low: may cause infection, may cause second fracture	Moderate to Quite Fragile	Excellent
Self-Reinforced	No	Yes, but degradation starts too quickly	Yes
Self-Resorbable	No1	Yes, but initial degradation too fast in first few weeks. Initial strength down to 10~20Mpa in 4 weeks (close to osteoporosis)	Yes: unchanged during first 12 weeks, hardness remains 70% min through week 20.
Stretchability	Strong	50~60 Mpa	170 Mpa (min)
Bone Healing	Bone mineral density decrease averages 18%	Bone mineral density decrease averages 7-10%	Bone mineral density decrease less than 5%
Implant Failure Rate	High to Medium	Medium to Low	Very Low
Need for Repeat Surgery	As Required2	Only if failure (second fracture)	No

1 Titanium and aluminum has been traced in serum and hair of 16 of 46 patients after receiving titanium implants. (cite: Kasai Y, Iida R, Uchida A: Metal concentrations in the serum and hair of patients with titanium alloy spinal implants.)

2Implant removal belongs to the most common elective orthopaedic procedures in the industrial countries. In a frequently cited Finnish study, implant removal contributed to almost 30% of all planned orthopaedic operations, and 15% of all operations. (cite: Bostman O, Pihlajamaki H: Routine implant removal after fracture surgery: a potentially reducible consumer of hospital resources in trauma units.)

Towards the end of the last century, spinal and orthopedic implants evolved towards progressively stronger and stiffer devices, as it was presumed that increased construct rigidity would optimize the biological milieu and provide more rapid and robust healing and arthrodesis. For the past 20 years, titanium has been the most widely used, and the most expensive material for fixing fractures (in both elective and emergency surgery). More than 1,000 tons (2.2 million pounds) of titanium devices of every description and function are implanted in patients worldwide each year. Although metal exhibits the desired strength and rigidity to allow the healing process to begin, there are a number of issues associated with using permanent titanium systems. Biodegradable systems deliver many of the benefits of their metal counterparts, without the disadvantages:

	METAL	ABMT’s PA devices
Cranial Growth	• Growth restriction • Intracranial implant migration	• Stimulation of growth leading to better bone healing
Accumulation of Metal in tissues	Yes	No
Adverse Effect	• Many necessitate removal operation either for mechanical strength of the overall structure • majority of implant failures occur at the bone-screw interface with screw pullout being the most common mechanistic cause of construct failure • should the bone fail to heal, these micromotions will persist and cause the metallic screw to oscillate within the far softer surrounding bone interface	None
Stiffness for optimal healing	• Too stiff • Stress shielding can result in bone atrophy and degradation	• Optimal stiffness/flexibility characteristics to achieve surgical fixation, while conforming to the softer, more pliable bone of the patient
Other Effects	• Implant palpability • Temperature sensitivity • Occasionally visibility • Could cause trauma in the event of mechanical failure • Imaging and radiotherapy interference • Potential for cross contamination	• No long-term palpability • No temperature sensitivity • Predictable degradation • Reduced patient trauma • No imaging and radiotherapy interference • No second surgery required
Cost of product	Cost to hospital: $400-$2200	Cost to hospital: $300

Intellectual Property

The Company has been granted one patent for its material by the State Intellectual Property Office of the P.R.C. Patent no. ZL971190739, PRC. This patent also protects the use and manufacturing process of the material.

Chinese Patent

Title: High molecular human body embedding article and its preparing process product and use

Application Number:	971190739	Application Date:	1997.10.22
Publication Number:	1214939	Publication Date:	1999.04.28
Approval Pub. Date:		Granted Pub. Date:	2002.08.14
International Classification:	A61F2/02,A61L27/00,C08L33/00
Applicant(s) Name:	Liu Jianyu
Address:	518111
Inventor(s) Name:
Attorney & Agent:	Li Zhi Ning
Abstract
The present invention discloses a macromolecular implant for human body and its preparation process, and relates to the products made up by using said macromolecular implant and their application. Said invented product is made up by using resin fibre through hot-pressing treatment according to the formula provided by said invention, and its strength is high, tenacity is good and its shape can be processed according to the requirement in the period of bone union after implantation, and said implant can be made into the fixation block, eurymeric block, fastening piece and suture for reduction of fracture, and can be started to be degraded from twenty-fourth week after implantation, and can be completely absorbed by human body after 1.5-2 years, and its cost is low.

Employees

As of October 31, 2014, we had 24 employees, with 11 employees in Research and Development ("R&D"), Clinical and Regulatory, 5 employees in Manufacturing, 3 employees in Sales & Marketing, 4 employees in General and Administration, and 1 employee in Accounting. The Company intends to offer more engineer positions in future.

We believe that our future success will depend in part on our continued ability to attract, hire and retain qualified personnel. None of our employees are represented by a labor union, and our employee relations have been good.

The company’s facilities are located at Block A, Longcheng Tefa Industrial park, Longgang, Shenzhen, China.

Availability of new qualified employees

Shenzhen is located in the southern part of the Guangdong Province, on the eastern shore of the Pearl River Delta. Neighboring the Pearl River Delta and Hong Kong, Shenzhen's location gives it a geographical advantage for economic development.

Shenzhen’s well-built market economy and diversified culture of migration have helped to create the best-developed and most dynamic market economy in China. Shenzhen is China’s first special economic zone. After more than 30 years of development, Shenzhen has grown into a powerful city boasting the highest per capita GDP in China’s mainland. Its comprehensive economic capacity ranks among the top of the country’s big cities. The combined value of imports and exports has remained No.1 for 20 years in China’s foreign trade.

Since 1997, China has accelerated the development of higher education and increased enrollment in regular universities and colleges. In 2003, 2.12M students completed their undergraduate courses or graduate courses in China. In 2014, this number is more than tripled to 7.27M.

Guangdong has entered a transition period from an elite education to a popularized higher education. There are 120 universities and colleges offering higher education in Guangdong province with over 472,000 students graduated in 2014. Combined with graduates from other parts of China, there are over 750,000 job-seeking graduates in total in Guangdong in 2014. 94.61% of the graduates from Guangdong have successfully found their first employment, and 50% of these employments are based in Guangzhou and Shenzhen.

Insurance

While we are carrying out the Clinical Trials, we do not have any Product Liability Insurance coverage for the use of our proposed products. We intend to obtain Product Liability Insurance coverage for commercial sale of our products in due course.

Government Regulations

Our primary target market is the medical community of the People’s Republic of China (PRC). Medical devices manufactured by the Company in China are subject to regulation by the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The manufacturing facilities are also required to meet China’s Good Manufacturing Practices (“GMP”) standards.

The Company’s production facilities are fully compliant with GMP requirements. The Company’s CFDA Application for its PA Screw is still under the CFDA Review Process.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

There are no unresolved comments from the SEC.

ITEM 2. PROPERTIES

None.

ITEM 3. LEGAL PROCEEDINGS

We are not involved in any pending or imminent litigations or current legal proceedings.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Only a limited market exists for our securities. There is no assurance that a regular trading market will develop, or if developed, that it will be sustained. Therefore, a shareholder in all likelihood will be unable to resell his securities in our company. Furthermore, it is unlikely that a lending institution will accept our securities as pledged collateral for loans unless a regular trading market develops.

Our company's securities are traded on the world's largest electronic interdealer quotation system “OTCQB” operated by the OTC Markets Group under the symbol “ABMT”.

Fiscal Quarter	High Bid		Low Bid
2014
Fourth Quarter 08-01-14 to 10-31-14	$	0.51	$	0.43
Third Quarter 05-01-14 to 07-31-14	$	1.00	$	0.51
Second Quarter 02-01-14 to 04-30-14	$	0.71	$	0.60
First Quarter 11-01-13 to 01-31-14	$	0.95	$	0.65

Fiscal Quarter	High Bid		Low Bid
2013
Fourth Quarter 08-01-13 to 10-31-13	$	0.71	$	0.70
Third Quarter 05-01-13 to 07-31-13	$	1.00	$	0.70
Second Quarter 02-01-13 to 04-30-13	$	1.62	$	1.00
First Quarter 11-01-12 to 01-31-13	$	3.89	$	1.02

Shareholders

At October 31, 2014, we had 40 shareholders of record of our common stock, including shares held by brokerage clearing houses, depositories or otherwise in unregistered form. We have no outstanding options or warrants, or other securities convertible into, common equity.

Dividend Policy

We have not declared any cash dividends. We do not intend to pay dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

Section 15(g) of the Securities Exchange Act of 1934

Our shares are covered by section 15(g) of the Securities Exchange Act of 1934, as amended that imposes additional sales practice requirements on broker/dealers who sell such securities to persons other than established customers and accredited investors (generally institutions with assets in excess of $5,000,000 or individuals with net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouses). For transactions covered by the Rule, the broker/dealer must make a special suitability determination for the purchase and have received the purchaser's written agreement to the transaction prior to the sale. Consequently, the Rule may affect the ability of broker/dealers to sell our securities and also may affect your ability to sell your shares in the secondary market.

Section 15(g) also imposes additional sales practice requirements on broker/dealers who sell penny securities. These rules require a one-page summary of certain essential items. The items include the risk of investing in penny stocks in both public offerings and secondary marketing; terms important to in understanding of the function of the penny stock market, such as “bid” and “offer” quotes, a dealers “spread” and broker/dealer compensation; the broker/dealer compensation, the broker/dealers duties to its customers, including the disclosures required by any other penny stock disclosure rules; the customers rights and remedies in causes of fraud in penny stock transactions; and, the FINRA's toll free telephone number and the central number of the North American Administrators Association, for information on the disciplinary history of broker/dealers and their associated persons.

Securities authorized for issuance under equity compensation plans

We have no equity compensation plans and accordingly we have no shares authorized for issuance under an equity compensation plan.

ITEM 6. SELECTED FINANCIAL DATA

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.

Overview

The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Annual Report on Form 10-K, and elsewhere in our other public filings. Factors that may cause actual results, our performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include without limitation:

1.	The company's lack of funds in new R&D, especially in clinical testing;
2.	The company's lack of funds in new equipment and the utilization of the production process after CFDA approval;
3.	The company may need to seek funding through such vehicles as convertible notes and warrants, private placements, and/or convertible debentures;
4.	The company needs funding for marketing and network build-up;
5.	The company plans to seek approval for clinical testing and marketing on a worldwide basis, including US FDA approval for testing and marketing in the United States of America, and there is no guaranty that we will obtain any such approval;
6.	While the company currently holds a patent originating in China, the patent does not protect our intellectual property in the United States, and the company is unsure of the validity of the patent in other countries. However, specific trade secrets are involved in the manufacturing of our product to help protect our technologies, and reverse engineering is unlikely for our types of products and technologies. Additionally, all machinery used to manufacture our products is protected by Chinese patents.

The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products from larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, product liability, and the dependence on key individuals.

All written and oral forward-looking statements made in connection with this Form 10-K that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements.

Our Business

We are engaged in the business of designing, developing, manufacturing and the planned future marketing of self-reinforced, re-absorbable biodegradable internal fixation devices. Our polyamide materials are protected by Patent no. ZL971190739, PRC, issued by the State Intellectual Property Office of the P.R.C., is used in producing screws, binding wires, rods and related products. These products are used in a variety of applications, which include orthopedic trauma, sports related medical treatment, or cartilage injuries, and reconstructive dental procedures. Our products are biodegradable internal fixation devices which are made of a very unique material called Polyamide ("PA"). Our PA products, such as screws, rods, and binding wires consist of enhanced fibers and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system. Our products offer a number of significant advantages over existing metal implants and the first generation of degradable implants (i.e. PLLA) for patients, surgeons and other customers including:

1.	A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care;
2.	Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit;
3.	Improving the biological activity of materials. Clinical trial results have shown that as PA implants degrade, they promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to 'stress shielding';
4.	Reducing the chance of post-operative infection;
5.	Effectively controlling the degeneration speed, so that there will be no complications in treating repeat injuries;
6.	Ease of post-operative care i.e. no distortion during x-ray imaging;
7.	Simple and cost-effective to manufacture.

Our products are designed to replace the traditional internal fixation device made of stainless steel and titanium and overcome the limitations of previous generations of products such as PLA and PLLA. Our laboratory statistics show that our PA products have a higher mechanical strength, last longer in degradation ratio and are more evenly absorbed form outer layer inwards as compared with similar materials such as PLA and PLLA. Thus PA allows increased restoration time for bone healing and re-growth. The Company's PA Degradable and Absorbable Screw ("PA Screw") and Degradable and Absorbable Binding Wire ("PA Binding Wire) are currently being tested in human trials under permit from the China Food and Drug Administration ("CFDA"). As of October 31, 2014, the Company completed 83 successful PA Screw trial cases, and 57 successful PA Binding Wire. Upon the completion of these trials the Company has already exceeded China CFDA’s requirement on PA Screw trial. The Company’s CFDA Application for its PA Screw is still in the CFDA Review Process.

CFDA Application Process for PA Screws

The Company first submitted its application for PA Screws to the CFDA, formally SFDA, in 2008. The application has been withheld by the CFDA pending additional clinical trial cases. This is due to the amended CFDA regulations, which unlike previous regulations require the applicant to specify the position on the body where the clinical trial is carried out. Our amended CFDA application has specified the ankle fracture as the body part of our clinical trial. This is because bones around this part carry most of the body weight. As of October 31, 2011, we have completed all additional clinical trials required by the CFDA with 100 percent success rate. As of October 31, 2014, the company’s CFDA Application is still under the CFDA Review Process.

In March 2013, The State Food and Drug Administration of the PRC (“SFDA”), China’s medical device market regulatory agency, underwent a reorganization that saw much of China's food and drug regulatory powers consolidated into the agency, elevating it back to a ministerial-level agency directly under the State Council. The new name for the agency is China State Food and Drug Administration (“CFDA”). The name change meant the CFDA reports directly to China’s State Council and has broader authority to oversee medical device as well as food and drug sectors. This reorganization leads to a more streamlined and efficient registration process for medical devices in China. Since the reorganization, the CFDA has issued series of circulars and guidelines to help applicants. Following the CFDA guidelines, the Company has improved its GMP facilities, updated its Technical Documentation System to cover key areas such as Clinical Trial, Manufacturing Process, R&D, Monitoring and Quality Control. Due to the uniqueness of our material, there are no established CFDA Product Standards that we can follow during our application process for our PA Screws. To establish our own Product Standards, the Company has been carrying out extra tests. The Company has submitted its Product Standards and supplementary reports to the CFDA in 2014.

The Company’s production lines are fully operational. We have been producing products for further researches, testing and product quality control improvements. Following the CFDA final approval, the company will be earning revenues in the same quarter upon when its application is approved. However, we are not able to anticipate the timeline for completion of the CFDA Review Process the CFDA Review Process.

Clinical Trials on Other Products

Currently, we have been conducting clinical trials for PA Binding Wires at the 6 state level hospitals authorized by the CFDA in cities throughout China, including Nanchang, Changsha, Luoyang, Nanning and Tianjin. We have successfully completed all 60 clinical human trial cases required by the CFDA, and we have completed 42 comparison cases. CFDA regulations require each successful clinical trial case to be accompanied by a trial case that uses a different product for comparison reasons. We intended to start CFDA Application Process for our PA Binding Wires when we complete the remaining 18 comparison cases.

The Company has setup a joint research project with Sichuan University. The Company has completed the design and production of testing mini-screws using its patented PA material. This project is currently under way.

The Company is studying and test-producing Class II devices using our patented material on current production lines. Class II devices are generally subject to a lower level of regulatory control than Class III devices such as our PA Screws. The Company also plans to expend its GMP facilities in 2015.

However, there can be no assurance that the company will be able to obtain any further clearances or approvals, if required, to market its products for their intended uses on a timely basis, if at all. Moreover, regulatory approvals, if granted, may include significant limitations on the indicated uses for which a product may be marketed. Delays in the receipt of or the failure to obtain such clearances or approvals, the need for additional clearances or approvals, the loss of previously received clearances or approvals, unfavorable limitations or conditions of approval, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on the Company's business, financial condition and results of operations.

Government Regulation

Medical implant devices/products manufactured or marketed by the company in China are subject to extensive regulations by the CFDA. Pursuant to the related laws and acts, as amended, and the regulations promulgated there under (the "CFDA Regulations"), the CFDA regulates the clinical testing, manufacture, labeling, distribution and promotion of medical devices. The CFDA also has the authority to request repair, replacement, or refund of the cost of any device manufactured or distributed by the Company.

Under the CFDA Regulations, medical devices are classified into three classes (class I, II or III), the basis of the controls deemed necessary by the CFDA to reasonably assure their safety and efficacy. Under the CFDA's regulations, class I devices are subject to general controls [for example, labeling and adherence to Good Manufacturing Practices ("GMP") requirements] and class II devices are subject to general and special controls. Generally, class III devices are those, which must receive premarket approval by the CFDA to ensure their safety and efficacy (for example, life-sustaining, life-supporting and certain implantable devices, or new devices which have not been found substantially equivalent to legally marketed class I or class II devices). The Company is classified as a manufacturer of class III medical devices. Current CFDA enforcement policy prohibits the marketing of approved medical devices for unapproved uses.

Before a new device can be introduced into the market in China, the manufacturer generally must obtain CFDA marketing clearance through clinical trials. Since the company is classified as a manufacturer of Class III medical devices, the company must carry out all clinical trials in pre-selected CFDA approved hospitals.

Manufacturers of medical devices for marketing in China are required to adhere to GMP requirements. Enforcement of GMP requirements has increased significantly in the last several years and the CFDA has publicly stated that compliance will be more strictly scrutinized. From time to time the CFDA has made changes to the GMP and other requirements that increase the cost of compliance. Changes in existing laws or requirements or adoption of new laws or requirements could have a material adverse effect on the company's business, financial condition and results of operations. There can be no assurance that the company will not incur significant costs to comply with applicable laws and requirements in the future or that applicable laws and requirements will not have a material adverse effect upon the company's business, financial condition and results of operations.

Regulations regarding the development, manufacturing and sale of the company's products are subject to change. The company cannot predict the impact, if any, that such changes might have on its business, financial condition and results of operations.

Results of Operations

The “Results of Operations” discussed in this section merely reflect the information and results of Masterise and Shenzhen Changhua for the years ended October 31, 2014 and 2013.

Revenues

The Company is in its development stage and does not have any revenue. The management team is continuously looking for fundraising possibilities for product improvement, machinery upgrades, facility expansions, continuous research and development, and sales and marketing preparation.

Our facility is located in Shenzhen, China, which is built to meet the GMP standards. Our facility covers about 865 square meters, which includes the combined facilities of offices, laboratories, and workshops. There is one production line for the PA Screw and another production line for the PA Binding Wire. The annual production capabilities of each production line are 100,000 pieces for PA Screw, and 240,000 packs for the PA Binding Wires. Both production lines, at their maximum production capacities are capable of generating approximately $30,000,000 in annual revenue.

Estimate current production lines in full capacity

	Output Quantity (Max.)		Price at ex-factory (US$)		Total Turnover (US$)
PA Screw	100,000	(piece)		180		18,000,000
PA Binding Wire	240,000	(pack)		50		12,000,000
			Total:			30,000,000

The Company will market its products through a hybrid sales force comprised of a managed network of independent regional distributors/sales agents (80%) and direct sales representatives (20%) in China.

There are two ways the company will generate revenue, 1) through our nationwide and regional distributors and 2) through our direct sales channels.

Funding Needs

The Company estimates that it will need to raise minimum $750,000 over the next 12 months to bring its current products to market, and begin earning revenues. This amount may increase if we decide to start clinical trials on new products. Once we receive the CFDA permit for our PA Screw, our revenue will cover our expenditures. Otherwise, we will continue to rely on external investments and shareholder's loans to meet our cash needs. While the Company has no outside sources of funding, the Company’s shareholders have committed to advance the Company funds as needed. There is a Letter of Continuing Financial Support signed between the Company and two of its major shareholders and related party, Titan Technology Development Ltd, Ms. Hui WANG and Mr. Chi Fung Yu.

China's Marketing Analysis and Sales Strategy

We have established long term relationships with many hospitals and national distributors in China. Ms. Hui WANG, the Company's CEO, has over 20 years sales experience in medical distribution. She will be in charge of our sales programs. Professor LIU, Shangli, our chief medical advisor for Greater China, is one of the highest ranked orthopedic doctors in China as well as being highly renowned in the rest of the world. He will assist the Company in nationwide product promotion and joint projects with associated academic institutions and medical schools.

During product development and clinical trial stages we developed close relationships with many major national hospitals. We expect these relationships to boost our revenue generation following CFDA final approval. In order to better serve our customers, including hospitals, distributors, patients and the general public, the Company will set up Regional Service Offices to provide technical support, product information, and customer aid service.

China's market for PA devices depends on 3 major conditions:

- Patients

- Advanced technology level

- Performance and price of the materials

The demand for internal fixation medical devices has rapidly increased during the last decade. According to China Health Care Year Book 2013, the total revenue of Chinese orthopaedic hospitals in 2013 was US$1.28 billion with over 11.5 million patients. From 2009 to 2013, the market size of China’s orthopaedic devices has grown from US$1.1 billion to US$1.92 billion, and it is estimated to reach US$2.17 billion in 2014. The market size for trauma treatment implant devices such as our PA Screw and PA Wire was US$626.3 million or 32.6% of the total market value in 2013, and it is estimated to grow to US$1.164 billion in 2019. New and improved medical technology will continue to rapidly grow throughout hospitals in China, and material optimization and product pricing is expected to directly stimulate increased sales.

The Company has advantages and more opportunities over others competitors due to:

- No other similar patent registrations in China.

- We are the only company qualified and permitted to perform PA clinical trials by the CFDA

- We have a timing advantage over other companies in China, which would have to go through the preclinical testing for the CFDA permit on clinical trials.

- Under new regulations by the CFDA, it will take at least 5-10 years for clinical trials.

- Our patented material will enable us to rapidly diversify our product line according to market trend and demand.

Number of Hospitals in China in year 2014 Statistic and Census report by the National Health and Family Planning Commission of the People's Republic of China.

Statistic and Census report by National Health and Family Planning Commission of the People's Republic of China
(November 2014)

	November 2014		November 2013		Increase / (Decrease)
Total No. of Hospitals		25,509		24,470		1,039
Public Hospital		13,343		13,441		(98	)
Private Hospital		12,166		11,029		1,137
Hospital Rating
AAA		1,898		1,738		160
AA		6,807		6,692		115
A		6,853		6,385		468

In general, technological advancements and the marketing potential within Asia are the biggest factors in driving significant growth within the global orthopedic devices market. Another major factor that positively influences this market is the growing number of aging baby boomers with active lifestyles. This sector represents a large portion of the total population.

Research and Development

Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2014 and 2013 was $47,700 and $30,749.

We expect research and development expenses to grow as we continue to invest in basic research, clinical trials, product development and in our intellectual property.

Pre-Market Research

The Company has been conducting Pre-Market Research while its PA Screw Application is under CFDA review. The research is intended to estimate the potential market success of the company’s products that can be expected. The research also looks beyond the Company’s initial market - China, and covers international markets. Based on the results of our Pre-Market Research and the positive feedbacks, we have received from trade shows and industrial conferences, it is the Company’s intention to apply for additional international regulatory approvals in due course.

Finance Costs

As of October 31, 2014 and 2013, the Company owed $459,131 and $349,911 respectively to a stockholder – Titan Technology Development Limited, which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.

Total interest expenses on advances from a stockholder accrued for the year ended October 31, 2014 and October 31, 2013 are $26,081 and $20,755 for Titan Technology Development Limited.

Total interest expenses on advances from following related parties accrued for the year ended October 31, 2014 and October 31, 2013 are $87,351 and $66,844 for Chi Fung Yu; $67,961 and $49,903 for Tie Jun Chen.

As of October 31, 2014 and 2013, the Company owed the following amounts respectively to two directors for advances made - $382,280 and $435,344 to Hui Wang, $20,230 and $20,230 to Chi Ming Yu. These advances were made on an unsecured basis, repayable on demand and interest free.

Imputed interest charged at 5% per annum on the amounts owed to two directors for the year ended October 31, 2014 and 2013 respectively is $20,079 and $22,936 for Hui Wang; $0 and $0 for Chi Ming Yu.

On November 10, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB250,000 (equivalent to approximately $41,000).

On November 28, 2014, the Company received cash advance from a related party, Chi Fung Yu, amounted to RMB250,000 (equivalent to approximately $41,000).

On December 12, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB300,000 (equivalent to approximately $49,000).

On January 20, 2015, the Company received cash advance from a related party, Chi Fung Yu, amounted to RMB250,000 (equivalent to approximately $41,000).

Income Tax

ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2014 and 2013. ABMT has net operating loss carry forwards for income taxes amounting to approximately $1,512,723 and $1,423,563 as of October 31, 2014 and 2013 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2014 and 2013 was $514,326 and $484,011 respectively. The net change in the valuation allowance for 2014 was an increase of $30,315.

Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.

Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been charged at 25%. No income tax expense has been provided by Shenzhen Changhua as it is waiting for CFDA approval and it has incurred losses.

Net Loss

As reflected in the accompanying audited consolidated financial statements, the Company has an accumulated deficit of $5,400,107 at October 31, 2014 that includes a net loss of $827,756 for the year ended October 31, 2014. We are in Clinical Trial phase and do not have a CFDA permit to produce, market or sell in China.

We therefore do not have any revenue from inception to October 31, 2014 but have to incur operating expenses for the upkeep of the Company and the clinical trials.

Liquidity and Capital Resources

We had a working capital deficit of $3,863,028 at October 31, 2014 compared to a working capital deficit of $3,062,153 as of October 31, 2013. Our working capital deficit increased as a result of the fact that we are in clinical trial phase, the company has put all resources to complete the clinical trials. We do not have a CFDA permit to produce, market or sell in China. We had no revenues during the year and that our sole source of financing came in the form of loans from our related parties and stockholders.

Cash Flows

Net Cash Used in Operating Activities

Net cash used in operating activities was $732,421 in the year ended October 31, 2014. This amount was attributable primarily to the net loss after adjustment for non-cash items, such as depreciation and imputed interest on advances from directors.

Net Cash Used in Investing Activities

We recorded $23,802 net cash used in investing activities in the year ended October 31, 2014. This amount reflected purchases of property and equipment, primarily for research and development to our facilities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities in the year ended October 31, 2014 was $782,228, which represented advances from related parties.

Operating Capital and Capital Expenditure Requirements

Our ability to continue as a going concern and support the commercialization of current products is dependent upon our ability to obtain additional financing in the near term. We anticipate that such funding will be in the form of equity financing from sales of our common stock. However, there is no assurance that we will be able to raise sufficient funding from the sale of our common stock to fund our business plan should we decide to proceed. We anticipate continuing to rely on advances from our related parties and stockholders in order to continue to fund our business operations

We believe that our existing cash, cash equivalents at October 31, 2014, will be insufficient to meet our cash needs. The management is actively pursuing additional funding and strategic partners, which will enable the Company to implement our business plan, business strategy, to continue research and development, clinical trials or further development that may arise.

Going Concern

These factors raise substantial doubt about our ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent up the Company's ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Management has taken steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern. The Company is now pursuing additional funding and potential merger or acquisition candidates, which would enhance stockholders' investment. Management believes that the above actions will allow the Company to continue operations through the next fiscal year.

As of October 31, 2014, loans from the Company's stockholder, two directors, a related company and two related parties totaling $3,850,379 were provided to us for use as working capital. Management believes that such financing will allow us to continue operations through the next fiscal year. The Company is also actively pursuing a number of private placements funding which would ensure continued operations.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our investors.

CRITICAL ACCOUNTING POLICIES

The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including but not limited to those related to income taxes and impairment of long-lived assets. We base our estimates on historical experience and on various other assumptions and factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Based on our ongoing review, we plan to adjust to our judgments and estimates where facts and circumstances dictate. Actual results could differ from our estimates.

We believe the following critical accounting policies are important to the portrayal of our financial condition and results and require our management's most difficult, subjective or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain.

1. Property and equipment

Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

2. Long-lived assets

In accordance with FASB Codification Topic 360 (ASC Topic 360), “Accounting for the impairment or disposal of Long-Lived Assets", long-lived assets and certain identifiable intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, the recoverability test is performed using undiscounted net cash flows related to the long-lived assets. The Company reviews long-lived assets to determine that carrying values are not impaired.

Long-lived assets, such as property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income. For the year ended October 31, 2014 and 2013, the company has not recognized any impairment charges.

3. Fair value of financial instruments

FASB Codification Topic 825 (ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued expenses, due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

4. Income taxes

The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.

5. Research and Development

Research and development costs related to both present and future products are expensed as incurred.

6. Foreign currency translation

The financial statements of the Company’s subsidiary denominated in currencies other than US $ are translated into US $ using the closing rate method. The balance sheet items are translated into US $ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

Recent Accounting Pronouncements

On June 10, 2014, FASB issued a new accounting standard that reduces disclosure and reporting requirements for development stage entities. Among other things, development stage entities will no longer be required to report inception-to-date information. The change will be effective for interim and annual reporting periods beginning after December 15, 2014, with early adoption permitted. The Company has elected to early adopt these amendments.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

AS OF OCTOBER 31, 2014

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

AND SUBSIDIARIES

CONTENTS

		Pages

Reports of Independent Registered Public Accounting Firm		F-2

Consolidated Balance Sheets		F-3

Consolidated Statements of Operations and Comprehensive Loss		F-4

Consolidated Statements of Stockholders’ Deficit		F-5

Consolidated Statements of Cash Flows		F-6

Notes to Consolidated Financial Statements		F-7–F-12

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors of:

Advanced Biomedical Technologies, Inc.

We have audited the accompanying consolidated balance sheets of Advanced Biomedical Technologies, Inc. and subsidiaries, as of October 31, 2014 and 2013, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficiency and cash flows for the years ended October 31, 2014 and 2013. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits of the financial statements provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Advanced Biomedical Technologies, Inc. and subsidiaries, as of October 31, 2014 and 2013, the results of its operations and its cash flows for the years ended October 31, 2014 and 2013 in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 9 to the financial statements, the Company had a net loss of $827,756, an accumulated deficit of $5,400,107 and a working capital deficiency of $3,863,028 and used cash in operations of $732,421. These factors raise substantial doubt about its ability to continue as a going concern. Management’s plans concerning this matter are also described in Note 9. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Baker Tilly Hong Kong Limited

BAKER TILLY HONG KONG LIMITED

Certified Public Accountants

Hong Kong

January 29, 2015

F-2

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	October 31,			October 31,
	2014			2013

ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	74,354		$	48,380
Other receivables and prepaid expenses		18,768			21,105

Total Current Assets		93,122			69,485

PROPERTY AND EQUIPMENT, NET		108,254			126,568

DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT		16,238			1,140

TOTAL ASSETS	$	217,614		$	197,193

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Other payables and accrued expenses	$	105,771		$	59,237
Due to directors		402,510			455,574
Due to a stockholder		459,131			349,911
Due to related parties		2,988,738			2,266,916

Total Current Liabilities		3,956,150			3,131,638

COMMITMENTS AND CONTINGENCIES		-			-

STOCKHOLDERS' DEFICIT
Common stock, $0.00001 par value, 100,000,000 shares authorized, 56,874,850 shares issued and outstanding as of October 31, 2014 and October 31, 2013		569			569
Additional paid-in capital		1,927,968			1,907,889
Accumulated deficit		(5,400,107	)		(4,572,351	)
Accumulated other comprehensive loss		(266,966	)		(270,552	)
Total Deficit		(3,738,536	)		(2,934,445	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	217,614		$	197,193

The accompanying notes are an integral part of these consolidated financial statements

F-3

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Year ended October 31,
	2014			2013
OPERATING EXPENSES
General and administrative expenses	$	543,414		$	661,794
Depreciation		26,640			26,201
Research and development		47,700			30,749
Total Operating Expenses		617,754			718,744

LOSS FROM OPERATIONS		(617,754	)		(718,744	)

OTHER EXPENSES
Interest income		137			70
Interest paid to a stockholder and related parties		(181,393	)		(137,502	)
Imputed interest		(20,079	)		(22,936	)
Other, net		(8,667	)		(11,231	)
Total Other Expenses, net		(210,002	)		(171,599	)

LOSS FROM OPERATIONS BEFORE TAXES		(827,756	)		(890,343	)
Income tax expense		-			-

NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS		(827,756	)		(890,343	)

OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation income/(loss)		3,586			(55,510	)

COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	$	(824,170	)	$	(945,853	)
Net loss per share
- basic and diluted	$	(0.01	)	$	(0.02	)

Weighted average number of shares outstanding during the year
- basic and diluted		56,874,850			56,578,138

The accompanying notes are an integral part of these consolidated financial statements

F-4

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

													Accumulated
	Common stock				Additional		Deferred						other
	Number of				paid-in		stock			Accumulated			comprehensive
	shares		Amount		capital		compensation			deficit			loss			Total

Balance at October 31, 2012		56,574,850	$	566	$	1,671,956	$	(1,667	)	$	(3,682,008	)	$	(215,042	)	$	(2,226,195	)

Stock issued for services ($0.71 per share)		300,000		3		212,997		-			-			-			213,000

Imputed interest on advances from directors		-		-		22,936		-			-			-			22,936

Amortisation for stock issued for services		-		-		-		1,667			-			-			1,667

Net loss for the year		-		-		-		-			(890,343	)		-			(890,343	)

Foreign currency translation loss		-		-		-		-			-			(55,510	)		(55,510	)

Balance at October 31, 2013		56,874,850	$	569	$	1,907,889	$	-		$	(4,572,351	)	$	(270,552	)	$	(2,934,445	)

Imputed interest on advances from directors		-		-		20,079		-			-			-			20,079

Net loss for the year		-		-		-		-			(827,756	)		-			(827,756	)

Foreign currency translation loss		-		-		-		-			-			3,586			3,586

Balance at October 31, 2014		56,874,850	$	569	$	1,927,968	$	-		$	(5,400,107	)	$	(266,966	)	$	(3,738,536	)

The accompanying notes are an integral part of these consolidated financial statements

F-5

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year ended
	October 31,
	2014			2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(827,756	)	$	(890,343	)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation		26,640			26,201
Stock issued for services		-			214,667
Imputed interest		20,079			22,936
Changes in operating assets and liabilities
Decrease in:
Other receivables and prepaid expenses		2,270			978
Increase in:
Other payables and accrued expenses		46,346			20,592
Net cash used in operating activities		(732,421	)		(604,969	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(8,793	)		(8,166	)
(Increase) decrease in deposit for purchase of property and equipment		(15,009	)		562
Net cash used in investing activities		(23,802	)		(7,604	)

CASH FLOWS FROM FINANCING ACTIVITIES
Due to a stockholder		109,253			82,142
Due to directors		(51,460	)		(62,450	)
Due to related parties		724,435			591,492
Net cash provided by financing activities		782,228			611,184

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND
CASH EQUIVALENTS		(31	)		677

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		25,974			(712	)

CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		48,380			49,092

CASH AND CASH EQUIVALENTS AT END OF YEAR	$	74,354		$	48,380

The accompanying notes are an integral part of these consolidated financial statements

F-6

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

(A)	Organization

Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or ”Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006 .

Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, formerly known as “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.

Accordingly, these financial statements include the following:

(1)

The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

(2)

The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

F-7

(B)	Principles of consolidation

The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.

All significant inter-company balances and transactions have been eliminated in consolidation.

(C)	Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(D)	Cash and cash equivalents

For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2014 and 2013, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.

(E)	Property and equipment

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

(F)	Long-lived assets

The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2014 and 2013, the Company has not recognized any allowances for impairment.

(G)	Fair value of financial instruments

FASB Codification Topic 825(ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

(H)	Income taxes

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

(I)	Research and development

F-8

(J)	Foreign currency translation

The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.

Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.

The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:

	October 31, 2014	October 31, 2013
Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end	US$1=HK$7.7551=RMB6.1124	US$1=HK$7.7530=RMB6.0943
Amounts included in the statements of operations and cash flows for the year	US$1=HK$7.7543=RMB6.1498	US$1=HK$7.7561=RMB6.1717

The translation (gain)/loss recorded for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.

No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.

The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.

(K)	Other comprehensive loss

The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive (gain)/loss for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.

(L)	Loss per share

Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There were no potentially dilutive securities for 2014 and 2013.

(M)

Segments

The Company operates in only one segment, thereafter segment disclosure is not presented.

(N)	Recent Accounting Pronouncements

F-9

2.	PROPERTY AND EQUIPMENT

The following is a summary of property and equipment at October 31, 2014 and 2013:

	October 31,
	2014		2013

Plant and machinery	$	272,214	$	266,931
Motor vehicles		45,105		45,239
Office equipment		34,523		31,824
Computer software		5,017		5,017
Office improvements		131,439		131,829
		488,298		480,840
Less: accumulated depreciation		380,044		354,272

Property and equipment, net	$	108,254	$	126,568

Depreciation expense for the year ended October 31, 2014 and 2013 was $26,640 and $26,201 respectively.

3.	OTHER PAYABLES AND ACCRUED EXPENSES

Other payables and accrued expenses at October 31, 2014 and 2013 consisted of the following:

	October 31,
	2014		2013

Other payables	$	929	$	790
Accrued expenses		104,842		58,447
	$	105,771	$	59,237

4.	RELATED PARTY TRANSACTIONS

As of October 31, 2014 and 2013, the Company owed $459,131 and $349,911 respectively to a stockholder which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.

As of October 31, 2014 and 2013, the Company owed $2,988,738 and $2,266,916 to two related parties which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.

Total interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2014 and 2013 were $181,393 and $137,502 respectively.

As of October 31, 2014 and 2013, the Company owed $402,510 and $455,574 respectively to two directors for advances made. These advances were made on an unsecured basis, repayable on demand and interest free.

Imputed interest on the amounts owed to two directors are $20,079 and $22,936 for the years ended October 31, 2014, and 2013 respectively.

For the years ended October 31, 2014 and 2013, the Company issued restricted common stock as directors’ services compensation for past services nil shares and 300,000 shares valued at $0 and $213,000 respectively. Please refer to Item 11 for details of directors’ emoluments.

F-10

5.	STOCKHOLDERS’ DEFICIT

Common stock

On December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Company’s chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on the date of grant yielding an aggregate fair value of $20,000. In this respect, the Company recognized $0 and $1,667 for the year ended October 31, 2014 and 2013 respectively as consultancy fees included in general and administrative expenses.

On October 28, 2013, the Company issued 150,000 shares of restricted common stock as directors’ services compensation for past services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71 per share on the date of grant, yielding an aggregate fair value of $213,000.

For the years ended October 31, 2014 and 2013 the Company recognized $0 and $214,667 respectively as consultancy fees included in general and administrative expenses.

6.	COMMITMENTS AND CONTINGENCIES

(A)	Employee benefits

The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $74,189 and $68,711 for the years ended October 31, 2014 and 2013 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.

(B)	Lease commitments

The Company leased from third parties office space and an apartment for a director at monthly rent prevailing at October 31, 2014 of $2,348 and $1,309 (2013: $2,243 and $1,313) respectively. Both of these operating leases expired on July 20, 2014 and June 30, 2014 respectively. The Company continues to lease these premises at same monthly rent pending a formal renewal of these leases.

The Company also leases eight apartments (2013: seven apartments) and one canteen (2013: one canteen) for staff under three operating leases (2013: two leases) from a third party at monthly rental totaling $965 (2013: $766), all of which will expire in April 2015, June 2015 and July 2015 respectively.

As of October 31, 2014, the Company had outstanding commitments with respect to the above operating lease, which are due as follows:

2015			8,151
Total		$	8,151

(C)	Capital commitments

As of October 31, 2014, outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and equipment totaled $16,238 (2013: $1,140).

F-11

7.	INCOME TAX

Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.

Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been charged at 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.

8.	CONCENTRATIONS AND RISKS

As at October 31, 2014, 91% and 9% of the Company’s assets were located in the P.R.C. and the United States respectively.

As at October 31, 2013, 96% and 4% of the Company’s assets were located in the P.R.C. and the United States respectively.

9.	GOING CONCERN

As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $5,400,107 as of October 31, 2014 that includes a net loss of $827,756 for the year ended October 31, 2014. The Company’s total current liabilities exceed its total current assets by $3,863,028 and the Company used cash in operations of $732,421. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year.

10.	SUBSEQUENT EVENT

The Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial statements were issued and has determined that there were no subsequent events or transactions which would require recognition or disclosure in the financial statements other than stated below:

On November 10, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB250,000 (equivalent to approximately $41,000).

On November 28, 2014, the Company received cash advance from a related party, Chi Fung Yu, amounted to RMB250,000 (equivalent to approximately $41,000).

On December 12, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB300,000 (equivalent to approximately $49,000).

On January 20, 2015, the Company received cash advance from a related party, Chi Fung Yu, amounted to RMB250,000 (equivalent to approximately $41,000).

F-12

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

There were no disagreements related to accounting principles or practices, financial statement disclosure, internal controls or auditing scope or procedure during the two fiscal years and interim periods, including the interim period up through the date the relationship ended.

ITEM 9A. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our disclosure controls and procedures are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of October 31, 2014 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of October 31, 2014.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of October 31, 2014, based on the criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission (1992). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of October 31, 2014. The Company’s internal control over financial reporting as of October 31, 2014 has not been audited by the Company’s independent accountants.

Changes in Internal Control Over Financial Reporting

During the year ended October 31, 2014, there were no significant changes in our internal control over financial reporting that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Officers and Directors

Our directors serve until his successor is elected and qualified. Each of our officers is elected by the board of directors to a term of one (1) year and serves until his or her successor is duly elected and qualified, or until he or she is removed from office. The board of directors has no nominating, auditing or compensation committees.

The name, age and position of our officers and directors are set forth below:

Name and Address	Age	Position(s)
Chi Ming YU	41	President, Director
Hui WANG	45	Chief Executive Officer, Director
Kai GUI	45	Director, Secretary, Chief Financial Officer

The person named above has held his offices/positions since inception of our company and is expected to hold his offices/positions until the next annual meeting of our stockholders.

Background of our Officers and Directors

Chi Ming YU, Director and President, is Director of Operations at Titan Holdings, Inc. where his main responsibilities are in Administration, Company Finance and Investment, Marketing Research and Customer Relationship. From 2000 to 2003, Mr. Yu worked as a sales manager at Fu Feng LLC. From 2003 to present, Mr. Yu worked as Vice President at Titan Technology Development Ltd. Mr. Yu studied Computer Science at Rutgers University, New Jersey. Mr. Yu has extensive knowledge of the Company’s product line, and is fluent in several languages, including English and Chinese. The Board concluded that Mr. Yu should serve as a Director due to his background in the Company’s product line together with his communication skills

Hui WANG, Director and Chief Executive Officer, started her career at Hainan Xinte Pharmaceutical Ltd in China in 1990. She worked her way up from cashier to sales representative and then to sales manager. She then worked as District Manager of Southern China with Hainan Tianfeng Pharmaceutical Ltd, from 1995 to 2000 and as General Manager with Hainan Yichen Pharmaceutical Ltd. from 2001 to 2004. She is now the General Manager of Shenzhen Changhua. Ms Wang has skills and experience in R&A, marketing and business development in Chinese medical industry. The Board concluded that Hui WANG should serve as a Director due to her skills and experience in pharmaceutical sales and business development.

Kai GUI, Director, Secretary and Chief Financial Officer, worked as an Analyst Programmer in the British media industry, and as IT Manager, Circulation Manager, and Foreign Publishing Director at S.J.P. Ltd in London from 1994 to 2008. Beginning in 2000 Mr. Gui participated in several business projects involving Chinese publicly listed companies. He is the Director of China Feed Industry Association Information Centre’s European Office and Vice President of Titan Technology Development Ltd. After graduating from the University of Westminster in London, Mr. Gui took a Post-graduate course in Financial Management at Middlesex University in London. The Board concluded that Kai GUI should serve as a Director due to his business experience and financial management skills.

Involvement in Certain Legal Proceedings

To the best of our knowledge, none of our directors or executive officers, during the past ten years, has been involved in any legal proceeding of the type required to be disclosed under applicable SEC rules, including:

	1.	Any petition under the Federal bankruptcy laws or any state insolvency law being filed by or against, or a receiver, fiscal agent or similar officer being appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

	2.	Conviction in a criminal proceeding, or being a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);


	3.	Being the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:
		i. Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;
		ii. Engaging in any type of business practice; or
		iii. Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

	4.	Being the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) of this section, or to be associated with persons engaged in any such activity;
	5.	Being found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;
	6.	Being found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;
	7.	Being the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:
		i. Any Federal or State securities or commodities law or regulation; or
		ii. Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or
		iii. Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
	8.	Being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Audit Committee and Charter

We have a separately-designated audit committee of the board. Our board of directors performs audit committee functions. None of our directors are deemed independent. All directors also hold positions as our officers. Our audit committee is responsible for: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; (3) establishing procedures for the confidential, anonymous submission by our employees of concerns regarding accounting and auditing matters; (4) engaging outside advisors; and, (5) funding for the outside auditory and any outside advisors engagement by the audit committee. A copy of our audit committee charter is filed as an exhibit to this report.

Audit Committee Financial Expert

None of our directors or officers has the qualifications or experience to be considered a financial expert. We believe the cost related to retaining a financial expert at this time is prohibitive. Further, because of our limited operations, we believe the services of a financial expert are not warranted.

Code of Ethics

We have adopted a corporate code of ethics. We believe our code of ethics is reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of code violations; and provide accountability for adherence to the code. A copy of the code of ethics is filed as an exhibit to this report.

Disclosure Committee and Charter

We have a disclosure committee and disclosure committee charter. Our disclosure committee is comprised of all of our officers and directors. The purpose of the committee is to provide assistance to the Chief Executive Officer and the Chief Financial Officer in fulfilling their responsibilities regarding the identification and disclosure of material information about us and the accuracy, completeness and timeliness of our financial reports. A copy of the disclosure committee charter is filed as an exhibit to this report.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth information with respect to compensation paid by the registrant to its officers during the last completed fiscal year ended October 31, 2014.

Executive Officer Compensation Table

Fees

Earned

Nonqualified

Non-Equity

Deferred

Paid in

Stock

Option

Incentive Plan

Compensation

All Other

Cash

Awards

Compensation

Earnings

Compensation

Total

Name

(US$)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Hui WANG

38,167

Chi Ming YU

Kai GUI

The following table sets forth information with respect to compensation paid by the registrant to its directors during the last completed fiscal year ended October 31, 2014.

Director Compensation

Fees

Earned

Nonqualified

Non-Equity

Deferred

Paid in

Stock

Option

Incentive Plan

Compensation

All Other

Cash

Awards

Compensation

Earnings

Compensation

Total

Name

(US$)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Hui WANG

Chi Ming YU

Kai GUI

All compensation received by our officers and directors has been disclosed.

There are no stock option, retirement, pension, or profit sharing plans for the benefit of our officers and directors.

Long-Term Incentive Plan Awards

We do not have any long-term incentive plans that provide compensation intended to serve as incentive for performance.

Indemnification

Under our Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit, because of his position, if he acted in good faith and in a manner he reasonably believed to be in our best interest. We may advance expenses incurred in defending a proceeding. To the extent that the officer or director is successful on the merits in a proceeding as to which he is to be indemnified, we must indemnify him against all expenses incurred, including attorney's fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officer or director is judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.

Regarding indemnification for liabilities arising under the Securities Act of 1933, which may be permitted to directors or officers under Nevada law, we are informed that, in the opinion of the Securities and Exchange Commission, indemnification is against public policy, as expressed in the Act and is, therefore, unenforceable.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The registrant has no compensation plans (including individual compensation arrangements) under which equity securities of the registrant are authorized for issuance.

The following table sets forth, as of the date of this Annual Report on Form 10-K, the total number of shares owned beneficially by each of our directors, officers and key employees, individually and as a group, and the present owners of 5% or more of our total outstanding shares. The stockholders listed below have direct ownership of his/her shares and possess voting and dispositive power with respect to the shares.

(1) Title of Class	(2) Name and address of beneficial owner	(3) Amount and nature of beneficial ownership		(4) Percent of class
Common Stock	Hui WANG, CEO & Director		22,153,540		38.951	%
Common Stock	Chi Ming YU, President & Director		150,000		0.264	%
Common Stock	Kai GUI, Secretary & Director		300,000		0.527	%
Common Stock	Titan Technology Development, LTD., Room 1903 Hing Yip, Commercial Centre, 272 Des Voeux Road Central, Hong Kong, 718332		19,497,130		34.281	%
Common Stock	WU Ai Ping, Room 802, 35 Weicheng Street, Hongyun Garden, Zhongtangshi Lane, Huangpu Road, Tianhe, Guangzhou, 510655		5,000,000		8.791	%
All Officers & Directors			22,603,540		39.742	%

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Kai GUI, officer and director of Registrant owns five percent (5%) of the outstanding capital stock of Titan Technology Development, LTD., and Chi Fung Yu, brother of Registrant’s president Chi Ming Yu, owns seventy percent (70%) of the outstanding capital stock of Titan Technology Development, LTD.

As of October 31, 2014 and 2013, the Company owed $459,131 and $349,911 respectively to a stockholder - Titan Technology Development Ltd., which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed. An agreement between Titan Technology Development Ltd. and the Registrant for a loan in the amount of $110,000 is included as an exhibit to this Form 10-K. There is no formal written agreement between Titan Technology Development Ltd. and the Registrant for the balance of funds owed to Titan Technology Development Ltd.

As of October 31, 2014 and 2013, the Company owed $1,618,333 and $1,395,501 respectively to Chi Fung Yu, $1,370,405 and $871,415 respectively to Tie Jun Chen, which are unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed. There is no formal written agreement between the Company and Chi Fung Yu or Tie Jun Chen. Chi Fung Yu and Tie Jun Chen are directors of Titan Technology Development Ltd. (TTD), and have been lending money to Shenzhen Changhua on behalf of TTD.

Total interest expenses on advances from a stockholder accrued for the year ended October 31, 2014 and October 31, 2013 are $26,081 and $20,755 for Titan Technology Development Limited.

Imputed interest charged at 5% per annum on the amounts owed to two directors for the year ended October 31, 2014 and 2013 respectively is $20,079 and $22,936 for Hui Wang; $0 and $0 for Chi Ming Yu.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

(1) Audit Fees

The aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for our audit of annual financial statements and review of financial statements included in our Form 10-Qs or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years was:

2014		$	32,650		Baker Tilly Hong Kong Limited
2013		$	33,400		Baker Tilly Hong Kong Limited

(2) Audit-Related Fees

There is no fee billed in each of the last two fiscal years for assurance and related services by the principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported in the preceding paragraph.

(3) Tax Fees

There is no fee billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning.

(4) All Other Fees

There is no fee billed in each of the last two fiscal years for the products and services provided by the principal accountant, other than the services reported in paragraphs (1), (2), and (3).

(5) Our audit committee’s pre-approval policies and procedures described in paragraph (c)(7)(i) of Rule 2-01 of Regulation S-X were that the audit committee pre-

approves all accounting related activities prior to the performance of any services by any accountant or auditor.

(6) There is no hour expended on the principal accountant’s engagement to audit our financial statements for the most recent fiscal year that were attributed to work

performed by persons other than the principal accountant’s full time and permanent employees was.

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

		Incorporated by reference
Exhibit	Document Description	Form	Date	Number	Filed herewith

3.1	Articles of Incorporation	SB-2	01-16-07	3.1
3.2	Bylaws	SB-2	01-16-07	3.2
4.1	Specimen Stock Certificate	SB-2	01-16-07	4.1
14.1	Code of Ethics				X
10.1	Titan – ABMT Loan Agreement				X
31.1	Certification of Chief Executive Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.				X
31.2	Certification of Chief Financial Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.				X
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)				X
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)				X
99.1	Audit Committee Charter				X
99.2	Disclosure Committee Charter				X

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

Signature	Title	Date

/s/Chi Ming YU	President and Director	January 29, 2015
Chi Ming YU	(Principal Executive Officer)

/s/Kai GUI	Director, Secretary and Chief Financial Officer	January 29, 2015
Kai GUI	(Principal Financial Officer)

/s/Hui WANG	Director and Chief Executive Officer	January 29, 2015
Hui WANG	(Controller)

EX-10.1 2 abmt_ex101.htm LOAN AGREEMENT abmt_ex101.htm

Exhibit 10.1

Loan Agreement

TTD/ABMT/L1410-01

Lender:	TITAN TECHNOLOGY DEVELOPMENT LIMITED

Address:	1903 HING YIP COMMERCIAL CENTRE, 272 DES VOEUX ROAD CENTRAL, HONG KONG.
	(Hong Kong Company Registration No.: 718332)

Borrower:	ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
Address:	350 FIFTH AVE., 59TH FLOOR, NEW YORK, NY 10118
	USA (Incorporated in the State of Nevada, USA)

Borrower is the controlling shareholder of Shenzhen Changhua Biomedical Engineering Co. Ltd., approved by Shenzhen Bureau of Trade and Industry’s permit, February 25, 2008 (2008) No. 0539 and Guangdong Shenzhen Joint Venture Permit (2008) No. 0008. Shenzhen Changhua Biomedical Engineering Co., Ltd. is a company engaged in research and development and production of biodegradable medical materials. Lender is a major shareholder of Borrower.

Loan:

Lender agrees to advance to Borrower’s subsidiary Shenzhen Changhua Biomedical Engineering Co., Ltd. (Changhua) the total amount of USD110,000 - (One Hundred and Ten Thousand US dollars).

Borrower accepts that Lender may send the total amount in several advances using different financial institutions, associated companies or individuals that is appointed by Lender.

2)	Use of Proceed: For Changhua’s R&D, Clinical Trial, GMP Facilities Upgrading and Operation Expenses.

3)	Interest Rate: Annual interest rate is seven percent (7%).

4)	Loan Repayment period: 12 months

5)	Repayment:

Debt maturity: after 12 months, Borrower will repay Lender the total amount of loan plus interest.

Outstanding loan: after 6 months, Lender may demand the return of part of the loan plus interest occurred.

6)	Repayment Methods and Repayment Source

Repayment Methods: cash or securities;

Repayment Source: banks and securities firms.

Warranty:

Borrower and its subsidiary guarantee that the loan will be used for the purposes stipulated in this agreement and the fund may not be used for other purposes or illegal activities;

Borrower will return the loan within the terms stipulated in this agreement;

Borrower and its subsidiary agree to accept the supervision of Lender on the use of proceed provided under this agreement.

8)	Miscellaneous

This Agreement may not be amended or modified except by a writing executed by each of the parties. Neither party shall assign (including the engagement of subcontractors) any of its rights or obligations under this Agreement without the prior written consent of the other party. The provisions of this Agreement, including without limitation the obligation to make loan and interest repayments, shall be binding on Borrower, its Parent Company, its successors and assigns. All terms of this Agreement, which by their nature extend beyond its termination, shall remain in effect until fulfilled, and shall apply to the respective successors and assigns of the parties;

This Agreement, including all controversies arising from or relating to performance under this Agreement, shall be governed by and construed in accordance with the laws of Hong Kong, China. Venue for any action or dispute arising from or relating to this Agreement shall conclusively lie in the Courts located in Hong Kong, China. Each party hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue or forum non conveniens.

Lender:	TITAN TECHNOLOGY DEVELOPMENT LIMITED
Signature:	/s/ Chi Fung YU
Name and Title:	Chi Fung YU, Chairman

Borrower:	ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
Signature:	/s/ Hui WANG
Name and Title:	Hui WANG, Director and Chief Executive Officer

Date: October 31, 2014

EX-14.1 3 abmt_ex141.htm CODE OF ETHICS abmt_ex141.htm

Exhibit 14.1

ADVANCED BIOMEDICAL TECHNOLOGIES, INC

CODE OF ETHICS

TOPICS

	1.	Statement of Policy
	2.	Implementation and Enforcement
	3.	Relations with Competitors and Other Third Parties
	4.	Insider Trading, Securities Compliance and Public Statements
	5.	Financial Reporting
	6.	Human Resources
	7.	Environmental, Health and Safety
	8.	Conflicts of Interest
	9.	International Trade
	10.	Government Relations
	11.	Contractors, Consultants, and Temporary Workers
	12.	Conclusion

1. STATEMENT OF POLICY

The Company has adopted eight Corporate Values (Focus, Respect, Excellence, Accountability, Teamwork, Integrity, Very Open Communications and Enjoying Our Work) to provide a framework for all employees in conducting ourselves in our jobs. These policies are not intended to substitute for those Values, but will serve as guidelines in helping you to conduct the Company's business in accordance with our Values. Compliance requires meeting the spirit, as well as the literal meaning, of the law, the policies and the Values. It is expected that you will use common sense, good judgment, high ethical standards and integrity in all your business dealings.

If you encounter a situation you are not able to resolve by reference to these policies, ask for help. Contact Chi Ming YU, President and Director, who has been identified as responsible for overseeing compliance with these policies.

Violations of the law or the Company's policies will subject employees to disciplinary action, up to and including termination of employment. In addition, individuals involved may subject themselves and the Company to severe penalties including fines and possible imprisonment. Compliance with the law and high ethical standards in the conduct of Company business should be a top priority for each employee, officer and director.

2. IMPLEMENTATION AND ENFORCEMENT

Chi Ming YU, our President and Director, has been appointed as Compliance Officer of the Company, responsible for overseeing compliance with, and enforcement of, all Company policies.

Employees are expected to be familiar with these policies as they apply to their duties. They should consult with their managers if they need assistance in understanding or interpreting these policies. Each employee is required to follow these policies and to comply with their terms. A refusal by any employee to agree to be bound by these policies shall be grounds for discipline up to and including dismissal.

Any employee who, in good faith, has reason to believe a Company operation or activity is in violation of the law or of these policies must call the matter to the attention of Chi Ming YU, our President and Director. All reports will be reviewed and investigated and as necessary under the circumstances, and the reporting employee should provide sufficient information to enable a complete investigation to be undertaken.

Any employee who makes an allegation in good faith reasonably believing that a person has violated these policies or the law, will be protected against retaliation.

3. RELATIONS WITH COMPETITORS AND OTHER THIRD PARTIES

The Company's policy is to comply fully with competition and antitrust laws throughout the world. These laws generally prohibit companies from using illegal means to maintain, obtain or attempt to obtain a monopoly in a market. They also prohibit companies from engaging in unfair trade practices. "Unfair trade practices" include fixing prices, dividing markets, agreeing with competitors not to compete, or agreeing to boycott certain customers. It is advised that you consult with Chi Ming YU before attending a meeting with a party who may be viewed as a competitor.

4. INSIDER TRADING, SECURITIES COMPLIANCE AND PUBLIC STATEMENTS

Securities laws prohibit anyone who is in possession of material, non-public information ("Insider Information") about a company from purchasing or selling stock of that company, or communicating the information to others. Information is considered "material" if a reasonable investor would consider it to be important in making a decision to buy or sell that stock. Some examples include financial results and projections, new products, acquisitions, major new contracts or alliances prior to the time that they are publicly announced. Employees who become aware of such Inside Information about the Company must refrain from trading in the shares of the Company until the Inside Information is publicly announced.

Employees must also refrain from disclosing that information to persons who do not have a Company need to know, whether they are inside the Company or outside, such as spouses, relatives or friends.

The Company makes regular formal disclosures of its financial performance and results of operations to the investment community. We also regularly issue press releases. Other than those public statements, which go through official Company channels, employees are prohibited from communicating outside the Company about the Company's business, financial performance or future prospects. Such communications include questions from securities analysts, reporters or other news media, but also include seemingly innocent discussions with family, friends, neighbors or acquaintances.

5. FINANCIAL REPORTING

The Company is required to maintain a variety of records for purposes of reporting to the government. The Company requires all employees to maintain full compliance with applicable laws and regulations requiring that its books of account and records be accurately maintained. Specifics of these requirements are available from Chi Ming YU.

6. HUMAN RESOURCES

The Company is committed to providing a work environment that is free from unlawful harassment and discrimination, and respects the dignity of its employees. The Company has policies covering various aspects of its relationship with its employees, as well as employees’ relationships with each other. For more detailed information, you should consult Chi Ming YU. Each employee is expected to be familiar with these policies and to abide by them.

7. ENVIRONMENTAL, HEALTH AND SAFETY

The Company is committed to protecting the health and safety of our employees, as well as the environment in general. The Company expects employees to obey all laws and regulations designed to protect the environment, and the health and safety of our employees, and to obtain and fully observe all permits necessary to do business.

At the very least, all employees should be familiar with and comply with safety regulations applicable to their work areas. The Company will make, to the extent possible, reasonable accommodations for the known physical or mental limitations of our employees. Employees who require an accommodation should contact Chi Ming YU. The Company will then engage in an interactive process to determine what reasonable accommodations may exist.

8. CONFLICTS OF INTEREST

Each employee is expected to avoid any activity, investment or association that interferes with the independent exercise of his or her judgment in the Company's best interests ("Conflicts of Interest"). Conflicts of Interest can arise in many situations. They occur most often in cases where the employee or the employee's family obtains some personal benefit at the expense of the Company's best interests.

No employee, or any member of employee's immediate family, shall accept money, gifts of other than nominal value, unusual entertainment, loans, or any other preferential treatment from any customer or supplier of the Company where any obligation may be incurred or implied on the giver or the receiver or where the intent is to prejudice the recipient in favor of the provider. Likewise, no employee shall give money, gifts of other than nominal value, unusual entertainment or preferential treatment to any customer or supplier of the Company, or any employee or family members thereof, where any obligation might be incurred or implied, or where the intent is to prejudice the recipient in favor of the Company. No such persons shall solicit or accept kickbacks, whether in the form of money, goods, services or otherwise, as a means of influencing or rewarding any decision or action taken by a foreign or domestic vendor, customer, business partner, government employee or other person whose position may affect the Company's business.

No employee shall use Company property, services, equipment or business for personal gain or benefit.

Employees may not: (1) act on behalf of, or own a substantial interest in, any company or firm that does business, or competes, with the Company; (2) conduct business on behalf of the Company with any company or firm in which the employee or a family member has a substantial interest or affiliation. Exceptions require advance written approval from the Legal Department.

Employees should not create the appearance that they are personally benefiting in any outside endeavor as a result of their employment by the Company, or that the Company is benefiting by reason of their outside interests. Any employee who is not sure whether a proposed action would present a conflict of interest or appear unethical should consult with Chi Ming YU.

9. INTERNATIONAL TRADE

The Company must comply with a variety of laws around the world regarding its activities. In some cases, the law prohibits the disclosure of information, whether the disclosure occurs within the U.S. or elsewhere, and whether or not the disclosure is in writing.

Payments or gifts to non-U.S. government officials are prohibited by law and by Company policy. The Foreign Corrupt Practices Act precludes payments to non-U.S. government officials for the purpose of obtaining or retaining business, even if the payment is customary in that country. This law applies anywhere in the world to U.S. citizens, nationals, residents, businesses or employees of U.S. businesses. Because Advanced Biomedical Technologies, Inc. is a U.S. company, this law applies to the Company and all of its subsidiaries. Any questions on this policy should be directed to Chi Ming YU.

10. GOVERNMENT RELATIONS

The Company is prohibited by law from making any contributions or expenditures in connection with any U.S. national election. This includes virtually any activity that furnishes something of value to an election campaign for a federal office. Use of the Company's name in supporting any political position or ballot measure, or in seeking the assistance of any elected representative, requires the specific approval of the Chairman and Chief Executive Officer of the Company. Political contributions or expenditures are not to be made out of Company funds in any foreign country, even if permitted by local law, without the consent of the Company's Chairman and Chief Executive Officer.

U.S. law also prohibits giving, offering, or promising anything of value to any public official in the U.S. or any foreign country to influence any official act, or to cause an official to commit or omit any act in violation of his or her lawful duty. Company employees are expected to comply with these laws.

11. VENDORS, CONTRACTORS, CONSULTANTS AND TEMPORARY WORKERS

Vendors, contractors, consultants or temporary workers who are acting on the Company's behalf, or on Company property, are expected to follow the law, Company policies and honor Company Values. Violations will subject the person or firm to sanctions up to and including loss of the contract, contracting or consulting agreement, or discharge from temporary assignment.

12. CONCLUSION

This Code of Ethics is not intended to cover every possible situation in which you may find yourself. It is meant to give you the boundaries within which the Company expects you to conduct yourself while representing Advanced Biomedical Technologies, Inc. You may find yourself in a situation where there is no clear guidance given by this Code of Ethics. If that occurs, return to the foundations stated earlier: common sense, good judgment, high ethical standards and integrity. And refer to the Company's Values. In addition, there are many resources upon which you may rely: your management chain, Human Resources, Legal or other Advanced Biomedical Technologies, Inc. departments, and the CEO.


	Employee

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

VALUES

FOCUS We exist only because we are involved in medical device research and manufacturing.

RESPECT We value all people, treating them with dignity at all times.

EXCELLENCE We strive for "Best in Class" in everything we do.

ACCOUNTABILITY We do what we say we will do and expect the same from others.

TEAMWORK We believe that cooperative action produces superior results.

INTEGRITY We are honest with ourselves, each other, our customers, our partners and our shareholders.

VERY OPEN COMMUNICATION We share information, ask for feedback, acknowledge good work, and encourage diverse ideas.

ENJOYING OUR WORK We work hard, are rewarded for it, and maintain a good sense of perspective, humor and enthusiasm.

Reportable Violations - Anonymous Reporting Program

Accounting Error

Accounting Omissions

Accounting Misrepresentations

Auditing Matters

Compliance/Regulation Violations

Corporate Scandal

Domestic Violence

Discrimination

Embezzlement

Environmental Damage

Ethics Violation

Fraud

Harassment

Industrial Accidents

Misconduct

Mistreatment

Poor Customer Service

Poor Housekeeping

Sabotage

Securities Violation

Sexual Harassment

Substance Abuse

Theft

Threat of Violence

Unfair Labor Practice

Unsafe Working Conditions

Vandalism

Waste

Waste of Time and Resources

Workplace Violence

EX-31.1 4 abmt_ex311.htm CERTIFICATION abmt_ex311.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Hui WANG, certify that:

1.	I have reviewed this annual report on Form 10-K of Advanced Biomedical Technologies, Inc.; (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 29, 2015

By: /s/Hui WANG

Name: Hui WANG

Title: Director and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 5 abmt_ex312.htm CERTIFICATION abmt_ex312.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kai GUI, certify that:

1.	I have reviewed this annual report on Form 10-K of Advanced Biomedical Technologies, Inc.; (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

c)	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 29, 2015

By: /s/Kai GUI

Name: Kai GUI,

Title: Director, Secretary and Chief Financial Officer

EX-32.1 6 abmt_ex321.htm CERTIFICATION abmt_ex321.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Advanced Biomedical Technologies, Inc. (the "Company") on Form 10-K for the year ended October 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "report"), I, Hui Wang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 29th day of January, 2015.

/s/ Hui WANG

Hui WANG

Director and Chief Executive Officer

EX-32.2 7 abmt_ex322.htm CERTIFICATION abmt_ex322.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Advanced Biomedical Technologies, Inc. (the "Company") on Form 10-K for the year ended October 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "report"), I, Kai GUI, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 29th day of January, 2015.

/s/ Kai GUI

Kai GUI

Director, Secretary, and Chief Financial Officer

EX-99.1 8 abmt_ex991.htm AUDIT COMMITTEE CHARTER abmt_ex991.htm

Exhibit 99.1

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

CHARTER - AUDIT COMMITTEE

Committee Role

The committee's role is to act on behalf of the board of directors and oversee all material aspects of the company's reporting, control, and audit functions, except those specifically related to the responsibilities of another standing committee of the board. The audit committee's role includes a particular focus on the qualitative aspects of financial reporting to shareholders and on company processes for the management of business/financial risk and for compliance with significant applicable legal, ethical, and regulatory requirements.

In addition, the committee responsible for: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; (3) establishing procedures for the confidential, anonymous submission by our employees of concerns regarding accounting and auditing matters; (4) establishing internal financial controls; (5) engaging outside advisors; and, (6) funding for the outside auditor and any outside advisors engagement by the audit committee.

The role also includes coordination with other board committees and maintenance of strong, positive working relationships with management, external and internal auditors, counsel, and other committee advisors.

Committee Membership

The committee shall consist of the entire board directors. The committee shall have access to its own counsel and other advisors at the committee's sole discretion.

Committee Operating Principles

The committee shall fulfill its responsibilities within the context of the following overriding principles:

(1)	Communications - The chairperson and others on the committee shall, to the extent appropriate, have contact throughout the year with senior management, other committee chairpersons, and other key committee advisors, external and internal auditors, etc., as applicable, to strengthen the committee's knowledge of relevant current and prospective business issues.

(2)	Committee Education/Orientation - The committee, with management, shall develop and participate in a process for review of important financial and operating topics that present potential significant risk to the company. Additionally, individual committee members are encouraged to participate in relevant and appropriate self-study education to assure understanding of the business and environment in which the company operates.

(3)	Annual Plan - The committee, with input from management and other key committee advisors shall develop an annual plan responsive to the "primary committee responsibilities" detailed herein. The annual plan shall be reviewed and approved by the full board.

(4)	Meeting Agenda - Committee meeting agendas shall be the responsibility of the committee chairperson, with input from committee members. It is expected that the chairperson would also ask for management and key committee advisors, and perhaps others, to participate in this process.

(5)	Committee Expectations and Information Needs - The committee shall communicate committee expectations and the nature, timing, and extent of committee information needs to management, internal audit, and external parties, including external auditors. Written materials. Including key performance indicators and measures related to key business and financial risks shall be received from management, auditors, and others at least one week in advance of meeting dates. Meeting conduct will assume board members have reviewed written materials in sufficient depth to participate in committee/board dialogue.

(6)	External Resources -The committee shall be authorized to access internal and external resources, as the committee requires, carrying out its responsibilities.

(7)	Committee Meeting Attendees - The committee shall request members of management, counsel, internal audit, and external auditors, as applicable, to participate in committee meetings, as necessary, to carry out the committee responsibilities. Periodically and at least annually, the committee shall meet in private session with only the committee members. It shall be understood that either internal or external auditors, or counsel, may, at any time, request a meeting with the audit committee or committee chairperson with or without management attendance. In any case, the committee shall meet in executive session separately with internal and external auditors, at least annually.

(8)	Reporting to the Board of Directors - The committee, through the committee chairperson, shall report periodically, as deemed necessary, but at least semi-annually, to the full board. In addition, summarized minutes from committee meetings, separately identifying monitoring activities from approvals, shall be available to each board member at least one week prior to the subsequent board of directors meeting.

(9)	Committee Self Assessment - The committee shall review, discuss, and assess its own performance as well as the committee role and responsibilities, seeking input from senior management, the full board, and others. Changes in role and/or responsibilities, if any, shall be recommended to the full board for approval.

Meeting Frequency

The committee shall meet at least three times quarterly. Additional meetings shall be scheduled as considered necessary by the committee or chairperson.

Reporting to Shareholders

The committee shall make available to shareholders a summary report on the scope of its activities. This may be identical to the report that appears in the company's annual report.

Committee's Relationship with External and Internal Auditors

(1)	The external auditors, in their capacity as independent public accountants, shall be responsible to the board of directors and the audit committee as representatives of the shareholders.
(2)	As the external auditors review financial reports, they will be reporting to the audit committee. They shall report all relevant issues to the committee responsive to agreed-on committee expectations. In executing its oversight role, the board or committee should review the work of external auditors.
(3)	The internal audit function shall be responsible to the board of directors through the committee.
(4)	If either the internal or the external auditors identify significant issues relative to the overall board responsibility that have been communicated to management but, in their judgment, have not been adequately addressed, they should communicate these issues to the committee chairperson.
(5)	Changes in the directors of internal audit or corporate compliance shall be subject to committee approval.

Primary Committee Responsibilities

Monitor Financial Reporting and Risk Control Related Matters

The committee should review and assess:

(1)	Risk Management - The company's business risk management process, including the adequacy of the company's overall control environment and controls in selected areas representing significant financial and business risk.

(2)	Annual Reports and Other Major Regulatory Filings - All major financial reports in advance of filings or distribution.

(3)	Internal Controls and Regulatory Compliance - The company's system of internal controls for detecting accounting and reporting financial errors, fraud and defalcations, legal violations, and noncompliance with the corporate code of conduct.

(4)	Internal Audit Responsibilities - The annual audit plan and the process used to develop the plan. Status of activities, significant findings, recommendations, and management's response.

(5)	Regulatory Examinations - SEC inquiries and the results of examinations by other regulatory authorities in terms of important findings, recommendations, and management's response.

(6)	External Audit Responsibilities - Auditor independence and the overall scope and focus of the annual/interim audit, including the scope and level of involvement with unaudited quarterly or other interim-period information.

(7)	Financial Reporting and Controls - Key financial statement issues and risks, their impact or potential effect on reported financial information, the processes used by management to address such matters, related auditor views, and the basis for audit conclusions. Important conclusions on interim and/or year-end audit work in advance of the public release of financials.

(8)	Auditor Recommendations - Important internal and external auditor recommendations on financial reporting, controls, other matters, and management's response. The views of management and auditors on the overall quality of annual and interim financial reporting.

The committee should review, assess, and approve:

(1)	The code of ethical conduct.

(2)	Changes in important accounting principles and the application thereof in both interim in and annual financial reports.

(3)	Significant conflicts of interest and related-party transactions.

(4)	External auditor performance and changes in external audit firm (subject to ratification by the full board).

(5)	Internal auditor performance and changes in internal audit leadership and/or key financial management.

(6)	Procedures for whistle blowers.

(7)	Pre-approve allowable services to be provided by the auditor.

(8)	Retention of complaints.

EX-99.2 9 abmt_ex992.htm DISCLOSURE COMMITTEE CHARTER abmt_ex992.htm

Exhibit 99.2

ADVANCED BIOMEDICAL TECHNOLOGIES INC.

DISCLOSURE COMMITTEE

CHARTER

Disclosure Policy

All financial disclosures made by the Corporation to its security holders or the investment community should (i) be accurate, complete and timely, (ii) fairly present, in all material respects, the Corporation's financial condition, results of operations and cash flows, and (iii) meet any other legal, regulatory or stock exchange requirements.

Committee Purpose

The Corporation's Disclosure Committee (the "Committee") shall assist the Corporation's officers and directors (collectively, the "Senior Officers") fulfilling the Corporation's and their responsibilities regarding (i) the identification and disclosure of material information about the Corporation and (ii) the accuracy, completeness and timeliness of the Corporation's financial reports.

Responsibilities

Subject to the supervision and oversight of Senior Officers, the Committee shall be responsible for the following tasks:

●

Review and, as necessary, help revise the Corporation's controls and other procedures ("Disclosure Controls and Procedures") to ensure that (i) information required by the Corporation to be disclosed to the Securities and Exchange Commission (the "SEC"), and other written information that the Corporation will disclose to the public is recorded, processed, summarized and reported accurately and on a timely basis, and (ii) such information is accumulated and communicated to management, including the Senior Officers, as appropriate to allow timely decisions regarding required disclosure.

●	Assist in documenting, and monitoring the integrity and evaluating the effectiveness of, the Disclosure Controls and Procedures.

●

Review the Corporation's (i) Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, proxy statement, material registration statements, and any other information filed with the SEC (collectively, the "Reports"), (ii) press releases containing financial information, earnings guidance, forward-looking statements, information about material transactions, or other information material to the Corporation's security holders, (iii) correspondence broadly disseminated to shareholders, and (iv) other relevant communications or presentations (collectively, the "Disclosure Statements").

●	Discuss information relative to the Committee's responsibilities and proceedings, including (i) the preparation of the Disclosure Statements and (ii) the evaluation of the effectiveness of the Disclosure Controls and Procedures.

Other Responsibilities

The Committee shall have such other responsibilities, consistent with the Committee's purpose, as any Senior Officer may assign to it from time to time.

Disclosure Control Considerations

The Committee shall base the review and revision of the Disclosure Controls and Procedures on the following factors:

●

Control Environment: The directives of the Board and Audit Committee; the integrity and ethical values of the Corporation's officers and employees, including the "tone at the top"; the Corporation's Code of Conduct; and the philosophy and operating style of management, including how employees are organized and how authority is delegated.

●	Risk Assessment: The identification and analysis of relevant risks to achieving the goal of accurate and timely disclosure, forming a basis for determining how the risks should be managed.

●	Control Activities: The procedures to ensure that necessary actions are taken to address and handle risks to achievement of objectives.

●	Information and Communication: The accumulation, delivery and communication of financial information throughout (i.e., up, down and across) the organization.

●	Monitoring: The assessment of the quality of the financial reporting systems over time through ongoing monitoring and separate evaluations, including through regular management supervision and reporting of deficiencies upstream.

Organization

The members of the Committee will be comprised of the Corporation’s officers and directors.

The Committee may designate two or more individuals, at least one of whom shall be knowledgeable about financial reporting and another about law, who can, acting together, review Disclosure Statements when time does not permit full Committee review.

The Senior Officers at their option may, at any time and from time to time, assume any or all of the responsibilities of the Disclosure Committee identified in this Charter, including, for example, approving Disclosure Statements when time does not permit the full Committee (or the designated individuals) to meet or act.

Chair

The Chief Financial Officer of the Corporation shall act as the Chair of the Committee (unless and until another member of the Committee shall be so appointed by any Senior Officer).

Meetings and Procedures

The Committee shall meet or act as frequently and as formally or informally as circumstances dictate to (i) ensure the accuracy, completeness and timeliness of the Disclosure Statements and (ii) evaluate the Disclosure Controls and Procedures and determine whether any changes to the Disclosure Controls and Procedures are necessary or advisable in connection with the preparation of the Reports or other Disclosure Statements, taking into account developments since the most recent evaluation, including material changes in the Corporation's organization and business lines and any material change in economic or industry conditions.

The Committee shall adopt, whether formally or informally, such procedures as it deems necessary to facilitate the fulfillment of its responsibilities.

Full Access

The Committee shall have full access to all of Corporation's books, records, assets, facilities and personnel, including the internal auditors, in connection with fulfilling its responsibilities.

Charter Review

The Committee shall review and assess this Charter annually, and recommend any proposed changes to the Senior Officers for approval.

Interpretation

Any questions of interpretation regarding this Charter, or the Committee's responsibilities or procedures, shall be determined initially by the Chair and, to the extent necessary, ultimately by the Senior Officers.

GRAPHIC 10 img002.jpg begin 644 img002.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_ MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L M(QP<*#7J#A(6&AXB)BI*3E)66EYB9 MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+ M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1 MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15 M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W M^/GZ_]H`#`,!``(1`Q$`/P#WXGFC)JAJ&M:7I88W^HVEMM&2)9E4_D37`^(_ MC5X?TN-X](#:I==`5!2('W8]?P%5&$I;(F4XQW9Z#J>K66C6$E]J-U';VT8R MSN+>)/CM>23M#XD3U[P[\;-7DG%GK'V0>:0L=V(R!&W; M>H/*^I&"*[2X\<^(HY'@:VT"V>,[6DFU#(S[*/F_2OFVO8O#GC72(_!\%]J> MIO'JMF1;K`%0M*%QM;.TMMQP>>U88JA)V=,Z\#BH1O&LDS8\4>+O%>D^'(M1 M76M.\V>5!9"RA$@NC^&+O5;WPW8W.M6RVVH21YFB7C![ M<=B1@X[5Y%I?Q&\&QZZ-6U:#4;S4.D=P\""*W'I%&&^4>_)->Q:-KNFZ_9B[ MTRZ6>(@9(!!&?4'D5+@X046OF/VBJ5'):>1I9-&3245F6+DT9-)10`N31DTE M%`"Y-&3244`+DT9-)10`N31DTE%`"Y-&3244`+DT9-)10`N31DTE%`"Y-&32 M44`+DT9-)10`N31DTE%`"Y-&3244`+DT9-)10`N31DTE%`#ATHH'2B@#)U;P MUHFN_P#(4TNUNC_>DC!8?\"ZUSES\)O"$R_N=-6V;NT9W?\`H617<'K252E) M;,EPB]T>?6_P8\(0R>9-!=W)SG$L^!^2@4V^^%7@:RL;FZO8I((50EIGN"HB M`].P_*NKUK4M4M1Y&CZ0]]=L,AI)!%"G^\QY/T`->=ZS\//''C*16\0>(;*W MMPE6S2M_'(>$C'JQ[?SKVW2?@7H%HROJ5Y=7[#^#(B0_ES^M M>C:=I5CHUD+33+."UA4?*D:X&?4^OUK:6(25HF$,,V[R..\(?"C0_#<<<]Y& MFHZB.3-,N40_["GI]3S7>A0H`4``<``5Y\GC?Q%<>)]8T*TTG3YKC2XO-8F= MU\T<<+P<'GO72^$?$T'BWP_%JD$#P%F:.2)SDHZ]1GN*YYJ3UD=4'!:1-VBL M'QCXCC\*>&+O5F19)(P%BC8X#N3@#_/I6AHVIPZUHMGJ5N_UJY^:2`.RI%'WD9OX5SP,]:?*[7)YU=HZBBLVXGU.WT66QH M7*@MY9QSC/6N+T+QOXK\2>'I-9TW0=-:%&9?+:Z<.2O7`V\_G0HMJXW-)V/1 MJ*HZE.(R%)20IP,D<G451T;5;?7-'M-4M"WD7,8D3<,$9['W'2K`_&-_XP%_+/96UK#9S&`A)&9F;U&1TKJ-3FN;?3IY[18FFC0N%E)"G` MSCBAQ:=F"DFKHMT5R?@'Q5>^,=&?5)[2WM8?,:)8XW9FR,9))XQS57Q?XRU3 MPEJ-BT^GVTFD74ZQ-=AVS#D_Q+CTR?PI\CORBYUR\W0[:BN?\6>(9M!TB&XL M8([N\N9XX+:W9B/.9CT!'MSGT%;%B;QK2,WZP)Q8 MHHHI#"BBB@`HHHH`****`"BBB@!PZ44#I10`AZTE*>M)0`4444`%%%!SCB@# MQVTLM4OOC!XOATG4H["X:V4>8\'F`@A!CJ,?6NA^%NKH;&\\,2V*6E_HTACG M$9)64DG+Y/.20<_6G6W@SQ%8>,M2\26>JZ:)K]=DD,ML[*JC&,$,#G@5L^'O M"C>'_P"TKY;E+O6=1D\VXN)$VH6[*%'11GUK:4DU;T,(1DI7]3GO%][%JOC6 MSTB73KW4+#3H&N+N*TA\P^;(I6,,,CH,G\157X/:G+;PZIX5O$EBGTZ8R0QS M+M<1,>A';!Y_X%76^%O#]]HMSJMSJ%U;W5QJ-Q]H>6*,H1Q@)@D\`=*SM1\% MW[?$&+Q7I5_;V\GDB*>"6-F$PQ@Y(/IC\A1S1MRARROSF)\;PQT#1PA`?^T4 MVDC(!VFI?A]K(L->U+P_X@B$/B624RM=.<_;4_A*D]@.BCC'XUL>._!^H>,; M6PMH[ZVM$M91.2T;.6<#&.HXJ?Q/X*C\6:=;-=S+::Q:G=;WUJ"#&WISR1[9 MH4H\BBP<9<[DCHM3_P"05>?]<'_]!->1_"^V\3R>`VET74K.*(74F();;[AM8WD5Y))$+'Y3D``$5KZ':7>GZ/;65[)#+);QK$'A4@,%` M`)![\4VUR)$I/G;//_B__P`?WA'_`+"0_FM>H]ZXOQMX.U#Q7>Z7+!?6UK%I M\WGH'B9F=N.#R..*ZS_3/L/)@^U[>H!\O=_/%$FG%((IJ39YM\%?^/#Q#_V$ MF_E7H^I?\@N\_P"N#_\`H)K@?#?@7Q3X36\73=>TUUNY?.D6>S8X;VPU==!I MNIQ>&'L9;Z*XU&1'#W+H0A9R"?%OA+27TW3-?TQH&_FM(+HBQE:&57C`.]>J MCGG%1VOB[2;KPZNNB26*Q=ML;21D,[9V@*HY))X`KC?"%FMW!XHG&L7MHJZG M$]2MXI+F/2-1-Q>6\8)?9O;YMO4D9SCWK M;D5S#VDK'I"^+;%-1MK&]MKW3Y;H[;Z3% M./MUEM,T)X.&`(8>HYKC_&5U9>,=-T[3-$N$O+J6]AF#Q<^0BG+.Q_AXXYYY MJI/H0U[Q-XAO=)O5M->L+J-K2X4\,/)4%''\2$@@^AI(I#I6L>X+Z@XR/6M[7O'$=SI6FRZ# M>1FZN+N*&:SEAW2*K'YLH>05_*CD707M'U.QU?58-$TNXU&Z25K>W4O)Y2[B M%'4XJG!XGL[FYLK:""[DENX!M5?'S!/`&MAFR3:.H_VB M1@#ZFN3\*W\OARRBTW5'!M=4@$EIJX7C>4`\J4]BO0'I@8I1BG&XY3:E8["; MQ=8HMQ);VE_>V]LQ2:XM8-Z*5^\`'_"R:)K4JV.H:>SI)%*"#*"Q(=/[X(/;-8=IHL=MX M9T>QUJW5+?4M=DG^R3<;(75\`CMV/L2*?(KBYW8]-U#6K?3;NQMYHIW:]E\J M%HTW+NP3@G/'`)_"JT_B:TCOY[*UMKR_GM\"<6D6X1$C(#,2!G';.:XZ&PUK M0_$N@:%=^9?:3%>F6POCRT:B)QY4GN,\'N!4WA*_C\+W&MZ+KLWV&YEOI;JW MNIAA+A'Z,&/!(QR#2Y%;0?.[ZZ';Z3JT&LV1NH(YXE#M&T<\91U93@@@U7MO M$5C=Z_=:+$)_MEJH>8-$0JJ>AS[UF^`M5U#6O#[W^HLID>YE5-L7E@HK8#>^ M1SFL&RUG3=,^+/B:6]O8;>-K2W57D;`)4<@'U'I2Y=6A\^B9V,OB&QA\10Z$ MXG^W31F5%$1VE!U.[IQ4]GJ]E?:A?6%O,&N;%U2>/&"I90P/N,&N.N;VVF^, M&BS)*NQ](DQN..68$`^A([5B7$EW;>*KG7]`VW$]UJ$FF7** M?2GR)B]HU]YZ$OB?3)(-5FBDDE32I#'=&-"=I"[CCUP.OT-1)XKT^73K*^@A MOIX;U2T/DVK.Q4?Q$`9`Y'6N&T!;/3M'^(%A%.I2)G"L6Y?]S@M[Y;/XUU_@ M*:+_`(5YHS>8F([-0YS]T@<@^E$HI!&;9+IGC72M8,)LH[Z2.:1HDE-HX3>, MY&XC`/!HL?&FF:E=M;VT-^S)<&UD3EAGD M`N2":PO!=[;0ZQK3-KS6Q?792MDH4BX#'`P,;CG/4''%-P5WY"YW9>9V9\<: M,LMZK_;%2RD\JZE-J^R%O]HXX'?-=#%+'/"DT,BR1.H9'4Y#`]"#7F^BZ[I5 MC=^.!6X<9!&1V&2/3@9XI!KVCB M/S1J%L$)`W!Q@D]/SQ6'86>HV/A>/19-(,T\,;Q^>KIL;@X<9.=QSTQW-90T M36O[!T^Q6SNQ/#);.\LDD1\KR^H09Y`Z\UBZD^QUJC3>[Z]U]YV']NZ-$1B_ MM5\P!AM8?-GITZ]#2+K^C;'==0M@J`%CN`P"<`GZFN;CT;4;?1-,LO[-)N+7 M4DGGDC==LJABQD&3WST[4FOZ+J5W=:[]DL'*74%M'"RL@!*/N;J>.M'M)VO8 M%1I-VO\`EW.H&O:26P-0M\[2V-_.!U/X4W^V]&VB?[=:X8A1)N')(X`/O7.W M^BZB-1$L4%Q=JVG7,32R%`WF2$%5/(Z8QFJT>E:O%INDP'3[N5[2XMII3++& M2H1<%4P>@ZC/K2]I/L"HTFD[_D=K'>VD]JUS'/%)`N=SJP(&.N?I55=>T9H# M(NH6IBRH)#C&6Z?GVJAI^FW<-QKE_)`8OM^#%:A@2-J;=QQQN8_TK#A\(W2> M%[:00.=6B2V1H7=0-L3[MJD<<\\FJFJ:=/-#$EW!)).I:)0P)=1U(]:YK6M-U+4E^U16,Z&2]MY/ M+#H)$2/.6SG&>>!572=)U?2KW3)7TQY8K6.Z0"-TW`2."F[D`MPM+VDKV ML-4:;A>^OR['7_VOIVR=C>0;8'V2DN/D;T/O[5);W=IJ,3-!)'.BMM;OM/H0 M>AYKC5T75VU)]1:P.(M4^V?9FD7]ZAC"9!SC-:Z<\-Q,0 MD>2N\Y`!<\XXYXSG@4XS;W1$Z4%9)E\ZC9)9B[-U"+;H)-XVDYQ@?C5:8_."*1DI_>^GO6##::A;:_6PB$",F^$AF//.,-G)QWZU3TG0]3\/SZ?,;4WBI926[K"ZYC8R;U'S M$94`XS[4^>78/94[;G30:GI5WO6"YMI=B>8X4@X3^]CT]ZA&OZ$HVB_M`&[! MAALC/X\5@MX;OS(DENIM]0L[.)+:ZR#&[#=OC8=2IR!T]^U6)-,OE7PQBP+& MS??=!"OR_NRO<\\G\J7//L'LJ719(FSAEZ<'!_6N2AT:YDT?4[>\TV;]_J+SI MY$;+5-+GCN4DUB[A$"2B=Y2?ER03D@`GU[U?)I-RG4M*Q[`;B!6D4S1@Q#=(-PR@]3Z"HH-1L;F01V]Y;S.R;PLF:X[PS!=VUYHE MVD&MD?V5"L8M8$1GQ+EE&1R@!!/Z$@`DG`'4FHK:[MKV`3 MVMQ%/$>DD3AE/XBN!\?:]=F]C\.D2V-K>1%FN4PSRKN"[.HV*2P!;.:Y.PUV M^L;FTMO#-^MH+ZXCBAL6LAY$:G*[L%RP.4.3W[T*DVKA*JD['MIFB6983(@E M8%E0L-Q`ZD"FFZMUNEM3/$+AEWB(N-Y7U`ZXKB/&5M?-/#=>?=>=8_O+>:VL MURC,NQOG9PO?."/3K69=:X+;X@6%ZUEJ-]P&X^@SU-.=UC1GD8(BC+,QP`/Y#D9'(J**ZMY_,\F>*3RF*R;'!V$=0?0UP?B%G MM;/PW/80W,'VMHX9(4FD?RHMA/`5QDC@9KA85F73M96(R,L^L^3.'6159&90 MQ\C.,C-0+>6KS)"MS"TKJ65`X+,`<$@=QFN'\? M/:Z-H<306I,MLB1)++`TJ>6QV[=_9AG(R>H'K7!7$^F:7;QW&A7%S;"5#903 M,75[.(./,GDX.5./>O/-:D%O; M>$+'0M0NI["YFD@WP7?S3Q["<>8?<=:Y;2-1T>74)K.^6]TGP[]@D>2T6[D= M'=9BI9F7G!YSTR:2IW5QNK9V/;00P!4@@C(([U'#=6]R9!!/%*8V*.$<-M8= MCCH:Y26^M++P3%JUE=7VCZ=9V[$6[Q+O('"J1(">O`^MI#,_/#LG/!'.<4*%T-U+,]9:1$(#.JD]`3C-$Y+JM.UCVE65U#(P93R"#D&D9T3&YE7)`&3C) M]*XCPAJ$&A?"+3]08$K%:&0*"271F>,;A(44>RDXQWJ>35E>TT1ZK1BN5Y4@=JYMOL5Q?Z=:VC:`'N9?N?;Y9&E0#+!<8P<<@FA1N-SL>BHZ2+N1E M9>F5.13JXKX5PI#X'BV`C?%'.,J2/7-0P1#3_&=J9TNK91J$BR@1F(2,2K0QDJ M2%)(SC/0>]>\S:?:SWUO>RP*US;AEAD/5`PPV/K@5#+H>ES6*V4MC"ULL@E$ M97@.#D-]<]ZT5;2UC-T-;W.&\5PK8>.M*6W=HQJ%O<"[)NO*\T#&`78'`&3@ M51TC2;+4?B';:?=1I-8V&FB:VMC=+<1QN),`C``&,#BO2;G2=/O+Z"]N;2*: MY@5EBD=MS@_%L4F MK>)M6TZ\N-D%KHDD\$5NQ!D#'Y@Y^JKTZC\:Y/38-&NI-!O;_5K'RELX8$CL M]1=;A9V=!DC.1QD''%>X&V@,YG,,9F*>69"HW%>N,^GM5*+P[HD%P+B+1[!) M@=PD6W0,#ZYQ352RL)TFWTV%'BMC+)>,I+C+QJ2.K-W8UZI?:38:FT#7UI%M"J65@=*\KGG7Q$U7[+K.I0M#I M3F+38IXOMEN)&=C+MVC)YXYZ&N@)(^*VE*2N[^PWSM&!_K%Z5TUWHFEW\LLM MW80322QB*1I$!+(#D*?;/-2G3;(ZDFHFW3[8D1@6;'S!"<[?IFESJUA\CO<\ MU\=7?V/Q9J\JW[VDJ^'B8]@!\QM[84Y!X_*N,N)+DQ/F&ZN[B* M(;L#J,GM7O[M;LVL?GVBLD# M@8,:L`"!]0!51JI+8F5%MWN?Z5Y MO;:)=Z[X:UX:=9O=+)JI`:'R&&-R9P0,].?E.*]W(!!!&1Z56T_3++2;8VVG MVL5M"79RD:X!8G)-3&I9%2I([R2VU&*UAT[39F.(HU5IW'R0],.0HS@Y(R*]9O],LM4A6 M&_M8KB-'$BK(N0&!R#4#Z#I4FG'3Y-/@>T9Q(T3)D,^<[CGJ<]Z<:EE84J5W MR36L-Q:/:RQJT$B&-HST*D8(_*J MTFBZ9-ID.FRV,,EC"$$<#KE5V_=X/IBE&=ARIW.3\9?:!!X1^RB(W/\`:$?E MB7.TMY38!QSBN!T^":EAMH+8.((DC$CEWV*!N8]2?4TU4LK"E2N[ MW.-TR_\`#6F>!;+5)M3DO],M'$BW#C=LGQZ5I\-F;..RMTMF;>85C`4MG.2/KS M5O8NS9M&S&,8XI&5%>-U*NK#(8'J#24[#<+G(?"U@_@2V=3E6GG(([@RMS795#:6 MEM86D5K:0)!;Q+MCCC&%4>@%35,G=W*BK)(****10X=**!THH`0]:2E/6DH` M****`"BBCK0!RT]U>:3J&H7JW4][9VUHSSQ2,`#,#D*G'&%SD>XJ>+Q.TDYL MI+`I?-,(HXO.!5LQ^9G=CCY?;K1<:3X4L%G>Y6S@#JRRF6XQD-RV7*7UO$)@SB6X,@D40.Q8#)[]O:MDR>%K31A8&YM M$TZ=&<1F<[77=AN<],G!^M:ATK3YHK0&!72VY@RQ(7C'KSQQS3YD%K]3''B] M%EMX);)TN+M(I+5/,!$BR'`R5)RTP41&-@ MKT6RJPC> M)6!)(5_O=>#GOG-+W>P_>[D'B&_N;9;&TL\B>^G\H.I`*J%+-@GC)"X'UK+E MGEOM&MIM)NKRVN?.\J.!WSAU?$AD)SN``/.R7 M)5DXX(.01ZU#?Z!X>2#[1>VL*0V\1&YG*JB=3GGIGD^O>A-+0&F]2JLE]:>+ M$%\TKVUXSK:>3/\`NUPN<-'@W6M^WETC^TMR7D4EVT:M&K3`E4;IL'8'';KBIKG3M,^TS7MS'&)9(3 M%)([D9CQR",XQ0GKJ*VFC,>YU7^P[JYBB6YNHX+6!U62<$-OD*YR1G/KSBB; MQ@;>)A)ISBX22:-X_-&W,8!(5LBV0O!+;RVL(A62XN4DN9(G&[`\W#SGM5VXL;":_M;F=$-U% MGR&+D$9ZX&:5TF.S:.?M/$LEEH]N)B-1FAL%O+F>-PH,9)&1Q\QX/IT]ZGE\ M8V\-U+$UNQ41J\3+("7)<(`1_#DL.IZ=<5>7P_H9E<)9P[E)WHK'`R<=*:?#N@2W$V;*W:64,)%W'D,TSQ'#';SFR$M_O\^[!>8\0HV,`MW[`?G4\_B^7[/=W%IIGFP0> M2%D>8)O,H4KQC(X?]*UVT71[@%/LL!V,^X1G&"QRP.#T/<'@U6G@\.(VHP3F MU0L$:\1I,8`&5)&>.%XQZ47CV%:7YL]?OX;BU8PW.H)!O\[=Y3F%6P M`>HX/(QUZ4_Q$+M_$,,%H]V9)+"9DCAF*#S`RA6/..,G_P"O6E9:9H%ZBW=D ML,Z^:LPDCF+C>%P&Z]<'\JT'TVTDU"._>'-U$I1)-QR%/48SBBZ3&D['.Q^* M)/[-C6XA>O2MAM#TQI)9#9INEW;^3CYN&(&<`GN1UJ/_A'-(QC[$N/W?\`&W\' MW._;M1>(6EW#1=5FU2"66:V2W59Y(HP)=Q?8Q4GIQTK-NI[N#QN4MX9[F,V` MD,(GVJK;R-V"<9P,5IC0=/2[BN(X?+>.9IP%/!=@03[=3P.M6/[,L_[1.H>3 M_I93RS+N.=OIUQBE=7'9V.6T/6YK6U>!H9[F]DGNI!'+/G9'$^,;CGID``5= MB\8">:,PV#M:,;<&8R`,/.'R_+CL>O-::^'-(6/8MDH7>S\.V>X[T MY_#^ER.SFS3(CJ]\T$=BZ1!"YE+@[<,5VL M.S9!./2L.&[D?Q+J.F75Q=PVS5ENG$DX+-\[#H>O7@?E1>*86 MDT9C>*XH4#+9R-;,TT4$GF,BENSS::\1MK#AANSM/?:,BM6Z\+:/>7US>36KFXN559F6>1=X`P.`P'2K%IHE ME86<-I:BXC@A0)&@NI<*HZ#[U:RFG&QE&FU*YXGJL=QJ4OG&!YDDL9Y(&BMP MK3XE4;BJ@X)*Y.<';J.".:P M8K`&$6+F5=@8Y(&&[GFK8\,:2NDG2A;R?8"AC,'VB3;M/48W42FI)(4*;BVS MS&!XKOQ(ENFKB-_[5OVDNXMH8)Y*993T!."`>U=YXEN2WPZO;NTO9XQ]@,D< MP(WL-G&3ZGCI5VY\':!>645G<:3R6&I:,XO$@GL1&+2"VF6/855G42@<=\\ MDUZ%XYM9+S0S;P:?]KED(4L45A'&2/,))(Q\N6W2I+GP[IUY)YDXNF;;M_X_ M)AQZF!TXJC\1I+N' MQ(SK$[(+']T?,4CF1`V5QG;S@#N23VKO[;PAHEG);R6]M-&UN"(<7:C%XI,URT-S<7FI3VLT+1_O;6)`3&RMGA,` M=L'?78Z;X;TC1[A[BQLUBF==K/O9CCTY)K2\J,2&0(N\C!;')'IFDYW;' M2.(TAO#Q\:23:7>6Z2Q0202I&^7N'W!F=_4+CJ>Y-.\)V<5EXDO3:75OJ=K= M0?:#?K&HD5RY_=LZ_>!Y([C%=HMO"C;DBC4^JJ!2QPQ1+MCC1%SG"C`S20`0U==<^%M#O+YKVXTR"2Y<@O(1RV.F?7\:L6.B:9IMQ=7 M%G9Q0RW;;IV0??//7\S^=7*HG&QG&DU/F.7\+MH$GB>\GT6YMP&MQ"8(6R92 MK9:5_?)P">3S7G/C""];Q/K4\EM,8!V:]Y2"*,D MQQ(A/4JH%9]UX=TJ]GGFN+7>]P5,Q$C@/M!`R`<'@D?C2C4Y7<P*B GRAPHIC 11 img001.jpg begin 644 img001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W6_G>WL+J M>,_/'$S*/<#-\G_H M)JOX<7'AS3_^N"_RH`S_`.Q/$/\`T-US_P"`=O\`_$4?V)XA_P"ANN?_``#M M_P#XBNEQ1B@#FO[$\0_]#=<_^`=O_P#$4?V)XA_Z&ZY_\`[?_P"(KI<48H`Y MK^Q/$/\`T-US_P"`=O\`_$4?V)XA_P"ANN?_``#M_P#XBNEQ1B@#FO[$\0_] M#=<_^`=O_P#$4?V)XA_Z&ZY_\`[?_P"(KI<48H`YK^Q/$/\`T-US_P"`=O\` M_$4?V)XA_P"ANN?_``#M_P#XBNDP**3=@.;_`+$\0Y_Y&ZY([_Z'!_\`$4?V M)XA`_P"1NN3CN;.W_P#B*V[R26*VF>WC\R94)2/.-Q]*X6?QGX@M_%5AX?DT MZR%S=PF4/N;">Q]ZUITI5-(]`>B-[^QO$&1GQ=]C>U MC)#R=E(Z@T.C.,5)BOK>+Y(O$,?A[1[47>IE=\NXX2!?5JF% M.8;J)OW9]N>E2V/B72=2G>&TO5DE0%MN,;@."1Z_A0XR6NX7L5/[#\1 M?]#=<_\`@';_`/Q%+_8?B'_H;KG_`,`[?_XBD'C?P\Q/_$UB`$GEDD$!6]#Z M5:A\3Z1.MV8KY'^R#=.`.4'KCTH<)VNXBN5O[#\0_P#0W7/_`(!V_P#\12?V M'XB_Z&ZY_P#`.W_^(J:R\8Z%J,\4%KJ,I9W-]''<. M0`I]3T!/04O9SO:S&4_[#\1?]#=<_P#@';__`!%']A^(?^ANN?\`P#M__B*L M:AXKT?2KW['?7R0W)7>(R"25]:;<^+=$L[.TNYM1C6WNVVP28R'/I1RST?+N M*Y#_`&'XB_Z&ZY_\`[?_`.(I?[#\0_\`0W7/_@';_P#Q%:MOJMK(?^ANN?\`P#M__B*/[$\0_P#0W7/_`(!V_P#\ M1728HQ3`YO\`L3Q#_P!#=<_^`=O_`/$4?V)XA_Z&ZY_\`[?_`.(KI<48H`YK M^Q/$/_0W7/\`X!V__P`11_8GB'_H;KG_`,`[?_XBNEQ1B@#FO[$\0_\`0W7/ M_@';_P#Q%']B>(?^ANN?_`.W_P#B*Z7%&*`.:_L3Q#_T-US_`.`=O_\`$4'1 M/$6/^1NN<_\`7G;_`/Q%=+BD(S0!R8&MZ5KVE17.O27T%U(\;QR6T2=%)SE5 M!KK1TKG]<_Y#_AX?]/$G_HLUT`Z4`4]7_P"0+?\`_7O)_P"@FH/#O_(N:?\` M]<%_E4^K_P#(%O\`_KWD_P#034'AW_D7-/\`^N"_RH`TZ***`"BBB@`HHHH` M****`"FTZBDU<"(_>Q@^OUKRW6'G;XR:9J2V5TUG;PM#+*(B0&/2O5Z*UHU/ M9MNU[JP/56/-/B-%+/K_`(<9+.:>*")[2UM)X; MF6]-Q'$5*B107LL*+<_:`1R M!T`K+N]+O_#/Q*N?$GV26\TR_C$F\4<"H6)FIRD_M*S]!V.4 MU&XG\3>'-3M=,@FC:2W9$EE4IEO3![5Q>@:9>W&N^'&BL9;,:-:LEX[*1N/] MU?7UKU_@TM3#$>SBXI?UL#5SY\N].NI=%UV%=(N#+,-?N?L$T-K/I@1&>(A17KU5=1LUU#3YK21W5)5*L4ZXKH^OWCR./\` M6G^0N4\,\.V-QJVE^$K.PLG62TOI)IIPN!LR?XN_TJQXUL-0OMM?#&EC3K.262W#%E$AR5SUK1>)HII_'EC>'3IYH4TQHF<0DC>1P.E&D>'O[4^$!TN]A-O?0,\D"SC:P<'< M,9KUP_C6-K7AZTUN:RFN7E#6LGF)L;&3Z'VK+ZZW!02M9K\`Y2IX.M[U?#]K M/JJK_:$D:B4J,9`X%=*.E1HH5`H`51P![5+BN2I)SDY%!1114@%%%%`!1110 M`4444`%%%%`'/Z[_`,C!X>_Z^)/_`$6:Z"N?UW_D8/#W_7Q)_P"BS704`4]7 M_P"0+?\`_7O)_P"@FH/#O_(N:?\`]<%_E4VKH]ZJ_P!D::QR=/M#]85_PJ]10!1_L?3/^@=9 M_P#?A?\`"C^Q],_Z!UG_`-^%_P`*O44`4?['TS_H'6?_`'X7_"C^Q],_Z!UG M_P!^%_PJ]10!1_L?3/\`H'6?_?A?\*/['TS_`*!UG_WX7_"KU%`%'^Q],_Z! MUG_WX7_"C^Q],_Z!UG_WX7_"KU%`%'^Q],_Z!UG_`-^%_P`*/['TS_H'6?\` MWX7_``J]10!1_L?3/^@=9_\`?A?\*/['TS_H'6?_`'X7_"KU%`%'^Q],_P"@ M=9_]^%_PH_L?3/\`H'6?_?A?\*O44`4?['TS_H'6?_?A?\*/['TS_H'6?_?A M?\*O44`4?['TS_H'6?\`WX7_``K"UK3;"+6=#5+"U"M<-NQ"H_A^E=77/ZY_ MR'="_P"OAO\`T&@"GX8TRPDM;PR6%JQ%TX&85/&?I6]_8^F9_P"0;9_]^%_P MK-\*?\>U]_U]/_.M\4`4O['TS_H'6?\`WX7_``H_L?3/^@=9_P#?A?\`"KU% M`%'^Q],_Z!UG_P!^%_PH_L?3/^@=9_\`?A?\*O44`4?['TS_`*!UG_WX7_"C M^Q],_P"@=9_]^%_PJ]10!1_L?3/^@=9_]^%_PH_L?3/^@=9_]^%_PJ]10!1_ ML?3/^@=9_P#?A?\`"C^Q],_Z!UG_`-^%_P`*O44`4?['TS_H'6?_`'X7_"C^ MQ],_Z!UG_P!^%_PJ]10!1_L?3/\`H'6?_?A?\*/['TS_`*!UG_WX7_"KU%`% M'^Q],_Z!UG_WX7_"@Z/IF.-.M/\`ORO^%7J*`*<6FV5O('M[.VB<=&2(*1^5 M6QTI:*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N?UW M_D.:%_U\-_Z#705R^I7$EYXRTVPCM9/]%SZM\>:N`I/ M0$G%4(K;Q3)$C_VC9?,H/^K-`'2T5SOV/Q3_`-!&R_[]FC['XI_Z"-E_W[-` M'145SOV/Q3_T$;+_`+]FC['XI_Z"-E_W[-`'145SOV/Q3_T$;+_OV:/L?BG_ M`*"-E_W[-`'145SOV/Q3_P!!&R_[]FC['XI_Z"-E_P!^S0!T5%<[]C\4_P#0 M1LO^_9H^Q^*?^@C9?]^S0!T5%<[]C\4?]!*R_P"_9H^Q^*?^@C9?]^S0!T5% M<[]C\4_]!&R_[]FC['XI_P"@C9?]^S0!T1Z5SGB;S;)(-9MD9Y;0XDC0 MU+]C\4_]!&R_[]FD-EXH;(.HV6,?\\S2`F\.6T@LWOKA2+B]8R/NZJ.P_*MM M>N.<#M7/?8O%/_02LA_VS-'V/Q3_`-!*R_[]FF!T=%<[]C\4_P#01LO^_9H^ MQ^*?^@C9?]^S0!T5%<[]C\4_]!&R_P"_9H^Q^*?^@C9?]^S0!T5%<[]C\4_] M!&R_[]FC['XI_P"@C9?]^S0!T5%<[]C\4_\`01LO^_9H^Q^*?^@C9?\`?LT` M=%17._8_%/\`T$;+_OV:/L?BG_H(V7_?LT`=%17._8_%/_01LO\`OV:/L?BG M_H(V7_?LT`=%29KGOL?BG_H(V7_?LTGV+Q3_`-!.R_[]F@#H\T5@>'[Z_N+O M4K/47BDDLY5021C`8,N:WAU/'TH`6BBB@`I"*6CM0!@^+Q_Q35Q_O)_Z$*V+ ML/^X/Y4`2T4=J*`"BBB@`H MHHH`****`"D-+0:3V`8QQD@9QVKDHOB!IS>*$\/3P3V]Z^=OF#Y3]#76DX[@ M"O)/B#:"]BGUW2Y$FO\`2+M9@(SEBH'(XKIPE.$Y\M3^F)WZ':>)/'-AX8O; M6TNX9I9;G`C$8SR>`#[UO"]7RXC,Z0/(`1&[`-]!7COCF]$__"(7UP1'=W-Y M'/+&3RBG&"?05!\4-5C?5=1-I=2RSP)$PYP(ADVW$.N2/F3'4^M7+5;K6_&>IQWVI/I]Q;R1RVV_AO+XX7USW M%.6`2;GS:!S,]J0DCFG5'#_JER(_P#KXC_]%BNA%<]H'_(Q>(_^OB/_`-`%=%0`4444`%': MBCM0!@^+_P#D6KC_`'D_]"%;-O\`\>L/^X/Y5C>+_P#D6KC_`'D_]"%;-O\` M\>L/^X/Y4`2]J*.U%`!1110`4444`%%%%`!1110`TJ,'C/MZU5CL+2,/Y5I" MGF??*H!N]CZU-%',UU`J-IUDP17LX&$?$8,8.WZ>E/:SMFG$YMXC*!@2;!NQZ9JQ13 MYF!3&F6*R22"SMPTHQ(1&/G'H?6A=.L5@:W6R@6!N3&(P%/X5),_\` M/Q%_Z`*Z(=365HVAPZ/]H:.:2:2Y@#E=1=3XZL%#` ME;.3(!Y'7K5OP@Z-X>B".&Q))G!Y'S&JCPV^C>,)+V:(!;V$_OF/W2O51Z<" MIO"6GK;V=Q?+&4-[,95CSPHZ#'UZT/34#I1THI!G`R.:,^U`"T444`%%%%`! M1129]J`%HI,TM`!1110`4444`%%%%`!12$^U&:`%HHHH`*1N!2T=J`,7Q1<3 MVN@7,D$ICD^50XZC)Q5.+PW<-"CG7;XDJ#VJQXO_`.1:N/\`>3_T(5LV_P#Q MZP_[@_E0!A?\(Q&](-].I?Y MPB*.['@9/84U>4N5`51X9FSC^W;[/X4?\(Q/_P!!V^_2BQUC4IY8X[JPC4R0 MF6.:%]T61_"36?X6\?V>N6\@O?*LKE;AH%B+_?(]*I49N^FP7-'_`(1B?'_( M=OOTH_X1B?\`Z#M]^8K1N=8L+.ZCMKBZ2*>096,GG\:K3>*]#@GEAFU.W26+ MAU+R"Y7_`.$8G_Z#M]^8I/\`A&I@ M/0KZYKGM2\?6]CXATNS1(IM.OT9Q>!N$Q3C1G+:(7-3_`(1B?_H.WWYBC_A& M9_\`H.WWZ5IQZO836'V^.[B:TQD2AOEP*K/XET6.U6[DU"%86;:'+8&?2DJ< MF[),+HR-2\#IJML+>[U:^DCW;L9`*D=ZM1^%I8T54UN]"H,`<<#%:MEJ^GZI MY@L;J./K:]U+4K'4U MALI+.X\@$M\LA[8IJE.=W%;;BNC2_P"$8G_Z#E]^8H_X1F?_`*#E]^8K1O\` M6=.TP(;V[C@#]-S=O6FW>N:78I`]S>P1K/S$S-P_T-2H3ELGJ.Z,\^&9_P#H M.WWZ4'PS..NNWWZ5H6VMZ;=VDMU!>PO!"2)7SPI]ZJQ^)],O7>"QO8Y[E4+" M(=Z:IS?V0N0_\(Q/_P!!V^_2E_X1F?/_`"';[\Q6?X6\=V>NVI-V8K.Z\]H! M"S\LP..*W)O$6D6\UQ!-?1)+;KF5">4'J:&FNH]0UB MQGNY+E+69%B9_O`%,G-=(#US7/:!_P`C%XC_`.OB/_T`5T5`!1110`4=J*.U M`&#XO_Y%JX_WD_\`0A6S;_\`'K#_`+@_E6-XO_Y%JX_WD_\`0A6S;_\`'K#_ M`+@_E0!+VHH[44`%%%%`"5SOC(%]&$+:=]O@F<)-#WVGJ?PKHZ8ZE@`#CWIQ MERNZ!GEGAG1I=&\4,NA75_)X?:W8W,-R#B)NP3/6N-M]/N4L[,G3;D2KK1E8 M^2'3+Z)# M;2P*2,CL3U6L37M-_P")OXJ6'3+AT>RCBMG\@EI"`.AQUKW818!`/!ZT[8<_ M>.*4,?./3I8.4\<\1-/=>%O#^BQ6XAC2[N?(),48QN4\=:;K=O;OK_AL6 M.F7(TVT@D0CR#TQ@$C'>O9-A/4YS1L.20>:<<&1Z3J\_PK>W MM+2X62#43+)#M*LT>[/`[\5:\1:19+X44Z7:7L\MU>122K+">",9P.W%>T"- M@^XMQV%+L&,4_P"T&I\U@Y3S/P'$T/CK7I1:306\L<9B+1E%;CGK4WQ`T?4' M\0Z'XEL+=KM=.8B>!>H0]6'J:]&,>1\QY_E2&/)SGZ'TK%XI^U]I;I8:1CV& MOVVH.B6D-P^?F8O$4"#WSU->+ZO97,]KXG*:=^)S/W<#?"T/]FW#31J59 M_+8K`V,'*]ZZ3X417%MX6DM[J*6.5+ASMD0KP2>1[5WGEY')/7/6CRSNR6S[ M5G5QCJ4_9VZW&D/'(I:!P**XR@HHHH`****`.=T#_D8O$?\`U\1_^@"NBKG= M`_Y&+Q'_`-?$?_H`KHJ`"BBB@`H-%(?UH`PO%_\`R+5Q_O)_Z$*V+?\`X]8? M]P?RJIK.G'5=+FLUD\IVP5?T(YK(32/$Z1JHU^,X7'^I%`'4#I17,_V3XG_Z M#T?_`'X'^%']D^)_^@]'_P!^!_A0!TU%C_[\#_"BP'2T5S7 M]D^)_P#H/1_]^!_A1_9/B?\`Z#T?_?@?X46`Z6BN:_LGQ/\`]!Z/_OP/\*/[ M)\3_`/0>C_[\#_"BP'2T5S7]D^)_^@]'_P!^!_A1_9/B?_H/1_\`?@?X4P.E MI#UKF_[)\3_]!Z/_`+\#_"C^R?$__0>C_P"_`_PI-7`Z6BN:_LGQ/_T'H_\` MOP/\*/[)\3_]!Z/_`+\#_"G8#I:,US7]D^)_^@]'_P!^!_A1_9/B?_H/1_\` M?@?X4K,#I@Z/ EX-101.INS 12 abtbi-20141031.xml 0001385799 2013-11-01 2014-10-31 0001385799 2013-10-31 0001385799 2012-10-31 0001385799 us-gaap:ManufacturingFacilityMember 2013-10-31 0001385799 us-gaap:TransportationEquipmentMember 2013-10-31 0001385799 us-gaap:OfficeEquipmentMember 2013-10-31 0001385799 us-gaap:BuildingImprovementsMember 2013-10-31 0001385799 abtbi:StockholderMember 2014-10-31 0001385799 abtbi:TwoRelatedPartiesMember 2014-10-31 0001385799 2014-10-31 0001385799 abtbi:TwoDirectorsMember 2014-10-31 0001385799 abtbi:StockholderMember 2013-10-31 0001385799 abtbi:TwoRelatedPartiesMember 2013-10-31 0001385799 abtbi:TwoDirectorsMember 2013-10-31 0001385799 us-gaap:CommonStockMember 2012-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2012-10-31 0001385799 abtbi:DeferredStockCompensationMember 2012-10-31 0001385799 us-gaap:RetainedEarningsMember 2012-10-31 0001385799 abtbi:AccumulatedOtherComprehensiveLossMember 2012-10-31 0001385799 us-gaap:CommonStockMember 2012-11-01 2013-10-31 0001385799 us-gaap:CommonStockMember 2013-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2012-11-01 2013-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2013-10-31 0001385799 abtbi:DeferredStockCompensationMember 2012-11-01 2013-10-31 0001385799 abtbi:DeferredStockCompensationMember 2013-10-31 0001385799 us-gaap:RetainedEarningsMember 2013-10-31 0001385799 abtbi:AccumulatedOtherComprehensiveLossMember 2012-11-01 2013-10-31 0001385799 abtbi:AccumulatedOtherComprehensiveLossMember 2013-10-31 0001385799 2012-11-01 2013-10-31 0001385799 us-gaap:CommonStockMember 2014-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2013-11-01 2014-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2014-10-31 0001385799 abtbi:DeferredStockCompensationMember 2013-11-01 2014-10-31 0001385799 abtbi:DeferredStockCompensationMember 2014-10-31 0001385799 us-gaap:RetainedEarningsMember 2014-10-31 0001385799 abtbi:AccumulatedOtherComprehensiveLossMember 2013-11-01 2014-10-31 0001385799 abtbi:AccumulatedOtherComprehensiveLossMember 2014-10-31 0001385799 2014-08-01 2014-10-31 0001385799 2013-08-01 2013-10-31 0001385799 2015-01-29 0001385799 2014-04-30 0001385799 abtbi:USMember abtbi:RateForBalanceSheetItemsMember 2014-10-31 0001385799 abtbi:HKMember abtbi:RateForBalanceSheetItemsMember 2014-10-31 0001385799 abtbi:CNMember abtbi:RateForBalanceSheetItemsMember 2014-10-31 0001385799 abtbi:USMember abtbi:RateForTransactionsOccuringThroughoutTheYearMember 2014-10-31 0001385799 abtbi:HKMember abtbi:RateForTransactionsOccuringThroughoutTheYearMember 2014-10-31 0001385799 abtbi:CNMember abtbi:RateForTransactionsOccuringThroughoutTheYearMember 2014-10-31 0001385799 abtbi:USMember abtbi:RateForBalanceSheetItemsMember 2013-10-31 0001385799 abtbi:HKMember abtbi:RateForBalanceSheetItemsMember 2013-10-31 0001385799 abtbi:CNMember abtbi:RateForBalanceSheetItemsMember 2013-10-31 0001385799 abtbi:USMember abtbi:RateForTransactionsOccuringThroughoutTheYearMember 2013-10-31 0001385799 abtbi:HKMember abtbi:RateForTransactionsOccuringThroughoutTheYearMember 2013-10-31 0001385799 abtbi:CNMember abtbi:RateForTransactionsOccuringThroughoutTheYearMember 2013-10-31 0001385799 abtbi:ComputerSoftwareMember 2014-10-31 0001385799 us-gaap:ManufacturingFacilityMember 2014-10-31 0001385799 us-gaap:TransportationEquipmentMember 2014-10-31 0001385799 us-gaap:OfficeEquipmentMember 2014-10-31 0001385799 abtbi:ComputerSoftwareMember 2013-10-31 0001385799 us-gaap:BuildingImprovementsMember 2014-10-31 0001385799 abtbi:CNMember 2014-10-31 0001385799 abtbi:USMember 2014-10-31 0001385799 abtbi:CNMember 2013-10-31 0001385799 abtbi:USMember 2013-10-31 0001385799 us-gaap:GeneralAndAdministrativeExpenseMember abtbi:ChiefOfficeDentalMember 2013-11-01 2014-10-31 0001385799 us-gaap:GeneralAndAdministrativeExpenseMember abtbi:ChiefOfficeDentalMember 2012-11-01 2013-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares abtbi:HK iso4217:CNY xbrli:pure Advanced Biomedical Technologies Inc. 0001385799 10-K 2014-10-31 false --10-31 No No Yes Smaller Reporting Company FY 2014 0.00001 0.00001 100000000 100000000 3131638 3956150 2266916 2988738 349911 459131 455574 402510 59237 105771 197193 217614 1140 16238 126568 108254 69485 93122 21105 18768 569 569 1907889 1927968 -270552 -266966 197193 217614 56874850 56874850 56874850 56874850 48380 74354 56874850 8436210 -2934445 -2226195 -3738536 566 1671956 -1667 -3682008 -215042 569 1907889 -4572351 -270552 569 1927968 -5400107 -266966 -210002 -171599 -8667 -11231 -20079 -22936 181393 137502 137 70 -617754 -718744 617754 718744 47700 30749 26640 26201 543414 661794 -827756 -890343 -827756 -890343 0 0 -827756 -890343 3586 -55510 3586 -55510 -55510 3586 -824170 -945853 -0.01 -0.02 56874850 56578138 56574850 56874850 56874850 300000 3 212997 213000 1667 1667 20079 22936 22936 20079 -20079 -22936 0 -214667 -26640 -26201 2270 978 46346 20592 -732421 -604969 -23802 -7604 15009 -562 8793 8166 782228 611184 724435 591492 -51460 -62450 109253 82142 48380 49092 74354 25974 -712 -31 677 <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; font: 8pt Times New Roman, Times, Serif; text-align: right">(A)  </td> <td style="font: 8pt Times New Roman, Times, Serif">Organization</td></tr> </table>   Advanced Biomedical Technologies, Inc. (fka Geostar Mineral Corporation or Geostar) (ABMT) was incorporated in Nevada on September 12, 2006 .   Shenzhen Changhua Biomedical Engineering Co., Ltd. (Shenzhen Changhua) was incorporated in the Peoples Republic of China (PRC) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (CFDA, formerly known as SFDA) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, is considered a Development Stage Company.   Masterise Holdings Limited (Masterise) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhuas 70% majority stockholder and 37% by a third party corporation.   On January 29, 2008, Masterise entered into a Share Purchase Agreement (the Agreement) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.   On December 31, 2008, ABMT consummated a Share Exchange Agreement (the Exchange Agreement) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.   Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the Affiliate Agreement) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMTs common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.   On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.   On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.   The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (the accounting acquirer) and a re-organization by ABMT (the accounting acquiree). The financial statements have been prepared as if the re-organization had occurred retroactively.   Accordingly, these financial statements include the following:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 8%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; font: 8pt Times New Roman, Times, Serif">(1)</td> <td style="width: 82%; font: 8pt Times New Roman, Times, Serif">The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 8%"> </td> <td style="width: 10%">(2)</td> <td style="width: 82%">The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.</td></tr> </table>   ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (the Company).     <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(B)  </td> <td>Principles of consolidation</td></tr> </table>   The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders 30% proportionate share of the results of Shenzhen Changhua.   All significant inter-company balances and transactions have been eliminated in consolidation.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(C)  </td> <td>Use of estimates</td></tr> </table>   The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(D)  </td> <td>Cash and cash equivalents</td></tr> </table>   For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2014 and 2013, all the cash and cash equivalents were denominated in United States Dollars (US$), Hong Kong Dollars (HK$) and Renminbi (RMB) and were placed with banks in the United States of America, Hong Kong and PRC.  Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(E)  </td> <td>Property and equipment</td></tr> </table>   Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.   Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(F)  </td> <td>Long-lived assets</td></tr> </table>   The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) Accounting for Impairment or Disposal of Long-Lived Assets.  In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an assets carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2014 and 2013, the Company has not recognized any allowances for impairment.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(G)  </td> <td>Fair value of financial instruments</td></tr> </table>   FASB Codification Topic 825(ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(H)  </td> <td>Income taxes</td></tr> </table>   The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (ASC 740-10-25). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.   We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(I)  </td> <td>Research and development</td></tr> </table>   Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2014 and 2013 were $47,700 and $30,749 respectively.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(J)  </td> <td>Foreign currency translation</td></tr> </table>   The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.   Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.   The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year.  All exchange differences are recorded within equity.   The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="width: 56%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 21%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2014</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 21%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2013</td></tr> <tr style="background-color: #CCEEFF"> <td>Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end</td> <td> </td> <td style="text-align: center">US$1=HK$7.7551=RMB6.1124</td> <td> </td> <td style="text-align: center">US$1=HK$7.7530=RMB6.0943</td></tr> <tr style="background-color: white"> <td>Amounts included in the statements of operations and cash flows for the year</td> <td> </td> <td style="text-align: center">US$1=HK$7.7543=RMB6.1498</td> <td> </td> <td style="text-align: center">US$1=HK$7.7561=RMB6.1717</td></tr> </table>   The translation (gain)/loss recorded for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.   No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.   The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in Chinas political and economic conditions. Any significant revaluation of RMB may materially affect the Companys financial condition in terms of US$ reporting.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(K)  </td> <td>Other comprehensive loss</td></tr> </table>   The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders deficit. Other comprehensive (gain)/loss for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(L)  </td> <td>Loss per share</td></tr> </table>   Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There were no potentially dilutive securities for 2014 and 2013.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(M)  </td> <td>Segments</td></tr> </table>   The Company operates in only one segment, thereafter segment disclosure is not presented.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(N)  </td> <td>Recent Accounting Pronouncements</td></tr> </table>   On June 10, 2014, FASB issued a new accounting standard that reduces disclosure and reporting requirements for development stage entities. Among other things, development stage entities will no longer be required to report inception-to-date information. The change will be effective for interim and annual reporting periods beginning after December 15, 2014, with early adoption permitted. The Company has elected to early adopt these amendments.   In August 2014, FASB issued Accounting Standards Update (ASU)  No. 2014-15 Preparation of Financial Statements Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entitys  Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entitys liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entitys liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial StatementsLiquidation Basis of Accounting. Even when an entitys liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entitys ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure.   The following is a summary of property and equipment at October 31, 2014 and 2013:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">October 31,</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2014</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2013</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%">Plant and machinery</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">272,214</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">266,931</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Motor vehicles</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">45,105</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">45,239</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Office equipment</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">34,523</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">31,824</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Computer software</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5,017</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5,017</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Office improvements</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">131,439</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">131,829</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">488,298</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">480,840</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">380,044</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">354,272</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3pt">Property and equipment, net</td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">108,254</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">126,568</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td></tr> </table>   Depreciation expense for the year ended October 31, 2014 and 2013 was $26,640 and $26,201 respectively. Other payables and accrued expenses at October 31, 2014 and 2013 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">October 31,</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2014</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2013</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%">Other payables</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">929</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">790</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Accrued expenses</td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">104,842</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,447</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">105,771</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">59,237</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td></tr> </table>     As of October 31, 2014 and 2013, the Company owed $459,131 and $349,911 respectively to a stockholder which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.   As of October 31, 2014 and 2013, the Company owed $2,988,738 and $2,266,916 to two related parties which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.   Total interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2014 and 2013 were $181,393 and $137,502 respectively.   As of October 31, 2014 and 2013, the Company owed $402,510 and $455,574 respectively to two directors for advances made. These advances were made on an unsecured basis, repayable on demand and interest free.   Imputed interest on the amounts owed to two directors are $20,079 and $22,936 for the years ended October 31, 2014, and 2013 respectively.   For the years ended October 31, 2014 and 2013, the Company issued restricted common stock as directors services compensation for past services nil shares and 300,000 shares valued at $0 and $213,000 respectively. Please refer to Item 11 for details of directors emoluments.   Common stock   On December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Companys chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on the date of grant yielding an aggregate fair value of $20,000. In this respect, the Company recognized $0 and $1,667 for the year ended October 31, 2014 and 2013 respectively as consultancy fees included in general and administrative expenses.   On October 28, 2013, the Company issued 150,000 shares of restricted common stock as directors services compensation for past services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71 per share on the date of grant, yielding an aggregate fair value of $213,000.   For the years ended October 31, 2014 and 2013 the Company recognized $0 and $214,667 respectively as consultancy fees included in general and administrative expenses.     <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; font: 8pt Times New Roman, Times, Serif; text-align: right">(A)  </td> <td style="font: 8pt Times New Roman, Times, Serif">Employee benefits</td></tr> </table>   The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $74,189 and $68,711 for the years ended October 31, 2014 and 2013 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; font: 8pt Times New Roman, Times, Serif; text-align: right">(B)  </td> <td style="font: 8pt Times New Roman, Times, Serif">Lease commitments</td></tr> </table>   The Company leased from third parties office space and an apartment for a director at monthly rent prevailing at October 31, 2014 of $2,348 and $1,309 (2013: $2,243 and $1,313) respectively. Both of these operating leases expired on July 20, 2014 and June 30, 2014 respectively. The Company continues to lease these premises at same monthly rent pending a formal renewal of these leases.   The Company also leases eight apartments (2013: seven apartments) and one canteen (2013: one canteen) for staff under three operating leases (2013: two leases) from a third party at monthly rental totaling $965 (2013: $766), all of which will expire in April 2015, June 2015 and July 2015 respectively.   As of October 31, 2014, the Company had outstanding commitments with respect to the above operating lease, which are due as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 89%">2015</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">8,151</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3pt">Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8,151</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 75px; text-align: right">(C)  </td> <td>Capital commitments</td></tr> </table>   As of October 31, 2014, outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and equipment totaled $16,238 (2013: $1,140).   ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2014 and 2013. ABMT has net operating loss carry forwards for income taxes amounting to approximately $1,512,723 and $1,423,563 as of October 31, 2014 and 2013 respectively which may be available to reduce future years taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Companys limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2014 and 2013 was $514,326 and $484,011 respectively. The net change in the valuation allowance for 2014 was an increase of $30,315.   Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.   Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been charged at 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.   As at October 31, 2014, 91% and 9% of the Companys assets were located in the P.R.C. and the United States respectively.   As at October 31, 2013, 96% and 4% of the Companys assets were located in the P.R.C. and the United States respectively. As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $5,400,107 as of October 31, 2014 that includes a net loss of $827,756 for the year ended October 31, 2014. The Companys total current liabilities exceed its total current assets by $3,863,028 and the Company used cash in operations of $732,421. These factors raise substantial doubt about its ability to continue as a going concern.  In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Companys ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.   To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year. The Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial statements were issued and has determined that there were no subsequent events or transactions which would require recognition or disclosure in the financial statements other than stated below:   On November 10, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB250,000 (equivalent to approximately $41,000).   On November 28, 2014, the Company received cash advance from a related party, Chi Fung Yu, amounted to RMB250,000 (equivalent to approximately $41,000).   On December 12, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB300,000 (equivalent to approximately $49,000).   On January 20, 2015, the Company received cash advance from a related party, Chi Fung Yu,, amounted to RMB250,000 (equivalent to approximately $41,000). Advanced Biomedical Technologies, Inc. (fka Geostar Mineral Corporation or Geostar) (ABMT) was incorporated in Nevada on September 12, 2006 .   Shenzhen Changhua Biomedical Engineering Co., Ltd. (Shenzhen Changhua) was incorporated in the Peoples Republic of China (PRC) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (CFDA, formerly known as SFDA) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, is considered a Development Stage Company.   Masterise Holdings Limited (Masterise) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhuas 70% majority stockholder and 37% by a third party corporation.   On January 29, 2008, Masterise entered into a Share Purchase Agreement (the Agreement) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.   On December 31, 2008, ABMT consummated a Share Exchange Agreement (the Exchange Agreement) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.   Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the Affiliate Agreement) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMTs common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.   On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.   On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.   The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (the accounting acquirer) and a re-organization by ABMT (the accounting acquiree). The financial statements have been prepared as if the re-organization had occurred retroactively.   Accordingly, these financial statements include the following:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 8%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 10%; font: 8pt Times New Roman, Times, Serif">(1)</td> <td style="width: 82%; font: 8pt Times New Roman, Times, Serif">The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 8%"> </td> <td style="width: 10%">(2)</td> <td style="width: 82%">The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.</td></tr> </table>   ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (the Company). The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders 30% proportionate share of the results of Shenzhen Changhua.   All significant inter-company balances and transactions have been eliminated in consolidation. The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2014 and 2013, all the cash and cash equivalents were denominated in United States Dollars (US$), Hong Kong Dollars (HK$) and Renminbi (RMB) and were placed with banks in the United States of America, Hong Kong and PRC.  Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government. Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.   Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years. The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) Accounting for Impairment or Disposal of Long-Lived Assets.  In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an assets carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2014 and 2013, the Company has not recognized any allowances for impairment. FASB Codification Topic 825(ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements. The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (ASC 740-10-25). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.   We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2014 and 2013 were $47,700 and $30,749 respectively. The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.   Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.   The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year.  All exchange differences are recorded within equity.   The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="width: 56%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 21%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2014</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 21%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2013</td></tr> <tr style="background-color: #CCEEFF"> <td>Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end</td> <td> </td> <td style="text-align: center">US$1=HK$7.7551=RMB6.1124</td> <td> </td> <td style="text-align: center">US$1=HK$7.7530=RMB6.0943</td></tr> <tr style="background-color: white"> <td>Amounts included in the statements of operations and cash flows for the year</td> <td> </td> <td style="text-align: center">US$1=HK$7.7543=RMB6.1498</td> <td> </td> <td style="text-align: center">US$1=HK$7.7561=RMB6.1717</td></tr> </table>   The translation (gain)/loss recorded for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.   No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.   The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in Chinas political and economic conditions. Any significant revaluation of RMB may materially affect the Companys financial condition in terms of US$ reporting. The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders deficit. Other comprehensive (gain)/loss for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.   Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There were no potentially dilutive securities for 2014 and 2013. The Company operates in only one segment, thereafter segment disclosure is not presented. On June 10, 2014, FASB issued a new accounting standard that reduces disclosure and reporting requirements for development stage entities. Among other things, development stage entities will no longer be required to report inception-to-date information. The change will be effective for interim and annual reporting periods beginning after December 15, 2014, with early adoption permitted. The Company has elected to early adopt these amendments.   In August 2014, FASB issued Accounting Standards Update (ASU)  No. 2014-15 Preparation of Financial Statements Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entitys  Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entitys liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entitys liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial StatementsLiquidation Basis of Accounting. Even when an entitys liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entitys ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="width: 56%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 21%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2014</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 21%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2013</td></tr> <tr style="background-color: #CCEEFF"> <td>Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end</td> <td> </td> <td style="text-align: center">US$1=HK$7.7551=RMB6.1124</td> <td> </td> <td style="text-align: center">US$1=HK$7.7530=RMB6.0943</td></tr> <tr style="background-color: white"> <td>Amounts included in the statements of operations and cash flows for the year</td> <td> </td> <td style="text-align: center">US$1=HK$7.7543=RMB6.1498</td> <td> </td> <td style="text-align: center">US$1=HK$7.7561=RMB6.1717</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">October 31,</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2014</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2013</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%">Plant and machinery</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">272,214</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">266,931</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Motor vehicles</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">45,105</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">45,239</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Office equipment</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">34,523</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">31,824</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Computer software</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5,017</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">5,017</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Office improvements</td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">131,439</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">131,829</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">488,298</td> <td nowrap="nowrap"> </td> <td style="text-align: right"> </td> <td> </td> <td style="text-align: right">480,840</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">380,044</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">354,272</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3pt">Property and equipment, net</td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">108,254</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">126,568</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">October 31,</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2014</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2013</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%">Other payables</td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">929</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%; text-align: right"> </td> <td style="width: 1%">$</td> <td style="width: 8%; text-align: right">790</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Accrued expenses</td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">104,842</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,447</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">105,771</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt; text-align: right"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">59,237</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 89%">2015</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">8,151</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3pt">Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8,151</td> <td nowrap="nowrap" style="padding-bottom: 3pt"> </td></tr> </table>   1.0000 7.7551 6.1124 1.0000 7.7543 6.1498 1.0000 7.7530 6.0943 1.0000 7.7561 6.1717 480840 266931 45239 31824 131829 488298 5017 272214 45105 34523 5017 131439 354272 380044 59237 105771 58447 104842 790 929 459131 2988738 402510 349911 2266916 455574 181393 137502 181393 137502 20079 22936 8151 8151 1423563 1512723 0 0 484011 514326 30315 .91 .09 .96 .04 0 214667 0 1667 -4572351 -5400107 EX-101.SCH 13 abtbi-20141031.xsd 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. OTHER PAYABLES AND ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. INCOME TAX link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. CONCENTRATIONS AND RISKS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 2. PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 3. OTHER PAYABLES AND ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 6. COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 2. PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 3. OTHER PAYABLES AND ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 4. RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 5. STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 6. COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 7. INCOME TAX (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 8. CONCENTRATIONS AND RISKS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 10. GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 abtbi-20141031_cal.xml EX-101.DEF 15 abtbi-20141031_def.xml EX-101.LAB 16 abtbi-20141031_lab.xml US Geographical [Axis] Rate For Balance sheet items Investment [Axis] Rate For Transactions Occuring Throughout The Year Plant and machinery Property, Plant and Equipment, Type [Axis] Motor vehicles Office equipment Office improvements Construction in progress Stockholder Related Party [Axis] Two Related Parties Two Directors Common Stock Equity Components [Axis] Shares to be issued Stock subscription receivable Additional Paid-In Capital Deferred stock compensation Accumulated deficit Accumulated Other Comprehensive Loss Non-controlling Interest US HK RMB Computer software General and administrative Income Statement Location [Axis] Dr. John Lynch StockIssuedForServices Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Other receivables and prepaid expenses Total Current Assets PROPERTY AND EQUIPMENT, NET DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Other payables and accrued expenses Due to directors Due to a stockholder Due to related parties Total Current Liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' DEFICIT Common stock, $0.00001 par value, 100,000,000 shares authorized, 56,874,850 shares issued and outstanding as of October 31, 2014 and October 31, 2013 Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Condensed Consolidated Balance Sheets Parenthetical Common Stock Shares Par Value Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Outstanding Income Statement [Abstract] OPERATING EXPENSES General and administrative expenses Depreciation Research and development Total Operating Expenses LOSS FROM OPERATIONS OTHER EXPENSES Interest income Interest paid to a stockholder and related parties Imputed interest Others, net Total Other Expenses, net LOSS FROM OPERATIONS BEFORE TAXES Income tax expense NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS OTHER COMPREHENSIVE INCOME (LOSS) Foreign currency translation income/(loss) COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS Net loss per share-basic and diluted Weighted average number of shares outstanding during the year - basic and diluted Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Stock issued to founders for cash, Shares Stock issued to founders for cash, Amount Amortisation for stock issued for services Distributed to the stockholders Contributed capital Stock issued for cash in private placement ($1.15 per share) , Shares Stock issued for cash in private placement ($1.15 per share), Amount Stock issued for services, Shares Stock issued for services, Amount Recapitalization, Shares Recapitalization, Amount Imputed interest on advances from directors Net loss for the year Foreign currency translation gain (loss) Ending Balance, Shares Ending Balance, Amount Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock issued for services Imputed interest Changes in operating assets and liabilities Decrease in Other receivables and prepaid expenses Increase in Other payables and accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (Increase) decrease in deposit for purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Stock issued to founders Proceeds from issuance of shares Contribution by stockholders Distributed to stockholders Due to a stockholder Due to directors Due to related parties Net cash provided by financing activities EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR CASH AND CASH EQUIVALENTS AT END OF YEAR Accounting Policies [Abstract] 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION Property, Plant and Equipment [Abstract] 2. PROPERTY AND EQUIPMENT Payables and Accruals [Abstract] 3. OTHER PAYABLES AND ACCRUED EXPENSES Notes to Financial Statements 4. RELATED PARTY TRANSACTIONS 5. STOCKHOLDERS DEFICIT 6. COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] 7. INCOME TAX Risks and Uncertainties [Abstract] 8. CONCENTRATIONS AND RISKS 9. GOING CONCERN Subsequent Events [Abstract] 10. SUBSEQUENT EVENT Organization Principles of consolidation Use of estimates Cash and cash equivalents Property and equipment Long-lived assets Fair value of financial instruments Government Grant Income taxes Research and development Foreign currency translation Other comprehensive loss Loss per share Segments Recent Accounting Pronouncements Exchange rates used in translation Property and equipment Other payables and accrued expenses Rate For Transactions Occuring Throughout The Year Operating lease outstanding commitments Investment Type [Axis] Exchange rate Gross Value of property plant and equipment Less: accumulated depreciation and amortization Total property and equipment, net Other payables Accrued expenses Total Related party debt Imputed interest on advances from two directors Interest expenses on advances from stockholder and related parties Consultancy fees Share based compensation Commitments And Contingencies Details 2015 Total Income Tax Details Narrative Net operating loss carry forwards Expiration for carry forwards begins Deferred tax asset valuation allowance Deferred tax asset Net change in the valuation allowance Percent of assets located in country Going Concern Details Narrative Current liabilities exceeding current assets Cash used in operations DueToDirector Due to directors IncreaseDecreaseDueToDirectors Interest expense on advances InterestExpenseToStockholderAndRelatedParties Interest owed to directors and related company Rate For Transactions Occuring Throughout The Year Stockholder StockIssuedForServices Stock subscription receivable Two Related Parties Stock subscription receivable Three Directors Two Directors Unsecured debt owed to related party InterestExpenseToStockholderAndRelatedParties Custom Element. Rate For Balance sheet items Rate For Transactions Occuring Throughout The Year Recapitalization, Amount Recapitalization, Shares Shares to be issued StockIssuedForServices Stock issued to founders for cash, Amount Stock issued to founders for cash, Shares Stock subscription receivable Stockholder Two Directors Two Related Parties Government Grant Exchange rates used in translation Total Income Tax Details Narrative USMember Assets, Current Assets Liabilities, Current Retained Earnings (Accumulated Deficit) Stockholders' Equity Attributable to Parent Liabilities and Equity Income (Loss) from Continuing Operations Attributable to Parent InterestExpenseToStockholderAndRelatedParties Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Issued DepreciationCashflow StockIssuedForServices [Default Label] Amortization of Debt Discount (Premium) Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Other Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Stock Issued During Period, Value, Other IncreaseDecreaseDueToStockholder IncreaseDecreaseDueToDirectors IncreaseDecreaseDueToRelatedParties Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] CommitmentsAndContingenciesTablesAbstract Operating Leases, Future Minimum Payments Due EX-101.PRE 17 abtbi-20141031_pre.xml EXCEL 18 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`F`F&2W0$``(T4```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%UOVC`4AN\G[3]$OIV( ML5EI-Q%ZP;K+%6G=#_#L`XEP;,MV6_CW.PD?FBH*0D/:N2&"V.=]\,6CY)W< MKUM;O$!,C7<5$^60%>"T-XU;5NS7T_?!'2M25LXHZQU4;`.)W4\_?I@\;0*D M`G>[5+$ZY_"5\Z1K:%4J?0"'=Q8^MBKCU[CD0>F56@*7P^&8:^\RN#S(W0PV MG7R#A7JVN7A8X\];D@@VL6*V7=AE54R%8!NM,I+R%V?>I`QV"27N[->DN@GI M$V(P?C2AN_-^P&[?(QY-;`P4BZY5A',SQRQEKHZP-^SSW!H9?6LQG[FRH=PF'LJ M'TNC>?0A87T6X7*`?3_6[1X$'`0Q-W!HR(XU38=$K-XN#WQ3=4%7[ADP1[)Y M7R9._P```/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL: MNI3\(V(T'4\4"_'L M)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1? M````__\#`%!+`P04``8`"````"$`:9FV=.`!``!F$P``&@`(`7AL+U]R96QS M+W=OS&YX5@4.K2EQ;^@%68DA$<"+; M??#WM2@X16JWEV@O2-Z(S6AV/&-GL?H\U,F[MJYJ3"9@,!2)-GE35&:7B=?- MT]U,),XK4ZBZ,3H31^W$:GE[LWC6M?+A3ZZL6I>$+L9EHO2^O9?2Y:4^*#=H M6FW"DVUC#\J'I=W)5N5[M=,2A\.)M#][B.55SV1=9,*N"TA%LCFVX=7_-V^V MVRK7CTW^=M#&__(.^='8O2NU]J&ILCOM,Q%+3IZ>0#H(F(7\`T[@@Q?.C(*# M$V8X.*'@<,^*'!4"-S=`>&,Z?@<*<"&0K'^OJ?=SIP$9!L"-!D@XV&LV15UTXXFEBU3HDR?W)0') M2P)PYP&0>0#<>0!D'J2]NIX/-U_=Z>:TE*=?TNNXK8YT.N[YD.,!;FJ`Y`9[ M38%H*YUB8NGB-.3)$[FO+$A>65)NITE)I^&VX>C"\NKKV/(+``#__P,`4$L# M!!0`!@`(````(0#K4U9*7@,``!(*```/````>&PO=V]R:V)O;VLN>&ULE)9? M4ZI0%,7?[\S]#@SO-_ZI99,V"*=B4O`"UNWI#,DQSX3@`&9]^[N!I`V44T]Z M0-99>^W?V7)Q^;J)A!>69CR)1Z)R(HL"BY=)R..GD;CPK_Z]?%_LD?7Y,DFQ9XT*ZVTYV/(*[ M0TW61&E<%SE/A9"M@EV4^U#>01WR4GNJ.BA^641QQ]D^^WBH6`JO]SP.DWWQ M4XCVK5YI8&!?WKKG8;Z&^[(LU]=N&']:YX>+("\A_3)!V*?\%.*RO$,B%#I% M29SS_(U:<94^3Z"%1>H65*:(0GK.X4MJA4IA'*L8CFT2VR,FA6^>,[5,W8?% M1)_JMD&0BHI4U)^I@(':C(9DRKR_8<;SP=,,F^DAE=XG9CX*>7_6]CWJ7%'/ M=Y`7R+X.IO^)RF?!O.OAD@9(I@0#EZ10;S&;Z>Y#N;UU;5M7EJ';/M4-PUD@ M,QINTVG;C4KGKC,GKO]`==NDY._"FL^([6,!W*&SMH!&'?^&N'2N/^B3*?%* M&?#@+J#;.%H-=VC8ENE1ETQ+0N9Z8<9W==O3#=\">+`7W"!%;JOTBT88MS?. MU"2N1TT"F5B-6G!KE`ZT`X!U-K/\(H&J$H#7M^QK8AM6HQC<&Z6#[2FU;%`B MU-?_8?>GJ*-*A]*SXJ@8L+6KEW674;J6=]M(`(9H#9?2871(KQWP6RFY-MY\ MB!_L8*G(`-3$`P#``"5W309Z,'`^=OTAC)CI'J91Z>!XG&H`L3[O/4RETL'R M*ZZI'SQ&#.M@+)4.E\?Q;E2&T80!W9J'Q]%J"&%&U0ZCQR.":NJ(5!P1+%J. MOHS(9'G`L0Z.2.U@>SPBW#.U$5&'W6,S@)K84".A#LJM*5#,-)@H95511K$. M/L75?R\>L<=;UB@,'VRU0S4>![4/.TA3>-=XP3"J^'##HM6QKP=$H8H+PV== M[4`-9[TQ)9J>D(Z&CSTLP(]4)@2O#,L@6L*[3/%1O@ST^H,*5NGP.C?^#P`` M__\#`%!+`P04``8`"````"$`?M;_W)\$``"6$```&````'AL+W=O MEX[39"=6ILVEVD+C_71:*X;.66:5S9:6-93;/## M(<_8,\\N):M:-%*S(FV!OSGEY^9FK)YMK-9=0'ZGK-KH_QM-2=^_:/.]W_E%8-H0YY$!G:=T=LO70;^KJT].Z27HOV'7_]D^?'40KI#\$@XMMQ_/+,F@XB"F;D7"DL9 M+P``?EIE+DH#(I*^=[^O^;X]K6T_FH?4]0G(K1UKVI=;\0'^GX>ANZ_["!(Y]=SVJ:;5A)6U#54.KS>0EK=-&*V<-XADUDNV8PG1%X&VQ0&P/:!YQKJ?*.@@T4@@0--)A!CRJRP<2K/(AI)@@$V4`6WA MX)&%A7AM@U>#Q^%B\`<71DF$F0K\@`2Z(%$%441H+`4:&)3*](@(L0$6Z^MN M44([,"^*`E>?3_1YSY4UI&%%CV`)L8X5&VA5D_&O3XR>WVON06.N*Z2M#YR:.:6>DK"6`97 MQS,:_L3R&W?^2"[0;PZUM<\6'G0SF;X>4Y?$KA_("M4Q'SH`R/@$4+9?CX<: MW+MR;_9@GT_J2$;SGQBY\2E`9>7T:&J7_TGD=,F]R!E'P41,;.>P"X9O#BH[ M0X^)&J7S$F5$CY71]"="8"=7-RJ5]=%#H`8KW0\7HQ)3YV=A&!*9:PW1,TZ' M:8C=6_HI0$W>' MV,R=*Y]@N!E&`ED(.IIHUTH7%A$45X]?(&*3UY)L)'$+-T#Q&8!)#B/X[%F$ M,HT]I:X)*9QWLG,B*%X#\;I4LOK($E84C97QB[CB>1"!872X?CYUMT]C?`O7 MTNX.YPP3<"L\IT?V+:V/>=58!3N`27=.(0`UWBOQH>7G[I*VXRW<@/G#>WA[$Q6GXC\+F?P```/__`P!02P,$%``&``@````A`,:R53PR M`@``^@0``!D```!X;"]W;W)K&ULE)3;CML@$(;O M*_4=$/=K[)S7BKW:*$J[4BM550_7!.,8Q8`%Y/3V'2!QL\UVM7N3F/#/-_// M3#Q_.,H6[;FQ0JL"9TF*$5=,5T)M"OSSQ^INAI%U5%6TU8H7^,0M?B@_?I@? MM-G:AG.'@*!L@1OGNIP0RQHNJ4UTQQ7-Z.R%)ME;<)*:[:Z[8UIV@%B+5KA3 M@&(D6?ZT4=K0=0N^C]F(L@L['&[P4C"CK:Y=`C@2"[WU?$_N"9#*>27`@6\[ M,KPN\&.6+T:8E//0GU^"'^S5,[*-/GPRHOHB%(=FPYC\`-9:;[WTJ?(_03"Y MB5Z%`7PSJ.(UW;7NNSY\YF+3.)CV&`QY7WEU6G++H*&`209C3V*ZA0+@$TGA M-P,:0H_A^R`JUQ1X.$G&TW28@1RMN74KX9$8L9UU6OZ.HNR,BI#!&0+?9T@& MCZ\'DUA(\+6DCI9SHP\(=@52V8[ZS7].QNJVKR`L9*W60T MB6)*H!$ZETV9T3^_'V^^4&(=;W)>ZP8RN@-+[^:?/\TVVCS;"L`19&AL1BOG MVBEC5E2@N(UT"PUF"FT4=[@T);.M`9YWFU3-TC@>,\5E0P/#U%S#H8M""GC0 M8JV@<8'$0,T=ZK>5;.V!38EKZ!0WS^OV1FC5(L5*UM+M.E)*E)@^E8TV?%5C MW=MDR,6!NUM)]/EB++Y MK//GKX2-/?I-;*4W7XW,O\L&T&QLDV_`2NMG#WW*?0@WLXO=CUT#?AJ20\'7 MM?NE-]]`EI7#;H^P(%_7--\]@!5H*-)$:2=#Z!H%X"=1TD\&&L*WW?=&YJ[* MZ&`N". MSV=&;PC."AYE6^XG+YDBX:&@<'Q?XGL5HBI/L[C$)*>(Y0'A.X#R>HU8W;'&M\T^2/%@+\4[YK4M0@"Y7[6=G?L&8M)# M3I2@0]",(OGKP9-!SQO$!B?`L'.-D? MV^0WG8L;G@I8!,RPMW)Y%#BQ!6?W>EL\^/SDT=G)`?.V+2$7;$DN30EW-\RX M`E/"$NK:$J'7_EZFZ&8?[9^,^]37>!9?X%/273S6)_`JM[R$']R4LK&DA@(I MXVB"DDQX#,+"Z;:[62OM\!)W/RM\LP'',8X07&CM#@L_[/V_P/P_````__\# M`%!+`P04``8`"````"$`>N64SWX#``!+"P``&0```'AL+W=O.08(=5S6[:<'C\^KS'!SB+^Y>ZLIXQXX0VJ>U-7-O"34%+TNQ2 M^]?/Q[N9;7&!FA)5M,&I_8JY?;_\^&%QI.R)[S$6%B@T/+7W0K1SQ^'%'M>( M3VB+&[BSI:Q&`B[9SN$MPZCL%M65X[MNY-2(-+92F+/W:-#MEA0XH\6AQHU0 M(@Q72$#^?$]:WJO5Q7OD:L2>#NU=0>L6)#:D(N*U$[6MNIA_V364H4T%OE^\ M*2IZ[>[B2KXF!:.<;L4$Y!R5Z+7GQ$D<4%HN2@(.9-DMAK>I_>#-<\^UG>6B M*]!O@H]\\-OB>WK\Q$CYE308J@WG)$]@0^F31+^4,@2+G:O5C]T)?&=6B;?H M4(D?]/@9D]U>P'&'X$@:FY>O&>8%5!1D)GXHE0I:00+PUZJ);`VH"'KI_A]) M*?:I'423,'8##W!K@[EX)%+2MHH#%[3^HR#O)*5$_),(K#B)>!!Z>[&C$NE\ M94B@Y8+1HP7-`EOQ%LG6\^8@V!M2VY\M_LLA6),B#U(EM:'+(7D.Q_*\]*/I MPGF&4A8G9C7&A#JS[AE9.2F<]8&+L*!7&0ZN%2HZY&58I0#;^8% M26!8T(`@#EU?!S(-&%'(-4!7T#S"$_3^II.PZ6VF9[92S*6Z:S.0F8%\$-!R MBV[)3<)F;D9GK!2CZCX-$R\P'LWU$`BF2>(90#8$QA3R(6`H:-[B6[Q)V/`6 MNT;=%3.HNQG(S$`^"&BYR6__X`W[]A,K82.WR*R[8DY/;#*;Q8'1-6N-\*,H M\"&XG>TD=U5 M]4_0J>U=/_2,WEGK1!B&L?$IS'1B1$,.,;)0_<.E:2B':D91W_(:LQU>XZKB M5D$/&ULE%1=;]L@%'V?M/^`>*^Q':>.HSA5DZI;I4V:IGT\ M$XQC5&,L($W[[W>!QHN3KLI>$@/GGGO.O1<6-\^R14]<&Z&Z$B=1C!'OF*I$ MMRWQSQ_W5S.,C*5=15O5\1*_<(-OEA\_+/9*/YJ&K101\JMP7!Y"SZWC?@FT85K^FNM=_5_C,7 MV\9"MZ=@R/F:5R]WW#`H*-!$J9?!5`L"X!=)X28#"D*?_?]>5+8I\>0ZFN;Q M)`$XVG!C[X6CQ(CMC%7R=P`E3M1`DKZ23$#]ZSELO1],@A#OZXY:NEQHM4
V8%+ M#%1#9KB=)YD#)O-%*])B?+H^/LV+O[$C3=G_:'+@4TW)..LJ8'*O*8FS69:. M`>MCP'269?]H$XSPY<5RX+&PV4G:58`<=$WS_$0XW'3'$0#3(IV'> MB>'Y7OX!``#__P,`4$L#!!0`!@`(````(0"40&0X:0,``#L+```9````>&PO M=V]R:W-H965TS^_<=,VS`)$J3%Q+,F>,SQ\,P\_NWLK!>62.YJ!8V MF;BVQ:I49+S:+NS?OY[N8MN2BE89+43%%O8[D_;]\O.G^4$T+W+'F+*`H9(+ M>Z=4/7,Y82>5$U*R")[EH2JK@MMDZLFX8S=J@LG`\UXVLD>1[DM6*21I6$$5Z)<[7LL/MC*]AJZDSDME6F ML^=M)1JZ*2#O-Q+0](.[O3FA+WG:""ER-0$Z!X6>YIPXB0-,RWG&(0-MN]6P M?&$_D-F:!+:SG+<&_>'L(`?_+;D3AR\-S[[QBH';<$[Z!#9"O&CHJZ'+>B(,%Q0);R9KJTB,S(-0)^6#+^80@$QWSH(/:4$!+ M.(77I1J@A0W77F3D'OG;1%:( MB=H4@CCVDM@$K$V`&P<]@Z$0K+M=H0X:*R2F@!5BIJU"/W;=(#`!:P,0!M[4 M.P(,A8&I\/(!:_!86<^+WB$&E1$W]L*Q,@/@16'4FVLH@\H?>G=9F0:;RDC< M\Z(RQ+1MH%U8#Q:,G2-SY^N*7P>9"KR3ND(,>@,GXI&Q-P8@BA*_/W=#X=14 M>-D;#3:5D:2O5_0&,0-O!@O&SOJ3=7-CT$&F@E-O$(/>!"%QPV.]XF&9SSV_ M;RR&OL34=]D9#39UD:1W')U!S,"9P8*Q,X'^>+LU;92IX=2;#M2][D'H^2-S M3`")O;ZP3(VCOG[9'H*M>-@K23)^WSO0P*#ABKF[;ILW%P_!9CM4<<8A!*%# MH4OZ+P963T=RYKFI<-2P_^//::AH5@1!0W\&*^;NHV9\7>.!P69'4<>Y?_````__\#`%!+`P04 M``8`"````"$`H<;KC34#``"E"@``&0```'AL+W=OW.!0!H$5"U5=RMMI=5J+\\F<8C5)(YL4]J_ MW['-Q78I!1Z`.&?.G#F>3#R]>6V;X(5P05DW0TD8HX!T!2MIMYJA/[\?KJY1 M("3N2MRPCLS0&Q'H9O[URW3#^+.H"9$!,'1BAFHI^TD4B:(F+18AZTD'=RK& M6RSADJ\BT7."2QW4-M$@CL=1BVF'#,.$G\/!JHH6Y)X5ZY9TTI!PTF`)^D5- M>[%C:XMSZ%K,G]?]5<':'BB6M*'R39.BH"TFCZN.<;QLH.[7),7%CEM?O*-O M:<&98)4,@2XR0M_7G$=Y!$SS:4FA`F5[P$DU0[?)9)$,432?:H/^4K(1UO]` MU&SSC=/R!^T(N`W[I'9@R=BS@CZ6:@F"HW?1#WH'?O*@)!5>-_(7VWPG=%5+ MV.X15*0*FY1O]T04X"C0A(.18BI8`P+@.VBI:@UP!+_JWPTM93U#PW$XRN)A M`O!@281\H(H2!<5:2-;^,Z!D2V5(!EN2(:C?WH>ET\&1$:+KNL<2SZ><;0)H M%D@E>JQ:+YD`H2HH_;`@J$3%W*H@'0IH`;OP,A^,DFGT`LX56\S=$8R+6!Q! M9'M(!/KV(J$\6^1QMW?B%'B&X-L2-]CSZ@+N#";5MJJ*%M:"DQDL.3^S`ON9 MAUYF@TFU:9YEB^/W'#VIJT=MUQ"Z^+0C*LC7E7JZ#,9RQ%IP%$!SG.^(`ON9 M?4<,YK@CQ^\Y>L:7Z%%@7\_(<\)@+">L!2=S=DEF!?8S^TX8C'$B"[/1*,X/ MG\.CH5MXX8.'L?4Y=):C6+V&O(?]\^Y10;[RL>>9P5B>60N.@MQ5<+IO%=C/ M['MF,`?/TL'!LMSWS`>//_`I@4?*-NJT3(WV=7JI[[8@RR)[Q?$H\6;R)]G- M&'7GG>^2IH3)KL?..$R207JT6TQK>>@X=TP][+VK6HW0BYLK,8/757_M==<6 M9'MGPO2*J^*B@0U'A<\[;`O:>Y?FF=5BN:M5G3X4Y1Z=)9GE]&'J&M7FH&%> MR#U>D2?,5[0304,JF.PQS``4<'/,,!>2]?K%NV02C@?Z;PW'00+OL#@$<,68 MW%VH@\S^@#G_#P``__\#`%!+`P04``8`"````"$`4OMR(L<"``!^!P``&0`` M`'AL+W=O[Q@D)M)J2%\#V\?&YYUY?EG>OHD$O3&DN MVQR'7H`1:ZDL>%OE^/>OQYLY1MJ0MB"-;%F.WYC&=ZO/GY9[J9YUS9A!P-#J M'-?&=`O?U[1F@FA/=JR%E5(J00P,5>7K3C%2])M$XT=!,/,%X2UV#`MU"8@F=(.IYU]U0*3J@V/*&F[>>%"-!%T]5 M*Q79-A#W:Y@0>N3N!^_H!:=*:ED:#^A\)_1]S+?^K0],JV7!(0)K.U*LS/%] MN-ADV%\M>W_^<+;79]](UW+_1?'B&V\9F`UIL@G82OELH4^%G8+-_KO=CWT" M?BA4L)+L&O-3[K\R7M4&LIU"0#:N1?'VP#0%0X'&BU++1&4#`N")!+>5`8:0 MU_Z]YX6I>26$B.ZTT:*OPX4'J@<270@@?>!))QY291F M\VM8X@,+O(\L0/A_";X+IW?G@1BR6BJY1U!Q(%AWQ-9ON`#"C^T`'RSVWH)S M##<"(M60PI=5E,V7_@OX3@^8M1*$)X:1LMDURBQXJFQ2*FN'27K7)HYN/EX;Z&ULE%3;CMHP%'ROU'^P_+YQPG5! MA-4NB':E5JJJ7IZ-XQ"+.(YL<_O['ML0(*`5?0G8GC-G9GR2REFC+M1&J M2G$2Q1CQBJE,5*L4__ZU>'K&R%A:9;14%4_Q@1O\,OW\:;)3>FT*SBT"ALJD MN+"V'A-B6,$E-9&J>04GN=*26ECJ%3&UYC3S1;(DG3@>$$E%A0/#6#_"H?)< M,#Y7;"-Y90.)YB6UH-\4HC8G-LD>H9-4KS?U$U.R!HJE*(4]>%*,)!N_KRJE MZ;($W_ND1]F)VR]NZ*5@6AF5VPCH2!!ZZWE$1@28II-,@`,7.](\3_%K,I[U M,9E.?#Y_!-^9B__(%&KW18OLFZ@XA`W7Y"Y@J=3:0=\SMP7%Y*9ZX2_@AT89 MS^FFM#_5[BL7J\+";??!D/,US@YS;A@$"C11Q\M@J@0!\$12N,F`0.C>_^Y$ M9HL4=P=1?QAW$X"C)3=V(1PE1FQCK))_`RAQHAJ2SI&D"^J/Y[#U<3$)0KRO M.;5T.M%JAV!6H)6IJ9N\9`R$SE`78KEO"$2XFE=7Y$L!;>`2MM/.[F"N$;,[B&$#(:"O$0GV+D5^+,Z!4PS/"W']AM<;>`N8GH_5.9I=;%QU MAD@>[^S`[`Z75\:G$T2J[/9^WS<_V5KM[_Z'+@MJYSTB&1@+E(Y&+C MJC/,Z>.).'"[\]E1Z!PP32+QJ)5(^_P\:$%7>%G#4-=TQ;]3O1*5027/80+B M:`@$.KRJ86%5[8=WJ2R\8OYO`5]4#G,01P#.E;*GA?L8--_HZ3\```#__P,` M4$L#!!0`!@`(````(0!:`EH&G`(``%(&```9````>&PO=V]R:W-H965T-Q M-,/(6-KDM%8-S_`K-_AN]?'#\J#TSE2<6P0,C\D;ZTDTKZD%_:82 MK>G9)+N%3E*]V[*I;)2FVQI\OT0)93UWM[BBEX)I M951A`Z`C7NBUYSF9$V!:+7,!#ES:D>9%AN^CQ2;%9+7L\O-+\(,Y>4:F4H=/ M6N1?1,,AV5`F5X"M4CL'?6"5_>U#D1`TD\9%D#.J/[V'KWX>)%]+Y>J"6KI9:'1#T"H0R+76= M%RV`L#?DPP\6_^805#F2>\>286AR$&^@*L^K>#9;DF=()3MBUM>8Z!RQZ1&N M`B!OT`CN3C6^G^Q>B@,[*2YC3MO:;P#WF[:+N.\@I@/D3`EDZ'8E#@P%/@T\ MFP^\7IS')(/:S3D?R([<(;!UF`YF5P$]I!)5ZM1FH1A%+YY[K1MSB!) M.HW'Z5O%SL1![]Z>%@<^%S>_B+SVD*.X63R=IA?R8<8=28^8A^-D/!CTTOP, M^UZ77)=\P^O:(*;V;CYC,#[L#E?'?>P*<;&_ABNE&T`RO("1;FG)OU)=BL:@ MFA=`&0934*7]I>`75K7=A&V5A6'N'BNXNSFT91@`N%#*]@O7],/78/4'``#_ M_P,`4$L#!!0`!@`(````(0#@?#HU>@0``%$0```8````>&PO=V]R:W-H965T M&ULE%A=;Z,X%'U?:?\#XKT!@\U'E&0TH>KN2#O2:K4[\TR( MDZ`&'`%MVG^_U[Y.P";MD)>VX./CM*6HERZ9^:[#ZT)L MRWJ_=/_[]^DA<9VVR^MM?A0U7[KOO'6_K'[_;7$6S7-[X+QS@*%NE^ZAZTYS MSVN+`Z_R=B9.O(:1G6BJO(/'9N^UIX;G6S6I.GJ![T=>E9>UBPSS9@J'V.W* M@C^*XJ7B=8AO#^6IO;!5Q12Z*F^>7TX/A:A.0+$ICV7WKDA=IRKF MW_:U:/+-$>)^(S0O+MSJ841?E44C6K'K9D#GH=!QS*F7>L"T6FQ+B$"FW6GX M;NE^)?,L"%QOM5`)^E'RZ/93ZH"?S?.EN_REV/WCSC_R>K MG*2F`KJ%*KRN@FCAO4+B"@U9WX"8B.P&(KY"/)!WU0C1#35^KDV"(0;7Z;4E M5UHE?XT0JI(JX\D&+XR%@67ZPA*\=(&J7SBU%D9(I#(6TY!12.++RE@W'`T)\=EL>=/+TK$FP)8M<:5$6 M0E!6"CLE,,>SX7B4TN0#6=$]LB38DF4MNT:(SI:?!*-J&H`@8H-\&N6,36'3 MRBDG60)#,R]KA&B!41#:Y33&">V[P5`GCZZ!07R^^2384F7U^!HAJ"H@<40L M0#8$D#0F:1^7(2R]1Y@$FZX0]FV";8:0@2L,7A@+$_#'Z2E1:"LG([.4C$OW MTDLLCJT]D&D61+`T"#^P2F+Y^>?E4FA+6T^,:=$87)GZ`2-]HRA$9B(88W%? M4C-QTF9/1F[?6B[O<;@ MTD&:)+&M/S,A012EI.\-4YYE^K\H[-CM!_M;%W9HYV'*(L)&E34@D-QH$($I M[R[3EY],ED_0OBQ:'F)`P?4\I98%9YKG`XPI\"[[)^C=4.1^\=Z&M$#$#`Q# MSU)OS,5O6'P,\?VBB&./I_W.TB(00]69S2*K!3/RT;`I[RZ/)V.3I[:7:@RV M/DF#.!TH&T/;8/V>TIG#3$H[X%1WR>^Y7N9YM$8 MRN(@9'V/&@(#ZT"8=H*K6:;Y4DO$6F.T".D/D15+9D%BG[%^FY@R[SH;`OP^ M-_)H?4&L-4;+"\'?6#C2ASR7$-*0TD&[F`*E5P_.AXEY1(&PO=V]R:W-H965T&ULE)5; M;]HP&(;O)^T_6+YOG'!L$:$J,+9*G31-.UP;QR$6<1S9YO3O]]D&VH0.42X@ M#N_W^OD.<<:/>UFB+==&J"K%211CQ"NF,E&M4OS[U^+N'B-C:9714E4\Q0=N M\./D\Z?Q3NFU*3BW"!PJD^+"VGI$B&$%E]1$JN85_),K+:F%I5X14VM.,Q\D M2]*)XP&15%0X.(ST+1XJSP7C<\4VDE4@O\IA"U.;E)=HN=I'J]J>^8 MDC58+$4I[,&;8B39Z'E5*4V7)>2]3WJ4G;S]XL)>"J:54;F-P(X$T,N<'\@# M`:?).!.0@2L[TCQ/\5,RF@TPF8Q]??X(OC-OKI$IU.ZK%MF+J#@4&]KD&K!4 M:NVDSYF[!<'D(GKA&_!#HXSG=%/:GVKWC8M58:';?4C(Y37*#G-N&!04;*). MWSDQ50(`?",IW&1`0>C>_^Y$9HL4=P=1?QAW$Y"C)3=V(9PE1FQCK))_@R@Y M6@63SM&D"_3'_^'6]6`20'Q>23E,Q>T+Z_*:O;G1``"7MP#7-W;B%(/5Z\:MU*=!\N`K!X=% M\Y-\N>LW06>WZQO8O8]@.W$+N]O$F`;),&"?H)N:V75-`P_&[/:J.G$+K]?< M>AHD`:\_N!_V[MM3.;LJ:<`-/@+GQ"VX5@NG07(5[JHDP(6#*3S`-5WQ[U2O M1&50R7.8MC@:0H(Z'$MA857M']2ELG"<^,L"WAX3 M?P```/__`P!02P,$%``&``@````A`,Q3/3AF+```Q8,``!0```!X;"]S:&%R M9613=')I;F=S+GAM;+R=VVX;29KG[P?8=T@8*HP,T"J=93>JJD%+E,VV3BM2 M[O8.YB)%IB1V422'25I68RX:\PJ[-P/L`/TLO6_23[*__Q<1>:8LNV>F@*JB MF)$17WSG4P1_^NV7^W'T.9FGH^GDYQ=;&YLOHF0RF`Y'D]N?7USUCU^]?A&E MBW@RC,?32?+SB\W$SG]_&"/^>W/Z:S>1(/T[LD6=R/?]S>W-S_\3X>35Y$@^ERLOCYQ=[6 M_HMH.1G]RS(Y=-]LO]E\\B7GQ:_'$T'R_MDLH@`(^I,%J/%8]2=N/D! M.UJ_ZAU%:R]_^G'QRT\_ZA7WVM9V=#J=+.Y2WADFP^KC\\%B(]K9:D7;FUN[ MU8>_BR<;T?8;>[A7?=B>S7ESL_G-WF(Z^+6;ILMD>#R=]Y+YY]$@2:M3^%U< M)K>C=#&/V=M9?)]41[6'G^/)(!E&;T?3^V0X&L3CJ)\,[B;3\?1VE*1@8;!1 M?6OSU8>5+UPD\]%4E!A&1_&B]FX; M6@V-7L?C^+8ZR^%R/@>TZ'B4:CN?DGB^+A87H]'@^AX M/(T7U4WZ(4QPCU`8'[:BWET\AU'.EPN38K92?2WC`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`UXA\D"QG6E>KF<(H%1=J'$9_2Z7@T M-,Y\&X]EFU&P.#5I5)JKBLJB2@X:F1>BCV*.YPQN9XSRG-'.^WC.R"?,P@IU MW>NCM9T\H8FDRMK]+OK<2]?IQ67G/5J^^[$3G9SWGJ?/W21G[Z+.'RYD(6JZ MZ%TR2>3+2`?'P_O1Q)RFA5ALE2H^2N##P2@6KU!T#9PF&R>=D/)W) M7ZF.=K!> MG:C?_D.=K'BO;#9:Q%\"&:M@810=&[7[_G??R(T]/S MLZBH'JH3.+0SL,"7W3/^[D3K@O=E]05\]F1TBU(T-W7P&,D[3]&""C0<=7Y< MEUZKO5E>Q)#QO5"?)0O3G1&LY\S%J^LXQ>^3``Q'8Y&R"OCO`?M.)(Z)YN+; M))HL[V4=,!3.X$0%(Q(-EW-YM1`U>I0'_BKZZ@(EKZVL!HH4"#;R.9Y<42]6 M]U,P5!RSMKE/RBP7(.#B`4#-;)*H-5A>XM M@=MD(A1Z.]"*VO>*7*-X(<.<19;;SWC3^^A?>Y,%<(;!/%`>&^*`*Y!,ON&U67ZCJEPAIB5WTFD8W\^G]:J\P8W8!%ABR.O_Q M4V)Y2RHA:A9*8M1G$*GF)55?:Z;05U]K9HG=ZN:>MUKMM6=9Z,-V[WUT?'+^ M^V>9XL+HHCW#-+WF^V$)O]/!K"=]>/T.;R=R MGWL1OH@)D")[^Z#P_F/[1-%G%7!Y-C@BEYTV,?WZ4<=]>LEWSY]CY6)1NX_C M]:Y[=B9,`.^G3ONR"L&3;W?8PHKWMC:BWM7I:?ORDT;TNN_.N@3%;>5<#@_/ MKRR^CB[([RC$MK#@_/)=^ZS[ORQ0J$*!19;9%.(OB*T&RFK^4_M:2='!XI^K MH]?;+YN"]//Y;3P9_:G9Y'\EA]JR)&JT?O-K'/WMS__W73(E43:/3DA^ M)'@^GBQO8+/E/+%9[N/YKRC=-!G?O"(*4(6!Y'N+F5_%U^ET?JU4&!KO=@Y! M]?&B':7H^`<"I_GTVN4(KT?.Y5`VRC3AS>B+BQX`^6[)FOA#;E$V2AH[W8CZ M;$R.J+`'$ESLL1@+I9/ADCU![\&8L%<9\\5\%(_!%.$(EA5\:(1;6]'=9.C, M;3Q"H\=YML=G>62*W3NE/9>FPH.^3^8$SV-`P)\2D;+>73ZQK', M\91R@"S&T7QY&[4+$3I02D`.CX_:,%1+"&%JIG69?#B)ISWW]*4HJDGAONKV MRCC"6D43N12?DPDYQQ21PTZ#!'V8&7,`34NFFYSE=#ZT3(WQ94'?D-*GK#4' M7X?4NTAP.3*90/<<__>G,Z*N-UMP/G`>Y:D"U0.(L3JJ3D!HVYLH1X8(BR*> MCZ/Z<$_CFM"?QA(4$>P]25&HG48G7KP$3?;X2:%^.P<4LMH?1W.T!+41^)V] M08'3^-$G"35AC,,>`&PP/T&0"";[AF_V='TPT(5$ZF^*Q MB6`U,3:U(L&\C_](&&*/YB['*U;/%&T-/^>3B(+<4C4; M5Y/;?-TJ@(F+:2B'_94:,6<]RKR:]NT\26RGPJ7X*_O&X=.IJR*03=N*'LB0 M),N9X3,@*![@(HG:VF_C6PIJKGIK^[LM4L!B2+ETCIOM9?PEZ3(9#L0.K2R= MRA?'R?7<;=AIW=<;43M%7Z!:<_I(Y&KXC\AJ4DN%"S6C2D%PY6(^=>DS]`^, M*W2T3-:J0$A>L,<`(\E#<&DD0ER5*6;?7N&:H'ZXP1!0)`0^"=QK`DC;Q$+7$7@T$RTY83 MF"=L74_,+%3]B?,)4CIP-MFET<59EES2\LM[*MA`%'BJ\P5'F8`BYR#3;H*V M_BAG+CTOL)RAXY]I,@P6T^CI!75<:YU M36&5=@,#BOH+J^NQM3T*.%N%(D[8KND\+VU&:2<]_L7X%A5TJWV+J60?O$.` M.Z09Z23(H=]M[>Z\;FWG9:"O$;A&.I@Z8U[O)VEW=0XU9:Q'#=AV@BNUUJC& MP47&.]%U,J!Y`3R]WMQ`M1=8/>"G"<932\%O[9A32:>%`)EH'N;69[C<'")3 MC29VZ"1EDH)X-+CHDH:O-4TXA[^J"?JLB&=RZS*FCH71KODF!<:">#Y3C7G@ M`C<1^.+NF;K,'"TECIU.,D23`''Y2Q^HR)3FTP?;Y/6O\;$S+G-3)%+U4L6O M2KJ8*0S4U6_CY?_'2V=O&G7H'>EB"(@PS53<-L\E4ZO5Y;Y!LU9M`,Y"X_I> MZQO%;Z;C\?2!K=<2/J+.M2^XI2JX.4E*S3/V_*)44NQ2._X;;YTQ8XOHCE@$ M;T0.](`(+V/]E6_!S[6W:FPLN#*#),8M6+IJ$K7^MC%6OR!Z'8QP=,P,2E$Y(X^FJL[09UN2!],#DHA\M/P3E[$I MNP0E=FH:`/(SX5;$\(#[2SCBXLYT>8UZ'L5S7/HJCC38O#R+4+.1&,>:!^;$ M;8(%=8X7D=LM&EY.:LHLR)FCL-&M,JR@/(DJ_ITVLQ\4K_F85S1.U3X0*,U$ MRS%SLJTZ&%5\MC&,*<4MBW5P.`RD5QZ_0;Y<)%G@(#E4048=;5RJ&I'". M\BVHS8*FSIG/>YE7$\MB$,X!"Z0Q?S[%Z`4W62;E/OZ52G.`V'0'FF9Y;Z$F M9N$.51'?W)!],)("/2D*K>Q*0A#'*R8)6TB8*#^@OXK$HZ%X2WSJM)*=^@9\%AAS#$27@&A$V MHQ>"$L(&YEBJ\\-1(S\&P"7R80IKT>FEB]/WV8.@ZU(WDLMI+9O[5JNLK%I>6UV1^.F M+&1Q2:&.=,R&LJZ^T@G3D.+/=.MH@EPLEB[T@I9&O%<^CV?+:66_I#([TEZ3 M*5.`7L04AJ=@O1@IGV8!/.)&3Y2)PC]8@ M<8&&_J,)Y)3F`A^V2;@4"$L/LU,'\^A>SIM+.K*&7K^=`M)$06:=BSN-7'SQ MK+I)\RC#B*$-CI5GDQ*;&Q^BN0HM6+.LH64#9][R5!@)!)>)PNLCX^:P7_FB4I)\=Q4`(UAV73JSB:7:*C6`"GD$9PIXH%,_&0\ M$V%6I7:LM,5?%G'7,%;LQ!%AE$*TJ@M2JCZ6>:S&A5<82?EXZ8@=V.:#OM7B M6&4I'VNFBT0<8V"O5/.!I*1NEF,T+,DM9X2;GP56"5J93>U9'T1:@W[]N)'> M)\@C('\6_AK;/&7&0@3C#9`C%&WTY3=]$D7\?=SNO2TG(UT"J;Y#'9%7!8JC$=FY%'0AT@;GB<'9-CC1#2;,W8;4*`MDZT&$ M&J!WB:)AN`$\9_*2;1(D8E9&R0//!!1R%8`B=38A=SJ/E+"5MT)J*J_,#D9S MV!P!0*[%1^ISQ\\QJRJL#.+Y_%&FJ&!.@5[;@=9X8/.1O-]5A5^'2$VO+J&4Q-\0 MZCYA!0N08(*5I5\887`ZZ7(%&?AE"O(]=XVR=YRA1("7+='<#HK4 MG,I5@O5Z>\_DRK$]?V%O7R`_P2%K7\NPV((?U:NI!8\ST]?%]/D%6R_8IO<= M!Y@S=:3DCITN2&-78N(=N5@KZ8"R_V@TGS3:66$4)):'?BB)0NY\4K62`R M/"9"_H&[F*X[H;.^9RR?+D'UCL7AT9?G_TH,6KO"-:Y13QZ4S6Z;. M2_Q@:GPP]0(K"14@-T[SZ46I#UB=4V(*8!8X4M?+A95#C8<4$+AG.!T/2BS9 M^W6$5O6ZT]-?T$RFZUTF1ZQ7`H^_F0]VPRGPY5YK(,5SD,W/>@&_LL5[6GMP M=F3*M!J>SD`!F]XB[F1C\FS<5R0\9C.4)+OCL6W44\L[M4XU\H?3O+3TPT'4 M*`@"5;%R,9)'%]@MSHS5\':"Q4$U)FTQ3JCI-])/B$Q:2$SL3:UY M_=GVD"8M'-2RN6]B0+\E%_3QER_)V,K"D?D8"CUKTO![>8'0`#(N,?X9/T<6 M=UEAQND1U6,=R7`*;LS&L7,E[1TBBU;K2VRQDJ1=!(9IG,9,N= M)L#Q,5!EIW&;QU:3A_NH;XEO^(*F?I[&ZCSKY$Z3>="+!@3*+BC!\JP"JP,Y2/W#QQ ME]>,1#6^#P,&\6$1_DXA+L*WUNDP>^9"+>4I-%/SRGF4Y7-:MMR*XP_F<8N# MGN6GP7Q`N;9[T#J@**U=K'&<]6#WC<#)FVA^JARH7?]=(_+PM8L!.UR5M\Q7 MI^B71,Y5&&FR]R(<3","IKU<]7"%E1$A_?*LK+5%K7*]>!L344C\.2D3-?PS MT@86_T,1#X42#7@#!+9\`^0I,4EW..\HH3IO"4WB([YKK"TEUI'VT3D5"'FB-/ZTU;!5COJSREJ72X&7OX`@7"FJ$ M(R&06B=6#D=#H)8)3#[\WFV_0.&&Z3(V=`3Q/)`KD,JTQJ5NO5`A%0(^XWW3 M2B0IX_""QWMA8:8ME.XJ:ZX@/%C6?FV6((KX9I9@-#=;"WL=C4IHVJ_?33A+ M4UJWI&LMF:+"2C:DZN]E3.3SH`H3%X^-/)/-X5"ZE,'U*>QL!0538T5. MR*B#$-O6LXHTJ`!),Y#L]5`C6YHYD!>`MB7/7BN_^LPO<9Q*KX:PEC9,?<60 MD5I)RI.5Z#'O.B0%5#QCZDQ8*:MI!TOQVU@>8$U-DF6HV@TX>>OGM8.-@[V] MK9_?[F]L;6W7SD/D8W8V-6;SS6[MA$8[0V"YV2B3;(,B%VT#N)#O"0@6G*MA MW-TQ&'??O%X]9M_MXV#KH#I&(AE(+I]U7:KIY8_22[E&*@+RU;R,L_?K:SNM MO=?[J`H9_+V]UM[6IN1NM<$_4Z^HN3K.>\8NW\=#:5;D0[8Q\&-6(:15:!X] M6&WHFF///KD/&V4& M")=""I./[.RW^1`"28AQ%AW_S*5)2YJ@54H*L+N\$D#D:4ZOW(B-Z+U"-D8O MR:85R$%E`5A)A$Y.: M$C9T1#^X%U6LN54@E6=HKJED#[0J75O2!F(!?S+O( M.%ON%59&PH4-`:3BKSJ95:G-2Z?>`[2U/D3O`VK*,4;Z9 M@JK!!L$NTO(X&"9/T$:*':6OW4$FMT''79ZP]$/DL)?`J+HI3-5#N1[B,IX9H?J@KSK9V--4)D8\P?TF;LV#-] M4M8I*`KYH#7/!(#L(E)"B_,#M/_N`[5DHMPQ7<.U_.1OP1*;C?8:R2GH3&FK>@I7 M(L)"C^/7+,7@4.ZZ:BWR+EQ+X$"!!7OR?X`E)$"7=Y@%U:/#]4P^)@.EKEJ8GXU8U$'@]C6G=%X MM9B^LFBRD*#S`8*9GBQKYG*>8A/Q!IX$AN/>V".><"I`>2IRK:9^7>)2.:)P M/MN1,^M>UE$.<1<).#6"X,;)``VG[M0(KZO#0!G8(MWI+W\\M:2M_3LL`2O>PPRM7,D$)=ZLK8Z6S*361`_&IK M+[I@IX7&J.,LJ\[KA#'B)LK#_SMZ-Y4H']*!1A]#M-Y;7B_L),OVYMZKW4V* M7(4:%P;J2N.4F+1#2[$5OS\+;<7$8)NJ$7B)RXN%U/6S M^[#6W[7;%T"$C=>^,BGT?HN)Z[)`O%8LO;8=*=;ROR/,=?1Z;(7^>#7N#KW4AOW)*09LU$E MQ8H5AI8CSJ!T7,:?S(9HP7J5QDIMH+Q#MQTA)!/YC:C+GX!M%6H(]4R@.7Z5 M,0R2'AC&^[-(JT,8J%Q:^4C`E)!@F"V!(CTJP(I'K$K/TWG?WD]5G.*[$ZZ*2L)>;;UHE`B'612@D[9'$[Y.,[&KWZ* M!MEL<@D:Z5%:P?-ZB2*MB'*X3ZP_+` M5^S8'!-O1Y3K1_F&*HII""$EJQ``><"L.-.AUFG1!CARJNH@G3^%YX%3XJVL M\;60U_1.OT,+\U6:=?L^\0P@R%:4WD)[\'4P'\%2:*/.YL-@SAI0[@N'`<'9 M"IM@G1\^M'%N5YDT("0_ZF'^AE$`K=Z*[J8/(&@.G(Y2(5YU,-G!5']("RY$ MZXBCKRDO\1)TY"5JU[)))/$*H9>O/SKG+JNBF7UJY#E#4)ZJR3V&FF.SC;IK MO+:NZ@&%!C=DGM.'2`\([Z!%9S)-3YSK[D/AK/O?HE-$D<-7E$]A;FHK8(9R ME::3^^*F`P\K.U%J*:S"R!K0&:CW\4#)A_HUC6O5=TZGG";@WE1Z;3`BU:?G M:@2"BP.HU>?R1HE+"&>F-XL'&+XZP$]`"Q7-X@F!XV^D>QL[!*L3!L*4 M4=AXC5.I7\]G24V8)(8A/X?&*&"T[*];AGUM>[^UO^N+2WS&@T%9/)%KVB$" MM3NR+MJ?=,N3NSJ`*P4NK[@EF];6SI9Q MS]K.[IO6FZTR.;5VN6G(-4.@/Y>TBZ#@F$;B*Y?,$*+BY]!ZLV4G$0;5O1E. MVLFZ2Z'"`4[#AT;>TK&7-6?MPX922U.9[*#0+7UK^P=+70ILZ.P-?FHO=8H$::]HV M,[RK8[UF&^F]M113-JK$J(B:!,AS4PZN&&)MFX.]!V\\Y\&)._LE/;N*),Z] M46:DA),:9,??0MZRU/OX5#*I/GEVX`(6ERA3()9MA5")!(J[Y5JC9B157$*0Y?-0(NU.Z4)4E]1&2RRX0=4CA8,5NC&U9#AP+>Q>)HN+C&IKVN"RDGU_R&NZOJVI-%"(1FT-`]=EY MX7@TY\*2[*"%O7X]+?`!AQ@059B6$C8V-;VCFA_^-WT;A*=/$X&=Z5Y M+4S%94FH1IO+8=?]D294H\FB<%&X7;R1TT&8XE2S^C%EQ1Z2,8XEN[.3+GW@ M]D0RD;%:@Y%%.PI%9)J'\7`\KUO"@IFX&`4W[W%$G[CR#PA9?O0Y;P_5FL;[ MFYL^1$+M>Q*7ML>768M:8(FMUO[^04E,%`S`H"OM69B:_)%2/8J].=D_)NR@ M\>0F45`?VMP(DY[1:U/C(,@?5M]VY-\I[R.0OW:2?R7YOU/`8)<$'U88/H5M MJ-OH(J/;Z-/2!.I#/(K>+4=T@H8KFHW^.:.Z@.W9U(>.G/CFHF.YLE8#;F*( MUC,YP@E[#;O?I,9*4M?`/MMD_L1`18WR7\(3^V#_6^Z>[G#WQ_0Q(7WENR*K M.D9B:5UZUMM"=ZD--TU7U#06/9/`4!NIM$<8F,WKN5U<$7Y2@"YS"IUH@1N] MK1P(AV!U`I8LM*UCT1OM,4OD&ZF7[I::=XDQW\3)<3DKX<9V)U"E@*LC>.2; MAA$72B]&KSQ04M=$IF9=.)BE/F)-J8N:ROE7TP\$4W(BV9/S7X(2P,8'G"D? MPA#F\/E,<::2[T33&:8"1NQX+<=DZ(W@H?9DQSS1#ADHYE(+NP*)"4BL2%_R M12A\%UVI@,XF]+C]N'LD%-/1<8X6LE7+"YJ#(OUL=><`:[Y#=2^M<4_XUFOO M..SCOGKC)\">Y\L5V=^CNEYU]UI9`8\.YPDHK1"VF2%=^S4D>9;(6ZV@U37( MTY7Y?&0,M`I;JF?*3\RLR]$8N6LCFT0@6%3S`4CRN./OX1HAU\-GP796&S7K-1*%K1Z=L.Z6:[6SJX/%W"%-]]$ZW+% M?H-):VWO!L>XM;.U\[*D93:BM]1O/?^`!]]C@AC:5G#VOLR,P>'>WRV!!^\P MCZNM(*1<*FN57>&RI(B9E)DWSG5^DD,[&[LGPPG+X8^1D:ML.R341&5^D@+( M[?1@#JX#LJ:<^S!$((E=^1(VH]IICG:.M#HDI4H,%KY_:112$6Z`ZZ#3`GY@ MX:N7QGKD96]NLL0TGG@=@_Y5Q6T.#-X4?Y0OFJJ07)Z2&G.E$-?>['.BPI/S M8'^?LH3:H*&ZB_M_H>IMJUG8LO*@^$LM%JXP'=KES4PI=&2[A2,UILQ0CN6-J%9K'992 MD'#*C27$<1;LU(-*A]Q7Z"YO12JW-[??Z!*[[`('GSGWO0\B$`E_7LU*C?HJ MLV;A0A6@4$>)L#:;68)$!7M_L@\1<@8M*#]?,,1RR?_`ZV!RT.Q:5XDZ0)97 MS?K:30PMK7+&-[IC*S;WKNF4ED7&#EK4D3L\:2Q@_1CF3B@"TB+T5]3/!87- MY>_(,]:A$V<\\OZL?'JTY&J2FQ.RARN]L[UORZ[MOM:MGN6IN,D:W[FR[:=]Z6Z0G=#9A9VNO)M!Y)_4J07S[L6O@N7)FJ+*,XP=O MUR(&P$^NP))53/!4D$',L)/(VKKUGNU5Z]MU!U"%%0JSVP4%N;!GB5+8V*62 M<"JACA=3QZ_^'`Z@PX_,6.R(]&AE6H?Q@B*QED(I"^,4R!!2J]M[/VQ$M'<6 MQOJL8LXD&6/1/57?LS2:JT(QAU-L@:W[R).7':SZQ/=)_!#8Z!#*T;5I2L"?MK#4R7BJD^RJ.9J#?+%QN0&-1#]1 MM6PFON8HU$$AR?!FWX&R^]\'"KKUW;FNE3;$7YY5+6E;N9P;WRSC-RZ&?OXE M3E7_1QQ?*719RZ+IAKW6+EG$+7>Q*)@IOWU>FN7U-D>@]LII MUQ7Y)"=;14J[:"[3*OE5\M8:+[+3C5,>Y)D#@:(7^_4^V"X'AFRX(:?;J32-4UW`#1$.9FI]>@I8#%XO)I^20\4*K@R26&P$]R\O\FA ML]#6F!UMF%ZK32KT<&#*)_%^)V!=$F-?<6Q.'(3>A@ M3%-5XWWG2`%W,?I M4D@I$(CC4F8PC1QTZ_-KB_33*NJGG&_!,$>\[8JAA3PW"NMC*ZN;C%[K$+A. M+KO,TU.N(S+G3Q29'VJ43U/R-3$TGR^T&%.^,4O[,+)0G]2FQ0&RC+K%4$BOOS7Z"RFEK0 MS%KZ++E(*("R=B1!A/5CD7G>15P`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`";T%5]'?5;_>K"]0PH\O'YFD(>SZZ" MK#>(7]7RC8K72HFR)FA6:N32^:V:/LHA_C%-%[_\?P$```#__P,`4$L#!!0` M!@`(````(0!O!*J1TPH``$]<```-````>&POY*/\]5>VW M:L"X/1AZDT.W@XV[ZJFGJJN[JVV/O]_ZGO+9B6(W#"9J[[JK*DY@ATLW>)JH M?WXTKX:J$B=6L+2\,'`FZJL3J]]/?_VK<9R\>LZG9\=)%!`1Q!/U.4G6MYU. M;#\[OA5?AVLG@%]68>1;"1Q&3YUX'3G6,L9&OM?1NMV;CF^Y@9I*N/5M$2&^ M%;ULUE=VZ*^MQ%VXGIN\,EFJXMNW'YZ",+(6'D#=]@S+SF6S@SWQOFM'81RN MDFL0UPE7*]=V]E&..J,.2)J.@XUO^DFLV.$F2":J5IQ2TE\^+"?JC:JD)L_# M)8#XW;\V8?+=;](_[W[_[EWW']]^][>?G.7??_YF_[>?OU4[N1HB$WQP7.9U M]ZA8^#F5W,DLF(Y784`,`:\S@FY?@O!+8.)O$`Q@'EXV'<>_*)\M#\[T$)X= M>F&D).!EL(^="2S?2:^86YZ[B%R\;&7YKO>:GM;P!`N,[#K?!3?AR4ZJX;)Z M%H@FMVF(,#B;=#Q#;?+!)`M/'K?)^NK-5W[<;'' MX2FZ"E\1/='38J*:)N207K>+M%*'G4G9:-X%?1=3=M._F&6ZJ9N#5BWC8G'? M;ZA0-]NDLD:A^7YP=S$ZVU=695V6AB_5`[##MF/BY1)Q<>$`[ MB\?VQS+6\\K4^.CZ3JP\.%^4GT+?"I!7.J:QJ[DAF<9=F]*9DABTNYY73*CT M/DXYX,QT#'.[Q(D"$PZ4[/OCZQHF'`%,0Q%V)[VNYNJGR'KM:6S8%6L0AYZ[ M1!1/@DR41050DUS/CB#T/O9:-X^TOEHU+90S81/RT+? M]_'3LE`3_INWQFF6:(RV0!;RE,3%94GW>C`:C8:]F^%P.#+TGF$PDA=91+O! MTMDZN%)IC:9]!'U`,-*'HQL-@'2-(5-U400Z`!CT^\-^;Z09\#]+;>='T#:G M?56V5PD"25XE""1YE)0@D>94@N+17\V75 M_/[>9*O[_9E9:_/C3!=.XIOK8JM&6*\XJ@15I MY#X]X]\D7,._BS!)8$]A.EZZUE,86!Y\[>0M\K]'6L*N"VRP3-3DV;5?0!E7 MR4VY256<2T.1]0Q<31@#HSLP^MI-NF!K2;7O+-V-OV]=H?M@7`*-R&V]X83# MH%"2A4-96.J@%S+W";9@KF:>%FP`,9&'A&"+-FPLBZRB-I(68C:2!H(VDA:B M-D+7.=2YL;,PT_;'9\P-*:%OMVUC0X8&5-"U$;^;C)O,OG,AD-U0P%>PLELC+HQF;IY3'[SWW*?`=5A=44S$_1F'B MV`F[X8/M0E3AT2OP]#)!(GA.T6]4Z`>>A/DX13_4G0XZ$7B1JA^"2UA_F_&` MM[9D00TNH$%]#$^;"*"ZD",`)\A`@+?B9!Q`>,I``*NV'`$$:(D`X!R)BE/Z M08]D,XB!4B7H/Y=*R#&YE9S*,UI9E7Y!_Q$K32[]GD0SR;<0Z"7-<'`$P$DJ MJU*LK!1#W`X]K:0`#HY08,*HV\Z0UZO*^=(((4D7,)2,0!HXQDA[44ER+N@L M`1QG9-;B/(0$!:8BV1``CA0(Q!$]2>-OCV*0-`+3:)`T!%,(W!A\P3Y!/<&- MD)(P`!XIO:*<)_2X$>."-!`(LC(DB09-5HJD&&3ER-(5FJP422#(RI#4$[)2 M),4@*T<25\A*D00","(E0U)/R$J1%(.L'%FZ0I>5(@D$61F2>$(_\>;IZ2E>.X`NVEB)+:7SXRX-CWS);+6C\X6EJ+IMM-V55WK!21Y?6,W&'F$E9A* M_5!:5Y4FREOGYP0LIQ-1:SE;U-<6YGABVU$UAD,PA"D=GV^%":4(\6%6<'H?WE7+*]8']B<:Q`5MX@E';`ZH8K0'7G%)AR&^)BZH4 MQEL!TQWQ<5X8;TL4[X'[BBDFLV5^UGFF**8A\:9I,@7,QP14"<\0$R<#)DN] M'8:APYX!<&T05_4P+O/"*Y2D@*M*8C7@_C=Z&#"_8.M)K`S7=3#AK'5RA)(N MQ2.LZ5&70TCZ$(^PI@L)(ZSM-.BME82:)-N;@-T(AX-M3X&5O MW=\J5\I[&Y-KT8>Q*++8N!X\((JAA_M*]B:&9Y-FZV\L"_9_,UFX$USB,J`HWA07-,ED M\=SW!;DW#OF1W3-1XD*317!16:4?@KD$8L,^$'O:PWQ9:]L`Q\GPL0@O%U+2-*S8[\H MJQ#$]P<<1D4$W6_7GA5821B]*KAI7XCCG=X7%/>',"PXXB5H<"@"Z`=X M-2Z\=5,#_#07DXB[LN1OH-S:!'@?]HDA$9L181H@GGIT4W@6>N\$W,B M$)8(CL<0;J0I1.QD%$$9?[&B`'L+UW5W8K3"HO*V))C]+[?E$YV,]P1?'LV> M]2S6`T#4TEE9&R]Y+'Z1.U'_?SP:CNWM3NQIV9\,K0W?Z5Z/^[.ZJ;\QG=W?FJ*MU MY_\!RO!-V[?PJN83WF3-WK@--R;UC-O8@_==1YFQ&?A/Y;F)2@Y2^.R9<(`- M#TOG1G3BXDW@T_\"``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3 M````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQ MFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5 M]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[ M=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+ MRSPA,S*A/D%#3=+;RHCW M&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\ MRM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3 MXX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,G MO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q M)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@) MYQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+2L?V MW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV M:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD" M.S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8 MG,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z M+_NH9IR4Q>Q,O91&\\!)0 M.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63Y MPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7 MT#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43? M*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:- M`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2B MS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9 M_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<W_DF(\SH(>'FB;<&G[$P[ MN%.QOBT$7/;'@)][6AR&06T31&$X#]JB[GS)L.['<+"JJDN:L_+2TDY(DIXV MA0#]_%2?N6)KRS%T;=&_7,Z3DK5GH-C732W>!U+?:\OUUV/'^F+?P'._D;@H M%?=P\4#?UF7/.*O$%.@"*?3QF5?!*@"FW>90PQ.@[5Y/JZW_1-8Y6?C!;C,8 M]'=-K]SX[?$3N_[4UX=?ZHZ"V]`G4>S_H`TM!3U`YWP/.[)G[`6'?H52")/P M`8"3\'_5-$\1SA+H:C&^O"> M4UY"&V"N:90@:\D:H(!/KZUQ/8&-Q=O6CT!=?1"GK3^;3Y-%.",`]_:4B^<: M*7VOO'#!VG\DB-RH),GL1@+?-Q)"ILLDB>?+Q7B6^,8"WXHEFI(XG']?22"? M:C`L+T2QV_3LZL%R!=W\7.#B)VO@5>[(9]%^_9]=X!.2/"'+UH=]!DYPZ-GK M+MP$K]"5\H9()0(^-8+8B$PAL`5(FAN%`-1JR=`)4_*W&ZF4(1B5*=94%DPA MD2/D$3&S$?DC(M8(2RKT>[Q4!,/J,BQ*-.O@2"H1L7Z8S"WD1L$2`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`5PQ)M0%NJ=?'7?_ M`0``__\#`%!+`P04``8`"````"$`DT1^S6$#``#A"0``&0```'AL+W=O48JWK`5R3UT!6+G2_60T*("B@/)B7A3I+95).'3J:0,'7+0 M_>J/4=)PJQ>#OB`)HYP>A0-TKG;4U+QP%RXPK900:TFRD2PK&[H.HLFA3%[6P7B^=%\@MTEMLS5M_+[%KK&0 MB92TT1#8#X&X`[B@J)4%R?H/LB2+E-4XM&V`CLZ!AL:BV1(-@?T0B#M`3\/( MU#""%KI=_$TFY"8H\UXF%GT?M]HF4+VG`KTSD,A`]@82=Y&>YU#FW>B_[[$T M7MD!9/)/\4R\@;+&\UXD]U[7O^ MI.__KEUO=D0&LJ]9%XIC[D\&[1'7ZV,9@Y[OT+==WW4/._)F$1E)SENJ[[@; M:1C!6;J#)4=?DD;\;E//@X&LUJ:5I9$1U'2;37\^*,!];21/?UG?4*K7@ZFA M=/:^TF=:J1OMAE*X\!NIDJ0OM48ZU64@D8'L#01&H6)6/#I#>K3I&[?`[(1W M.,^YE="+'%LS\*E%VXFZ4?L'^!8FK9I+0SP(X0*!\`_Q40C]:>*;<;A1$WMH M/PZA.4S[[:R>\&Z[`29LA4[X*V(G4G(KQT>0XJEZ8WI&ZQ=19^-`!`\5YI%0T+W"PVWZ&PO=V]R:W-H965T"O;KFHN*Q--;-,H+T6SKR['E?G7C_C;W#2Z/K_L\W-S*5?F M9]F9W]>__K)\;]J7[E26O0$,EVYEGOK^&EA65YS*.N\FS;6\P"^'IJWS'F[; MH]5=VS+?DZ3Z;#FV/;7JO+J8E"%H'^%H#H>J*,.F>*W+2T])VO*<]_#^W:FZ M=IRM+AZAJ_/VY?7ZK6CJ*U`\5^>J_R2DIE$707J\-&W^?(9Q?R`O+S@WN='H MZZIHFZXY]!.@L^B+ZF->6`L+F-;+?04CP+(;;7E8F4\HR)!O6NLE$>COJGSO MA/^-[M2\[]IJ_UMU*4%MJ!.NP'/3O.#0=(\A2+:T[)A4X(_6V)>'_/7<_]F\ M)V5U//50;A]&A`<6[#_#LBM`4:"9..0UBN8,+P!_C;K"U@!%\@]R?:_V_6EE MNM.)/[-=!.'&<]GU<84I3:-X[?JF_H<&(?Q2`XG#2.#*2!PTF2%[X)_$8 M"5P9"9K,?=^;SK]``H\CPX$K(_GZ:&!J$`ZX_O<763`2N'[U12Q:(E+Q,._S M];)MW@V81E"$[IKC28D"!$[AM::5&:K_L^)#P3#+$Z99F3`ZJ&L'CGU;.]YT M:;V!RPH6L]%CD!RQY1'8!Y@V5(%(!6(5V*E`H@*I"F0"8($L@S9@O?]#&TR# MM>&CVG!`$$L1@D?PE%`%(A6(56"G`HD*I"J0"8`DA'M#"!?,&%"6XC_:DJ M7C8-[6@W)'%A/M!9@DE6I@-^&Z8)\I1)L*%!:#KX9:LA(451LH#%/$!P#H=&YD1G3GG4SY@S M'J"O8`AO!L4-\?UY1<(5B>AV4O&/4OHM3Q0,Q"!A:8MX%+40C<*8\:N.>..L5X".&6G82WBE^0B>XL8>?#J[]!%!+7*@8Y8W%#/2KB M4:SAS.&UE<8?\Q#1..P-1NY$YTYY(N>VYY[2$C,>/,H:D*_I<95_:$] M(F);4%$J"BF.4F;]EB>.50\9!%MU+GO$(43:M3NW;4\ABCF1Z"CV4B-WPHE& M[I1#C-OWG)G2&3*)6W84WE3>4^^Q/1%B>U-1/@I)3M.@D"4*41'G&CT3.-[3XC$GL>VG*`6%%".KYF+<8OFTAZ7<**[CTMY%'N<,_6G2B?`QV1D*$(' MH\=>]!"D+MMCN2W/Y\XHFE=\I`4KPWHYP/2\+?0"^`B"*:3B?A`1C10\\0/X M&+@1/PU@KZWCR32`O;..PSG?DW,#W^#SOUNX$\`GO,ZS<0/XL-7Q)R]X`H'@ M!VL8`9SC7?-C^7O>'JM+9YS+`XABDQ[6TI-`>M.S3[GGIH<3//)5=X(3VQ). M;6S\O7=HFI[?X`<,9\#K?P$``/__`P!02P,$%``&``@````A`#EIX'R1!``` M>@\``!D```!X;"]W;W)K&ULK%?;CJLV%'VOU']` MO)^`N20!)3E*0@A$K515I^TS(4Z"!G`$S&3F[[M]@<%VVN:T?1DFB[V7V6M? M;"^^OE>E\8:;MB#UTD03VS1PG9-345^6YF_?XB]STVB[K#YE):GQTOS`K?EU M]>,/BSMI7MHKQIT!#'6[-*]==PLMJ\VON,K:";GA&MZ<25-E'?QL+E9[:W!V M8DY5:3FV/;6JK*A-SA`VSW"0\[G(<43RUPK7'2=I<)EU\/WMM;BU/5N5/T-7 M94-:_MZ'^CO9+[OBE. M/Q4U!K$A330!1T)>J&EZHA`X6YIWS!+P2V.<\#E[+;M?R3W!Q>7:0;9]"(C& M%9X^(MSF("C03!R?,N6DA`^`OT95T,H`0;)W]KP7I^ZZ--WIQ)_9+@)SXXC; M+BXHI6GDKVU'JC^X$1)4G,01)/`4),CY;A)/D,"S)YG,?=^;SF?/?PE8LG#@ M*4B^/QKH#,8!SW__(8$@@:<@\2#P(^EJ@UM#RHUI`P5P.<,-M'#:' M6*JW&A)IR$Y#8@W9:TBB(:F&',:(%#I,C@! M4FLY4(X@X!\:`(Z&Y#MC?W'%GA6+!,AX[=:[R)QIM*O/[<4\\5AS&MI!C,25VQ_S*6 M**&L'D>@(/L:V`J;4?5QQ(7$#D6K5Y\PF@OU_-E,R4$LB$<%J"V5/+-4*BWE M!XZK["!PM6!ALI6XH/RJP`^.%6XN>(O+LC5R\DJO`7!N7"T&F%]1(B^$'014 M47$_A#FLXXD?PB35\6@:PJ#2\60:PN#1<;@:K=G\4M;=P)6)S3X5=T(X]N@\ M&S>$0X&.K[UPS:Y>UD`$5Y];=L$_9\VEJ%NCQ&?0Q&:-V?#+$__1B6WP2#JX M]+`=\0IW7`RSV*9[Y9F0KO\!"UO#K7GU)P```/__`P!02P,$%``&``@````A M`-O&,I8BV_(]BHVQF"U4K7:;9\)'MLHAK&`Q,FW[YD;9N:X:;+M M2XA_G/DSYS]G+C#_^EJ>K1=2-P6M%K8[&-H6J7*Z+ZKCPO[Q/?XRM:VFS:I] M=J856=AOI+&_+G_]97ZE]5-S(J2U0*%J%O:I;2^AXS3YB919,Z`74L&=`ZW+ MK(6?]=%I+C7)]KQ1>7:\X7#LE%E1V4(AK#^B00^'(B<1S9]+4K5"I";GK(7^ M-Z?BTBBU,O^(7)G53\^7+SDM+R#Q6)R+]HV+VE:9A^FQHG7V>(:\7]T@RY4V M_X'DRR*O:4,/[0#D'-%1G//,F3F@M)SO"\B`V6[5Y+"P']QPYWJVLYQS@_XL MR+7I_6\U)WK=UL7^MZ(BX#:,$QN!1TJ?6&BZ9P@:.ZAUS$?@C]K:DT/V?&Z_ MT6M"BN.IA>$>048LL7#_%I$F!T=!9N"-F%).S]`!^&N5!2L-<"1[Y==KL6]/ M"]L?#T:3H>]"N/5(FC8NF*1MY<]-2\N_1)`KI82()T7@*D5<[],B@12!JQ(9 M3$>C8#R=?+PG$,G3@:L4^7PV,#6X!EQ_OB,S*0)7*3(:3-SAS/_W9!PQ1'S$ MHZS-EO.:7BV81C`(S25CD](-7:@4-=9B9+K1_Z?!AU%G*@],9F%#=C"N#53L MR]*=3>;."U19+F-6=V+TB+6*8"7%9",3;$P0FV!K@L0$J0EV/>"`+9TW4'K_ MAS=,AGFCLEHI<#/+,XQ0$:I)9(*-"6(3;$V0F"`UP:X'-"-\PXC["X&J!18- M4UZKA:F>X$K$>'P=XD.]1B1"9(-(C,@6D021%)%=GVBIP\JAU<#[J;/HA>U! M0;TS#V00F-T+FND&K;N@K@00V2`2([)%)$$D1637)YH=L`9^P@X6S>U02:PD MX9N7&'=$(D0VB,2(;!%)$$D1V?6)ENC82%2LBP.VTK:G(G]:4;&#W:D'']8_ ML2HR$3U_05R_6PS6B$2"^+#*W^IC:BRFFRY(61LCLD4D021%9">(.%]HEDSN M60);H73D.[WP[>3C]C!!W1Y!^O9($G2&18($0[[+>$,WT&?.IKO?.2,U;D6W M1:I)UXKM7:#JZZII=U^I[OJJFD_L&(RWU%OI**/NE`Z(Q+)5SPZDDZ!6*2*[OHYF`%2N9L#[B;)H/5%!7"C$;@+`&X`^ M(&O9[+:M1G>:N5-C7=UTS=@XSSSC=BQOW\IMVS50`Y]\Y#EIUXP]9S(S>K_K M/T?SCIW!-/-^:N'A*KJI$KDP:CU77<-5U5`\L.A\A;>`$QU__W9SOL*^9T5^BV(*TQBC#:8!1C MM,4HP2C%B+UB\Z[R?@DOQ"NS>($J27TD:W(^-U9.G]GK,"S-RWF'Q;OZ*@CA M-`658O)1"(>/.]SUU,N]T2(:A[!;XQ;1)(0]#_-D$L*NA7DT#6%3P#R9AK#( M8PY?&QZX!49_5NPKQ)WX%21P-]X/X9A]1S\('\!JN.%T3X"O"9?L2'[/ZF-1 M-=:9',#>(:^U6GR/$#]:>>9XI"U\1^#'CQ-\-R*P\0W9P>1`::M^L`=T7Z*6 M?P,``/__`P!02P,$%``&``@````A`.U2JJ6L!@``NAH``!@```!X;"]W;W)K M__K+\J.JWYI3GK<& M,%R:E7EJVZLW'C?9*2_39E1=\PO\X2N3.NW]^NGK"JO M0/%:G(OV>T=J&F7FQ<=+5:>O9YCW-S)),\'=?4'T99'555,=VA'0C=F-XCDO MQHLQ,*V7^P)F0&4WZORP,E^(EY"%.5XO.X'^+O*/1OK?:$[5QZXN]K\5EQS4 MACS1#+Q6U1L-C?<4@L%C-#KL,O!';>SS0_I^;O^L/J*\.)Y:2+<+,Z(3\_;? M_;S)0%&@&=DN9FB M)!X!IXA0""$Q0A*&V!-ZBXHDLUN2P);(%?E27;MMY7%Y M**$J#T/(4#.W/(:U&]W>P!#'[78;VR+:=A/TO_?*<(Y!]!UBC?I1=`\#5D?5 M.^Y_%ZR)S*KH1-MAO+4.UA%"W;`.]$G".Y1%%8N:L@A<(LD MXL)2;V`K!@X+SA\&"J<'(FK1B39QB:5MYZ&(Z(H&\Y2`!NH(4\D1H_R8OM/L^Z\(UD5@'J#IMH65I*P9*5N.05*@"$<690_I M]H>!@BL042S=KD6T;2T4`;*1^"T-S!%FCL7`'S$G(N"&CVCS]X1$O%>4)6*0 MYB,M_UO"!P[)]CFD^(A'L603ATST)1$*(ME(B#O"W+$8V'//;;3<.-$-)]&F M\`F9>`\IR\0@>0T@%"&R<1!WA+EC,5!P6_.) M5B43$7+#.K1_E#7YJ3:1GK%H6R"'-$=IRWXK!LJ.8ESPE#8L.@Z1KGP[<\N: M:$2A()(=Q6]JX(YXE,0="XASNQ-[IE6&1.%6:Q-M->^I]UBG1"N3+A^#)`]M M>90$^1@*."25L5!`LK,0?82Y8C%P\'8BH!M.HNWD/2T>>N`@O"F5%QV#-"=I M&_A6#!RR[7/(@?(K/8=H]2(04?2A!PY_K+GM(G/)G3)O#C@T7"X21'`\VHD`X("'!5B:(>A"$,QANBA M^7`33`9V",Z.1,N\/N;;_'QNC*QZIP?<4/'7RQYFI^^;B0?G(E!5==SUX!CA M!D[F<%S?+7Y]!%F(@WSM%W_JP1,YYO)G'CS78CR:>?!DBG%_[L&#'\:CN0V!X>&F&?C>'"4AO&7B?<"28`?QOT5X,W!-3WF MOZ?UL;@TQCD_@/!6]YAJQ;>&71'#"=X1Y3#.;%%#Q\.5=6* M+_0"_5NG];\```#__P,`4$L#!!0`!@`(````(0`AZW:.G0\``,!8```8```` M>&PO=V]R:W-H965T&ULK)Q;;R.Y$87?`^0_&'I?2ZV[#-N+ M<9-,%DB`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`(_@V#C&>7BVJTFBPPR!L= MIZ$C_CW_Z/,P"/X-@U2+R^5L-ITORXO@;9G$3;.X* M-MJBCA9^RORP)@!Q#G.8H@6L8O) M@HZ8][ M[(WQ(\0,OE$TK5&%BDR,YCJN.ACID1:=D7(11?!Q%[UQXV*^,8EB&B"7B4J)<7O1QV1MKEP-) M4DK$$+%$7$J4?U[XLR5NOKC$#/1<#?PXVO5`=+976;8[HR[;1"P1EQ(5S4I' M\_:JX(VURX$DV29BB%@B+B7*/_];S=,]'I^1[F8@[7Q$*N'C499PL>HRSL@R MPJZE35>3'!V4UYFDAM[.>M6J$I:VZ,!=1$G>&1E&EI%32+OII21QTZOYM'^A M5WZ8+/,!Z>8[JQBXB6-)X):14TB'Y,4F">F=S`=I2C,?D#A05X0,(\O( M*:3=S*3/9_Z\JN]D,:;PK@I(YS[?>(A5[&@8649.(1V45ZF/YSYH6IK[@-+< M$S)^8^;+3:PL(Z>0=M,K4^)FLX>=7,I&^./;V*!Q:0B=["6*.I[DA=]92?() MV8J04TA'Y?4LB>J=P@_JEWJ>"F(K_!4AP\@R<@II-[U0?=S-(&NIFYW2I0G. M3A[JJK.2!!.R;.44TIY["?NXYT'P4L]3#0P))F0J0I:14TBYB>UZ#S<;:[UT M1Z27C^SOAK35KU:D:&D67D M%-)N>LE)W$RT\1V/@U:E'K<(V\^8LGK<(7_-YZ=L/VBD.5W;Y714N]I+\,8L M>!&E)=Q(_W_$OJ%3J'PE7/29D&%E&3B'EIK_8^'$W&VLM;Q&I%6"2GQ.*5:Q= MP\@R<@IISWO)VX3E+:*D7AD91I:14TB[Z27HPW4P\=99@@.:R,\^6@DRC"PC MIY!VLY=@35BP`O+G\'+I:Y*M2'6TPFPD5O)#TS[U4J<)JU-$Z0R3[ABVLHR< M0MK-3(K.WL!,6*4BTK^N_/1'K.371?)FVF/6$F"2=HL6SF%M.>9CKV38-:O24"2S9J18609 M.86TF[UD;,(R%E"V+N2G/]%*KPNR45<^37MI5F.ME]2(DM0Q,HPL(Z>0=C,3 MJ&3OU_/*]Y3%*R)=M_G&6ZRZNF5D&3F%=%1>CCZL9U-OG24_H#3YA$SL*%:6 MD5-(N]E+SZ:L9P%E=2M[Y_;,)EJE=3O^P8YPVDO.&NLLN(&=G7,3V7?*9[S0I%7_)5DAI9R4U2\C&X25PIY`.J9>835G,(I*CU8P, M(\O(*:3=["5F4Q:S@'3-3O.]>+1*:[::RDY-^]1+IJ8L4Q&EJ2/E,FQE&3F% MM)N93)V]!YNR@D6$14KVK%/9LX:R#1TE3B,=8R5;1DXA%=2LE\XUUGK!B$A\ MJAD91I:14TB[F>GZ\V$MFP652L[1 M(TH3'*P$&;:RC)Q"VLU>6C9C+0LH6Q?R36ZTTNN"[-2T3[W$;!:4*TT=BUFT M2E-'5I:MG$+:3:\>C9C/8M(?*H9&4:6D5-(N]E+SV:L9P%E=9MONG9C/4LHC1UK&=L91DYA;2;!3T[8Q,V8S6+2"^V^29,K&*%&D:6D5-(A33O MI6:-M5:SB)+,,S*,+".GD':SEYK-6P'F[!Y+YUJK+/4 MD2C5T4JR:1A91DXAG;I,I_QB>T;1SEG`(E)%.\NW8&+5%2TCR\@II$/J)7-S MEKF(),TU(\/(,G(*:3>]H&0R=T[F6>/FG50E&C?+]V9B)9GO.D9DV0"FK12^0: M:[U21R2W=FI&AI%EY!32;O82N06+7$!9U>9;WVB55FTUD_V;]JF7R"V"HB7; M\8B2LF5D&%E&3B'M9D'DSBK;!LG<@F4N MHC3WP4J082O+R"FDW2S(W.2L)PW]PXG9U.$JB1CG$^+".GD(ZJ MEU@N6"PC$I]J1H:19>04TFYF8OGV-;8%*V)$.L%ROA$2'#I*,$8Z2H+)RBDK MY?FRER(VUEH1(Q*?:D:&D67D%-)N9HKHJ[O"&X7X;9\>=YNO=WL/BH\93?#" M79.^3TL6RH#PY'I,7\W(1#1KWMV;5JMIML.VT4+&<1'%3K.%*(6.#9.>GQU, M9LU%L":V7_>O/XH-%\JZX/PHV=2TR#]$C>R$%P_G^6G9LK.**3`1X?><=*28 MJ:,K=Y3=LHZ[)-63)NZW?S]+EN:`_./,B=UJ;9E+IOES&Q MDFGH.D9DVLDA'A)]E4LKY#DFL M8J8-(\O(*:2CZB722Q;IB-+D!RM!AJTL(Z>0=M/K8G85YJQ3@V40V.3D)B*5 M^X5<`0B%'SJF01&R,E:<(:>0"FK52[\;:[VR1"0^U8P,(\O(*:3=S/3[[95E MQ4(=D#ZC7>0;I&B%_O(36(CB:9^\?B7U\(Y/K=KA18DX*W>K@-+4$3)L91DY MA;2;)9D\YXW1%Y9$*.53(=A M9!DYA;2;O01QQ8(84%:VLB%JUX5HI>LUZ,/J4(V\>>YM8+I*\PU9UU4<0P!=UUBZ"(`8`DA9%H"7HAX! M>/,\@,#$L[H:$8.WQ.`M,7B;LLS;3.7>KMAJQ%H6F:[99;X'Z\R0.=&\I>PD M,K]Z"54U8J7JF,HBR1>R2`Q9)(8LIBSS-M.K\R\"5B,6LXYA&I/4R?:J7142 MLUB\""X,)TE`<,007,JRX'H)7S5BY>N8>(&"#G;"X"TQ>$L,WJ8L\[:@?U5U MSKZM&K$`=DQ/1;YS2\R2J6`-+-@AN-0N"ZZ7#/K/G?':$IBD'5-!#%-!#%-! M#-ZFK/6V_41:^SVOY^WAR[;>/CT=+S;[;_[S9SA7N+WN"TN[;VNVO-PV]FU-ZKAMZMNF MY>/-?%OSU;>\WPJNX/RMX.4*!\/I2:EE@I;FDB>-!B>PK2[U08*Q:RRU(+W8 M>15:EA@-5ZU*+0@(5X5*+3@.+L246G`<7,PHM6"F M:%E@--R9+K6@#G#CM=2".L#=RU(+9@XW#`LM'2JUX#AX>Z'4@N/@X?Q2"XZ#)]P++3/,#QXJ M+[5@8<)#VX66">H:K]256N`!WF(KM$QQ'+RD56K!`X>%NYU(+CX`7A4@N.@W=R2RTX#EXY+;5@?O#>9JD%\X-7)0LM8QRG M/2_)U]$Q*A[?ARCU@0?X_D*I!1[@QE"I!?.#5_=++:@#O(5>:*G@->X@E5HP M&KY\4VK!;.-63*D%Q\&]ED++&/.#CZ646C`_[66W/#L5^F"[7^A3H4_[Z0#J M@USC>UJE/LAU>R.0^B#7^`Y4J0]RC4\O<0L^\_JI?!1T*-C?^1(H<3A5FO]/ MTZM/?L_#1[Z#2R6/[C"1Q7GT8E0:!Y-8'!]3V,S@L$L3/A_[NOZR_>?Z\&7W MV@_0MG^"M_B8Z/W: MG!AK+8A0-6O[U+;GI>,TV8F5:3/G9U;!DP.OR[2%K_71:F]>O;>9;Q M\@PA=GF1MY]=4-LJL^7W8\7K=%=`WA_$3[,^=O=E$K[,LYHW_-#.(9R#1*SZ@3Z)V>71OG?:D[\\DN=[W_+*P9J M0YU$!7:L1@%L[UK0ON0AI M6]E;T_+R7P0106H(0F40#]C+YS!T>[*#1+J\GM,VW:QJ?K&@66"IYIR*UB-+ M""@2\D`67'Y(\5J&P$H$>1)1UC9T.4QOH"SOFSA8.>^@9"8AVRF$Z(BD1X@" M`+N!(B2G4ORQUCT3`19,A&""VA8'(/9`C1KK_@`1#1"-"0BD,NG%NLU(3`)1 M%0)Q.(1'C@CQ!]*),J`1\'4"MQ<6X+4-V0V9QV->N#!"PJYBLP6-HL"@ENB( MV/5\;R"O48/^?5P;,Q-\[7:,4ZK?NVEYBDMQ!Q#5VVB%%Z2!G0&!"P M/E69^RATLW2)B-(.V,<2)$6BD<$QD<^QL'$T;@.=H#!)I71W$D1K5:V`N(8- M;@F"D*`?>OY8I2Z#1`-0-XC'"#I'8:@*Q]OM1=!^=6ZCQTCQ$(3<9I%'?3IN M-\E.@X2N'X=C&^K\A+LJ_.[4$#T9/@<[):ZO>\*6*,8M:2DC.HN'O)Q,S9RX MDR,605*E110;,B8R2@\@RD;6N7W)S,4/(<,IB<T5:")`42N.Y8):E8;_#B M9T007FNRA^R>3/V>N*,YRB93'7U&O86Y11(9IF]#:+*A_KI^ANG?V6%HWWJ' MC3X@2?;^W__`28@RHK-XR.;)U.>]R>*JD1,WIL&DPU3$@A+_6OD,K_\?CT"_ M5CW"FU0/,;(V`9Q^$X?5$"'U@Q&A"4>-4^`VN0ZMN[]G]/168I!<1'W?,_9N MHB&"F/C7W)5^Z03H9NDDH7Y#]V)O29!DN:"4&@V0:(B0$+*XL@.H<..'/;:; M9;`D8Y$D2S1Z/"AGGGD.R!CX.(S&-M%++&SY<7YHYFH?@@:FB@A"%6D01Z-$ M70()18!,(")7M@@U#HC[3*2;94HXKB`E5`\*?P%.I^>0R"B8@Q_#3A\`NHQ? M.BC$7=<\*(CA)%L)PKM)!!MF(B-&08">!'+$6SS>=DM6'UG"BJ*Q,OXF;N@4 M?D$/H\/;@R*G17<&=X`)?Z&PO=V]R:W-H965T&ULG%C;CJ-&$'V/E']`O-O0W+%LK];FDI4V4A3E\LQ@;*,Q8`$SGOW[ M5%/5HE3Q.JVZ;%D\)UT6E:]OUT5<9%=(\9)>TOI'DU26LGCU[907 M9?1R`=T?S(CB+G?S99(^2^.RJ(ICO81T"@YTJME57`4R;=>'%!1PVZ4R.6[D MKVP5,DM6MNO&H'_2Y%:-/DO5N;B%97KXGN8)N`WSQ&?@I2A>.?7;@4,0K$RB M@V8&_BBE0W*,WB[UG\7MMR0]G6N8;A,4<6&KPP\OJ6)P%-(L-9-GBHL+#`#^ M2UG*2P,-K%M+TU9U!G3I):GJ(.4I92E^J^HB^Q=)K$V%2;0V M"5S;),Q8:H[)3.L36?0V"US;+)HQ>PC`;'3`M0NV/ZT#%#=)X-KI<&>/P&J# MX=H&_P\G[38)7+L1L+DR%)S:IE*\J(ZVZ[*X2;#\8/*J:\07,UM!8EXBQL,2 M@=K@,5]Y4!,*[`KJ^GUKVVOE'4HQ;BF[.Q1'I.SO4%R1XDTICBI2_"G%L$1* M,*4X3*2$=RA:3U'`J]XPJ&-JF`XK\_Z:Z@SC01L9_O>&.7J?OO%TAQ2K<=.T MB(3]^"ZS;.::A.&-&0MF661"?.&^;CFP%Y,)"02*QDS5&#QH!AF*#$VS8""] M#L$F6*B?MXD'$9N,/CW:A!2[M9S82T''?`X)A2?RRWN#1:\@.U^[`7?^G^^D_$@ MX@G91G9(&>9OCT!KA.;JI"*\+N"Q)K^C]#YTP..8\/%C!1MXMSLZ`9_7-R<3 M^>3,VB%E))\"'@5\"@0=\$0=4M#4A>.JNC'4GZ`/NI3Y^CA9U.<.U8-;%5)& M^BC@4<"G0(!`.WC3-!EY2/B$((ACSZ`MI%H9I:[I)1A*(',U639.>RX3BZH9A#$>,Z!AO=6;7 M.\/&",[]OG-QR<-W+0>M,"WGWIG<M;NB3M[#S->)'<]8 MYV1[8UWCU!TU^PGB31!_@@0M@AITTR&'7OCXOBB0=S(C@3/K&OL?0>AP/.`^ MSM\$P%[?_>(@\[T7;C-7LUV+K`ROI8!A_>8P+?/Q4Q:FH:I,)7U0(#QJH5F6 M2W__A")%MW7''+41HF.\_QDY]I/2QVY)<(K^YH!W--RIYQL<$27^[@E[JX-C_. M7XH:7LHT'\_P$BZ!]E%=`OE8%'7W!8I&PO=V]R:W-H965TC>,D5N,XLDUI__WNM2$C M0"E]2?<8D"6,2\):I0K153G[_NK_Z1`)C:5O0 M1K4\)R_PIM2:4DM/.HJ M,IWFM'!)LHG2.+Z.)!4M\0R9OH1#E:5@_$ZQM>2M]22:-]1"_:86G=FQ278) MG:3Z<=U=,24[H%B)1M@71TH"R;*'JE6:KAKP_9R,*=MQNXBF85D:5-@2Z MR!=Z['D6S2)@6LP+`0ZP[8'F94Z627:;)"1:S%V#_@B^,7N_`U.KS1 M[KAAT%&@"=,),C'50`%P#:3`T8".T&=WWXC"UCE)8316W-A[@50D8&MCE?SK M7SHG?7*Z38;[-GET'4ZF\2@!K3=((E^(\W5'+5W,M=H$,"P@:3J*HY=D0'S: M"#A`[!+!.8&*H58#W7]:I$D\CYZ@8VR+N?48N/:8I$=$(-HK@]KER@A&96PI MEG+K`_LRZ6F9T7MD$)P3N/;%I_&HY_7*'C-V<[+O9_P>(03#X0_J/VJE!R6# MS4^W;Z"$CA].^[NA[RNH%/QR'@SX\*Y@TE?.3`S2N'-AVJ MGI="\%#*1TZXP3V\-^WH9CI[VPRF#15\Y,#,_TD9M'`V%#UO!L%#*1\Y82:! M]77H9CP)IV^>C4L@/#,&&'0B?=^30!VI(`!MG;]S\RO6K27)= M\<^\:4S`U!K7:0K+IH_VJWZ9XK@>QL?9TG\"HOX-K.".5OP[U95H3=#P$CAC MURGME[A_L*IS&W&E+"QA][.&CRV'A1/CE)1*V=T#_E'ZS_?B'P```/__`P!0 M2P,$%``&``@````A`$[$4D<;`P``$`H``!D```!X;"]W;W)K&ULE%;;;J,P$'U?:?\!^;TQD#L*J=*MNEMI5UJM]O+L@`E6`2/; M:=J_WQD[H0&2-GD)81B?,V=FF&%Q^U(6WC-76L@J)L'`)QZO$IF*:A.3/[\? M;F;$TX95*2MDQ6/RRC6Y77[^M-A)]:1SSHT'")6.26Y,'5&JDYR73`]DS2MX MDDE5,@.W:D-UK3A+[:&RH*'O3VC)1$4<0J0NP9!9)A)^+Y-MR2OC0!0OF('X M=2YJ?4`KDTO@2J:>MO5-(LL:(-:B$.;5@A*O3*+'32456Q>@^R48L>2`;6]Z M\*5(E-0R,P.`HR[0ON8YG5-`6BY2`0HP[9[B64Q607073`A=+FR"_@J^TT?_ M/9W+W5ZX3R"C`#,(Q(B6R@`#@URL%M@9DA+W8ZTZD)H_),!B,I_XP M`'=OS;5Y$`A)O&2KC2S_.:=@#^5`PCT(7`\@DTM!J`O(ZKMGABT72NX\:!J@ MU#7#%@PB`#XM")2@[PJ=8P)-#;%JJ,+S,O3#!7V&S"5[GSOG`[^-3]!X4"!M MF('M`Z=OW4[F- M[FZ,K.U:7$L#F]C^S>'+B\/6\;%5,BG-X0:8:?,MM_P/``#__P,`4$L#!!0` M!@`(````(0"%7QV/KP(``$$'```9````>&PO=V]R:W-H965T/^ZMK2JQC M;<$:W8JJ`8B<;Z9Y[4DH4SSY7K39LUX#OISAE_,C=O[RB5Y(;;77I M`J`+?:*O/:_"50A,FW4AP0&6G1A1YG0;9[ M(B0A#ZCWN`=`]2.`W^ MVB;'HN(ZA$Y$3ZOJ0?$TL\60V:2PH'AY81'U_?,I?EC8EI"X3''.2K*V7XFP'S.1G1U2!4V!:VH8A MY&_A8*<334C$DFM!2FE(.,FQA/I%1BO1L!7)6^@*S"_7ZB%A10441YI3^:I) M;:M(PB_GDG%\S$'W"YKAI.'6#R/Z@B:<"7:2$Z!S3*%CS4MGZ0#39I524*#: M;G%R6MM;%,:![6Q6NC^_*+F)SO^6R-CM$Z?I5UH2:#;8I`PX,G91H5]2!4&R M,\J.M0'?N962$[[F\@>[?2;TG$EPVP=!2E>8OD9$)-!0H)FXOF)*6`X%P%^K MH&HRH"'X96V[\&*:RFQM>\'$GT\]!.'6D0@94T5I6\E52%;\-D&HIC(DLYH$ M/FL2-)\L?'\6+.9O9PEJ%OA\/XMC=.DV15CBS8JSFP6C!Y6+"JM!1B$PJ_YX MT&6CINW8OQH&G5(D6\6RMF%G(%V`R<\;=S9;.<_@3%+'[,8QJ!^Q;R*4#8HV M&@*'(1!W``<4M;+`KZ$L9?L[92D6):LI:-<`'9T##4U$DQ(-@<,0B#M`3X/7 MUW!_9!L'5#!8UW$`(;]?V\[$N'IC=(/W(R0:(8<1$G>17L4PX..N3]2,RXPF MEQTSJW)'B0=#8T9)<<"^@;&=61HJ,4'(:YW9CY"H1GP]CC.TG'G]=AQ&*?$@ MQ9\OVI2>3A`TU.GYZ@`Q.I]8I1?KCDZ(:80J$BVT&96=01"L82L=!6Y;@K&L M#6K2HAJ9]]*&8D=I\=VTOTO;$PPE#06[GA;\?XTJKZ_1(*A[5*!@8.^^#6HU MULBRIS'HM^8P2H.;1;T?]=/F;9K1:"X/#,JQ%VSMK MZZK1&^`[N,OTR3_$W1"6_$Z\%\(NC?'M+-SJ.]%IB>!.JO"9?,/\3$MAY>0$ MI4WU:G%SJYD'68_>D4FXC?049O#C@\!I.IV`XR?&9/,`+W;:GS.;/P```/__ M`P!02P,$%``&``@````A`!%+!>,:#```R3T``!D```!X;"]W;W)K&ULK)O;;B.Y$8;O`^0=!-V/Y3[*-FPOU$TR66`#!,$FN=;( M;5L826U(FL.^?7YV\U0LCF4I>S,>?2RRJXIL_M6G^U]^;#>3;]W^L.YW#]/L MZGHZZ7:K_FF]>WF8_OMW]>EF.CDN^WR<-6_=3NT//?[[?*(G_N7V>%MWRV?AD[; MS2R_OJYGV^5Z-QU'N-M_9(S^^7F]ZD2_^KKM=L=QD'VW61[A_^%U_7:PHVU7 M'QENN]Q_^?KV:=5OWS#$Y_5F??QC&'0ZV:[N?GW9]?OEYPWB_I&5RY4=>_C! MAM^N5_O^T#\?KS#<;'24QWP[NYUAI,?[IS4BT&F?[+OGA^DBNU/U?#I[O!\2 M])]U]_T0_']R>.V__VV_?OIMO>N0;3 MI^YY^75S_%?__>_=^N7UB.FN$)$.[.[I#]$=5L@HAKG**SW2JM_``?P[V:[U MTD!&EC\>ICD.O'XZOCY,B_JJFE\7&5P^WN_[[Q.L4T1Y>%OJ59_=832=RP(S,H[@LONSY"*K>I"%'N5ABA,, MW0]8$=\>\[*XGWW#+*Z,3<-M,FK16@L]97I8$0,9`Q6`&2)R86%NX[#T$CDS M+#V*#LLZU%@0Q!G%8"UL%Q$#&0,5`!(#EE880WIYVQG0QIBZ8`:RK**^-:-- M/IQ=0X);1@0CDA$5$N(QUG3HL5Y,>7YU?M[U..B*R77K*N,W'PP(AE1(2$!(I0PP/>G1!L/4=AC-X;D;D&UC`A&)",J),0_G,&A?WH" MYC=7?DOX\`FM!Z*^&T+3?1NEVQG9D`4CDA$5$A+.G(;S?KJU,779D"#=C`A& M)",J),0_75%$F^=%ZUV/0UTWA&0[OXZR[8Q6(\&1Y$@11-U$8D(W+][8,SU0E'N#:.[S M:*G;CCY.P9'D2!%$@](R]O'<&]$+2(T40C4I+6!#5B85O!"_T/-3`L9C1!5Y\ M?C(DN94BB+JII2EP\_*%;S0NC,#)7IC[,E[XSLJ>\R)C2'*D"*)!:3T+@CJ1 M>Z-^H>>A()K<,R0RAB1'BB#JIA:JC[MI9"UTTRE=F."H*&XS9^43S)#D5HH@ MZKF6L(][;@0O]#S40)-@AD3&D.1($43=(!(Z_CZ13J-6H;LC(NET:$AG5/Z)W#6'Z?17G]1/+3R!GR?\,S(5^L>4J\T9 M$AQ)CA1!U$VM,A]WTVA2Z*:3J2`I17R1F#LKNW8%1Y(C11#U7`M/X/G_(1Q& MPK`+^YLX133[3>Z$+K2*JU1OY0-U'2V2W$H11`+5=T+#0-]?28,U54&+@JV. M(\&1Y$@11-T\2_(*+GD6$2TIXE+46]EL"HXD1XH@ZKD6L3]E)15&#LE"BLJ- MQAK1.&/-]%8^3C.ZGT?)K11!-,Y(,_494]7Z\<2Y=R\*HZ=!G+G?!X=:L;$V M-,S(JO56/DPS>!@F0XITI&$F-/>B&V*%T^#@C"\CD6VL%8FSC':/UEOY.,WP M89P,*=*1QJGU-EBV)_8%H\[!UET8Y!UH.1(<28X40=1-K9J!FWK5738=H_RB MFK4I;`J#:.[C/=E;V8Z"(\F1(H@&%:F[#JJ>7_"0H3"2'IQ)61E='3;6B(89 M[2NMM_)ALH)!54@,UK20 ML,BGM>5(<"0Y4@11-Z-"XG*9*GF181$YE:IXQ_!6+OD<28X4030J'/%/V09+ M/1#F)3B9ZJC<;JQ-:)15T;;2>BL?I1G>, M3_.S*BJ2&FM%XXQVEM9;^3A902&YE2*(QAG5&.]K;^D*">M`8Y%/=,N1X$AR MI`BB;D8EPH7[M][RH_M3%M',Q[NUM[*!"XXD1XH@&E)43IS(/*\92E1($41#TCH;%'(G M,F]4.?2<"75;,B0XDAPI@JB;6A(_[J81T-!-IZG!UE-'*MZ6SLHGF"')K11! MQ//J+'T>K*D^6Q1L*AP)CB1'BB#J9D*?LVIX%GA\7:^^-#UV;-@DUD>!M[*& M:F]1<6DV"`\A;49;CH1%U?""5YG=QJ]X26OAQU$6V4YX0\X]`Z"Q:?T+%H_> M,(MJN$0>8ON]?_M9;+B,=L'I4:*I&9%^'N;UK(Z+OLI9V10(B[`1!!VC@D5: MJ]KE3EE$._K;*33NE&X70]R):0Q#=3IM/6ZJ$>DG4X''I9T5URZ+0K/,F/ED>!6DB-%$'4SDNX3T\`5NC(( M2RK(IE_WXQ,];^6GP76T2'(K11#U_"R%KKA"6^2SV7(D.)(<*8*HFPF%+BYZ MI:'B(FT137Y<'GDKFVG!D>1($42CTH(:;&`GEHV1WT#]*J;(+4>"(\F1(HBZ MJ:4R<%/OLQ==)U1&<\,(#"*YGT>72*WMZ!>9X$ARI`@B0=61?NN@LLM>?-0C M#0(2G+OS2"V:X7@Z;^$9/H^DH?56;I%Q)#E2!-%`HPK@_456_Y4AP M)#E2!%$WD9AXD5U0@]=Z&*299#F2L\8:4:M(NUIOY>?"C.Y3(;F5(H@&F5!N M4XV=F!:CW"2L2!Z:VAC1L.)]S%OYL%Q'BR2W4@31L"*5'@JQBW;GVBEX<"[= M1.5\8ZU(H#?1&==Z*QN5X$ARI`BB@9ZE\S77>8O\`FHY$AQ)CA1!U,U(U(>] M3=_T/_."MN9R;Q%-/=O&3$/GK`-X:NG MP1W64J!EN"2*6A9U>;?`T9'#J`4G!?J4R98*+<-G3:Q/C9;A,H2US-&2/$Z% M/BC4$AY4Z(-B)]5R@Y;A&B`^3G6+EMM$GT5]C4B'2B'N@Q8M)(GCE/``]T12 M+?``MR%2+?``E_F)E@K'P95UJ@6YQM5`J@6Y1K7-6Q;%[=T"=YQY2X,6_2`@ MT5+"`]Q[3[7@B[GT:"56%>[Y\CZ+LKA;)'.-6[/HDUION/6)EF2D)2*%0//C M-"56"&ZV\99%@=6+YW2\!0]FD8/D<0HCX5VW5`LRBKL"J1;D#:\?I5J0-[S>DVC),!I>ATZU8'YP M#R75@N/@-=Y4"XZ#FQ&I%LP"WDQ-M.28!;S=F6A!EV2/##WPB46B1X9,CV^9 MQ9G.D&E\&I#J@TR/-\)8'ZQJO-'.^^"#UT5Z+'1(V#=ZFE-<+YD$7^!$2T^7 M/I\3'1K,8G(2,8?)*<0,)B<0\S=,W\SE`A_2OBU?NG\L]R_KW6&RZ9XAB-?# M+*3Z8[?-9YK1_6/_?]T?Y`1F?N(^S'_P$` M`/__`P!02P,$%``&``@````A`';<$[::!0``6!8``!D```!X;"]W;W)K&ULK%C?CZ,V$'ZOU/\!\7XAAOQ6DM,F0'O25:JJ:_O, M$B=!&^((V,W>?]\9;,#V<%E.ZLNR?!X/WS?W[/+\X;+\I,7#F9YTDY$C=^A9&C*/*D@M?BY)6W@B>'>E)^\?SQ>.;E279UI8=5 M,<2'.!ZSE(;U]2D5^`Q?/V26K MOM=.72=/5U].5U$DSQ?0_VZ#M`_&;^7VO].>1;WWXKL\#6[;U4?XG[[SP[G2M(]Q04H;#5X7O(RQ0B"FY& M_A0]I>("!."ODV=8&A"1Y+U^WK-#==ZXP6PTG8\#!N;.,R^K.$.7KI.^EI7( M_Y5&3+F23GSE!)[*"5N.V&0\0Q\/Y@5J'CQ[/OY@XD1-A*>:..](/Y@'=&JU M\.R(SMEX&T,O&A34,J2FAZ-ZV/INNO3"#KH8'K+8V&360%C(*A12**!0;D$D3^X*65RS3(!AU375P MF3+T9$E0D%FHRS9@PKL,$V2V770!VG M/85""D44B@W(I(G]0:.)P??]T<]O$4PU&EV!@HS8^V,[]JU5(SUL?'72(PK% M!F2*P@ZBB?H@]JK?Z,SU%J1*A$`A(U!$H=B`3)K8:X;3E)W)*!$%F0&VMPP\ MT>.JZ*(94BBB4&Q`)G-L.<.9JP:E!UCO62K`!`H9@2(*Q09DTL16,IRF:CPZ M30G!%^IC\M@^)^]9:]`5+X$B9>4O:S<+-K52%#<&$US^I@3L-IH$>>:O-\?J MG*4O.P$+%O:XGA(/X&MU:)^8:EFZ,@GA2-O`%[Z]-%NC3IV$`KWDV,+:3R/U MP0`IO&W[!$LW_HP*MKJH+?B;N/U(,!QL6L6TO3(%=N'U1[V04M,2*&(0K$!FB].>0B&%(@KAA5'G2]*4%T#R*B'GQ8GO^>52.JEXQZ?6R? M)N"_;V`'*GI%`-,^HKOY"GXT]81CL8(?*STX&X,">378:H9[O5MRXG\DQ2F[ MELZ%'Z$TQG6C*>3-H'RIU/[[+"JXT:NWXC/]]DYX M^Q\```#__P,`4$L#!!0`!@`(````(0#&PH)'>0(``!H&```9````>&PO=V]R M:W-H965T4.,_;@C>FE3E]E8[>+3]_6NR-?7*UE)X`0^MR6GO?98PY M44O-760ZV<*?TEC-/2QMQ5QG)2_Z0[IA:1S/F>:JI8$ALV,X3%DJ(3=&[+1L M?2"QLN$>XG>UZMR!38LQ=)K;IUUW)8SN@&*K&N5?>U)*M,@>JM98OFW`]TLR MY>+`W2\NZ+42UCA3^@CH6`CTTO,MNV7`M%P4"AQ@VHF594Y72;:>4[9<]/GY MH^3>'7T35YO]5ZN*[ZJ5D&PH$Q9@:\P30A\*W(+#[.+T?5^`'Y84LN2[QO\T M^V]25;6':L_`$/K*BM>-=`(2"C11.D,F81H(`)Y$*^P,2`A_Z=][5?@ZIY,D MFJ:SZYL$\&0KG;]7R$F)V#EO]-^`2MZX`DOZQ@+O`\L\FEW'DQ$D+$34&]QP MSY<+:_8$F@8D7<>Q!9,,B-]W!%80NT)P3J&I(58'57A>INGM@CU#ZL0;9ATP M\!PPR8!@(#HH@]IX902C,N860UF'C6.9]'V9R?_((!B*CS M_6FVZJ\&-OR`T>QX)1^YK53K2"-+H(RC:[!NPW"'A3==/R!;XV$F^\\:[F`) M_1=C84MC_&&!V1IN]>4_````__\#`%!+`P04``8`"````"$`QS.UU>("``"/ M"```&0```'AL+W=O?Z^IKE MS4O;>,],*BZZC$1^2#S6Y:+@7961GS_NKZZ)IS3M"MJ(CF7DE2ERL_KX8;D3 M\DG5C&D/&#J5D5KK/@T"E=>LIO@EU+(EFIXE56@>LEH81:U31"'X2QH M*>^(94CE&`Y1ECQG=R+?MJS3ED2RAFK(7]6\5P>V-A]#UU+YM.VOOAI1X;9X^5)V0=-.`[Y?&5=PRJ#?N$.[`1X@FA M#P6&8'%PMOK>[,`WZ16LI-M&?Q>[+XQ7M8;MGH(C-)86KW=,Y5!1H/'C*3+E MHH$$X.FU'%L#*D)?S.>.%[K.2#SWI_-P$@';Y%!37`;MX#@Y*ZH%16YB MUT-B3EU!<7Q=$6S4A\+:"$CA>3CV-W-YT5\R]>=_-8CK7`D;.7&SN.QF[JJ^ MWY\(=J5LY((;G,Q'?3_:#:YS)6S$=9.$E]TL7-7WW2#8E;*1"VXBF&C_9<J:QX MI[R&E<`9FO,C[85B7[3HS53>"`T7@?E:P\7/8.B%.$U*(?3A!8_H\%=B]0<` M`/__`P!02P,$%``&``@````A`)T';R9X`@``%`8``!D```!X;"]W;W)K&ULE%3);MLP$+T7Z#\0O$>4Y"6)8#FP&Z0-T`!%T>5, M4Y1$6!0%DE[R]YT1'<%+@+@72:3>O#=O.,/9PUXW9"NM4Z;-:1+%E,A6F$*U M54Y__WJZN:/$>=X6O#&MS.FK=/1A_OG3;&?LVM52>@(,K9$+35W MD>ED"W]*8S7WL+050OZM5Y][8M+B&3G.[WG0WPN@.*%:J4?ZU)Z5$B^RY:HWEJP9\[Y,Q%V_< M_>*"7BMAC3.ECX".A40O/=^S>P9,\UFAP`&6G5A9YG219,LI9?-97Y\_2N[< MT3=QM=E]M:KXKEH)Q89CP@-8&;-&Z'.!6Q#,+J*?^@/X84DA2[YI_$^S^R95 M57LX[0D80E]9\?HHG8""`DV43I!)F`82@"?1"CL#"L+W_7NG"E_G-(7.6$GG MGQ1242(VSAO]-_Q,#A0A.#T$P_L0/)I&D]MXE(#6!R0L)-+[>N2>SV?6[`CT M"DBZCF/G)1D0OV\$'"!V@>"<0L:0JX/B;^?I:#1C6ZB8.&"6`0//`9,,"`:B M@S*H7:^,8%3&DF(JR[!Q+).^+S/Z'QD$YQ2>0_)I?&XP8,9]GQS[&9\*86ND MXSOL@P^JBH&`/?%R4=8`2DY2&XW?MPR*UU<6P;WZ4-JP`U(X"<<.IZ>\Z'!Z MC4&,.Y4(.V=N)F=NPA2&;M725O*+;!I'A-G@A*70?\/N,/R+%+,^WQ]GB_Y2 M8,,/&,J.5_*%VTJUCC2R!,HXN@7O-HQU6'C3]3.R,A[&LO^LX?:5T()Q!.#2 M&/^VP'(-]_G\'P```/__`P!02P,$%``&``@````A`*>?O/>5````J0```!`` M``!X;"]C86QC0VAA:6XN>&UL/(Y!"@(Q$`3O@G\8YNYF]2`J2184?($^(&1' M$T@F2R:(_MYX\=)0-%2WGMXYP8NJQ,(&M\.(0.S+'/EI\'Z[;@X(TAS/+A4F M@Q\2G.QZI;U+_A)<9.@&%H.AM>6DE/A`V/$K-KG6L3R5+)3=+(&HY MJ=TX[E7N`K3:0S5X/B+$_@$A_5)9K?XC]@L``/__`P!02P,$%``&``@````A M`-(AZ]/D`@``J`@``!``"`%D;V-0&UL(*($`2B@``$````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````G)9;;YLP%(#?)^T_1+RWD*3; MNHI0N>"VJ`DP<+KUR7*)TU@E@&PW:O?K=X"E23HGTO)F^]R^KS,JYDHGT;6E%R?G%L]I5DY8T55\I'UQI5UZ7W^Y":RJKG4 M@JL>N"C5R%IH75_8MLH7?,G4*8A+D,PKN60:KO+)KN9SD?.@RE^6O-3VP'&^ MVOQ5\W+&9R?UNT.K\WBQTL8YK;U_=+&<%]\&Q-V>%XJZ]>7!O.6N*EC`AE>>N M],6*Y[J2/25^0]D&5N^1*=[@C*P5DX*5&K`:M>[2GHM::>G]K.2S6G"NE6N# M0O?8'K=UM\_BS!L"*RC#:5>S>>Q(0+#+2(0NN(KG"9/:@#R$4=@PMQ0=<0>T M[B*%V:"XU%`O&I9=MT6U3?Z>@Q]'`8XR'%`X9?$X#!"!RQ4:H\C'1YCT_\O8D0R&E_3C,1'1#&3]6DVG4Q0^M`Z#F^B\#KT440H\OUX:@PS MH$D:)S@E#Q1%`<4_IF$RP1$Q*@]I3&YQ2A/T@*[&.&M-P'#(#\TXWV@8@1&F!/TRAC]O9L<'AREJ&=L4TS"[,]-^IS+9B;;GNEW[Q&3$M;1RMS/ M_5/>.#"2P13OC/INI&V3G97P80F,1?FLIC6I`J;Y>LOM/KK9@DD^@___M7SS MX-["@I-%X\1?L/*)S]8Z_PJ:G7S??7AX_;-39^@X[2I>O[GVYA/#^P,``/__ M`P!02P,$%``&``@````A`'R)M,@R`0``0`(``!$`"`%D;V-0UG7UAF]\I*\ M+P_/.92+G6Z23W!>M:9"),M1`D:T4IEMA9[6R_0:)3YP(WG3&JC0'CQ:L/.S M4E@J6@:%/3II: MA;V-,PVZIVPICN'4WGDU%;NNR[I9KQ']"7Y9W3_VHZ;*''8E`+'#?AKNPRJN M`"9Q/?HT6Y,GF>W=^LE8D5.+M*AL_EKBL37<9Q-0#P+_)HX`UGO__'/V!0``__\#`%!+`0(M`!0`!@`( M````(0`F`F&2W0$``(T4```3``````````````````````!;0V]N=&5N=%]4 M>7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````` M````````%@0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`&F9MG3@`0`` M9A,``!H`````````````````/`<``'AL+U]R96QS+W=O`P``$@H```\````````````````` M7`H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'KEE,]^`P``2PL``!D````````````` M````Z1<``'AL+W=O&P``>&PO=V]R:W-H965T M``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`*'&ZXTU`P``I0H``!D`````````````````Z"$``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%H" M6@:<`@``4@8``!D`````````````````Y"H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`*5+./^!`@``U`8``!@`````````````````9S(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)-$?LUA`P``X0D``!D````````````````` MZ7<``'AL+W=OP%``!(%@``&0````````````````"!>P``>&PO=V]R:W-H965T!\D00``'H/```9```````` M`````````*2!``!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`-O&,I&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`(5?'8^O`@``00<``!D`````````````````<[,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)T';R9X`@``%`8``!D````````` M````````NM$``'AL+W=O&PO8V%L8T-H M86EN+GAM;%!+`0(M`!0`!@`(````(0#2(>O3Y`(``*@(```0```````````` M`````"S5``!D;V-0&UL4$L!`BT`%``&``@````A`'R)M,@R M`0``0`(``!$`````````````````1MD``&1O8U!R;W!S+V-O&UL4$L% 3!@`````H`"@`P0H``*_;```````` ` end XML 19 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 20 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9

4. RELATED PARTY TRANSACTIONS (Details Narrative) (CNY)
3 Months Ended 12 Months Ended

Oct. 31, 2014

Oct. 31, 2013

Oct. 31, 2014

Oct. 31, 2013

Imputed interest on advances from two directors 20,079 22,936

Interest expenses on advances from stockholder and related parties 181,393us-gaap_InterestExpenseRelatedParty 137,502us-gaap_InterestExpenseRelatedParty 181,393us-gaap_InterestExpenseRelatedParty 137,502us-gaap_InterestExpenseRelatedParty

Stockholder

Related party debt 459,131 349,911 459,131 349,911

Two Related Parties

Related party debt 2,988,738 2,266,916 2,988,738 2,266,916

Two Directors

Related party debt 402,510 455,574 402,510 455,574

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: abtbi_ImputedInterestOnAdvancesFromTwoDirectors

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(3),(4))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 3, 4

-Article 9

+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of interest expense incurred on a debt or other obligation to related party.

+ References

No definition available.

+ Details

Name: us-gaap_InterestExpenseRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abtbi_StockholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abtbi_TwoDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abtbi_TwoRelatedPartiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9

3. OTHER PAYABLES AND ACCRUED EXPENSES
12 Months Ended

Oct. 31, 2014

Payables and Accruals [Abstract]

3. OTHER PAYABLES AND ACCRUED EXPENSES
Other payables and accrued expenses at October 31, 2014 and 2013 consisted of the following:

October 31,

2014 2013

Other payables $ 929 $ 790

Accrued expenses 104,842 58,447

$ 105,771 $ 59,237

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 22 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D,#0R7S1B8F9?8C(R.5]B8SEF M9#=E969A,30B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7U-4 M3SPO>#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K M#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C=?24Y#3TU%7U1!6#PO>#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/CA?0T].0T5.5%)!5$E/3E-?04Y$7U))4TM3 M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C%?4U5-34%265]/1E]324=.249)0T%.5%]!0T-/ M53$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/C9?0T]-34E4345.5%-?04Y$7T-/ M3E1)3D=%3D-)13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C5?4U1/0TM(3TQ$15)37T5154E465]$971A:6QS7SPO M>#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I7 M;W)K#I7;W)K#I3='EL97-H M965T($A2968],T0B5V]R:W-H965T3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D,#0R7S1B8F9? M8C(R.5]B8SEF9#=E969A,30-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,S(Y,6$R-&-?9#`T,E\T8F)F7V(R,CE?8F,Y9F0W965F83$T+U=O'0O:'1M;#L@ M8VAA2!296=I2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P M,3,X-3'0^,3`M2SQS<&%N/CPO'0^+2TQ,"TS,3QS<&%N/CPO'0^3F\\2=S M(%)E<&]R=&EN9R!3=&%T=7,@0W5R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S,R.3%A,C1C7V0P-#)?-&)B9E]B,C(Y7V)C.69D-V5E9F$Q-`T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,CDQ83(T8U]D,#0R7S1B M8F9?8C(R.5]B8SEF9#=E969A,30O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'!E M;G-E'0^)FYB'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$F5D+"`U-BPX-S0L.#4P('-H87)E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^)FYB'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)FYB2!T'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)FYB'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D M,#0R7S1B8F9?8C(R.5]B8SEF9#=E969A,30-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,S(Y,6$R-&-?9#`T,E\T8F)F7V(R,CE?8F,Y9F0W965F M83$T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\S,CDQ83(T8U]D,#0R7S1B8F9?8C(R.5]B8SEF9#=E969A,30-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(Y,6$R-&-?9#`T,E\T8F)F M7V(R,CE?8F,Y9F0W965F83$T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'1A M8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@6QE/3-$)W9E6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!W:71H(&$@FAE;B!#:&%N9VAU82!I2!T=V\@2!P96YD:6YG M('1H92!A<'!R;W9A;"!FFAE;B!#:&%N9VAU82!AFAE;B!#:&%N9VAU82!W97)E(&EN M8VQU9&5D(&EN('1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N M=',@87,@:68@=&AE('1R86YS86-T:6]N2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE&-H86YG92!!9W)E96UE;G0F(S$T.#LI('=I=&@@=&AE M('-T;V-K:&]L9&5R2!I;G1EF%T M:6]N(&)Y($%"350-"B@F(S$T-SMT:&4@86-C;W5N=&EN9R!A8W%U:7)E928C M,30X.RDN(%1H92!F:6YA;F-I86P@2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2P@=&AE M6QE/3-$)W9EF4Z(#AP="<^*#$I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`X,B4[(&9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q,"4G/CQF;VYT M('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0M MFAE;B!#:&%N9VAU82X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!B86QA;F-E6QE/3-$)W=I9'1H.B`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`[)B,Q-C`[/"]F;VYT M/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M2P@=VAI8V@@87)E M('-U8FIE8W0@=&\@979A;'5A=&EO;BP@8V]N6QE/3-$)W=I9'1H.B`W-7!X.R!T97AT+6%L:6=N.B!R:6=H M="<^/&9O;G0@F4Z(#AP="<^1F%I6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE M0T*:7,@;V8@=&AE(&]P:6YI;VX@=&AA="!T:&4@0V]M<&%N>2!I6QE/3-$)W=I9'1H.B`W-7!X.R!T97AT+6%L:6=N.B!R M:6=H="<^/&9O;G0@F4Z(#AP="<^26YC;VUE('1A>&5S/"]F;VYT/CPO=&0^/"]T"!AF5D(&9O"!B M96YE9FET"!P;W-I=&EO;G,@=VAE"!B96YE9FET('1H870@;6%Y M('!O=&5N=&EA;&QY(&)E(')E86QI>F5D('5P;VX@=6QT:6UA=&4@6QE M/3-$)W=I9'1H.B`W-7!X.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@F4Z(#AP="<^ M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]F;VYT/CPO=&0^/"]T'!E;G-E9"!A65A'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,"XU:6XG M/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`@6QE/3-$)W=I9'1H.B`W M-7!X.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@F4Z(#AP="<^1F]R96EG;B!C=7)R M96YC>2!T2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE&-H86YG92!O;B!T:&4@9&%T97,@;V8@=')A M;G-A8W1I;VYS+B!-;VYE=&%R>2!A2!W87,@86-Q=6ER960N($5X8VAA;F=E M#0IG86EN6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE&-H86YG M92!R871E&-H86YG92!R871E'!E;G-E&-H86YG92!R871E6QE/3-$)W=I9'1H.B`U-B4[('!A9&1I;F6QE/3-$)W=I9'1H.B`R,24[(&)O6QE/3-$ M)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M M6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!O9B!234(@9F]R(&-U'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^*$LI)B,Q-C`[)B,Q-C`[ M/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!T M'!R97-S960@ M:6X@4DU"(&%N9"!(2R0@=&\@55,D(&ES(')E<&]R=&5D(&%S(&]T:&5R(&-O M;7!R96AE;G-I=F4@9V%I;B!O6QE/3-$ M)W=I9'1H.B`W-7!X.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@F4Z(#AP="<^3&]S M6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^*$TI)B,Q-C`[)B,Q-C`[/"]F M;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`W-7!X.R!T97AT+6%L:6=N M.B!R:6=H="<^/&9O;G0@F4Z(#AP="<^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E M;65N=',\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$ M)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2!H87,@ M96QE8W1E9"!T;R!E87)L>2!A9&]P="!T:&5S92!A;65N9&UE;G1S+CPO<#X- M"@T*/'`@'0M:6YD96YT.B`P+C5I;B<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE28C,30V.W,F(S$V,#LF(S$V,#M!8FEL:71Y#0IT;R!#;VYT M:6YU92!A2!A8V-E M<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@*$=!05`I+"!C;VYT:6YU871I M;VX@;V8@82!R97!O2!B92!C;VYD:71I;VYS M(&]R(&5V96YT0T* M=VEL;"!E=F%L=6%T92!T:&4@9V]I;F<@8V]N8V5R;B!C;VYS:61E6QE/3-$)V9O;G0Z(#AP="!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2P@4&QA;G0@86YD($5Q=6EP;65N M="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2!O9B!P2!A;F0@97%U:7!M M96YT(&%T($]C=&]B97(@,S$L#0HR,#$T(&%N9"`R,#$S.CPO<#X-"@T*/'`@ M'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W9E'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X M="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP M="<^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA M;&EG;CH@6QE/3-$)V9O;G0M6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[ M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#AP="<^36]T;W(@=F5H M:6-L97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^-#4L,3`U/"]F;VYT/CPO=&0^#0H@("`@ M/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#AP="<^,S$L.#(T/"]F;VYT/CPO=&0^#0H@("`@ M/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^-2PP,3<\+V9O;G0^/"]T9#X-"B`@("`\=&0@ M;F]W6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^-#@X+#(Y.#PO9F]N M=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP M="<^-#@P+#@T,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R M87`^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#AP="<^3&5S6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V9O;G0M6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M2!A;F0@97%U:7!M96YT+"!N970\+V9O;G0^/"]T9#X-"B`@("`\ M=&0@6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,3`X M+#(U-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,3(V M+#4V.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@6QE/3-$)V9O;G0Z(#AP="!4:6UE'!E;G-E(&9O65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@ M6%B;&5S(&%N9"!A8V-R=65D(&5X M<&5N6QE/3-$)W!A9&1I M;FF4Z(#AP="<^/&(^3V-T;V)E'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG M;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^/&(^ M,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`W."4G/CQF M;VYT('-T>6QE/3-$)V9O;G0M'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`X)3L@=&5X="UA M;&EG;CH@6QE/3-$)V9O;G0M6QE M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W M:61T:#H@."4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#AP="<^-SDP/"]F;VYT/CPO=&0^#0H@("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T M6QE/3-$)W!A9&1I M;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT M+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#AP="<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT M+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)V9O;G0Z(#AP="!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!O=V5D("0T-3DL M,3,Q(&%N9"`D,S0Y+#DQ,0T*6%B;&4@;VX@9&5M86YD M+B!);G1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!O=V5D("0T,#(L-3$P(&%N M9"`D-#4U+#4W-`T*2X\+W`^#0H-"CQP('-T M>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@6YC:"P@=&AE($-O;7!A;GDF(S$T-CMS(&-H:65F(&]F9FEC97(@;V8@9&5N M=&%L('1E8VAN;VQO9VEE6EE;&1I;F<@ M86X@86=G65A2!A2!F965S(&EN8VQU9&5D(&EN M#0IG96YE'!E;G-E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE65A2!R96-O9VYI>F5D#0HD,"!A;F0@)#(Q-"PV-C<@ M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'`@6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE M/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Q,#`E)SX-"CQT M6QE M/3-$)V9O;G0MF4Z(#AP M="<^3&5A6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE2!L96%S960@9G)O;2!T:&ER9"!P87)T M:65S(&]F9FEC92!S<&%C92!A;F0@86X@87!A2`R,"P@,C`Q-"!A;F0@2G5N92`S M,"P@,C`Q-"!R97-P96-T:79E;'DN(%1H92!#;VUP86YY(&-O;G1I;G5E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE2!A;'-O(&QE87-E6QE/3-$)V9O;G0Z(#AP="!4 M:6UE6QE/3-$ M)W=I9'1H.B`X.24G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^."PQ M-3$\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E#L@=&5X M="UA;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$"!P=7)P M;W-E&EM871E;'D-"B0Q+#4Q,BPW,C,@86YD("0Q+#0R,RPU M-C,@87,@;V8@3V-T;V)E&%B;&4-"FEN8V]M92X@5&AE28C,30V.W,@;&EM:71E M9"!O<&5R871I;F<@:&ES=&]R>2!A;F0@8V]N=&EN=6EN9R!L;W-S97,N($%C M8V]R9&EN9VQY+`T*82!F=6QL+"!D969E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UEFAE;B!#:&%N M9VAU82!W87,@:6YC;W)P;W)A=&5D(&EN('1H92!04D,@86YD(&ES('-U8FIE M8W0@=&\-"E!20R!I;F-O;64@=&%X('=H:6-H(&ES(&-O;7!U=&5D(&%C8V]R M9&EN9R!T;R!T:&4@2!3:&5N>FAE;B!#:&%N9VAU82!A65T(&-O;6UE;F-E9"!O M<&5R871I;VXN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D,#0R7S1B8F9?8C(R.5]B8SEF M9#=E969A,30-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(Y,6$R M-&-?9#`T,E\T8F)F7V(R,CE?8F,Y9F0W965F83$T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'`@2X\ M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#AP="!4:6UE6EN M9R!C;VYS;VQI9&%T960@9FEN86YC:6%L#0IS=&%T96UE;G1S+"!T:&4@0V]M M<&%N>2!H87,@86X@86-C=6UU;&%T960@9&5F:6-I="!O9B`D-2PT,#`L,3`W M(&%S(&]F($]C=&]B97(@,S$L(#(P,30@=&AA="!I;F-L=61E0T* M)#,L.#8S+#`R."!A;F0@=&AE($-O;7!A;GD@=7-E9"!C87-H(&EN(&]P97)A M=&EO;G,@;V8@)#2!A;F0@8VQA2!T;R!C;VYT:6YU92!I=',@ M;W!E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@6QE/3-$)V9O;G0Z(#AP="!4:6UE2P@5&EE($IU;B!#:&5N+"!A;6]U M;G1E9"!T;R!234(R-3`L,#`P("AE<75I=F%L96YT('1O(&%P<')O>&EM871E M;'D-"B0T,2PP,#`I+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP M="!4:6UE6QE/3-$)V9O M;G0Z(#AP="!4:6UE2!R96-E:79E9"!C87-H(&%D M=F%N8V4@9G)O;2!A(')E;&%T960@<&%R='DL($-H:2!&=6YG(%EU+"!A;6]U M;G1E9"!T;R!234(R-3`L,#`P("AE<75I=F%L96YT('1O(&%P<')O>&EM871E M;'D-"B0T,2PP,#`I+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE0T*)#0Y+#`P,"DN/"]F;VYT M/CPO<#X-"@T*/'`@6QE/3-$)V9O M;G0Z(#AP="!4:6UE6QE M/3-$)V9O;G0Z(#AP="!4:6UE0T*,C`L(#(P,34L('1H92!#;VUP86YY(')E8V5I=F5D(&-A M2P@0VAI($9U;F<@674L M+"!A;6]U;G1E9"!T;R!234(R-3`L,#`P("AE<75I=F%L96YT('1O(&%P<')O M>&EM871E;'D-"B0T,2PP,#`I+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D,#0R7S1B8F9? M8C(R.5]B8SEF9#=E969A,30-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,S(Y,6$R-&-?9#`T,E\T8F)F7V(R,CE?8F,Y9F0W965F83$T+U=O'0O:'1M;#L@ M8VAAF%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`X M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEFAE;@T*0VAA;F=H=6$F M(S$T.#LI('=AFAE;B!#:&%N9VAU82!P;&%N2!I2!H87,- M"FYO(')E=F5N=64@2!S=&]C:VAO;&1E2`R.2P@,C`P."P@36%S M=&5R:7-E(&5N=&5R960@:6YT;R!A(%-H87)E(%!UFAE;B!#:&%N9VAU82!W:&5R975P;VX@36%S=&5R:7-E M(&%C<75IFAE;B!#:&%N9VAU82!F;W(-"E53)#8T M+#$P,"!I;B!C87-H+B!4:&4@86-Q=6ES:71I;VX@=V%S(&-O;7!L971E9"!O M;B!&96)R=6%R>2`R-2P@,C`P."X@07,@8F]T:"!-87-T97)IF%T:6]N(&]F(&5N=&ET:65S('5N9&5R(&-O;6UO M;B!C;VYT2P@=&AE#0IO<&5R871I;VYS(&]F(%-H M96YZ:&5N($-H86YG:'5A('=E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE&-H86YG92!!9W)E96UE;G0@86YD('1H92!!9F9I;&EA=&4@06=R965M M96YT+`T*=&AE(#2!S=&]C:VAO;&1E6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$ M)V9O;G0Z(#AP="!4:6UE2!-87-T97)IF%T:6]N(&AA9"!O8V-U6QE/3-$ M)W=I9'1H.B`X)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V9O;G0MF4Z(#AP="<^5&AE(&)A;&%N8V4@6QE/3-$)W=I9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^5&AE('-T871E M;65N="!O9B!O<&5R871I;VYS(&EN8VQU9&EN9R!T:&4@;W!E'0^/'`@FAE;B!#:&%N9VAU82X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE2!B86QA;F-E6QE/3-$)V9O;G0Z(#AP="!4:6UE'0^/'`@6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2!A;F0@97%U:7!M96YT(&%R92!S=&%T960@870@8V]S="P@;&5S'!E;F1I='5R97,@9F]R(&%D M9&ET:6]N6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)V9O;G0Z(#AP="!4 M:6UE2!A8V-O=6YT6EN9R!A;6]U;G0L('1H92!A'0^/'`@'!E;G-E&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"!AF5D(&9O"!B M96YE9FET"!P;W-I=&EO;G,@=VAE"!B96YE9FET('1H870@;6%Y M('!O=&5N=&EA;&QY(&)E(')E86QI>F5D('5P;VX@=6QT:6UA=&4@'0^/'`@2X\+W`^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!O9B!T:&4@0V]M<&%N>2!IFAE;B!#:&%N9VAU82!M86EN=&%I;B!T:&5I M&EM871E(')A=&5S(&]F(&5X8VAA;F=E M(&]N('1H92!D871E&-H86YG92!A="!T M:&%T(&1A=&4N($YO;BUM;VYE=&%R>0T*87-S971S(&%N9"!L:6%B:6QI=&EE M2!I&-H86YG92!R871E(&9O65A'0M86QI9VXZ(&-E M;G1E6QE/3-$ M)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,C$E.R!B;W)D97(M8F]T=&]M M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^/&(^3V-T;V)E6QE/3-$)V)A8VMGF4Z(#AP="<^0F%L86YC92!S:&5E="!I=&5M6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)V)A8VMGF4Z(#AP="<^55,D,3U(2R0W+C6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E2!A9F9E8W0@=&AE($-O M;7!A;GDF(S$T-CMS(&9I;F%N8VEA;"!C;VYD:71I;VX@:6X@=&5R;7,@;V8@ M55,D(')E<&]R=&EN9RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O M;G0Z(#AP="!4:6UE2!T'!R97-S960@:6X@4DU"(&%N9"!(2R0@=&\@ M55,D(&ES(')E<&]R=&5D(&%S(&]T:&5R(&-O;7!R96AE;G-I=F4@9V%I;B!O M2!T:&4@=V5I9VAT960@879E&-E<'0@=&AA="!T:&4@9&5N;VUI;F%T;W(@ M:7,@:6YC2!O;F4@6QE/3-$)V9O;G0Z(#AP="!4:6UE2!A9&]P="!T:&5S92!A;65N9&UE;G1S+CPO<#X-"@T*/'`@'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M28C,30V.W,F(S$V,#LF(S$V,#M!8FEL:71Y#0IT;R!#;VYT:6YU92!A2!A8V-E<'1E9"!A8V-O M=6YT:6YG('!R:6YC:7!L97,@*$=!05`I+"!C;VYT:6YU871I;VX@;V8@82!R M97!O2!B92!C;VYD:71I;VYS(&]R(&5V96YT M0T*=VEL;"!E=F%L M=6%T92!T:&4@9V]I;F<@8V]N8V5R;B!C;VYS:61E6QE/3-$)V9O;G0Z(#AP="!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB M;W1T;VTZ(#$N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,C$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@ M=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#AP="<^/&(^3V-T;V)E6QE/3-$)W=I9'1H.B`R,24[ M(&)O6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M&-E<'0@9F]R('-H87)E(&-A<&ET86PL(&%D9&ET:6]N86P@<&%I M9"UI;B!C87!I=&%L(&%N9"!A8V-U;75L871E9"!D969I8VET65AF4Z(#AP="<^55,D,3U(2R0W+C6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#AP="<^ M06UO=6YT65A6QE/3-$)V9O;G0MF4Z(#AP="<^55,D,3U(2R0W M+C3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T M8U]D,#0R7S1B8F9?8C(R.5]B8SEF9#=E969A,30-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,S(Y,6$R-&-?9#`T,E\T8F)F7V(R,CE?8F,Y9F0W M965F83$T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V)O6QE/3-$)V9O;G0M M6QE/3-$)W!A9&1I;F6QE/3-$)W9E'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#AP="<^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\ M=&0@;F]W6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1EF4Z(#AP="<^4&QA;G0@86YD M(&UA8VAI;F5R>3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H M.B`X)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)2<^/&9O M;G0@6QE/3-$)W=I9'1H M.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#AP M="<^36]T;W(@=F5H:6-L97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^-#4L,3`U/"]F;VYT M/CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^,S$L.#(T/"]F;VYT M/CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^-2PP,3<\+V9O;G0^/"]T M9#X-"B`@("`\=&0@;F]W6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^ M-#@X+#(Y.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#AP="<^-#@P+#@T,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M)W9EF4Z(#AP="<^3&5S6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)V9O;G0M M6QE M/3-$)W!A9&1I;F6QE/3-$)V9O;G0M M2!A;F0@97%U:7!M96YT+"!N970\+V9O;G0^ M/"]T9#X-"B`@("`\=&0@6QE M/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#AP="<^,3`X+#(U-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@6QE M/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#AP="<^,3(V+#4V.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0Z(#AP="!4:6UE6QE/3-$)W9E6QE/3-$ M)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A M9&1I;F'0M86QI9VXZ M(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V9O;G0M6QE M/3-$)W9EF4Z(#AP="<^3W1H97(@<&%Y86)L97,\+V9O M;G0^/"]T9#X-"B`@("`\=&0@F4Z(#AP="<^)#PO9F]N M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@."4[('1E>'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^.3(Y M/"]F;VYT/CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS M1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Q)3L@=&5X="UA;&EG;CH@6QE/3-$)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)V9O;G0M6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)V)O M6QE/3-$)V9O;G0M M6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\S,CDQ83(T8U]D,#0R7S1B8F9?8C(R.5]B8SEF9#=E969A,30-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S(Y,6$R-&-?9#`T,E\T8F)F M7V(R,CE?8F,Y9F0W965F83$T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'`@'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\ M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H M.B`X)3L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M MF4Z(#AP="<^ M5&]T86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#AP="!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H86YG M92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&-H86YG92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XW+C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&-H86YG92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XV+C$T.3@\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!P;&%N="!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XS-"PU,C,\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D M,#0R7S1B8F9?8C(R.5]B8SEF9#=E969A,30-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,S(Y,6$R-&-?9#`T,E\T8F)F7V(R,CE?8F,Y9F0W965F M83$T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!D96)T/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DX."PW,S@\2!D96)T/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@-#`R+#4Q,#QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@ M,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ M83(T8U]D,#0R7S1B8F9?8C(R.5]B8SEF9#=E969A,30-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,S(Y,6$R-&-?9#`T,E\T8F)F7V(R,CE?8F,Y M9F0W965F83$T+U=O'0O:'1M;#L@8VAA"!$971A:6QS($YA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$"!A'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D,#0R M7S1B8F9?8C(R.5]B8SEF9#=E969A,30-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,S(Y,6$R-&-?9#`T,E\T8F)F7V(R,CE?8F,Y9F0W965F83$T M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM+2TM/5].97AT4&%R=%\S,CDQ83(T8U]D,#0R7S1B8F9?8C(R 2.5]B8SEF9#=E969A,30M+0T* ` end XML 23 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9

8. CONCENTRATIONS AND RISKS (Details Narrative)

Oct. 31, 2014

Oct. 31, 2013

RMB

Percent of assets located in country 91.00% 96.00%

US

Percent of assets located in country 9.00% 4.00%

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: abtbi_PercentOfAssetsLocatedInCountry

Namespace Prefix: abtbi_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementGeographicalAxis=abtbi_CNMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=abtbi_USMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9

7. INCOME TAX (Details Narrative) (CNY)
12 Months Ended

Oct. 31, 2014

Oct. 31, 2013

Income Tax Details Narrative

Net operating loss carry forwards 1,512,723us-gaap_OperatingLossCarryforwards 1,423,563us-gaap_OperatingLossCarryforwards

Deferred tax asset valuation allowance 514,326 484,011

Deferred tax asset 0us-gaap_DeferredTaxAssetsNet 0us-gaap_DeferredTaxAssetsNet

Net change in the valuation allowance 30,315

X

- Details

Name: abtbi_IncomeTaxDetailsNarrativeAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32123-109318

+ Details

Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 25 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9

10. GOING CONCERN (Details Narrative) (USD $)
12 Months Ended

Oct. 31, 2014

Oct. 31, 2013

Going Concern Details Narrative

Accumulated deficit $ (5,400,107) $ (4,572,351)

Net loss $ (827,756)us-gaap_ProfitLoss $ (890,343)us-gaap_ProfitLoss

X

- Details

Name: abtbi_GoingConcernDetailsNarrativeAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 26 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

2. PROPERTY AND EQUIPMENT
12 Months Ended

Oct. 31, 2014

Property, Plant and Equipment [Abstract]

2. PROPERTY AND EQUIPMENT
The following is a summary of property and equipment at October 31, 2014 and 2013:

October 31,

2014 2013

Plant and machinery $ 272,214 $ 266,931

Motor vehicles 45,105 45,239

Office equipment 34,523 31,824

Computer software 5,017 5,017

Office improvements 131,439 131,829

488,298 480,840

Less: accumulated depreciation 380,044 354,272

Property and equipment, net $ 108,254 $ 126,568

Depreciation expense for the year ended October 31, 2014 and 2013 was $26,640 and $26,201 respectively.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)

Oct. 31, 2014

Oct. 31, 2013

CURRENT ASSETS

Cash and cash equivalents $ 74,354us-gaap_Cash $ 48,380us-gaap_Cash

Other receivables and prepaid expenses 18,768us-gaap_PrepaidExpenseCurrent 21,105us-gaap_PrepaidExpenseCurrent

Total Current Assets 93,122us-gaap_AssetsCurrent 69,485us-gaap_AssetsCurrent

PROPERTY AND EQUIPMENT, NET 108,254us-gaap_PropertyPlantAndEquipmentNet 126,568us-gaap_PropertyPlantAndEquipmentNet

DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT 16,238 1,140

TOTAL ASSETS 217,614us-gaap_Assets 197,193us-gaap_Assets

CURRENT LIABILITIES

Other payables and accrued expenses 105,771us-gaap_OtherLiabilitiesCurrent 59,237us-gaap_OtherLiabilitiesCurrent

Due to directors 402,510abtbi_DueToDirectors 455,574abtbi_DueToDirectors

Due to a stockholder 459,131 349,911

Due to related parties 2,988,738us-gaap_DueToRelatedPartiesCurrent 2,266,916us-gaap_DueToRelatedPartiesCurrent

Total Current Liabilities 3,956,150us-gaap_LiabilitiesCurrent 3,131,638us-gaap_LiabilitiesCurrent

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' DEFICIT

Common stock, $0.00001 par value, 100,000,000 shares authorized, 56,874,850 shares issued and outstanding as of October 31, 2014 and October 31, 2013 569us-gaap_CommonStockValue 569us-gaap_CommonStockValue

Additional paid-in capital 1,927,968us-gaap_AdditionalPaidInCapital 1,907,889us-gaap_AdditionalPaidInCapital

Accumulated deficit (5,400,107) (4,572,351)

Accumulated other comprehensive loss (266,966) (270,552)

Total Deficit (3,738,536)us-gaap_StockholdersEquity (2,934,445)us-gaap_StockholdersEquity

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 217,614 $ 197,193

X

- Definition

Interest owed to directors and related company

+ References

No definition available.

+ Details

Name: abtbi_DepositForPurchasePropertyEquipment

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Stock subscription receivable

+ References

No definition available.

+ Details

Name: abtbi_DueToDirectors

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 12

-Subparagraph a(1)

-Article 6

+ Details

Name: us-gaap_DueToOfficersOrStockholdersCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 28 0001354488-15-000348-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-15-000348-xbrl.zip M4$L#!!0````(`&UB/48HASGP950``#3+`@`2`!P`86)T8FDM,C`Q-#$P,S$N M>&UL550)``.=:\I4G6O*5'5X"P`!!"4.```$.0$``.Q=;7>CMK;^?M>Z_X&3 MTW:U:\4)+\;8R=24Z2]IQ^ZB(@VSK%R$=`7OKK[Y8$1K;!!HQC MG'A6.Y.`T'ZT]>P7"2%]^,?SV%,>$0TP\3\>:$?J@8)\A[C8'WX\^/6NU;\[ MO[HZ4/[QZ7__1X$_'_[6:BF7&'GNB7)!G-:5/R"GRE=[C$Z4'Y&/J!T2>JK\ M9GL17/GGOZ_\$*XY(7Y$<%6(.5':1YJMM%H%ZKPC$770M,+^V?W9E:*IAJ:K M6AM^^*=Q]#P`@1=V"+?AHOFM?J%J\)?>N]>L$[5S8FH%185V&`534>JS&O\1 MCW]X?J`>/F%_*Z`S/SAY#O#'@U$83DZ.CY^>GHZ>C"-"A\>ZJFK'__[RRYTS M0F.[A?T@M'T''21/>=C_,^LYK=?K'?.[2=&%DDQX(L,X9K`PWCEFOM52M96A)<8H& MN9`[QW`W*8@#TM8U:UG[1(GD@2AH#6U[,GU@8`EQ^#)!QU"H!:40Q<[TN=4/S3X`&-CE;'3\3@8Z^R%\2#N$ M_T;&R,6.[1TY9,R?8/9TD%@(8]5)P+E[BP8*)^3)B'<3?[J5/''T'+@'\7TF M_>-!@,<3#^AUG-0E3,8AX`2>0P6['P\N*1E#!49+TP!G2#A@36VE`*:/(3_$ MXM].)Y_.!5WG"DOEC:! M'B#N(@HP)1HRK_,I;4Y24WIOX3'DN\E#<;M3\>[,(\GU&0#)Q5BE^7KN!]<# M`6P'=2L<5?@I;N)X<')#":@H?+GQ0'M] MW_W\WPA/6'UG+_?@W_K/.#CXE!1>HHB/V7YX`.8IX'S38W4'4*]O*!:;("0E]SV8RIX,W M;B%)KN1$04C&^U#9K%#YFMERS(!]Q&QLQ-P.&_8QH4DQX16GGO\X)^,Q\;D_ M?!M]SUZF\O$O&R^'+]"^"?'9<'AVP+S0[BWV]VO,HB?]W7==S&S!]FYL[%[Y MY_8$A[;WKOI^J0[>"0\NT`!1BEQN`4Q1H$L^B?PNF""<_@H=O!,FQ"K[XQ:% M-O:1^]FF/O:';R05*.@2LAO_3AC0=YQH'/'$Z#H<():-+JV2,?::XW4QQ9L&/7F7!S]R`8I,+?O8T:<"`8J,#R"4N M8C^X:-C@8K=[83W0T<:)C:[GJ M?M*CZ9,>NQ5H]H1J/*&V[W9V;)7:;EA@>R[`[Z>@MC\%M=%U;?G?71EC[.V$]0-7&":LMA M9C^MT/AIA9T,.WM>-9Y7K^R$VBVU^X:V1HJ;TR!#G#K[5,]O8%K0J*+GUY@6 M--E^9'IOQW0K&7W<@`WGGFJ[9:B[JZ2X`:^2H,>A\]<[X?B3WV^!NI>$GMD> MV^3P;H10>`5!YZU%T!\1&5)[,F([^,G1,U''ZO!81NR5_XB"D,E-=SL1\I:K M^ZT&Z6PJ_O3SGHH2-1)U[*GX^E0\_[JGHD2-1!U[*KX^%7,"M/PI^#4,^=@& MBO1[RFX]N.\I6R[@[RF[]21@ M3]FA."^I^)^Y-Z0H+VGXG[DWN"@O1LY97," M^9ZR6P_N>\J6"_A[RFX]"=A3-F^RB8PG48CH'1F$3S9%;X.&A<[XB`F9J8`W M/GTSOS)Z?P98D\\`VP8C]F>!-?TLL&VP8G\F6-/.!-O"9/\^96A:RO":>6/B M"O8'Q#7W@+@MOK3>]#ZB#X_LX__T>P$]?D(HX$8 MTEQ`B]_*!BQ7OD/&:,J67XC#Q^ZSF5LA1=4[35W^_*R<#GIM?C?\2^PEVU'N MS6)O%J]C%LW8QB_RL;")7^\N%C]_'B,[B"CZA`/2UC4+XN5%4EMR:U8&JRY' MP-W(IBC(%1%K@1>J+`/PW>3(N_@=(K MZ#:!'XO7[R)\\ID;_"T:^BYY_12V$@[+BMQZ=G#PF(&MA<@ M(6&F`KGF\XA2=AD'T*=L;4#9MK3DAN35MDB`?R'/^]DG3_X=L)?XR+T*@@BB M9E&Q7XE,@)S:%L7^1KP(PBA]N<0>HD%%<7.U9-!;Z.$6L==IV!^R5"0J+NUW MYC%7U;8HE:,Y!W4/"2UN4G=CVX/GE&GU"IOVM_T7&<),U5F&(+I<$/@2KA5O M[.7OLT:P4%.^.,:P<9�>O!QX.KKY?@U(Y4YM<^')<06A/.]A9Q"BG]*!P1BO^" MX%)(CSG8-#7^DXEN7M2:J!:UMC%4F"_V"F"4<@XXP#J1[["`6Y1S\.MS@$]\ M['T\"&F$#I3C-<5D4J:`F%^P_<"6F4"UL4,KTXA4L>K!)T,SM([1396Z6',SN:J9:1?A&A^[F#XM?5@:YW.CVMDZ+(E[$>FD(ZT7O=KB7W2$DT M8HA+`^9#P#)&Q'/AM[5YTN[U-&T.U%)1]8`KI+*VV=.,2N#B+4]9^>F9\Y5U MU#9-TX*8F%5I68'%VJWJIJ8N%SA=A,(VTZO1<9@]W;!2E>=4OP:*0AK05-.R MM-(P^D&`PNH=K?4LK6>D4D5UQ844\P.:U6$95K:09*_>"0EP>$DH#'2=D1V@ M9"'"=`%"]49J[91:J^74`JQ8GW=TYAY+(UNY5N,K6D-;>L?L2$Y[F9!U`16T MC*YNMJL!$E1;UT-T>NVN.<_?I0:YKC?H&9JN%Y1X0]'$QFX\1;UV"J&!)Y*5 MG5%Y903%^KMKS?*O``(I@>8CC>K!H-/+3,MYK56D%FIR*:DY)R>L$0-4J]N5 M`.0(6`-'L7[OZ59/[OFB.);MLRO>^K#==L$[7`_N[>?*>FKIEFJ:LE66$[P! MW(7TVF*#@DZG-MQ24@+>5TY)Q6[(M24CJP35`:Q2`E,6V,+PGL]$KC>W`3': M@JBT;!)!2%D#3.$IC?K`7$O"P<^D1.R=U$5L:+]5! MMVUT=&T&A%3MO+IK=)V@(Z/=;DN)VVJO5$R\7DR\KG>TW@;$%XMPAF5T3:.S ML=9G'/ZW(I_;();EIX>M&'!"A#4WB&W5L4/+NU'K=*S-84L60^4S:_/3M$M63:R*0ZJJ2M:Y7.;Z M"+,.Q5Z1:UB:V>NMA?`K\1T8Y@PW.H4$Q]?C55S3R3[[/ON[,OP M6G2C=36#S:)5D%\S]-)ZU0S+9%YC#>CI:O]D3R1!S5KII\GOB_,DK8.HM.8L MM0J@9*:7215+?"+P?;$3)'X]?&QU-,N29X96RZT':7FSMK2NU5X+Z32`Q*2M M1X7S&ER04@E&>9+-J6]_8R"S\]`/T)= M[-OTA6\KS<8!4"TEGL>'3^+!H+8!Y3P!M]FBIFMW?6HW3[M032SD##PA6%9&6;C3*MVKJK"9UOK>9^M6G2&M5K<%B4A;LV87RN4)7!-;>5KWVF;7-"IA M2UY%)M_"GMD!=MB,$/;86X1*NLO[-K>E'LG3+BM$UX!TI2:7(=4K(_T7D'P$ MU_N/,#P9HJ\1LY_K`7]46O.WMJH++^JL!FASS5K>+[G-,JVN)G^_64^S5JTZ M+K+F;@GDV9Y8MOBXX%KL:D#F*;$.D#)K4NH!Q*H6M^18(#\"H>4.T4?L%'ZY M4`6V,?>A?#E@!9O%O[+92*NR`O?*QF3#>96VK+&P2-?T7F]^T4RC&K>1)4FU M]\"&9H`W`785(8PBIKN<$&(E0'_,AN6BLUBAM*97H,'<`FJV,*<$J@TVI&ZJ MU`]Q0[I,&)5.WP3W),=U<"I:N$ETFHRJ."AK2VE+"4`2-O,R(?8XZ\,A3 M3:02:ZGRQ50#4D$I8F%542!7OD.1':`+)/Z]\KE)WR('X4?VLHM]SSZ[X48] M+-)U2TW7]98'L9EFE-9WS^INO!4W]DOR.+A>$WU]D2[8[0[*QJ1#V$#+2B? MM*AF3U^[!=+Z`F8K-Y2PO:3=LY=?`[:6?[JVM>^$^!'7MCJ_91EZ6]=FUC<4 ME%\O\O*^IJ.V>_+7;;4C%PO7-Z!SW>C*;Q>*BZ\7>(4%Z:#S.G"#.22)H?/? M"%,DC"1O(ZUZ/I(P555B2TD(&VA!A;?7'7US#=BL]KN6O)-.<>'UPBZM\JXF M?\M8'7:.J5QBW_:=^CV,U=5UO;O24C/$UPN\_#)S3=.ZJUW,$N#983ACI]=Z M%*VWVX:9%_PSI-8"L[1:S9[6SL]1JL',WF2U M-NL#)WTW6$]D4WNZ:2R%)XE<'V!Y+PICY>7LR\`W7W)VKT3(GSZ?*`'"?*-U)J-SC,>0O7]&3 MB".(N"NJ9#VX]GR'.1\!_IC-*/>=_-7)J4 MA'BJC&TZQ*!&5:"=5]JRG8OX24_*$PY'4(CR4]L0 M94L3XQV>0>HW,!([5#7K2%E4"@X4\N1#^8<7)7PBH/1T2Z*D31,8R8MO;5AM MEOHM!V'[KF*HWX+,8(+84!-Y+UD2)C#^#\!+0L3@W]$?0D?YT MWQ3*C1Q^GI;C89_S)J080AZK#4/D!+VP$L%4'1BBDN_RQE(;0T)C3U_M3OL# M[HGG9MHN5\YQR_/9]7P:P>1[;0B0]Z M@$[W(7\.P%@0?X3],.&H`.TAXY@-D9ZZS&D*'J>17[ECRY1M"CH])RY/#.;; MT[^;L:![,@%3ZVE@.VD9:0<'C@MJ'2*%[_D*3)&U@7D^%&"7VY"M2$\JXJFX MC3OL&;_8S$4P>OX$=LZ6[BN_".8NLJ$'=^K.&G%NOO:5 M_P-':],71>]QY74IQ&(C2:<%@D66\P8N[RO,I\"+\61_'KW3:=]".DY8QW;S$PX'EY! MP%TMC\R,2QYBY(0+E^B!"C6(@-H]4OH!N'_`*T$`,BR*93J)?#'5PU:. M24P]Y8&O]`<#2+O9X;I"T8ON4OF>:5[*3J9/+.,#IB%"+"CR0[(CEF(*TV5Q M$;+`-.3E=>EA!F_8`XMM!`?`.!V2>'!@`INT.4;)XT860B7GQZL2SBRNPQY" MRX;QB<,\JAU)CV8=OH'NKF5-HJKNXP"Z_]U(_$"LGV$#R2\,"Z MR);#:=_GYC$SIOV`''8NN*UTU2/(;3+8O=L:_<(V95,T@YMQ3P1=G[4XUFXR M!.%9`->S*T9+R4P)PQ)/LBC2!`LC8K&9F]U5'\N48*PWE#T=,"\E#U-:2)$] MS5?2@1BXEPD)4#S697G,=$";)@J\.HKB.TF&`_EU*F(N7$H2XB1P9BZ+U<<"\T#>)/IT'R: M&>1H*DXJN6(&Q//($SQSLKUV-V-^O_MMX=G]K'8MG8V?@BXKH\#K`NV'DJ\& MDO;J]8-AQOE@>WPB*!@AL6%:@/EZN<2_^W#5%D>#Y#4Q98^:PZ?PG]_^U=67/;2)+^*XA>=X0=`6EXDYK>W@@==K>V?2@L>R;V M:0(B00EK$-#BD*SY]9M7%:I`0`(/4:2D>>BQ)!+(RLK*RN/+3`RA@JJ-V,.8 MW/]EOPC\H@^O_FK3YT2K)\X8O.4M`5037(;O: M14CN)>3&OXF)3D=-Q@@^$)&TS$WU`0E%Z`^9[@SFF&[!Y0WO)'F0YA=I,`F\ MA%PX6W/@ARGH;'\2+.`YG<+.0V3U0I5DB#1$!2TCRIR-#NNC5HBC"*Y0"K5( ML*)6I\B(TNWPO#S,JH.\NZF@6(N'L,D%UH'"$-G,^^$7V\#Q MF33-9]=\/+,K<*<\PO^)]D*])J@5;X8OQZ6(*X;?#HOQS/3S)$C'89SFK`%1 M?P*U%".M^4XV9PY7)[:BB8ZD*JHIP:W7E72IE32R094$LU?1F'!+#0ET@32^NQUTP=P M8"4Y.QX M':F<3`?G*3:L#5M=GH"1YR664_G]_(WA3+K.GS'HCK_P/Q4?_O,O\\,:R_75 MC^"5%X'YT:^?CLHANH/#&ZE)@_0O76X:$,/YAJF+4.:&,\LQ$IP4IVO+_2]=0#.I<,FX*N8'6 M.G!``CG-)*E_RJA[UV2OLZF738:03 M.T$K"B/?+BM2K^@BA!I8]RG9)XJH.<,D0!`M@VP5R#5U!6X`1]>_11`#87+] M#%P[,<(2W]')00EX^N7'S3R"T5(6@/.)UUZ0R)?!-;X4-V MV">V)GD%A*VEPEZ\&!%8EWAXH/;"(,(T21JDLEW*P&2V`!L)0N+<4-T::C(. M(;/]K#_LY*D_S4,PIF\4#+KZ;SH&+08X;$/?N?/A`GM5CIM2CA\VH!P_@AVP MASL^D:U^]GK1A*R+:\PJ*"RS0I"9>`P^')X?66!T(H=AY]U!RWE[>'Z,_WAG MHL`*OQL??SI#C<8YI,0Y"5(P0!B,17OPD5Y\R'N@+;U*T^RT`CQ_?FQ3Y%8L MY\H/6?OFAN6C69&@M743^+<"`PD*>F^O0+>C2D%W.2.CCVTK#D,$"=P<:5:8 MBPAI&Z-O3I$!MK*YTM4QP@$1TP7;!ZDC'W6;EQ6N MN7R6:V+0']`KEFP/KMHEZG$KI3T;+B^G*I3"8P$F@CL@1*3Y=(J5AQS[D-=H M!IZ-5-@*^MI5L#S&V6CFEQ!]M'-;=BW MPHX8Y%TRYAC?`6$/0F+'M6$`<.!4&0',6WP%:70'KF)X>;W#9`G*%=R[R"ED MS&4D-_H=`A;C6X[?VM+S>E]LZK[X8P/WQ0T#^]4^5(W=YO)T6(\_`"'%>BAKCY#\7-#YJ;IP4W7?V$(CH[!O$">]D( MFV+H]M)+-!)A^O`VD?(A*DIJC/1/3'U(DZ)7'FF#:^Z65X1*^6/7TLN-(\/< MS6T^Q@NT8#V@:@OBVG4C.OJ1<-L5JLJA[V+YVT\R47%IL*YB<2DA7W,C)'45 M)]D>NAY.Y&5YD5$K+]R,<-OJEF\PK81A+R-"BJJKS"@;1#4(K*!``BQM+K6% MX'J\*\%#"4!A!ND/M*1I@(_&=-0`[EZUYJ:TYI\;T)H\<,C)<-+FLU>/M09V M8'"AH6T][+6PJT.G7RK^+/Y@`7V_TT.MO[O.1*.`O)^U":7$-PT:06L1(6(L M9CR9*@4=['.6VIA`R(H-0+!)@L9C[B5^)\4*/'66W%WCQ(FA-GW\&JDND]\2>&RZ*PM M,!/S1:8+R1`=2FWS9[T;+PCIF'EF@ADEE_>`3"DZLB1WUAJH\A2_E5!E\245 M.B2<-NJW?@4Y^>&'P54<3R2/;2Z5_4+R"5.TN+`_P:W/>!1FC$A%B!'*-"ME MO,TGT6K*;0Q4^AT`Z;05[!XJ9J+,[U%BX;G;A;5+9QR,*EV M>_!*Q")UA2G$3[,)0I3H=B'J'HU2?7-Q*@3<3RS0,C(LF$I(:M_.R15\K^"' MV(LS6HGQ%3)=)'C$:>HWO:$[;+7HMV^Z+7?8.[!;R#P"UU\QT2NH@O_> M1"S)SOO?,>@S?#F@Z,*.T2PH%;0&*8,YSIT)P4?VG5(EA'8+YJLA**7J\<4: M6&6=;+HHJ`A&5/)HK#H6%2`,H.7[^1O7^?.O-W1POWXZ>O1#NSDT4X7H*;RQ M`0!$'4>Z5LDFJ\K".2PS[DX9J6;<*E$@'`U*B2.-8.10D_'^?>=3'/D9>DXU M#HV!2A)OK!)$PX38Q76$F2PMJ!'%GMBP9'([G^-H;R94&MF62F]S_DWS3X?K M#JU\LG#Y,V`(^T9"!0U0W0"-FZQP^YA]75M/=%R"Q%.&*HS1N]&>?6)T1*FI MYMIA>:ZM<+;:!%3KB;>WZ`O4BC.HH#H%\*Z\O03G`ITA<07*_,$^D,Y!J9KY MX'=,.`!KBV4`!$N,X\%':J%A,=).H8Z(S$N\!'U5]3HNYL8#YSY/R3)*;N9$ M5>'>C#+1TGMK1':^/`]=JB#4WI:%-:9UUYU''N+,N3OSW8YI@56FB+'20G^E M''[1QT%P>MP/9L>EO[0YN<3D-5=UJ`T6;,HSRA<1@C*FJS2-M#,#\G5BI>J0 MD8F+CC@5QJ>[4A:_#BOU84NT/_CU-T?>O@>N31;/X%'[?3$"EZD/7O<#._C$ M"SP3B7[@1>B-?_!C'2HPLJWI,752:VI.XTHQ?;O MH#"'^\-^O_T[J,S!?KO=Z6TUH=T6$]HZZ'77)4UPAV?^"K)TJ.\?NSV?;:P9 M70!T40)#E,P[?ZN9W^N*E/0.1EM-Z$")\[`]?!'Q!B.^XKQ%1^G=W]!+*@S" M>R)[1$A-=._MFZ[;'PVX+.5-O^_VVZWG$BGX'*M0K(9HS[R)0!O1@%1VI2Y2 M=M'[O*6ZP`N?BXVDY,5T9Y2-?Q'?B,VZ[QR&X![EEU>ZR3.B0XJR%,3XY*%H MARB^9IXXS\!_R=##3&-TI.-)N M9USQ"&I,%HD.!2LR7C4<'5ZE$<'!?.$TS+'D-/,UCA.3Y`/YFI6&,1$7U-^FTJTO_7!B+]:JJY,9>< MXG,OXM:=WI/F<%`#J&BE%)47Z$`C'2))_=H0A/\3M6W*9B7I%CC:&.<0I4I( M%U4`KW";]H98I%09ITR$;:#6]#<1]V;?J=IYT_18/)=(5&RSQ?'"],?'C50I M@:A<^^)P/WNM<>2E4KBB7 M!GU(W17S]4ALZDA\W@CF#X-TYH2GLP2(R!STEE_I7$07R<&\9WA]$H2[HD"(!(:L/85,<;QL3XI33#2@V<`>^^ M(F!0_WE5'$N%JA(()."RC.^A(EFDHQCRM9?%>P0TL7#'E('G)*W"53.6'R]) M+A#!4,*,DR51Q'VV[`9MHB=]M/N*P82:!J,%PQ*3F$>/P2.P MG8QR*"L?SPK&4;_>!$7_$/)L1Y"B)G+?G^45& M94"=5G^OUWKG.B=6H[COD51",M0(RRJQ3IM&O)FAITJ$!(=+.2P9XSMAJ;G/ MTYHL.E0IBFZOYSS06N_M'X>'9^]L\X>7A%*U4F*)$P9P?"=2IN&C!R&U^S.P MQ*E&O+1W-2_C*BY-\+4*DO/T&&"6T819K<5>+*\,^:.YR4)T.N4^5XA6@FUM MM`9'T>]6$RP!ZPN_F/A05*)9ST.J5-C%V.>*R866F'9!Q9^9"8,:L5=2W_[M MH_'6(\6+XO3M.^]OI(M`,TZ(+54P@DLY,%;+`7>)\F*L1QHZ2+P=,6+8#1>. M.WE'DQA6)N>J4HI8!4OB`?9W;)TB:YOWG=-(JD[2(.-#D=Z_2?II7"96L6'T M!I5AJ1,FU[D0^@L]SO&M0"NT0BP8P\/B.O$Q.(V==X#S?%O&RG*U[C;A@^*3 M+KLQF$VA]INB_KB"EOLT+KG-UF5)"^)+DJ]&QHFQYUY]+0Y<+B>@I(KQ355R MQ;>O^EUAM8,(\IUX?1VJDO<@K;E.65+Q?I><@5]QYJVA408'SK^[SA6P'VQA M5Z7()(LE=+EFY?8D]E-)/H6!?R-9N8`S7GBMSWQK$[@\D:,$NF2M?NB)V><* MCX.^?)[<#"CFKC>;G5Z>N*Z:@YV%^+UH\EZU!BDNV.7FKJ\G8"[S9;C\C&9I M)7,M39ID9,]8&B`ZP/`8@[SF4DC#`ZS=G'NR27%Z\[;1Z;H?FMO7?W>>( MK@=_MN)3@&Y@9O3[+P/-N4VCV(BZA;!\47R;>->__\+__\NRK+@7R-1\S_]9 M!W#:P$;71C`6VOO.9O=^.0#GFC;]!3"W"21TJT]4$RW:=".6V;#&WRFQ;;=H MVI3Z4P%7-=CJ86$FZTHF1H\1SI7<-17D>9CW"F>X_+"F]+]9CMI1/;4/O[,S M[+B==E-X<=V!+RUUN1J#E\+QP<`]Z+8WP/%-J]6'U_XIQISSC0]^87A/:Z9J MYB\O'XO*T=)[V^N[[59_R:U=$Y5;QH].]V#M_'CL*ZCAZKY@XU*_08_SG=V_ M;L_M=^I+.EZ5ZCHCYF?!%.LI]FM_>!P'9V+_MNZYXZE!Z($ZM MWJH1G6V-C^_BAO1!QP\[&]Z0+;RD-JQYMR`2OXTK>:IKH=O\4JB>I>8ZD;]H MC*6"B$=3/YW]#JH+1'&%_F-%H!]^\PJ:JMW"0[[NJZ.[AHOC==_NW;?.P.T/ MEC6IE]NW"C6RWEJ!)\1I6T,"U?Q#LW3VH,9,?#M0QX0\['H$OG4H+,O]5-L=*,^&V-6P5V9P853 M#*1.6\'87E(_N/OO[2="%RV!=GF%D6WQ?NXJH.D5+?:*%JL_.&OWX5Z18,MY MDO?TC5P>"V;;&`L:ZR\/E'2P=)KD%0*V.+>'!\M&^Y\`_E7;B',M\?_#DN&_ M8GSG10:8VZV>.^IM.L#\NB'U6(J1V^LM"Z9XXH!_@]OX-<"W^M?^!VNNM6!+L4ERV"FDL&)LOQS:\\M^W,2[*[;T9OW:>.:3Y^4/J0 MZNQK@Z*N-1\O(O&5_9Y-)ISC:\"?PJ/Q9(/ZEZ,T@6& M0N:/KZ(XC"\#7`+-DU)GC2X=&HU`:();/[SA1JE`1W8E+:3,?L3%T3.'+EXG M6&5BS!K%IUTF6)5^%_@AMXJ".^OR,O$O:;"@%R3%C`I2S*V6M.ZB%O)TC+G% MCLE)8Y*[.OIM=S`8+@12L;0$:BN$5.1AYF'3_*GO6[.3B(0&$ZMW^#8`^=7, MZK``=ZL%N%\28&76/,8U0!TRP17`R:(@_\=7@?,)Y>A_:[R@_$[QQ`W;1@?Q*I%V39FFU]?+-5]+.RP;"UD*3O519<]/W]0].K"+ MG,$F$^,WRF.C+5K3>[5\(>/5%V1D81Q&$VX+>LGC>)[Z5EXSW.N16U(W7N3R MO:L/5^E=O>!F-"7J_>PZC.]\'$`0^=/@!32WII9]>1CR^&-?UE]6^=S!$AN( MAM)F>8Y1Y,*0=D$=/O,G-*-J#%]TX9((I_@$;$\:3,A@RB-^!+4`#$!+)=22 M%741JAYN"LN/!D(2&JSF58U50W^<8ETSG+ZS)X1QHVL<9!/YW(LT"2YR[B,= M>I'=0IILHZ(?-D=ME/&3%FO$B``B1"-'.A?CG8:8)^^RX)AF87$[$RVI%WI) M(.[7S/OA6U2E,I>>J*,Y'NIYR@4W8TF*NU7Y#MBL/AYC:51K6_&?;<]D@<_,'('8JOU_P"L_U[I.1;]8@\,5(1BXNJ4+U% M+5>3I6)N:NW%;'EI-NL%$V%H:NS(KLPEV'W=?K2%NOTCA2W&A87P(G2[TG$A MS^3AT61705+D!MBU=5`N?6G>[WCXQYF:/LG^K'('T,PG1Y;:@T6%::Q9CTJA$)94;6OJJZ;GQ=]X MVAM.EL%NQSBN23YL_.H=WT69-YWJ/N&)7['G\E4,1_-OWJG4#,FV3L+*SWAP,^EH0AX/!.Q=GLN*V2:=I:H--TH7NTB'XLR'*4=]EL<)_BI"1 MV+7[[Q-6!YE_WF2KC:D=ON[U!CQ<T!WL/: MRFR[[5[KW18EOQ<+F)?#[:RG(CDS-34((X_7UTG\,Y@!H2�D!B^NV..^QH)[G7 MZ;K]09?F@-^#H;)306Q=RQ`I<]:PS"=TIGF&8]DHGF>D%8%&T@02W`6R%7[* M7I=K.DLN3M_%N3YY%H28JG+IV*%4\0BN3JMSL.]\*B8!R0"@M!@JG/B@6_^M M9W#!KX@&'0&4.`9YU\!F9.3U-04C/#AS.'924B\AUX,A;910&A, M,45E)X+`C.*J[\LZB^]@W@\,$AG65/7X^UH<I$<_4\BGVW*[[?X..\"?O!1':L%RZA3+T3].95(? MABK4I*O0NS5%%C[DJJEN>FI53'L=1Z(+=IA+YU=^]&^<;'>,XG*5>[7<.OMZ MS+C)U.`#T8%_,52M!HSKL>2>.GKJ/.L9;<#L5)#,E]CQKQA(1B]D:3:>C13I M4\7PH`+?W.G_NN]\CLW/JW8M\X?WXLZ97SLN/;.O%Z4^D!!156,OXK%G3`!H MTH`3.ZA+\1GS#Z;;!;YS1R/12)D6NBN.MLBBN,\FF$_71Y@^XS5\#=(?3VY' M5+:*<9V#]J\D90>_EA*CYHU"JIL#Q82*`>HM^=__N@\"J7)7ME7R?(*&\_SK M`O\&S+_>AOEG&KH/BUI9/'FV9Y#=;8%8)OY4AAP+.U`G$@ME,B-5F1*_]#1$ MSCOKB8CEV"W=V7:OU&DP#LC)>=-W>ZV6VVX-ZPQ-'M;(<**4IF!G;/'BMT>= MH3OL#W3VZ`$0H3V"TA`)3F/KF[6H[0+%//:1&5GY0RQ%H)[9?NZZHT'7;75& M6G`4`W+,AXV]](K&WE_K<99(_[#;`4.[K8S=J<A!7M:/U*U M*@IP&CDW@:_L!Y""#$R0%#8F'2?!!=Y2&#UWR1R\`8KE;32>>.;]+\+]<$2Q M;30KVU%L2P4H2*_BVZA2FBZ\D.R[],KW*2D/[K!/UX"37\>13I9-2FPSN,L6 MLMSD\(J/479.2+L!-L$,>"CEDL(D=A4L2S M*2AE8:L<&3J)>?@N2[5#Z:[)_^:I!`RHQ,>R0JQ=(+\A!";31$\]6980R94[ M@+E4A>Z8^RXRU!1X.F\S2KA=H($^]M,4!VO*\%M3LB^PS$O[;0],]MW=R^;; MO0LK8VT=3SG#X,JGN1Y!7XC6-)=$+@H2WA3^93"F-'F$AQ!13\15-/'@AV!V M';+[2M"@/$4X2RKPHON<6Q1H+C'@4P+>,LEMFH(_*9XT.5G6"LQMQ!<:1T_A MHS+RW'YF(-PIXF50XU9>AO==;',U#J#M_/_+827O:0#R$Z$G*V*>3;$AY?'& M>/.IZ<9\U659H=]M`'U276 MBE0N*L"#6>I[AZ_P$9T`GJ,/+^3KA6&-7S\==:34X"T*!YP`$>B*L&.OC1^4 M2/4CR7R9`B"5(BL(`)9T?,BII&,']O^%[;6J:./#WGG4PZY*/!ML]L'K M9C_"9O^W%^5@H?.Y9L7>7\^Y?KR#;=3@U-E]90/Q2"S?$W)2K]'2X'8LDM@Z MB\,`\XE/%#IAIDZ=]Y.?WB.\D&'O_WAQV#S)%@;AR52 MQ+ICB6BC7R^Y^SKL?E4:QAON5X3Y`VRU$'%V`<&M1J,1G=:`(VT$>8:M7]F/ MI:+^7TL0Y_DW<'U)AEE'^$A\[6(!38X!+HR2<&U*\L/'DM%PNI?X032-DS'F M4'7\8OAP'*DLB>&S2U`O)(#V)!]3]&42C!:!^A#' M$TW$29)?.H=&=250:TC<\8>3PT+DJ(X<7@8O^A%A=`YDS3@%UF??J8@;9L]* M++#Y"*XED1-AMA]T>0YN:X`7#7X%_W'->=V(H2Z<;*.;B.2XT.08;(\FA&,X MCB=%I,K4<>?6"?H67\-1.\![K_C,"4N>+B\XQ_HI4`(9!;I,;@18_8ZI_3IV/`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`BR3"1Y(&JKB^IU_GNG`W(/$N/)N?`6X],$- M8*=#;*$R`<_2'"J;F6D-IQ18)=O%H76/5J2%A9\K9!8:5:6V%GU'@^*P]KN& MA6#E]7;63\RW.9R#3$G$XRSZ'5%_@KA3_6I$;R`0E"LJN!$0J'M]L=9^RZ_X M5D6J8LLJUW:L@'&T?"%VJW&=^-O.\I*\B(!J38B29'CAA8V+XC6/4]1BJN"I M\(D@GF`,%51ME`DLY]XO^T7D5_4R++GJVR^[ZZB\1C10F"Q&#@J_3INZ=)5'YKANFNO?IK0-^6:4DM MO<#]".\DD"L-V:@Q67D7\<,4`+0_"=;(W/Y*T1BX^1PD"Q6Z,M"C!!)?#A9? M`-9'+7?3J#[$?%:1[<(3)OU#E1F(O2VK`VZ[;/B%H85!)![NJ=2B7,C2`\T. M"HK)3)3XF*&,5$9@;$IY77U$[3DHGYGOJ?]E^A[L@!G57FSZE+!'8#GQ-<<# M2<.,&KKH%-N1EJ<"AH#CANG=B>58)7"J@NO0U_G6J4#NK M_4XV=R]51YAEAHA)50%0GZJ,(;]`S\28Y(FZ6OE+Q#JZ03%`GN74!HN/YYCP MJ)-@BOWBY<*,4X-;E?)HR]BMA`GB M,\661J[`?2+!_128';.+IL]_)/=6)D[(\`EI3I"J',^%%_U0_P9NY8F4A(0( M1R?\+G?14MW''YJ^P4*)+4&O_'I2.:4Q\:/8T#/V63D!]8XEV<;5_OW\C7&E MN\Z?,0C.7_B?B@__^9?Y89U2_^I'\,J+P/SHUT]'Y4`%T7<=>AA!(NX@GVI. M-5Z2,Q]]#I,D?`H6D595ZAR)'F:J,N-P!1%(;28--KF=6>;O":R#2$!JS*)8 MPG?#(V"3&.E`=CU5&F`V$#28#_>!@"'&2B/PX0/=ANV=)0NE.LYA*8/5191* M;,W"6RR@XKBGRI^ICN-L/L]0DAF'(E\O^G167R!-CF3Y')\E:%QG=V?80P.^ M_5YUT'C*HZR(*O7TH`:V#(3W,O),73YB=@D=W$X@!GS/XIZ\_TF8$42YJ'$T MC$))74D'2+]``8?MI!.#U2C;NC(;`Y]4P(/%4GM@8/IJE`]ME[IWF"W`1DKQJ/[R-SZ[ M@W*MZ@]CN>`T#^&.O5$XI>J_:1]1[F78AC[WU:@\-DU/P%SKE1EN,W[P2W(2 MI'!:O?#+]".HK8^(*#VDMS^U/Z-[1LJT/A+8$&C<"PGV*CQ2K1Y]Y\/A^9&% M+:(]8A11=]!RWAZ>'^,_WIDYO<)XP\<7C$'EJUB#NX+,V2/N.,R>XL:H*\:< MPT*=']L4N17+N?)#/JNYH4'-1MI@4P7^K03U@X+>6_!@?!3`HKZ'=33;LD$" M>B;-BFL'$Y1CKC12HQ>P*PM%VPN;,I*J0^S^PFT'BL+%T-]W#,N%A%=*HPK[ MKEQJ6JQ8?'= MA,2.:^.Z8-=+'6'FK:I]7FPDE.[X8`QGX?:KTGTE+4E/I7991DN4-,(_ MD(U?IA^4D7,*-D["DYSXVYNUM8ZQ/E<_H?#]=($[9.B#7-S`<,?Z8#*@3OU,:Q<]YD-P.24]U<6UXF#:OR[,CC2(" M7!JLJUA<2@GNW/!YKL`9W*/11Y&7Y46PIKQPTW\NM80@U:9/)^QE1`EAI>,, M>#">#V`%6:JPM+FH"4VR`R4*ADX`)RE(?^"%'-!T&J.#5)5C7'F<&AV%VB9I M6WD;6\W(FEW$PUX+2>OT2\#?X@]6CO<[/=3Z>U7/K(H01E&^^F]?#]$D0N1F MP2^C3J8Z%0J*93S<0'4WXZ@#_PTLZUM,*->$0LJW#-^%/R7=54VB/C-\+@KL M/5%V05V_G9.&2YWY7DI0^)SD$TQZ:O>ANA91HW/N`,*5/3+N-=.^S3_)/M&NRBDMOM!V/5<5(P M'6"6LI#ICGCH6@HVC;?>&;C\^!FRJ<[@-'D;:(8=54MB-GHBF&\W4P2(..#>7.CJ# M437=N\Q@I[(4D565NU[BF$=L0F<*9:41NS@O5+`LBJU/69T&Y>S=TQV@VMJL MN>GFIZZG/N+&P-TU*CK>LTWS!/:DHD>"K$6-"09Y4FT0H6)$E+I*9.&G^2(B MWNJ"(:5-HU3K+XZU.#QBV@CA8*PBJ7V[=*:#]S88U<;WXA*#IGM#=]B2.7+= MECOL'3S<3:O!#LZY$1S%/.8@IC5I%9Y"/TK_OJ>VDPI-)A'7NS*:,4@YAGSN M3"AJS2U@C02J-@SF4^$4K_/X:`46IH^5EXI0HYV=1V-5KU;$?H&6[^=O7.?/ MO][0IGW]=/19R(VOYCV)>5AFW)VZIDQO)E&Q M?QT+-R93L@-BO'_?^11'?H:V4XU)8R1#Q!ZKC-UG=1UD2@MJ1+$GMQA=NL[G M.-J;"95&<*;2WIQ_T_S3[=$^!&X)9KX1?\$K2)>_K2?>WJ(U4"O.H(+J%,"[\O92%@ETAG@6 M%"B4&:W4#W7F@^4AK85+O=^`8/%R'GRD%AH6(VT6:I]H7N(E%*"@R[B8&_#/ MXYP:.OK)S9RHJG2;@1$LO;=&9.>Q6=0O*=3VEI7?IG77G4>,AHI86^^VIN)5 M1I0/0X/EO[0YN41J-%>ULPT+-N49Y4M5&!80/2-*S2`0 M'6ZK.F1DWCSN)*%M!8@^#+/L#W[]S2G/$&GO]Y<8TJ)GW*SY@1U\8N4<%GJL M0W@E>Q+'F,IHF^)'\2,75,A2,I&)Q`N-TUP8P_I\6-%MP(H**&L!49Z?4_0? MQ\?OWW_X4`54;DCLT?P=Y5)#6.`$#9"[,C+GKMGV`8/G>U2J7-PX%1UP,39. M6D;UK&TH!HON[O+[!6JQ_3LHS.'^L-]O_PXJ<[#?;G=Z6TUHM\6$M@YZW75) MTVW=U*N&]!WJ^\>NS;:--0,"KK%0G-$T[_RM9GZO*U+2.QAM-:$#)<[#]O#9 MP^>_714F)K5204?IW=^HD;8V".^)ZA`A-9&=MV^Z;G\T8#3J!<^8QP%:6>Z,\K&IR&5";LHAR&X M1ZJS:\74:G/T1!3?2N]>#>/3N`DD"[=2:N$5!)D"TZ9?XEJ)3`N6EV8!19`Q MB+3O_(G.@\NSNPTA2E5/:`%:8(8LHY2P9^#P^:."_16FC84]3AUGX#_DZ6"N M(;I32>K=SKG@$=29>A(="E9DO&J<64NK-"(XF#&8ACG"G#-?PSXP+$]9,`+] M4(L^K)/+N(LN-O9Q33@/]8HR42[7,09GU%AW./L83!I3XZM``E"'P'-;-LSD M#5&!"T#Z,%R4<$+#P)U7-%LO7"?])KH#_62F8HU%1+0Z*[YL9'>^%F<&PGF% M0]UO?$XF\#>>.B(\K8Q+BLI&:5&1+0&]%_B"XG,&0+?:7?5_XLE,V00A.00Q M0)]8#B#E115`7R$_QB;+;%*J#!DFPC9F:HIOQ!3>=[Y4O,B\IA;/.1`5VW4[ M61/Q&@EA67C?>TF$A_S,3ZA!S5/*[)&7@N:@W;GVE3]$/I&:J'2!`(";8,(3 MV3@`9HR%DR(RHPF(P!AO:>0W2B!'P9PHIT8NV#==^I48TQ9+$?M]YR0(Z?4E MTLQ93VDP`S(21<1%U5+$U].0(!UX1T!+JN>04:C)+)(KB#5\0M7Y!!_&]D'1 M?,!8#.MX/K\Z7:R^C!T(Z`M&1W?Y[/R;N'"".4$!4*/)NYF(IH_@:4O],19U M!$:2SYY`6"7'#\CC7)M__Q*5Q%>EZ;=#\:J$&ZLLOCCC"'&7$;+E4G?Z@OVF MPE+YW5R?>\:*Z=K>2HXU8D&9;[`8H]HT@4L;!Q`:<+"G9"'VG,-)]45;><)U M*2%U(GB,D8!,I;VC&'HT&9)%SJ@^DQH#R9`*))+O%Q1,,X&=4HM&U4X-S)<* MBZC^\PHL3,!=\70(FR'-Z0@TC'04/2SWLGB/,FD6M()2#!R%5M`1ABOAV6(, M'-I*,XX&11$7K]E5;0B.`,9&>FP(29ON8]7N*P83,`1T'=I=DY@[:U[C5(=, MG78+X>N'&G1E?$EPB1YP95*&6ZSM+EQA8O.J%]:0?+L/C/@CYM;#-#C&>7N>7V2$ M=.RT^GN]UCO7.;&J+[^K$:.<2Z7A3U[$'4Q-V[HR!<3^H"K)X8F[:H"-18=" MV^F:5>>!>M6W?QP>GKUSU9@8O7K/D&8Z7'?T-L[+FB-SN(H&+-B9]/B\DLH9 M.B5%QJ72?,TC+H:B>9C@I@HPK\02)Z31,X)$\]'PD%J&&0X^0]J7L9` M54WPM8H"<&^T\,YL,:#68B^65T8#G14W68A.IUP_B.E8V-9&:W`4_6XUP>*1 M7_A%/Z,";&L]#ZG2<+%BGRL:\UIBV@45?V9&1&K$7DE]^[>/QEN/%"^*T[?O M8-]WHJ09)^2.+1C!:#49.ERXL>B@2(&+!!3N&ZI6*46L@HLI8??-MW).(P'6 MI4'&AR*]?Y/TTQ@)6[%A]`850JH3)M>Y$/H+/O^EUAS8$(\IUX?1VJ2H\@K;E.65)I"K7,=JHX\U9+ M1(,#Y]]=YPK8#TZ-JV*`:J`@T^6:!0N3V$\END:SO5B0`P[IX;4^\ZU-,`Q?91?#W\_$56)SG5]S[CN5:'[-N;_FW%]S[J\Y]]><^V[FW/_S;ZO<[(W[ M@NR(+5#7H)'O$;A6YLY4@&9D:__S+0 MG-OT9;FXR1#%MXEW_?LO_/^_+,N*>_5E\SW_9YT>WX_+"F]+]9CMI1/;4/O[,S[+B==E,OIN[`EY:Z7"CCI7!\ M,'`/NNT-<'S3:O7AM7^*$:1QXU\%X]!/%V3^\O*QBENUT-[V^FZ[U5]R:]=$ MY9;QH],]6#L_'OL*:KBZ+]C"S"^:1#X_>>[VW'ZG/G+TXN09W,Y1XY#?QN5Y MC8KZF`%Y.*%LFMUZB?_\9+N/8YA?1?MQV;%=FCJ889M8@4(\.X%N@W;J/<)M MN],,&76VUOQ89[ABAW:E-X+E-LZ(O``Q[8U:[JC7VE8Q725._?#B/_II^O?: M)NH+*NGUAV,;AF#7_L`5X@M=$*=6;]6(SK;&QW=Q0_J@XX>=#6_(%EY2&]:\ M6Q")W\:5/-6UT&U^*53/X'!QKE]JU"C9AXH.98GKE:1(TA$HAQ>L8- M[GFT([8R^%@T,]PEC/#]2O85\_.\,#^OT)Y7:,^V,'>GH#VOL)TMANW<4TNP M/'#GBS7'9D'+ZN4A2`Z6CFF_XG46Y_;P8-G0[!-@=6J+,]82K!7SNY@ZL)HS M_B*C@>U6SQWU-AT-?-V0^L3WR.WUELU\/W%TML%M_!J-V7P4K>\.AZL"/%_W M;=/[UC]P.]UU*X*U!-%6"8G5A]<^T/2B3T$4S/+95VP=$L)C"1SS(4Z^<`%F M=/D1FZFM$F=;N6,?I57?;"O?1`^/FS&)THPJ] M;5UCA^F7:7%U_6NY/&[XL47+JQ%.LP?WE_&8VO!^NTJPBWV<9]^N_/_QO>1Y">P:E\RM.[9H MR35"O,8EYC:]WN-BUOW5H7NQ=MT?)>@M9M)K!KUKJ#)S4= MF@GQ>K7NL#U<>]9FU$ M_>N3%^4X@YXX^\$;4YO7.896$-P9#`ZZ[_3WFI#Z!YNG MF*OA%J*TVQZ9EN^F*#W*@Q!]W%.C<*\)N6VD=X.<[34[44#3:.-$:84F);WG M4M';A(_]EJF@-D6P/&$%53#L=-H;%-LB:),+ M;:3FNZ-6J]=[O(5RITV*QQ-N3J4".0_X7@TQ;[1/7S\=E<_&0:<[5.T\'WK) MZB3-)%"(PV%[49H,]I?RH\?2VGU9#HUZO:&UO=7/7XF09GSIC7J=Y2@Q MD\C$S!69,CQH6834/7]%4IJPY<`T_!8@Y23WO\5??3JH9UYB\`].X>_Z!M.BP-"7@$NK_=EA[0@'HP94?#[FA+R#\)0+%F<=*$ M\EZK`T;64Q)>LF$6$YMN[^"@_:1B4R)_*>E!;[T]V*Y5+"1$_7Y_V%N9_E.L MZ/#33&XOXP%W33$V]UX1HW;WP##.[WG=BI1U#,J:7!CM[K#?ZFR"LMY>:[2= M/.L:E#T2S]AF.N7IFNKS7Z+#R0V&XE,DQ!3\=?"OTVH-#Y2UUOC-:R1X4;9V M.@?=P=($J\THX1,L,(.",8"26-&X&;7-_/IB[UR2XHV26D\C^+3'7I+<3>/D MEF94+6FIMGN=;G_0K:*L_(K5B&FD:_IM<(J7(N9$)MQ]\WX>IJF?I9_]I:UW MTQBJ>.RRKV["@55?_0\U`OT0)ZC1D)HEF0#.5,NRJQY^U9JH:\*G?KO7[0Q6 MHF[^$^6''%/"Z33B$2WK,$"ZK6[;"&2LWM'^AXPP,O73>%*KG\((6M@TU16),8?9B'@R>BL#D/>TM1 M>!Q':1YF(+YW'WR_Q@99[)RT%"&E9R_\XD7M\$Z[-Q@,'WB[CJ;`J27&T$SQ M(QRRCO%W,#XYT<%V:$-^Z(#X'SSB%N.@DQE8!&F&5^"-+X^ST_#'5X$_Y2S% M"4%$&_AJ9FBJT0K6M^Z*[=CLAKU$&"Y/WGWWY>)&'P=_PO_/C_4$L#!!0````( M`&UB/4::>/O5M`P``(N,```6`!P`86)T8FDM,C`Q-#$P,S%?8V%L+GAM;%54 M"0`#G6O*5)UKRE1U>`L``00E#@``!#D!``#575ESVS@2?M^J_0]<36U5YD&7 MCV3LB7>*EFB'-;*H2'(VV9<434(6-CP4'C[VUV\#%&7Q!B51P/C!MBATH[_N M1J-Q$/CXQXMM24_(\['K7+7ZG5Y+0H[AFMAYO&K=S]KR;*"J+M2N\W`<^:&GH$V#.7K^;4J]7NG_9-> M_PS^^7S:>5E`A4,]@*_AX?D_3X:]/OPZN9CW/USVWE^>]QFK"O0@]#=5]5YZ MZY^(_*.%G1^7Y->#[B,)M.CXER\^OFHM@V!UV>T^/S]WGD\[KO?8/>GU^MVO M=Z.9L42VWL8.T::!6C$5X9)'U[^XN.C2;^.BF9(O#YX5UW':C<79<(9O<4GY M+4E\?.E3\4:NH0?4&2JKD0I+D$_MN%B;/&KW3]JG_JZ%IF@A MD;_W4W53J_X0/GB8V=*MCN':7E.B"E4(;.8'LF(H3X."5F,RSJ<2`@K)< M>FAQU:(,VL0OB'^0BG]A(0Y>5^#B/K97%JBENX^L`],C$_[Q70N;X)3F MM6X1C<^6"`5^I<3L+(XJ]T3W0(U+%!#"`X#(Y=Q[3= M0/>7-Y;[?``S95@=$,P6UX4<'@[9T"$2&X880B9S'"8AC8$3<0_,> M=0?_CRVD[<7U@.@FG@LN'KR2T/HSQ"NBT$KARX@.*)L&D<6;Z*_Z@T55`?KQ M0F0J+ROB#-5NPTA_0(FGR"*N"6$Q>)U[NN.3E`E\ME+4*L)#^O,.D>18$<.V M<4";-(VVM"E`4HL9;,U`>T!)584/&L4??/0S!-S*$TN(*RC/NU^)'S?3OZ2Y\T8[IY&[ M&:Q)W@WWJ(Q`JDF/U[LRBER+RW'Z"D;)F3GP;@5#%.C8:J@9I)@WW`Y8H3#0 M'J\EL`I=C\T1LLYUC6/=(WW]$]HY"RUBU%!62DP>O-:6GIW%<>(0J]^PLV@B M@ZVMYDK*QC/0X?KN61/!XHTNR3HLQGTKO[L7P_5.&;7^.)\QB8Y1H),!:9N7>] MI$.LL=#I^87N/]`Y^M!O/^KZJDO\I(NLP(^?4,]I]_KKJ?I?UH^_R[X/N`:A MYVT-8BS]`5FTVN_KS*R+I$UR=9%F'4QN`1,?W"<^TRC:ZUY[((OZUIJ+4E/2/\N`Q` M7JZ6(7.LQ8:(OF73^PEGO6\C$4[-$8"JIBJ.BQ?H.-\.HBD['F=,+#WJU^+! MQAB5!ITR*E':0&'0J89\0#OEY#7TT?HCF[A![R`":O+XM:A2I4OP#:;6.\[>F2RH;` M0LL_XC*W"795B&G%K8DZEC!61L-FM3-AK%8*73AK9>,^U;=>A M0M&ME"5COTQ)_MUCL>+3@\$"F,*YDFR:F.#6K8F.3=49Z"L0>9BNXYV'GTMW"E-DEE[3>9*I^`3/VB2"-M M)LJ:WUHASF-ZHW/._%:V*,=('+UX9I&M,Z:-'>P'T6+W6KAB&)6$_.-PH5%2 M\8A1!\+UHD,$[<[`B.I(.,_KF`U$A-^X:SV-MZY`>#1[J\0P+YU:\6F8Z'E'_K8$:97+@H-GS5B MFZ\5Z3AV(V^$>"UUZ5)R%1U7QWQ"/MV6&(E%7P&')V7N6$3!WPG9#)1RP"H5 M'&/M+*YS+>SGPHJ6UFDP$Z)AKF6L7C(>/),4FM%!W\39K.X1$18@+F*YHCRR_+O^^I;(/T^3*$*CC)%1V.#ZOLA M,B%8SI#WA(WBZ=2BTOS[C#WM4*X&\=)(V2;]4W22B;88HH=@B'UZXLG$0S8. M[>+VSD#*?_YU=W.RHSSF1+AC>$CWT1!%?P$)R5BFR$#X*3XV)?E6=,F2QBZ\ M^,_3[ME"]U'A<9:K_Z7,R[K$98"C1E!`PLR]QT!H\A$W! M2XR;=N#:*A,O(4*")&^SHCK%?G,OEP?L% MTVC$-@P]YFHR4.'ZAF(=1\Z`RF;J3[\Q4S%O/^< M_RF?Y#U:^$/RIR?(I&!$&.7,:5PE.W5J<>$_RM@%=78O3]W1MZ#[3IM31ED# MVD,936:NS2FC;&99M*B@+!;0S\"0ZL58ZLXCFD(HTYQ\W11'A7I<^">\![#] M+HH3;D/5?G?5)?8;?2#'P&/?L%P_]!!\Z'>DV?W=G3S]1K=3J;=C]48=R..Y M)`\&VOUXKHYOI8DV4@>J$IV[H$UOY;'Z'WH20]/;JTHONDL`^RT-[*0C3:;D MR(CY-RJV\OE>G9`M5$W+S+IDF!#_(BW^:4?2YI^4J321O\G7H[7NP2;3>P7` M?)V076*SIK%47HNW#:+?2X,XZTA3941WL$UD8HCY5![/Y`$]Q*-IV5FW&_;[ M:;'/.[G["IO?2UA]A5Y"\).TX.\[Y%24.W4>;16,3DFA35@9D_;;-(+L97L) M>4_3\G[H2.H8)%:DN?SU"%LURZ[=2TAZEI;T-Z+9\0#4NGT$S52=_=FX4G,O MYDM(>YZ6]J(CW6HD<%.9IXV'Z:++^A)2OL]T/3W2]US/(#*#7B7ERQ&"\V&N MY4O@.G"7*KV+JVM\\_(A[NU+J"+3">^KBJBRQA7!<.]?`F>FMRY,-HX&H=X] M@-MH3C+=-EON<31H[!<%)F!ENO6JWO%H@`YR46`":R83V+?AK6OCTO)*D69R MB)*F=RP0-2\>3.#)9!JLC>]8X&K?29B`ETE-2H<$&U32AFWSC9']UL($LDPZ MDQXU$$<$?!P@U;C0,`$ID\E41\R-%PIPW.*(S`/Y-V$`PM]A!]NA'>^H&I8= MG\[,@.<[H&PR5E^H4I,/_Z6!FN8M.L*LEMZ$FP&LOO,ST9`S>7ABH,TG)-6Z M`32!)I-MEPS&>6!CNB=T&]%I)N,F0^'$B+T8Q]K[R*\'<&EX\G]02P,$%``` M``@`;6(]1GVT+)<6#P``"L$``!8`'`!A8G1B:2TR,#$T,3`S,5]D968N>&UL M550)``.=:\I4G6O*5'5X"P`!!"4.```$.0$``.U=6W.C.!9^WZK]#VRFMFKV MP;=9SFX1VTE3D]@>F\QV[XN+@&RSC9%'0"[[ZU<2V`T&(6<#^G$ MUA'?.9^N1SJ'3_]Z73K*,T">#=WKDTZS?:(`UX26[>_.N??_V+@O]]^ENCH=S:P+&NE!XT&YH[@S\K`V,)KI0[X`)D M^!#]K/QF.`'^Y-SYNL,/[!G^/AK_.'%WT][[0[^<7JI=SY>M3]<770$'^4; M?N!M'M5^;4?_0O%/CNU^NR(_G@P/*-B*KG?UZMG7)PO?7UVU6B\O+\V7LR9$ M\]9IN]UI?7FXGY@+L#0:MDNL:8*3M12I)4NN&0RP^60#@>US$XE4<%/?(0-B,"^`3 MP1*4R*RO:HW(6`!(<_"&L^&*C&JX&7BX;73AT>>CO25+S^^E$!3JJH2]9@$RZ6!WK#9 M[+EK8VL9>"`R31C@D0S1W'#M_XD-:7O56J)V(P1Q$_??R-#Z M>V"OB$&YX/.$2L0VQ",+&AEOQI-#38'M@P)@]5]7I#'PFXV@?(F(Q\`A31,/ MB_Z;C@S7(ZLKW&:Y4'F"9;;G'4:20XT8RZ7MTRY-1UO:%?#ZUQ;@6D"V1*0: M7I0O@6Z\\3U-CVO@F-ICEB)>*[@Y@#^C3$'Q"S"I17*JJBB52FAW'\KC%Z\BL.,0Z+M1KR**E:PA MFUILUV_AHJVH3"NS@NIQ;Q[6L.#2L`N"3DL?`#%]4F,)ED\`%82;%*T>J^$X MQ1!2@>IQN=!7BT);RQRT38*9$3C^SHUR+9[$C#^V79L,>??XSP1N\.H#UP+6 M&CFIL(P3'/PQJ2@ZF^LH#64M%?_5<"TEK$))U%$I_`(G,@DE3C'RC:L9_]X= M#GK]P:3?([]-AO=:3]7Q'S?JO3KH]I7)YWY?GR@_/@[4QYZ&O_F'=+VR#VD2 M2I[MJZ3R8^(I4I3>X=PF881S,2-,=/S?0W^`#3"\58:C_EC5-5Q`40>DY,-H MW/^,Q;3?^LK]<'+@IE#XO"=A@8NT!5AZ3_1A]Y?/P_M>?SQ1>OU;K:OI"54C M1=>J.M!,Z.>0TVJ(,H=..N3-#.^)CGN!UY@;QJI%UD8MX/C>^A.Z6FJT.]'Q M]`_1Q].-!MBH0,._;OAVC"?@T&=/H\)995LU@$X]$`*PHW+;D+\W+!6MP4?S MAN#D'$Y65R;>C>"FV'?HT_"$!^;QPYX9@DNN/2/;P5P-X@;&0$X4B'!SO3[I MM+]C<2#N\=FM!(^57(-#$058Y)RVWST[TTZ&#F41M%Y6[SL6 M[LL@59)%XIE<$HGS"KITA?$0[3=9!*:*3DOG+KGQ9?"2WTL@'W/9@UV&[X=^ M-)TL\*+:T^$-T#PO`!;3PK1X=ND*>DAY5N;A9EJZ?%,3BLFAKXGL%3',&)C` M?B8S(L?J/,%IUC!;+P*$5&#.(G+G>-6RJ!T-9V38EN9VC97M&PYO,,H5FV8- MJG6A3%@!YHQ1>N?!FTJ`$-ETXH9$X.,9E.Z^\[L.1VQZ7F,6A!5@L7`NM]N, MR8&""ZR^@5S;G7N\_I)=?GI18XKXR%G<7)3>0U33#)8!/5VEQ\0IEU1^3Q$4 MGWZH,1V%%6&Q\T%NSQE`E^P$L'EPU7,:0P,\G]=_\J2F'VM,FRA^%EL?Y;(5 M+B[#A66.:R96"B\\Y=`A[CM+H66NS23[R;8O9.0YQ[;+O@,>&)B9"Z]*-BUA M.]#A+0Q<@N06(A(.$3:2W%U+KF2-S5](`^8R8CK@%S M2B]]O;6$R+?#Q3C&$<-'_@+HV3;9G4-(N.Z4%%"".767OD^T/1_93X%/FDE\ M]&3N$%D"=;<^!WC>:9?$"7N$H`F`Y=UBKIP^2W M]+WR&)CA=!X%/N7OC[-+UY@"+FJFI4O?>VVCR-_\9I=^;Y86V>2>[KJ?*NN@ M]+^!%X89Z9!Q>DA]\GF'IH)5U)B^W51A[TGSZZ"H/B\/0&[+G;#1`"KAD/H51=B_[ET-'B#MN,**DBV\/39'RR M'`!_.(NEBTCS>8"'U[^A',P(S!886Z!\:FW9!Z/_)C7\(9T/*7'/_\,ND0Y= M=?)9N;T?_ON0(0W[I4E**/V1A"#9'KE%'B"`_^@TE-I6[(1FP*>1QU<,S*SU4`N2'U(S3)E/.S02/R-BJ2O^WZ@?E2)5?EP_KI:+B:U<0`E+I*;>?2T1/JQJ.PBDF4JHF9JCF2N,0VE0+.M4 M7)G3U&0MMN`XE&;B6:D26J4F<]ZD>"A]2DE*E5`U-?_OV^FBIQU#EH\ARW_\ MD.4[`.?(6"U(+Q4,5TZ+O)-099:N=0M3GH0M-`Z7%PR;(R(Y7)EI="BJ`-/7 M+O=R5)DLO8NPY7V9K"9LF7GL^#C)CZ%9?R\IZIC?X"$#;-F#%M."GW_)M^#Z M>UDAQ<5,F$#+M&'I1NP.\HVX_EY66'`Q(R;0,@=FN=.GYCZ#\"A7QX_*7]1D ME:WW:H:M7=W"?9)(NUBW.431CHX7'B%0].DEPKT!8+! M?`$#7U^`K\!`0@05J$E6LHK]6"NJ(+-CR9WSMNZ;]%_-A>'.`5$R=MNDPQX^ M!2N8=B2Q+.P=*Z0(B\V8C@>_5"/RSH&$(SIULIMS+'+T,1]]S']T'_.Z`XT< M(\P2O>Y%-V_\C9F0<+UW:@7TKYL'F@F=`.=Y.86$Y6S>BE`B2&;:(K7;SE7- M9ITW=)4R7N=$G`^&&\SP@IJNI&\-TW9L_XVW><\1DK07+-+O8!%=ZCGPTJ7Q M"B*?KHXWRO)XRQ63Y9[?G3J^.J7[[TL*!)G-;!,(TY997-9!P.YTL=4H_82` M?*6*P2?P^@4 M7B=AR\A*"+I[3^'HPF)-Y6/LY`CD9*B.Q/"E9>4)W9XZK M#8N[G7.'5KSVOT.\*-$Y^`6\CC+BLK^G1.V!%0*F'=V!73D@ M"EP,L)]6\%Y6I:SRT#$_0`Y+2!/*GZ\\I'+W#4=_`3A8(O M!$X<+J2BL43#%#8G#7(B))DO*DUHEPK?RHV8W"BE;*H]'J0<#U+^L`4=(21T^Y3.;.WX98]@#&MJK_`&$X;<.X-,HK+\ET+FC@/ M]>%5/(F8FA.6F"-4;_>,@+YU\\&)?/,+ M$59S#TT5G-79;U,RKW6^N7H'7(`,AQR064ML>\\/EPG1*HIW[T1(7-8K-L4Z M&]Q1(1:ADM^Y>3R_*/O\0NY&[GA^<3R_D#4/OO_SB^["!K/PRG0/:VHXG*O* MV<5E36""CN`\U,Q9JO0P?')I$SZMM51J:'X: MV@/=5]MD:1=S;J8R.R>RMF?Z-&5DS^]%=>W37_IG$^,*9R1]5PE)#WDQ13BU\+M(C)M`R[1AZ48!8&RKH10.8Z8K,A2P;V["'J!K?S!-X#Q-S`);3+.4N]5 M(2\[2KR2B;UKBM0C/Y[P7AE_\G]02P,$%`````@`;6(]1JCR\.MC+0``#6(" M`!8`'`!A8G1B:2TR,#$T,3`S,5]L86(N>&UL550)``.=:\I4G6O*5'5X"P`! M!"4.```$.0$``-5]^W/C-I;N[[?J_@_8GMV=3I7M;J>3S*1G9J=D2^K6QI84 M2OOWB0X@LOZ@$<;]5.W-(YT`?BX\'!P<'!7__^ MO`[1$T[2(([^]N;RXOT;A",_7@;1P]_>W,W/>_/KT>@-2C,O6GIA'.&_O8GB M-W__K__[?Q#YO[_^V_DY&@8X7'Y$_=@_'T6K^"]H[*WQ1_0)1SCQLCCY"_K) M"[?DDQ]_'D49^+RS]]?/_=QV\O#7\J M\[)MNONI]\_O\__CZG\-@^CWC_1_[KT4(_(4H_3CT^6;XN&S)YC$(9[A%6+=_)B];`C!TF"]"2DH]MEC@E=B,&&2O*/Z M[R+\0`9\27_H>_I#E]_1'_I#_O&-=X_#-XA*WLU&TGY]7VLK5WIG&^P4)T&\ M'$3[H6YJ.X)/WITD.Z`#57WK75C$F1?N!;ZJ:1WV&._WQ$L]^T^:3`!XOR== MT:S##NF'-^2O&G#\G.%HB9<%=-J6PL"QGV)V-V][UWKLU]H-J;&,D_H3\>ZS M^^"*3"TN4;MZW?-'Z:"O:3X=2_Q-5W()=[Y M,;'OF^P\Y`^+JZ^2>"WZU;QKO)5K))' ME`-:AT2`NBHX.K^;O_FON_E?WY5J^XQ>#HW!6GGI/<.V3<\?/&_SC@[J.QQF M:?$)&^;S]Y?YW/:'_./?J/>`USC*/N'X(?$VCX'OA;WG(&UTRT#>!A6,85-N M:(6=D\4489,]53'T*Q7\GT/I)#4&,P)M&"=77D@]L/DCQMF(@$T5!D*G8L]H MF($O#8E:WCE?.H!L4H8J(:*%$THV_!@OR4P@:)!&T: M'SG0JM5I2SFGCQ9:DS2EH"4KLTB\**7K[CA*)[Z_3G6Q9J`YM.*?=@<"EEJS:%"K:0F5CY$^,:',P[-NM%VU7 M!"Z#.?3\(`RR%R&7C31L6CP#Z%73IQ!W3D9SC$W>3Q%R\$_M\&&&NVK%\U,:J1IDV@=NE(EG($:&.*98VT1,-<\ M0R45=]IGB&H?:9H^#B^9?=[$2<;BM#ND2I.GT;')12/X518J%<#PSP1EDWFW M,:$(>L)DP1EB(,N%R6H5^-B,51)9FVQ2PJVR2"@(ACTJ=$W6<%F$"V$8O+G: M!B'=-1RM-TG\Q*(NXEB&B8)-!NF!5VDDEP;#)2U$":&"BCP,3EV3%4B6;-E2 M9!21>?J!/"LUJ]0J-GEE`K[*+)4\&&X9@&RRJZJ"@@AMS__AB' M2ZP*:0BD[$4LI!#+@$1+Q#D'U+B:PUZ1@V%,9CAD.\P>MXO8XC-GEJ_-R6G%WG5@*S[M$VA)SS0X>L[;M2.<0$8?!CE])`8P79 M"P&XB2.Z8C-)+A'K.$DP4<$7)IF(%,#PR01EDUM<%)6RIW9$YH\>Z??L%R%%U[FR#S0J6KH]&Q.7T9P:].7TH%YW3K@K))ME('4:7S481RM9-9 MK3Y>X23!2\9S.F]BLO2G&!0V2ZMCSV(9PB_ME4;!.7VZH&S2I]!"*3-:?D4/ MAJ6:X$D41`_J70>9L-TPH`IP/>0GDG1.)R-X+3/D^]OUED=NEG@5 M^,'!^Z%2^U/YK4GVB!-*]@0_$MX&3_@FENQ,==2U9X\Z=J>T2X:*S@FU#UH5 MOY@ZJNDCV@`,@S4FXQU'&7D:(=W\I2=M<:K.WU"KV#1>)N"K)DPE[YQW'4`V MZ494SBLZJ%`ZF4V[FRM/I+DXCR8_C>9@?)]P(B?WBUQP.=$T0!K9:PP453*LE)Y[FAQ3=A-_*U1M,3/ M/^`7:>=:A+0\[VN`MA-@E0$P+%!!$R*26X M,"+2K!*K"W;T")`E!3,,O0=!OQK?VV*#$%;!@MJ7($9?A*BU0UK(("KD8JRO MMTE",0:I[X6T,(W<&,A%;3%`![8@@TP.!"\TX%H16BZ.N#RK'>34.'!GY1\X M#'^(XB_1''MI'.$E6_$THQH&\G;=20WLNELI$09!(A.$K1!8BG)/TT-4\_QW MJHH*7<25_^Z.5#_%X3;*O.1E&(0X:<95%7)V222!62=/0P@0:<3(5&39:2"F MXI`AN3&<85HL)H@>>*%Y^?)+(FYY#:L$W5C*"F4!L4<)4$JB/Z9HIY'?#H#R MEARRB;'YFLRC#W$BCX`TI.QR1PBQ3IF:"""FB'!)(A],%!6R[@@QW=Z'@3\, M8Z\9AY?(V"6#`%Z="A4!0$1HHY+0@`LB)NEPCBG/M_)C99-MQJYP(;9+;A:5 M2I;G&X,.-&8=A08@(AG`E(56*V>1SU!^6K"B[3(&QQ=V/.PS))^)W!F%K.U8 MG!1N,Q[7$@3!)!TZ:5PN7W_GX3FFXIXU-!I@QIF*I!O&M*"*^;(3`\B6)C8= M5UBLYNA,.4+]@\EJ&$1>Y`?D#8C30)%_T$W5234$@\X(BR(H])QS;P^P[3R$ M(M,I7J&=,BJTT:^%/I#*O+TTQ5FJH6%3R.KY92'`VH'EF@08$@EAM78BYO/! M`L@%0!QP'A\P8D1+UCXQ)'#;_&@(`J.)&%UK4^)N-AN,%P@2:ZZ]]%'2-?Z5 MU1I/%3"ULD[D>,$R3RS/.2OI MI436[A4""KCU2P,$@F#XHD+7JHO,SON6)512QJ8-;P%AW@00-M4LGXEU=#B_ M:.<5JVS)*K=VZA^;K)(@;:38#D!<`P8QI/=BC+'4S";3P6SQ"^J-^VCPX]UH>DMBDN M@.\`-SK80<]FU1WC;E0K[VB5G-.I*])6I&>U, MS;+:7-TF8[IVJLHI4UWGMFE/P$U*WHQZ5Z.;T6(TF#-K-%],KG_X/+GI#V;S M/Z+^8#BZ'@&Q3)6>F@5]5`J.^&@0_I%+0^1+Z?;/'Q`@5R3WV+%V7%>[&;V!"QZ'\+ MP55<[=KWSD=?`:KE0&\QK=:\A'6!`(/.3XTGZ22ISKEJ^V&B:-.4F'>D:E7T M6LXIUAFJA'@>KYT*Z8XEUJ7ZO2L&I),H6">;$GB+9$)I6.120920*LEOP=D< MYQ:<4SG7QKZ?:V?:S(F&%28P=GKJ4>^*&@S:T(S)(&/W69+5YW4J-H9NGS__NP]_W^4LIS\__S#Y7?O_^)ML\[CB$7!,%F-3W%K"TUB.0\BY!_GUI;3W+I1 M*;_?Y[<[2!Z#B:++VSCD'5'=S-'6@E+\O#-B"Q=W',FZ+X"4XZ:4/8YQ- M5@OO6?9:=FW%JOG;KXLUL]BM"3CF^[QPTJOV">M`A;%#-&*TWNL9%0H+E*(TC@, MEM1N7GD$GH_GCQAGZ5WD;8ECRD+5."(&-0M\+U36$]Z[+9M7,1S4W>I=#7LU MY'S2/0;Z]I(\6M+M]"6JMHORAA%O&=5:A&%>*R$'@H[N]U'@+/HPQ0D[SZ\/ M5L@U'85^=%V11(-D:LXIVQVKZL[XHDP#:0(Q77!4Y`![NVB5_G&T-1Q13P9= M0KFF.$2J23":4*Q4`LHQ7D_>]!D4TDZY58>LY!47AJ_5`G2'H(A?&A4P+#/#:7YC(+#R`GV\2;`?L,NC)$^@ M+F(U>5<`KI:N6_D>#&$$H%HIN141X123Y_5(:-['3SB,V0%CM072Z-C= ME#>`7]^/5RB`H9()RM9]R;D.,SW+4@L&SUISMNG<[MA3,O*0P/!&ADR\5[F3 M1@-04U.Y:3\D@\/SBK<$9HXWCM27VZH5[2_D3#K27M.IM&!M7QKC;1T&G\SG M:#B;W*+<0Y^,@7CF+)&$]XN6(+W9A1EF#PL>6!*)F[7H*E!U\V86!8,E30`V\$I_C4*F/3) M4BJ*W\FYO8@K"2&$\O43@,+M^8XMV$N?V*MK9=)$)W4[-/N>TRS"#_2G1;/D M_M"E!&3%"IO'A9G;?^2SGG*.KC=;\CL2FR61L<@S,;P*D^H"SDV2"E6+!ER* MF"$N!F,Z8_/RF`R,ESYR4M@,M5DDU8%%+!U,29V#Y](6O#HAM^I7K%5[%"6[,WL4_ M"[>1_N_">\;IX)FL0N)D&41>\C+*\#JE[R)IECS=D#TUKIC*N>P6$JS@R.D? M?K>PR^GP@'G+`3P$DR@1NAH,)[,!6O1^AK.>SSN=/Y(K'.&5]'"C5-K^&RB% MW'XY6J+`>"O#)\DSR;SG8E,6!H?(2U"^@)*>-F1L\D4(K\J2F@`8;HA0-1DQ M'BP0,S2]Q6(VNKI;]*YNB'F9H-[5[0+1LB63<>UH#0S"",XZ%N<<-<%J(TW+ M296F76GD5NK4P!#1'*LX@$UH.)T-/@_&\]%/`S0:DW\/T%M*VZ]@T%%V_G9( M/(;@(>)EI?R71>)%*>DLO2XL6K)_A/>6 MGE$'8@D4IJZ[<00S$76<@&!MT^N!"JJU5>:;5^@>%25,BO-]5UX:^#2G*@AI M"%WRH+1:-MEHV(4J(S4J8.RJ&+Q=W^-DLF)]K1R3,2/EOHW9Y.IA':Y2>+^6P##[(/A-PA>- M(8^WAB+6'"TIE]>>JQ2<0\MM0O]#7!;T0B]Z/D=`WX[=(9\%=7\D#[(IY.0J MYQI`X:7-3`(,^X2PY!>4Q`OR;@FF6K!8'#,_`H_!!%UXHIJ M+6?Y.6`5/4[Z5NY9XEBYITH<\?T.LYM?$>@;8M/#_3G%8VS&*UR7?)'PJ[>-GG+ M3T8NSNO./2[48)"KW@DS[Z2!7KGJ3B0(ACPY?ZWQV*4]M$XVB5%+L@1R/G":QC_%REZ&5 M`U87Z=D-NY0:\6HU03#PTYPE0Y:X92A($*;)'CR,HPVH>?S@-#;?[^\ MN/RVW(GY"AUK97!2!K.ZG7L2N*D+@+_B[AC0MZX(G;U"M,!9GBF%E5P')LL`&L$0?, MOP5#G18D:<(J=7**O#P8+#CT9,,G+XAHSWM)D!(OL.H+:K+]K?SR:SJ;T^%1 M'O-$CL'/@GG3[/6UT^F;!](LTI^]@9)HYB+3:1`)2V,I\37'8,#SFU]YGMD' M@$]?CE(W!I`<\5V:ZF1%(DFU@!7IA7+)`'8Z\-0,ISC>,5 MHDJ(:8&[!X3,%Q0=\?V>@B5>7KW&WIKF[\W_XR&-Y-_U(O9C#^AWO5B]!.[P-71;&:\YK+K.QC< M52_`)EM^P3`\'!=Q^$;#HEL[W^WM/#6K5< MM_(8CZ!1W_*0)L%X>\?I1VOM^DC^A=.&M\::8H4EPK*Q$UZ+(>P9\6AQ\$0K M&-!>D1>:7HX@N6/LD(9L7I*Q?T>K=V5T;\4YBP^&WO8H>1.4N;P*>5*VPJB[ MX>T<[7+.KOR=>B]%EWJ^GQ!W9Q_RJEIQSEQ]%[6TE3E01F]3))^R*X-ENRT=&K":,]BY8[7]+6-M:(&-SLB;W)T2 M4(_4VXA7Q!'FNLS/P(4B4.9RY^I0^NI:<`W*?VV\*"_ M0LO*XF^)-W$:9"R4O'DEK)?X88(IJILC)VP`@%NMZ)B!6RW0?A5NM1RWUJT. M"M57Y%8/@\B+_..XU]U2H(`_*& M*LX9,W03WX5:$.+KX\6*V(C29+YF>?I:;.R!LV8<=+ M>M&2_H>NI9_(JCK*9`3NUH35*Q_WZ%SM_L<.^F!6"WN`;E4G&`X'UPLT&:+! MS]>?>^-/`S3K+0:(_SU'DS%B4>7>N,__&/QX-_JI=S,8+X"$DL7=Y2'*YCPD M>8[=FK!ZK^X>G:M=M-M!'PRM]P#=,LV#!;WK?3;HS0?H;7_`__J*?/8ZZ=PC M4U62O)!IA47=.SVXEJY[`DNZHV=N0Q'B!61=@`LW\$3<1+T%NAI\&HW'=#>/ M6.M?!KV9H\H')QY2@+66N@'O-*@#\KG!<%K,0O#9*3^ZRQ>'@6^0:J!0L)I/ MH`5>2QJ02H.9!K406Z4$=@JHT`!7!&@>/$3!*O!I8EJK?PO\G%V1'_]=MA%M MJ&PU!:!3AVIY`$::8.C8"6Z3FI<7:'YW>]N;_4*MW7ST:3P:CJY[XP7J75]/ M[L8L]WLZN1E=C\BB@QK+R>Q3;SSZ?[W%:#*&05UI5J7&0!KH6=Z;->M&8U=6 MK02&IJ9(!;D"3.\,,4V6V[K3!6=&I;VDI_3#.-TF6&=,NS4!@J&*SAF15:`/ MG[=RT$T*?WV!IC-:(FWQ"S.AU-6'YY1+=WR'L<9\:SC M?$/*"W>%7F5VTUS-WH:W>2?*_6Z]CG/"=03:BD]31;K1O5-%I2X,0UK9KJ^6 MA^]@/#NU8--@[M&UJI'LH.ZN,Y/5@R M&0/9.VE79:?OF3EA.^A;/V72I5OJ>OH293!4[8JX2=1O+]!\,;G^X?/DIC^8 MS5%_,!Q=CX`L@J[C]3K@Y5[ICD+,HF@X\CMYI5T;L;KAMU<':]M$G5H`0]N] M8#>Y^]T%NI[4&_=(91K>*89TJCIY*'S#2=0?O3!S8+T=VJB[\@@)ID71`;GZ34Z5A V`-LDY9^I"S>^ M)O[;C&U>7,&3XHXM5[<:GA%`[H639'(@J&2!F"K1,=. M''%Y<'-GLT/:&)Y#'.S(1HL%/8+(0KK9I M$.$T[>/43X)-?N-M]US$/=JQR;^]NUGE9>=&P/!U7^1-'D^2!R_*KT&!P5_B MF:8$_))!8MUX,5A#*%0LKQVTX!MK!JD\&*X9@&PG&P:1'VQH,DV\0GZU`1@L MNTMI;:4T"]:*TD--(9M,$@.L, M4>P(6):[#[$@]6B]\8*$W>B>](-T$Z=>.%G=Q-'#3?"$E_QN,3.B[M>4U5VO M`SI;VPW;HQTP9#X`?)/85.D\I%KYS7$P.#TD_>/57U>[_,51E&;)=EU.*I*G M8ZAKD[6=NE.EJ9$B&%YV0=LD(M5%3U29^J6K7=)J4.J?+`WZ4TS)@F._%I^/NDJ^V?(@H.&"X4#VK/J M=QW:[9HOMF]C8&SJH3UH^6R\/>3G#:*L;`(&[Z_C]2;!C^3M)4L8[?U^M5&4!BG0'R$H@+[%"=S>E^$&2NU M6E;+8IIUH58)4ZT"AGIF.-L1E31%&T(Z=@,(#)[-\0/U169X$R>[S6E#&VBH M:S7UI4MW:FDP)HI@^-<%;2OMBNL"L7-C_*62&9'$$?G3QY6@D!D5NS=CM\;U M?IVL5[KNU@88KNX)O+V*HDG1J%IGKM;6R4*`<_\1+[?LOJ=*J>.4%^RN>,8+ M6O1!QM/#FK(74#RLLV7<<;]VG'/V".!;1:[S)E!"V]A=!0IN/23=!MU["QO: MYO5^V]9@DRJ,$;^F'>ORU3.IIJ,TN<=ITJKS>H3.UWS:`]J#QO8C]$4<`-A4 M*XMYO"6$>5CW=$Z%XL#^@I=&4U59ZJ!MSW7HW*726S!6A<+*_6"W7%KB$:!A MG*!JN!5-?)]==(L6CTF\?7B,MQGY$Z-?L'?PQ6C'-M+#;;9-\&T0!>OM>D8> MA!>2UY+?(!TG$S+->/29W-#;$KI:ZX/:=F.VC_`XQ/;[@(:=^]2GZ$W+E!\^!,&>\+67Y.@*#65B!L;WM M7H@B*HM^I=)`SO4U=KNJJ[S*\N[2;*],KNUP/U/7)<7NI4P5C"'IAE>Y'H=! M1^E*[E,2IXJ[MY5*();9!ABJ&<%LY:W1[]!/1<+BIEAN;W:UW8$M MNLGZ:;O>LAJ-?;Q)L!^P-XC\'>+B].*:;C3PLXC2AR)YB,=KWG)AXZ,^E$:E MXZ.T#>8].7*'6ANG.$T_TL5Y\2-H6?D5OG*O-._(S9/V:HR[W6M!Y.&Y?D9H MFP.WH/>@EA:P9OO.4(3A&,!J2(D%AKA[H;EX2JSAL/ZZ"+JBQGI5')(QT6!4 M1_+`<*H1E-0R2B9OF4]JV`TVB84A<4F)4'"-F9T`,+.,C+=%')O_K8I:J1 M,E1USK[]\+;39+B#O*'%]HF;?'^PBR4U8:/U9IO1E(@,DV>03:+>\LDC(YD. MR=`MOL3]@+CHI#FQ+>N@;<^H=>Y2:=V,59T3;3^\K?@NUT=!W@"B"[&\"42? M*GTW02KNG(#F&-N;"CG9"O^L MS;JTO,&!K3>3BD$,3KJC'Z7;,"-(7H98XK^U9&SNS@OA5??@:P+.2:)"U:H1 M4TJA%0:S`@Q9XWC)C@A<>2E>TB,KA+*K'31866BURB/LZ\0'K597=U$-E$DDX9I1,U=)TS;D_`;0.X M:P"1%E"M"92W`<,J-M([:KD@118(60*I@V5=&[%I)??K8-5:=FO!.8OBJB'/0R0U#R`DU;)F-&0FVK/JAOHDT3TY-&3W7TVW#J/O81B?9+= M9F6L93%:8MJ%2I1$I^+LI0E&JD4 MW!@O&7"QO6I*.V>8,<36Q;TX0W&9Z4JSC'RJA@J]DQDKLN()^'TTPSAA4(?Y M3U[AAR`21SOT2O9,E6D'2DNETW!.HTXPVUF0A1HE3X-&Z)ZIPK!7?;S"Q&%< M$I/*JU?2Q#J&G*[2O]#(GVPCQ433ZB:6>5=J&UAZ->=D[(ZURN66+Z*.JM M:?Z3Y$ET;\8FV?;M9)6(7=L`0](]@8O?H&<(O_3R-@G-R=4'9.NG/M>@I!%["&^7[&I18 M/E<]8>EDLDIA=UDF4:<8AYFBS2++YAVI5E[6:P$A5P>H[1K-="F:ZQX_Y"$E M5R6A<_#L8TQ/>A994HSIPHX::-FCE7$72DYI58`0RA1G:QN+RZ"PU$>X:""O M)9H=Z38"^7:JESZ.HCPX$TMB&VTABUNC$H"5#="&!!!:2&`);_PIZB3%.VG+ MIWHXY,K!)GX.H5HNE,;M;O'Z'B?M(3!4_&T9^]9&AOP6NRZ!/4_A"'5#W5IY MT9F_VXN6]7,0CH9M$Z=!1JSJE#RT1_(&%T=A MA6>\C97`#9\I8NF+%G^A4=?*O%)+P*:YD%ZDC#><<@QWQ\6IV5Z%\1?AH+6D MX(V2#.)IJXN=;FB"-$N">WJ6I/;R"V8EJ2BT0=+@;&4,ER)NAB#O$3W5'V5! M]C**5G&RYJ%L:8#+1`O:P)A#%HY1R[]V,UPU!U(P,+7OH0V!")SP8:-T>Y_Z M2;!A&Q]$`0=/]#BNDV?>."W7?N@-`6!/78RNE?#X)4;%^5&7'I=ZQ21X]DIY M:$-A`O85O!"B;M2]=<.!JBN]AM$2(FZ]3(\)QLCM.E^(ON)M&(Y01>,U#$\; MKLC0P1J94<3BK;/=2TT/`DT3O/$"146-?5H!/H(=NM`O0!LRA[-Z!5QKZ(Y.\MPDR+\SK=K930E5RT`9/!5)PF5E- M^`QQ<1##P`H8"*8LL1SP8:B!U`\#%W!.SAJ MP.)`(']'Z`NSRG7S4WSIH].91-4MV:RBUWE%8Z><;0S&SN7T0]'-*Q'F,@0C MG8ET*A!'S@`O_.A[)0*B')RJ",3!$."#MCE>+84I>]9M&6`/6PH07F2<(*A' M]!0/720([\DK4$+=@?T4/^$DXA?=>"*/JR$`[*&+T;7/+A52B(FYL>1N+]R& M-6X'=>*X%V^?SKX=OVX^K$$TA-NYVM8I]V*/7\8*UIB8XCU6.:N3C=7=7.8. M%-]8OCFIAK3VS%N`6OO5N8"CZZKXMIWJ=I>J`(#'JL;5NLF%29VA7,[I0Y8_ M77"/5?,\'3U&L^N(!+?\P'F\"G"MZ^Y*4=?\G5&K'Y')VTNB('I(:Q?]K0(_ M$`Z$7@O0P'0`V]X_XJJHT$5O*]HH5__*T=A53Q[0,SSBBR+:4K]]`V9L%.`4 M<:+TCX@+HU[&#V)0-Y2&7,F:VMV[5'FM>]'2;'1T.H#>(V.H"G/'#HQQ<6=W MM5./EQYUI_?@\#KJ6_)JB\\IFVL!&J@.8"7K@;=4^2M^WTJIC\H&8+QX#K(O M/S@?Y4-0OZ;,RX+-M1(5G)]CG$U69,TJ>E,5XH!>41.4@CL@2AU4>U//$"L= MO*(+^3,8[^9NAF<[GGP[5>B>5+X'\'8I88GS6L[0R%U*RP$'G]T_;`-P[>*? M;6'7J1#[Y!)!>?@:>&9Y1.A7LA+RMF&&;FC;_^,J%E.Y(GZRZN/[K!^DK`KB M-,'K8+L6AFET2H!F#7.LK>!.19/.$U07%->7>9%<9M<'\%U$A.XS#P7X2)T)T4`;V? MW?!V&$G>!/HU_R]M"['&7$5@9SC%1)SVMH^?"]"(=@#;"MO4@S/UV`SZE1UD`#"(Y<&+ MGL]B_FF1NQ\M\_3]2I:._"S*,=H#-/!'Z48K/I`W2O=9BF91WB[C1]XRJN9% M.6=*47E_O0XR%HBD,Q9+_7G`Q/7+>Y_*CTP8JP(8_WT1"U(RS%IP]-J7-U#3 M15HZW&;;!-\&4;#>KHN`!,K;0+L0?5_H M,U<_NB%_D8^+C\C_W),FR2?_'U!+`P04````"`!M8CU&\UWPG<(=``"2O`$` M%@`<`&%B=&)I+3(P,30Q,#,Q7W!R92YX;6Q55`D``YUKRE2=:\I4=7@+``$$ M)0X```0Y`0``[5U;<]NXDG[?JOT/W)S:JMD'7^0DDTG.S)Z2=7%4<22-),]E M7Z9H"I)Q0A$:7GR97[\`*-D420`-BA2@3.9A8LMH"-T?&F@TNAL__NMQY3OW M*(PP"7YZU3H]?^6@P"-S'"Q_>G4S/6E/.X/!*R>*W6#N^B1`/[T*R*M__>]_ M_H=#__OQOTY.G#Y&_OR#TR7>R2!8D'\Z0W>%/CA7*$"A&Y/PG\XOKI_03W[^ M;1#$]#,OQO>(?II^ZP?GS6G+=4Y.`'U.21)ZZ+G#]N7L(_S3J[LX7G\X.WMX>#A]>'U*PN79Q?EY MZ^RWS]=3[PZMW!,<,&EZZ-66BO521M=Z__[]&?_KMFFAY>-MZ&^_X_79=CC/ M/=._8DG[S$@B_"'BP[LFGAOSR:#\&D?8@OUVLFUVPCXZ:5V3P?.WNK?Q+28K-,>>ZY]Z9'7&6IQ1E)(5"N)V,.\%,8Z? M&&3ABH^8!<''??8#:D8[U#,"&M@HK2_ICEB M"H[8=(A&B]&:+55T&D1T;G3(:AVB.TI`EZEK$E6$2;__>CDN'<@T)MZ7.^+/ MZ=K;10OLX1C"G6Y?A\2NXT9W?9\\U`!3H:L:^9@FJY4;/E&QX66`J;1HS"I1O@OV!+VEZ]ULC=."1TBL=/;&G],\%K)E#EX&5$ M-8YM1%>6<.P^N;<^%P653YB@>>]QS2:#>MH`Z6L<\03Y;&K293%^FH5N$#&3 MB-:5_';"/V94+Y[]Y`E M3M#>]+ZR_;B9_27?NVEN9WSE;H;7W;X;WE&!C*A)#[>[`H>LUD!KG.&]8#*"L`VL-I`G30>MT?X\J6Z&BCAJR M2AGD\9/VZ.%='&8=@LX;>!=-6+#:8E92-F[A:@]9KYN&+&#M44.(96-=ARBB M7'.FK^D'.R3H,4;!',VW';'AUN'#I1^SCC8N]Y9SXFRILC^ZP=Q)NW"R?6R& MOV7`)][.F'WFX2:A4G#\HS]DHVW?1C&[SMAVY;NWR.=?\`51GO1L3< M[1XA[W1)[L_F")\Q#M@/G)63\];&Z?X/^M$?Z1@F:(G95PZP_SR5%B%9:B MX"0K7CJ&@V/0XHQ`3RL&AZT&W/Z"^7[>OVL--SIA][O=G4^>YFV+[I#NA?_J>2_SP[ M"1=N=,L!3:*3I>NNTYF(_#C:?I*?DIN/_W@>]VC1QP'E%%.-(1%6.-LWY##J MO76L.GOM***PJ1G)MS/E>->2ZZZ>"3BI?\7;%XV-?0\%I=#!RBM8NWX24;+L0B%S0WYI^O@(&48SM`V6$' MN"09=!-7`*&4PXSPZ=@7B/YQ?IUR+1PA'UY,8M?G+0WK4AIO-O;=U"K=!IT- MD52E9%3&')J5-$O-_[X*)@[40&NV[?5).$Y"[\Z-T'8XA>220IP&A-28XTP' M"#@[]BUWJG7.I'NF\@KWM2QMU]B]Q3ZU*GE,:C%&4FT_PWLPYU;8WZ;6E9,= M"I@9-?@\)*.!(MB8*5(/@E8?C7B<>'&P8L"$!%"TZK_$AHN( MA;COC,:]R;MV8`V<-I#UO+S>-+[2,D&O_2E^-1L2$@,YW0H$,G'6ZA8MV.139\<\5G1Q/D* M![SD$RMSMAFU&"DL#S4`1(\AFV#K(BI.#^\4@"N)`=AI93KI0Q>0,A[M MD/Z$"HZ.X8[.E2ZZ1S[A`<)*E5&0F4X(T<4')`4[`"NPIK'_&*SH5!$8(;=V M@/'B@N]33M.8@H2.]L4$5!DY?M%FG#.2 MN3%A=91W8B%%;G7-3LR5VJD$4146JRZD[].%-$!+UMT^2ZD8\=4ZH7U+5"QE M.-_,>(I7%=3*>;5CT>/\#$G@N=%=RI;2M)>0F"O!L\^ZIY2!15`]&UP[`Y4F M$*OHC.?350=-*0T[D%-;O9=H04*46]^WOVYWX\V+""CJ/5+)4%APX(9/`VJ( M16SVTFZIS'TNC90PDLX+LZ,RG@-8T40RCZ1-75#AA*HC*W$9EJAP"(V'B6FYY;0$,@ M=B`H"J[MT[4>+X,TP+),/7"W7&41N-/-I,T+^!C"`DTT[E8(6 M9G,C6JH%3R$#:I>C[#6+#8!0-4;<#P,`)=/6,F!VII4(@,020DH MU2KK%$@2#9:_3AU;?/JP\=(S-A>77(649*:+RNLK$%`2=JA/ONZ+2F]$[4W' M"5=1&#GOC6F*M*0*NUN4:PR8W'3E?GW-T92,'1I4'D^ATB,YE>D8["K:!)&# M'8C!H M=-+-2)\D`1M[GX3LO:ET1DK/4`I*:VQ`(7)@5@YQE!4,H;VBOPLCX2&4UAAY MU7'8%4)S-MZ*!7.D9C_]YLR(V&\HO,>>6"6`Q-;8=W(TM$31W/&4I:"SL!HV M)[(+K/!@*B8PGMD#E+R29SO,L7%(/(3FSP'/FR$KB^:JZ(RG\H`W?)@$[$`K MH[_=)*26?OJB=+J_#=$#_Y/T+@U&;_PA##US#2P1JU'D)>2J@Y@G-QXTO"^& MY?*P&L+L^4]N:T"F;W6SH[E8S7H4LS$3I'D%W1]<43?&W]2H16$/;UU.D)?N MU?@O+BOYD5?4VGAT)-"NE'-[,"'+S[.BUA:\J%!)R/4>7.NZ>]WF,$0S(KA^ MY(Y\V3TLN`L+'E4`+D[:!8GLF7;6-!V73X`2O'F1T2WS>)Z,K% M`>.J'>*([H'9G5"=D7.0+X?.$?,6Q0&QL&/RZ5^#_7$!!]2@D2(8>2U7*+U@ MKWHU-MR$Z:!HT`J2CK\A+.TLY\SN+?H^>1!4;OZ^2N7F3GOZT>E?CWZUI41S M)N?CF5^M3)P2*K.%$=B`J.%QC^E\N'RZB5B%IN=Z,FVZ@]RG[[NYL=N)/>2M85P?ZQ-QV1,3F@[H M.<0T@4OC:YDS5'@AF_5%P[E27;483X@_"9-QVIS$%OU.S7L351YG`# MH29A-EAHNG1\+RET;&QTBJ]=/)<\G[`IQERE+].%P>M"B.PM"3-0C]VG[8C: MGA?2G;`BSK*.C$<@'A!EM4#M./_#S]-U>'HL"&^L>0Y4$,&>W@9+RJN]7!!O M=\&>G[I^T_<2M)T)E;HS7J2[DKM@#\G9L6K0U6T;)^#]F>`0T8E/IWK\-/;= M(&;%:>FG_"THB5=1HP\HS(UEMN^'&:G,^-=RG"CPG&Z2-+49)]+N[$D&J<,X`4C. M#N-$%F2MB.L$D!K/#MD/(7@\NBC4\TAWD&RV&N.8O;P^"J>NCT8+5302A-9X M4?@ZYP5<6':H?&DJ(GMVAGW07BSH.9[.0GF(`ZP#*,R-^2^:@AD@-CNPSN0' M;TL@B7$M;6P\%ZQ.#"7B.)@3N9OL/KH(]1D7Z8RG@AWZ8'3 MHWV`[P3R5,8?3F@8W8*`C@=;Z&.R`%(HR@8\+K6@7-=[LK9%#PK,'J]&$^FK'/*5!&@'29X^1A3WT%^R11#K]<+.-KT&*"O(D";H6_3Q2\, MGZ@(N.M(%_,"N?$;!%HC,=*W$XYDE.@F!=A\H=+FN9:98DD8X358K-WP: M+:9X&>`%_6,0MST>4\OQD%+YS3AP6C^N3*`D1 M_:5UZDQO/G]N3W[G#WL-KH:#_J#3'LZ<=J2J/1S\7WLV&`T-9A66"$!]1R6A,7D9(X-U1F?,)?WR+Y(;&2"]XC,:]R>QWKFJ]GV\&8Y;8:U#/A($3 M:G4#D)J]#RD?W0LD`-W3Z\6P!H*Q+-Z!:(O*%G6$1AKO:.;[O&:^/G5&LX^] MB3-N_]Z^O-YLA72+G-STJ)[^-F9I^5.3:IKCT/4!^Z&4R&1H2KK:1YOQO:"6 MB3?6TM+*'9I66#6J^=B4_41GB]9F_,?9NCSEZMHZSZOKFU-GTKOFQ3'&;;:; MSB;MX;3=839K-2T5WA0,2
-ML<95S_I;R'1/\X*832Z/M!Y1!H*9Y6)Z:4 M#8Q&J<95D),M6@9]&[K5RBO8V]/21Z"_J5;%*D]LP%J*I='%<:J5MHQL42KV MJ"A.>7Z_M3IC#Y_'LS2FD[,TNR,N">F-V1NF&]: M!G[/5@"$EJKI]G.<^E9-6K8H75K'(%N(<4?%7N=5[-VI,QA2)>LYL_9O!H]M MS^-^&1VH/("8R&P]A/RX`.HEIS)\``/@4ZQCH!2"+5I#M=RC'8:\1Z;V$QQ] M$>Q2;_(J]`/;I88=ND5-^%U`NE%-!M-/)OT@G`/*R0WE+&2/@,*R5Q1D1G>Q M#$9LF)I[%X3:L)*!,"ML5W"QV*)N5X1NJ7S@8?GU7.MM7LG>GSI7(W8%QU5M M4NW"[>]G^EUC>F*8TS.#EK+(J8[3K(-(PA;]8$_3HS\3VF?O7G1IUOJ^<(-] MSJZP+Z>]GV_H7N3T?C%[7Y9C`E+I5DAATD61&Q3$)2$F,5VS5H%)WO6@XMT> MA:D0&++]N%R]:@X0<;[;?IW)"M1?4:S(91+A`$51%T5>B->;QPHJA8U4Z.K8 M(D@J2\N20-+GLO%;O7V"V?P2*M/%J;4QA`C!#KAN(I;Z&\5X)4^DS;&+GQNL[:6J0CEN//TQ)&+($G`KP'X%QH+KY:=R[H"L<. MQ1ZLUBX.>:66D%JH:Q*Y_FAQ38+E-;Y'\[0F(1C>:KT9+_>M"_4^0K,#]CX= M?UIK9?'L_1@$E.ED];*"B7$&D@.!;2[-4A=8+;$T5N3@BM`5/V#?>!6ZXA<[ M"\V,UT,'B[M\_#8IR/.%$WSM$U*8KANNO[XIF+<#H@F5(AT#,\"ZZ![YA.^V MFQ!DU0H&(C9=&UP;.`V1'+\U*GYH,MI]:1)NO^S1I?$2X_J;W;[RLV,9*'F" M-!VOAFL'VH/Q&N(5_#QZTK$#TVT]J3$*^:ND8"B5A%`$[7$+`65A!W!3M&0[ MS@2MV7LU&Q[AF@@D-UY[73_I4D'9HGO$YJIJQ/E%:#REAS M7(XRK4U?IJO8V]'<9>[%I5VZ6Y8;+U/-0AZN,$/>!JW[^Z7*[W./8H\JUIX6 MW_2%FHV)]!(UOBCDY\+2Z:W0Z:\IK_YE$X&DB2NWW^V)8:]>3>N^=H9]'4+\ M&M8#2<*8;"THI!*KLAWW6P6$1JAR^*H0>(T.K%#Y?A)3@7_&`5XEJPF;"O[V MJ:0^>7G;[YK54ZR@^WMU;S2V7GLF"!>$&D1LBZ5>Z93=1;&+?8'B%]*<]SUF M;[ZMYG6A$N.JM6+/3HV6*M@DFO#I*ED(GIOII_1ZE;\V,W+ MWTVG)2@GR(XW-L^7E6^8?/PD%_[+WTTG(.@)/\]78]&-G:%<@"]_-YT.H"?` M/%]VW.*F3ZWRG89^E7S7+&MKV:(LVR[+AI_1,6M`Z%!>EB3<6,9"92CEJIS6 M#I#$4TT*5#E+3>V=['ZO3\)+UV+9'?H=N2$('ZV>3"<8[8=9!:'9L2'EHDZS M]^Z9"_>6>$$$=V"Z/(+0>2"/PU5)Q!9?9EG4@=1562@7)PD[V,L+^2WNX&MT M/NX95O#-Q6C:/K?8Q2B<5)=/ZF,3B/B(<`+Q8X<#4APK1+]9Y8H$$=N!F\;\ M!$=399C<\[!5#Y:?W2!9T/6;F[)]UV.A'D^JT[&4R/2I3&-VYE`#R,(.:YX; MJ"RG@0OUF4$5;`HRTY[3ZL"!Y&$'=*/%`GL(#)F@N6D?;76HI/PWY_TFJW42 MHW!*%O$#95#A"Q>T-NV[J"!U*3\VZ<5E0CFGR^Y@M0[)?9K"HU(.&8WIZB;5 M-40M"3L08[7,XC#ASK!!0/E=4A$K,9-3F2Y=4ATUB#3LP$W(XU5(HBH'K@W= ML3C^8/S;@57;\Y)5PM]DZB(J4`]O8A/7/MH6@%RQW-9-.501:V)4Z_L&TW8_ M>`+4+50[IHIPF$-4Q6?*J4R?"/;7Z0SS7T.>@B)O27H14'CT`IJX9,.MP->4 MN91+M>&8IM=0ZHSFHNL!)2<_\:.[#,2NWYV MO1,\=IP_O*OI3.]J&B@`.;+KBEKXB&BZCPS=D*4.W:/R;:KP;(ST_=OGWK:LBM1BZ^N17/J\BG[%_D-MDX?1X2: M#EMVW&=GQZ6ZOBYK:P+ILEOE2,1B#($945/$H:,_O6:9#U*>L M9>>52&TT.C!]EE>#H\N134JV'>_&TY!=.L2*)24RO;6`E0G`NBW^EHRA$;&+ M#[JN@SPMA=='WYXZT]FH\^GCZ+K;FTQY9L#L]]I<+!!C4,"`LB:)1@\VG-V/ MRX^B+>)O_A0K3^86^U/2&ODO`V3?Q`2HR)R6$!T1+E(^['"1"(:H\I8HR.S` M"##W8(!9%=A_A0(4NCZ[9)JO<(#9VLQ6Z8U!HXK3`Y*;?F0)-"]SZ&E)Q@Y# M_)N[N4YWL^&Z%-_>=HSE\KNG0C-&=I'W1#2W.BTKU-$K4$ MI+??X:;)D%V^'$G]7FEPYSO]2M3-E)Q5,[!'+>I"#R83^78K(.^42]X62NXF M2!DNJ-N/K>6E!>CFT_\J2%B1\<,.YY%`L MHS&ZTH(Q$NJ>2`B-6?_4I,(AETZ?A/RK^YNOOD1+'`B/`VHZ8U?PU:``KQ<; MX@*.,%:C&EC?XC4LN]JR.%[CV^LPWUZ',8",O:_#U/Z^AB6OP]3]OL;AGM>Q MY(67HWA>9XQ"9C",%NG)Z3J].1L$'694AV7!WIQ.278<%[M`[FTY5%P1'"RY MB1<&H*/$Z\*;U:WS4^=JQ-ZDY">*R;#Y`X1LU*IC`XS6:$@/'52`YCTW#.A0 MHYT24POL86GFOYK6J"M:![E"C`]4+B:7Q=H*<"UP?*VJH??P]0BXQ: MN:=E:M;T'CV$6$W-;3X<7^=%JPV`T*PSNPIV4,X:MO(Z;G0W"#:75$1\)U1L M9]8I75GD(H:UC(G-7]C_;MT(T4_^'U!+`P04````"`!M8CU&`0=.7HH+``"9 M9P``$@`<`&%B=&)I+3(P,30Q,#,Q+GAS9%54"0`#G6O*5)UKRE1U>`L``00E M#@``!#D!``#M7=USXC@2?[ZMNO_!2]55S3WPE4PRDVRR6PXXB6L(,-C,S>S+ MEK`%J,;8C&PGL'_]M60,_A2&)!?/01X26^J6NO53MUJRV[GZ8S&SI$=,7>+8 MUY5FK5&1L&TX)K$GUY6A5I6UEJI6I#]^_^&R M<7YYUBS8E8<\WUUWU5@T5C_%V!^(:ZR9ZS\F\Z;GX^^?3__>SF9_ZE\5J9+U>5Z:>-[^LUY^>GFI/IS6'3NHGC4:S_O6AHW&Z2D!XN;"(_3V+O'EQ<5'G MM2%IBG(QHE;8]&F=58^0B]AZ0 MDI#4Q`DZ%QNUB?-8AXHZFQ?51K-ZV@S)?;K3N+>>X#D15H,*4&&N^[4QQ!I"!%6=+QVLRI$,C;[09 M-G[GS+!)#&35#&?&.9A=@?E;>(9M[]:ALS8>(]\"`'_XR")C@LV*Y"$ZP1Z; M\^X<&;A(DZ'U(-MVP,C`!:Q*6-E\3L"*H.`?5VRZ7;+AU4$)B5T,!ZJ@`T91 M!SOTF;RR;2JV1[PE,THZX]U4)&)>5X04K&,0@W=MXC&Q"9=O9?K@.J20/7J) M;%,*VI(BC5W5D\U$&O==;/;LW_GUG&(7FN%,'2A8,:Y([8O$$6F)K>:WVZ[W7:RD"3 MVLJMVE+U(WZ%S+>%W.FMY3P5M=0-O1B]\WV,LB5K]])MI_>?H_5Q]#1_-D-T M"=9#)C;$Q0:"Z-(P'!]"0GO2!WP,@IG+[-$)LLG?D6!T/U8QIA]8:`K;3\MQ M?8KAIEF3M.'#@SSXQJU0O>NJ8'MR5Y?D5JLW[.IJ]T[J`]@M50G\;&]P)W?5 M/[GG/5Q<^]2!!<];LIW"#Y_,F8T$L&76B%'YF$3EI";U!VQ]T[_Q,5<^#]4^ ML['#'?`>1'*TCY9H9/%)#Y9`?6PJBSES=BO?MXU(#,-%$H;3FM33[Y6!U)>_ MR3>=E0&`80R&X/B4KWWF#K7#Q62`+;:X0*#M+76*;)<=W\&J$X"16RM$H=E( MHO"^)@V4#E]K^C*S"'T@=S6YQ4._PQW\W/AMYSBMV4P.^5DM,R`[W,&&##R`XML;O@1CFRW`8=253R`>_)/DX)_7V%[F0=6#H"K8V_"%6.FR5?AP45!M MN,0Z6@1COKD5C_!I7KB+]6(EXB,^20WQ1D^YZ+$CG M`STXX)!<\T.]*P M^!F;VG438O1>>',KO0O[/9Y?[(:7SO=?SP!\U8`8[M2N^;EP![T>,-A91Q=1 M+`7U8JA2.^O<`XXC"MM..J*`%",58G.2VF\7._4X`B7:%$9!VDXF!BBU.]^V M03Q"L]^RU<8>(M9SUJVP!3&@J1W_N5;<'C'?6RA2#4T0@1BMU>B!8NXY` M;%F18I@4I!7#DSIS*+I\';'*.Z!?C4P747;\\XC%Q_DI:C%>J0,,X?'^&B9I MW?X!`Q8]V6=>S%MF0U6`3@Q2ZAPD^4"`^3R`ZHA.L7`PYO8*T(G129US;`\( MC\YN_;`@VV3RJ\58I`XA8L\6C@:R_7E#-AX%:<7@I(X=!,\CCE#E/:/(!DA( M(83E-'7BP$[98P\Q_K_!8+]8KLP`CR6>8W/)4C&N*RZ9S2V6$U_[):,O/;4=Q+5=Y6$5-]D(:WNDYE*5Z"Y0SW)3N4]B;+@@OR]CF/P MI@0L[*X:\E594;5Y4CUMUA:NN9%T%R$VP[";$"'?'D((<_%RI,CD81?5#7/1 M_H6)?:+^,QGKV/+UASP%\A&+S)0H9S=@9%/E@DV5YODS MA=E/D&U2K!(:>8##O=5?0ZW=?,"S$:85+AS+=(Z4$,MBIU?7%8_ZS(^PK-=+ M\"_$,77N!TV?KE[I#OQBD/IY:3HS1&S5PS-&!FKX(Q?X&U*8)P M6G=NL.JZ/C83\R.OM@2"LZG+WKDR*)DS]@$V,'ED4F7,\2V$;Z\.A(*84I8^ M!=*RI$8,'H8U$U=F.]G;JR*#1YSYW$#Y+D;Z_:4$NNT"42[OY3 M7+C(_=L+U^K&A8O(5JTN@J5VEW)@`):@7CN99SZW'$)^VI)WZ?& M%':PX(?Z[\JT@Y;_VWFL9`ZH@V[P_01 M5O$U=D6)RZMNFS"G-6)V%?,7F]5#0%!>M6!SB>8$0JW5>YIQD\NM?7,S2TH6 M-ZW-_[676!O0AQ&WCX*]J M\YW_YF"&O8;1IWB.2.2S"V&LL1=O>2=JCD*B#U`(1T+(^/,,`]\\1-Q^GM89 M=#_-O,_>-FVE^KGTR]LR%"$MK:9=QV/GXK?$ANX(LC9?O4KN#8M0EF\;>.<\ M8FJSPCN*-G%`NGC?@R0/+[P;BRU<+[$^&E-L^A;NC96%,47V!+,'=>[097LV M_K#.VB1[ZF'/Z_5S7^Y2Z+XUYRM]6%&8H7SS0(/+.1\HV*[D!H'EW\ MX=.,HWD]E) MJF^Q-\Z6MW@S<=/%I45L>\[%#@XYQ5$^Q'+3&9)J%B`LGW;@&0D-3]E:(/$2 M_CXA:KHW>$+L]00M0/?FNA1+=,AXMK$35_DP[&/*-.B-9=?%GLO?X&/K0HLM M^'09*KJ=K/C:N`KW(-:;!ZV^3$R>GP>11*T8;?FPZA`T(A9AVS\(QC%F__*E MY5/V\"R`)52P"&%I8QEVYJC:F^^8KVTM7?[VZ]Q5/7CS%2[_"U!+`0(>`Q0` M```(`&UB/48HASGP950``#3+`@`2`!@```````$```"D@0````!A8G1B:2TR M,#$T,3`S,2YX;6Q55`4``YUKRE1U>`L``00E#@``!#D!``!02P$"'@,4```` M"`!M8CU&FGC[U;0,``"+C```%@`8```````!````I(&Q5```86)T8FDM,C`Q M-#$P,S%?8V%L+GAM;%54!0`#G6O*5'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`&UB/49]M"R7%@\```K!```6`!@```````$```"D@;5A``!A8G1B:2TR M,#$T,3`S,5]D968N>&UL550%``.=:\I4=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`;6(]1JCR\.MC+0``#6("`!8`&````````0```*2!&W$``&%B=&)I M+3(P,30Q,#,Q7VQA8BYX;6Q55`4``YUKRE1U>`L``00E#@``!#D!``!02P$" M'@,4````"`!M8CU&\UWPG<(=``"2O`$`%@`8```````!````I('.G@``86)T M8FDM,C`Q-#$P,S%?<')E+GAM;%54!0`#G6O*5'5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`&UB/48!!TY>B@L``)EG```2`!@```````$```"D@>"\``!A M8G1B:2TR,#$T,3`S,2YX`L``00E#@``!#D!``!02P4& 2``````8`!@`@`@``ML@````` ` end XML 29 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)
12 Months Ended

Oct. 31, 2014

Oct. 31, 2013

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss $ (827,756)us-gaap_ProfitLoss $ (890,343)us-gaap_ProfitLoss

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation 26,640abtbi_DepreciationCashflow 26,201abtbi_DepreciationCashflow

Stock issued for services 0abtbi_StockIssuedForServices 214,667abtbi_StockIssuedForServices

Imputed interest 20,079 22,936

Changes in operating assets and liabilities

Decrease in Other receivables and prepaid expenses 2,270 978

Increase in Other payables and accrued expenses 46,346 20,592

Net cash used in operating activities (732,421) (604,969)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property and equipment (8,793) (8,166)

(Increase) decrease in deposit for purchase of property and equipment (15,009) 562

Net cash used in investing activities (23,802) (7,604)

CASH FLOWS FROM FINANCING ACTIVITIES

Due to a stockholder 109,253abtbi_IncreaseDecreaseDueToStockholder 82,142abtbi_IncreaseDecreaseDueToStockholder

Due to directors (51,460)abtbi_IncreaseDecreaseDueToDirectors (62,450)abtbi_IncreaseDecreaseDueToDirectors

Due to related parties 724,435 591,492

Net cash provided by financing activities 782,228 611,184

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (31) 677

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 25,974 (712)

CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 48,380 49,092

CASH AND CASH EQUIVALENTS AT END OF YEAR $ 74,354 $ 48,380

X

- Definition

Rate For Transactions Occuring Throughout The Year

+ References

No definition available.

+ Details

Name: abtbi_DepreciationCashflow

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Stock subscription receivable

+ References

No definition available.

+ Details

Name: abtbi_IncreaseDecreaseDueToDirectors

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Three Directors

+ References

No definition available.

+ Details

Name: abtbi_IncreaseDecreaseDueToRelatedParties

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Two Directors

+ References

No definition available.

+ Details

Name: abtbi_IncreaseDecreaseDueToStockholder

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: abtbi_IncreaseDecreaseInOtherPayablesAndAccruedExpenses

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Unsecured debt owed to related party

+ References

No definition available.

+ Details

Name: abtbi_IncreaseDecreaseInOtherReceivablesAndPrepaidExpenses

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

StockIssuedForServices

+ References

No definition available.

+ Details

Name: abtbi_StockIssuedForServices

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow for acquisition of or capital improvements of property, plant and equipment, used to produce goods or deliver services, and not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 30 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details)

Oct. 31, 2014

Oct. 31, 2013

US | Rate For Balance sheet items

Exchange rate 1.0000 1.0000

US | Rate For Transactions Occuring Throughout The Year

Exchange rate 1.0000 1.0000

HK | Rate For Balance sheet items

Exchange rate 7.7551 7.7530

HK | Rate For Transactions Occuring Throughout The Year

Exchange rate 7.7543 7.7561

RMB | Rate For Balance sheet items

Exchange rate 6.1124 6.0943

RMB | Rate For Transactions Occuring Throughout The Year

Exchange rate 6.1498 6.1717

X

- Definition

Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521

+ Details

Name: us-gaap_ForeignCurrencyExchangeRateTranslation1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementGeographicalAxis=abtbi_CNMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=abtbi_HKMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=abtbi_USMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9

3. OTHER PAYABLES AND ACCRUED EXPENSES (Details) (CNY)

Oct. 31, 2014

Oct. 31, 2013

Payables and Accruals [Abstract]

Other payables 929us-gaap_AccountsPayableOtherCurrent 790us-gaap_AccountsPayableOtherCurrent

Accrued expenses 104,842us-gaap_AccruedLiabilitiesCurrent 58,447us-gaap_AccruedLiabilitiesCurrent

Total 105,771abtbi_TotalOtherPayableAccruedExpenses 59,237abtbi_TotalOtherPayableAccruedExpenses

X

- Definition

Total

+ References

No definition available.

+ Details

Name: abtbi_TotalOtherPayableAccruedExpenses

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableOtherCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
12 Months Ended

Oct. 31, 2014

Accounting Policies [Abstract]

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

(A) Organization

Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or ”Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006 .

Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, formerly known as “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.

Accordingly, these financial statements include the following:

(1) The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

(2) The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

(B) Principles of consolidation

The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.

All significant inter-company balances and transactions have been eliminated in consolidation.

(C) Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(D) Cash and cash equivalents

For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2014 and 2013, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.

(E) Property and equipment

Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

(F) Long-lived assets

The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2014 and 2013, the Company has not recognized any allowances for impairment.

(G) Fair value of financial instruments

FASB Codification Topic 825(ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

(H) Income taxes

The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

(I) Research and development

Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2014 and 2013 were $47,700 and $30,749 respectively.

(J) Foreign currency translation

The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.

Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.

The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:

October 31, 2014 October 31, 2013

Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end US$1=HK$7.7551=RMB6.1124 US$1=HK$7.7530=RMB6.0943

Amounts included in the statements of operations and cash flows for the year US$1=HK$7.7543=RMB6.1498 US$1=HK$7.7561=RMB6.1717

The translation (gain)/loss recorded for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.

No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.

The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.

(K) Other comprehensive loss

The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive (gain)/loss for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.

(L) Loss per share

Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There were no potentially dilutive securities for 2014 and 2013.

(M) Segments

The Company operates in only one segment, thereafter segment disclosure is not presented.

(N) Recent Accounting Pronouncements

On June 10, 2014, FASB issued a new accounting standard that reduces disclosure and reporting requirements for development stage entities. Among other things, development stage entities will no longer be required to report inception-to-date information. The change will be effective for interim and annual reporting periods beginning after December 15, 2014, with early adoption permitted. The Company has elected to early adopt these amendments.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)

Oct. 31, 2014

Oct. 31, 2013

Condensed Consolidated Balance Sheets Parenthetical

Common Stock Shares Par Value $ 0.00001 $ 0.00001

Common Stock Shares Authorized 100,000,000us-gaap_CommonStockSharesAuthorized 100,000,000us-gaap_CommonStockSharesAuthorized

Common Stock Shares Issued 56,874,850us-gaap_CommonStockSharesIssued 56,874,850us-gaap_CommonStockSharesIssued

Common Stock Shares Outstanding 56,874,850us-gaap_CommonStockSharesOutstanding 56,874,850us-gaap_CommonStockSharesOutstanding

X

- Details

Name: abtbi_ConsolidatedBalanceSheetsUnauditedParentheticalAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 35 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)
12 Months Ended

Oct. 31, 2014

Accounting Policies [Abstract]

Organization
Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or ”Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006 .

Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, formerly known as “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.

Accordingly, these financial statements include the following:

(1) The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

(2) The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

Principles of consolidation
The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.

All significant inter-company balances and transactions have been eliminated in consolidation.

Use of estimates
The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents
For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2014 and 2013, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.

Property and equipment
Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

Long-lived assets
The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2014 and 2013, the Company has not recognized any allowances for impairment.

Fair value of financial instruments
FASB Codification Topic 825(ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

Income taxes
The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

Research and development
Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2014 and 2013 were $47,700 and $30,749 respectively.

Foreign currency translation
The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.

Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.

The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:

October 31, 2014 October 31, 2013

Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end US$1=HK$7.7551=RMB6.1124 US$1=HK$7.7530=RMB6.0943

Amounts included in the statements of operations and cash flows for the year US$1=HK$7.7543=RMB6.1498 US$1=HK$7.7561=RMB6.1717

The translation (gain)/loss recorded for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.

No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.

The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.

Other comprehensive loss
The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive (gain)/loss for the years ended October 31, 2014 and 2013 were ($3,586) and $55,510 respectively.

Loss per share
Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There were no potentially dilutive securities for 2014 and 2013.

Segments
The Company operates in only one segment, thereafter segment disclosure is not presented.

Recent Accounting Pronouncements
On June 10, 2014, FASB issued a new accounting standard that reduces disclosure and reporting requirements for development stage entities. Among other things, development stage entities will no longer be required to report inception-to-date information. The change will be effective for interim and annual reporting periods beginning after December 15, 2014, with early adoption permitted. The Company has elected to early adopt these amendments.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Accounting Standards Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met conditions which would subject these financial statements for additional disclosure.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.

+ References

No definition available.

+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for comprehensive income.

+ References

No definition available.

+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6390181&loc=d3e202-110218

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document and Entity Information (USD $)
12 Months Ended

Oct. 31, 2014

Jan. 29, 2015

Apr. 30, 2014

StockIssuedForServices

Entity Registrant Name Advanced Biomedical Technologies Inc.

Entity Central Index Key 0001385799

Document Type 10-K

Document Period End Date Oct. 31, 2014

Amendment Flag false

Current Fiscal Year End Date --10-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Smaller Reporting Company

Entity Public Float $ 8,436,210dei_EntityPublicFloat

Entity Common Stock, Shares Outstanding 56,874,850dei_EntityCommonStockSharesOutstanding

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2014

X

- Details

Name: abtbi_DocumentAndEntityInformationAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.

+ References

No definition available.

+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 37 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)
12 Months Ended

Oct. 31, 2014

Accounting Policies [Abstract]

Exchange rates used in translation

October 31, 2014 October 31, 2013

Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end US$1=HK$7.7551=RMB6.1124 US$1=HK$7.7530=RMB6.0943

Amounts included in the statements of operations and cash flows for the year US$1=HK$7.7543=RMB6.1498 US$1=HK$7.7561=RMB6.1717

X

- Definition

Exchange rates used in translation

+ References

No definition available.

+ Details

Name: abtbi_ScheduleOfExchangeRatesUsedInTranslationTableTextBlock

Namespace Prefix: abtbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (USD $)
12 Months Ended

Oct. 31, 2014

Oct. 31, 2013

OPERATING EXPENSES

General and administrative expenses $ 543,414us-gaap_GeneralAndAdministrativeExpense $ 661,794us-gaap_GeneralAndAdministrativeExpense

Depreciation 26,640us-gaap_Depreciation 26,201us-gaap_Depreciation

Research and development 47,700us-gaap_ResearchAndDevelopmentExpense 30,749us-gaap_ResearchAndDevelopmentExpense

Total Operating Expenses 617,754us-gaap_OperatingExpenses 718,744us-gaap_OperatingExpenses

LOSS FROM OPERATIONS (617,754) (718,744)

OTHER EXPENSES

Interest income 137us-gaap_InvestmentIncomeInterest 70us-gaap_InvestmentIncomeInterest

Interest paid to a stockholder and related parties (181,393) (137,502)

Imputed interest (20,079)abtbi_ImputedInterest (22,936)abtbi_ImputedInterest

Others, net (8,667)us-gaap_OtherNoncashIncomeExpense (11,231)us-gaap_OtherNoncashIncomeExpense

Total Other Expenses, net (210,002)us-gaap_OtherOperatingIncomeExpenseNet (171,599)us-gaap_OtherOperatingIncomeExpenseNet

LOSS FROM OPERATIONS BEFORE TAXES (827,756) (890,343)

Income tax expense 0us-gaap_IncomeTaxExpenseBenefit 0us-gaap_IncomeTaxExpenseBenefit

NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS (827,756)us-gaap_NetIncomeLoss (890,343)us-gaap_NetIncomeLoss

OTHER COMPREHENSIVE INCOME (LOSS)

Foreign currency translation income/(loss) 3,586 (55,510)

COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS $ (824,170)us-gaap_ComprehensiveIncomeNetOfTax $ (945,853)us-gaap_ComprehensiveIncomeNetOfTax

Net loss per share-basic and diluted $ (0.01)us-gaap_EarningsPerShareBasicAndDiluted $ (0.02)us-gaap_EarningsPerShareBasicAndDiluted

Weighted average number of shares outstanding during the year - basic and diluted 56,874,850 56,578,138

X

- Definition

Two Related Parties

+ References

No definition available.

+ Details

Name: abtbi_ImputedInterest

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

InterestExpenseToStockholderAndRelatedParties

+ References

No definition available.

+ Details

Name: abtbi_InterestExpenseToStockholderAndRelatedParties

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations (before interest income and interest expense) attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before interest income, interest expense, income taxes, extraordinary items, and noncontrolling interest.

+ References

No definition available.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.

+ References

No definition available.

+ Details

Name: us-gaap_OtherOperatingIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 39 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

6. COMMITMENTS AND CONTINGENCIES
12 Months Ended

Oct. 31, 2014

Notes to Financial Statements

6. COMMITMENTS AND CONTINGENCIES

(A) Employee benefits

The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $74,189 and $68,711 for the years ended October 31, 2014 and 2013 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.

(B) Lease commitments

The Company leased from third parties office space and an apartment for a director at monthly rent prevailing at October 31, 2014 of $2,348 and $1,309 (2013: $2,243 and $1,313) respectively. Both of these operating leases expired on July 20, 2014 and June 30, 2014 respectively. The Company continues to lease these premises at same monthly rent pending a formal renewal of these leases.

The Company also leases eight apartments (2013: seven apartments) and one canteen (2013: one canteen) for staff under three operating leases (2013: two leases) from a third party at monthly rental totaling $965 (2013: $766), all of which will expire in April 2015, June 2015 and July 2015 respectively.

As of October 31, 2014, the Company had outstanding commitments with respect to the above operating lease, which are due as follows:

2015 8,151

Total $ 8,151

(C) Capital commitments

As of October 31, 2014, outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and equipment totaled $16,238 (2013: $1,140).

X

- Details

Name: abtbi_NotesToFinancialStatementsAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

5. STOCKHOLDERS DEFICIT
12 Months Ended

Oct. 31, 2014

Notes to Financial Statements

5. STOCKHOLDERS DEFICIT
Common stock

On December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Company’s chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on the date of grant yielding an aggregate fair value of $20,000. In this respect, the Company recognized $0 and $1,667 for the year ended October 31, 2014 and 2013 respectively as consultancy fees included in general and administrative expenses.

On October 28, 2013, the Company issued 150,000 shares of restricted common stock as directors’ services compensation for past services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71 per share on the date of grant, yielding an aggregate fair value of $213,000.

For the years ended October 31, 2014 and 2013 the Company recognized $0 and $214,667 respectively as consultancy fees included in general and administrative expenses.

X

- Details

Name: abtbi_NotesToFinancialStatementsAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

2. PROPERTY AND EQUIPMENT (Details) (USD $)

Oct. 31, 2014

Oct. 31, 2013

Gross Value of property plant and equipment $ 488,298us-gaap_PropertyPlantAndEquipmentGross $ 480,840us-gaap_PropertyPlantAndEquipmentGross

Less: accumulated depreciation and amortization 380,044 354,272

Total property and equipment, net 108,254us-gaap_PropertyPlantAndEquipmentNet 126,568us-gaap_PropertyPlantAndEquipmentNet

Plant and machinery

Gross Value of property plant and equipment 272,214 266,931

Motor vehicles

Gross Value of property plant and equipment 45,105 45,239

Office equipment

Gross Value of property plant and equipment 34,523 31,824

Computer software

Gross Value of property plant and equipment 5,017 5,017

Office improvements

Gross Value of property plant and equipment $ 131,439 $ 131,829

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=abtbi_ComputerSoftwareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TransportationEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

2. PROPERTY AND EQUIPMENT (Tables)
12 Months Ended

Oct. 31, 2014

Property, Plant and Equipment [Abstract]

Property and equipment

October 31,

2014 2013

Plant and machinery $ 272,214 $ 266,931

Motor vehicles 45,105 45,239

Office equipment 34,523 31,824

Computer software 5,017 5,017

Office improvements 131,439 131,829

488,298 480,840

Less: accumulated depreciation 380,044 354,272

Property and equipment, net $ 108,254 $ 126,568

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

9. GOING CONCERN
12 Months Ended

Oct. 31, 2014

Notes to Financial Statements

9. GOING CONCERN
As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $5,400,107 as of October 31, 2014 that includes a net loss of $827,756 for the year ended October 31, 2014. The Company’s total current liabilities exceed its total current assets by $3,863,028 and the Company used cash in operations of $732,421. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year.

X

- Details

Name: abtbi_NotesToFinancialStatementsAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References

No definition available.

+ Details

Name: us-gaap_LiquidityDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

7. INCOME TAX
12 Months Ended

Oct. 31, 2014

Income Tax Disclosure [Abstract]

7. INCOME TAX
ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2014 and 2013. ABMT has net operating loss carry forwards for income taxes amounting to approximately $1,512,723 and $1,423,563 as of October 31, 2014 and 2013 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2014 and 2013 was $514,326 and $484,011 respectively. The net change in the valuation allowance for 2014 was an increase of $30,315.

Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.

Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been charged at 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

8. CONCENTRATIONS AND RISKS
12 Months Ended

Oct. 31, 2014

Risks and Uncertainties [Abstract]

8. CONCENTRATIONS AND RISKS
As at October 31, 2014, 91% and 9% of the Company’s assets were located in the P.R.C. and the United States respectively.

As at October 31, 2013, 96% and 4% of the Company’s assets were located in the P.R.C. and the United States respectively.

X

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

10. SUBSEQUENT EVENT
12 Months Ended

Oct. 31, 2014

Subsequent Events [Abstract]

10. SUBSEQUENT EVENT
The Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial statements were issued and has determined that there were no subsequent events or transactions which would require recognition or disclosure in the financial statements other than stated below:

On November 10, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB250,000 (equivalent to approximately $41,000).

On November 28, 2014, the Company received cash advance from a related party, Chi Fung Yu, amounted to RMB250,000 (equivalent to approximately $41,000).

On December 12, 2014, the Company received cash advance from a related party, Tie Jun Chen, amounted to RMB300,000 (equivalent to approximately $49,000).

On January 20, 2015, the Company received cash advance from a related party, Chi Fung Yu,, amounted to RMB250,000 (equivalent to approximately $41,000).

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

6. COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended

Oct. 31, 2014

CommitmentsAndContingenciesTablesAbstract

Operating lease outstanding commitments

2015 8,151

Total $ 8,151

X

- Details

Name: abtbi_CommitmentsAndContingenciesTablesAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

5. STOCKHOLDERS EQUITY (Details Narrative) (CNY)
12 Months Ended

Oct. 31, 2014

Oct. 31, 2013

Consultancy fees 0abtbi_ConsultancyFees 214,667abtbi_ConsultancyFees

General and administrative | Dr. John Lynch

Share based compensation 0 1,667

X

- Definition

Interest expense on advances

+ References

No definition available.

+ Details

Name: abtbi_ConsultancyFees

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (UNAUDITED) (USD $)

Common Stock

Additional Paid-In Capital

Deferred stock compensation

Accumulated deficit

Accumulated Other Comprehensive Loss

Total

Beginning Balance, Amount at Oct. 31, 2012 $ 566 $ 1,671,956 $ (1,667) $ (3,682,008) $ (215,042) $ (2,226,195)us-gaap_StockholdersEquity

Beginning Balance, Shares at Oct. 31, 2012 56,574,850

Amortisation for stock issued for services 1,667 1,667

Stock issued for services, Shares 300,000

Stock issued for services, Amount 3 212,997 213,000

Imputed interest on advances from directors 22,936 22,936

Net loss for the year (890,343)us-gaap_ProfitLoss

Foreign currency translation gain (loss) (55,510) (55,510)

Ending Balance, Amount at Oct. 31, 2013 569 1,907,889 (4,572,351) (270,552) (2,934,445)us-gaap_StockholdersEquity

Ending Balance, Shares at Oct. 31, 2013 56,874,850

Imputed interest on advances from directors 20,079 20,079

Net loss for the year (827,756)us-gaap_ProfitLoss

Foreign currency translation gain (loss) 3,586 3,586

Ending Balance, Amount at Oct. 31, 2014 $ 569 $ 1,927,968 $ (5,400,107) $ (266,966) $ (3,738,536)us-gaap_StockholdersEquity

Ending Balance, Shares at Oct. 31, 2014 56,874,850

X

- Definition

Due to directors

+ References

No definition available.

+ Details

Name: abtbi_AmortisationForStockIssuedForServices

Namespace Prefix: abtbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of other increase (decrease) in additional paid in capital (APIC).

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a-c)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

4. RELATED PARTY TRANSACTIONS
12 Months Ended

Oct. 31, 2014

Notes to Financial Statements

4. RELATED PARTY TRANSACTIONS

As of October 31, 2014 and 2013, the Company owed $459,131 and $349,911 respectively to a stockholder which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.

As of October 31, 2014 and 2013, the Company owed $2,988,738 and $2,266,916 to two related parties which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.

Total interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2014 and 2013 were $181,393 and $137,502 respectively.

As of October 31, 2014 and 2013, the Company owed $402,510 and $455,574 respectively to two directors for advances made. These advances were made on an unsecured basis, repayable on demand and interest free.

Imputed interest on the amounts owed to two directors are $20,079 and $22,936 for the years ended October 31, 2014, and 2013 respectively.

For the years ended October 31, 2014 and 2013, the Company issued restricted common stock as directors’ services compensation for past services nil shares and 300,000 shares valued at $0 and $213,000 respectively. Please refer to Item 11 for details of directors’ emoluments.

X

- Details

Name: abtbi_NotesToFinancialStatementsAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9

6. COMMITMENTS AND CONTINGENCIES (Details) (CNY)

Oct. 31, 2014

Commitments And Contingencies Details

2015 8,151

Total 8,151

X

- Details

Name: abtbi_CommitmentsAndContingenciesDetailsAbstract

Namespace Prefix: abtbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 65 122 1 false 20 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://abtbiomedical.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://abtbiomedical.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://abtbiomedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Sheet http://abtbiomedical.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (UNAUDITED) Sheet http://abtbiomedical.com/role/ConsolidatedStatementsOfStockholdersDeficit CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (UNAUDITED) false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://abtbiomedical.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) false false R7.htm 00000007 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION Sheet http://abtbiomedical.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION false false R8.htm 00000008 - Disclosure - 2. PROPERTY AND EQUIPMENT Sheet http://abtbiomedical.com/role/PropertyAndEquipment 2. PROPERTY AND EQUIPMENT false false R9.htm 00000009 - Disclosure - 3. OTHER PAYABLES AND ACCRUED EXPENSES Sheet http://abtbiomedical.com/role/OtherPayablesAndAccruedExpenses 3. OTHER PAYABLES AND ACCRUED EXPENSES false false R10.htm 00000010 - Disclosure - 4. RELATED PARTY TRANSACTIONS Sheet http://abtbiomedical.com/role/RelatedPartyTransactions 4. RELATED PARTY TRANSACTIONS false false R11.htm 00000011 - Disclosure - 5. STOCKHOLDERS DEFICIT Sheet http://abtbiomedical.com/role/StockholdersDeficit 5. STOCKHOLDERS DEFICIT false false R12.htm 00000012 - Disclosure - 6. COMMITMENTS AND CONTINGENCIES Sheet http://abtbiomedical.com/role/CommitmentsAndContingencies 6. COMMITMENTS AND CONTINGENCIES false false R13.htm 00000013 - Disclosure - 7. INCOME TAX Sheet http://abtbiomedical.com/role/IncomeTax 7. INCOME TAX false false R14.htm 00000014 - Disclosure - 8. CONCENTRATIONS AND RISKS Sheet http://abtbiomedical.com/role/ConcentrationsAndRisks 8. CONCENTRATIONS AND RISKS false false R15.htm 00000015 - Disclosure - 9. GOING CONCERN Sheet http://abtbiomedical.com/role/GoingConcern 9. GOING CONCERN false false R16.htm 00000016 - Disclosure - 10. SUBSEQUENT EVENT Sheet http://abtbiomedical.com/role/SubsequentEvent 10. SUBSEQUENT EVENT false false R17.htm 00000017 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies) Sheet http://abtbiomedical.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationPolicies 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies) false false R18.htm 00000018 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables) Sheet http://abtbiomedical.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationTables 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables) false false R19.htm 00000019 - Disclosure - 2. PROPERTY AND EQUIPMENT (Tables) Sheet http://abtbiomedical.com/role/PropertyAndEquipmentTables 2. PROPERTY AND EQUIPMENT (Tables) false false R20.htm 00000020 - Disclosure - 3. OTHER PAYABLES AND ACCRUED EXPENSES (Tables) Sheet http://abtbiomedical.com/role/OtherPayablesAndAccruedExpensesTables 3. OTHER PAYABLES AND ACCRUED EXPENSES (Tables) false false R21.htm 00000021 - Disclosure - 6. COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://abtbiomedical.com/role/CommitmentsAndContingenciesTables 6. COMMITMENTS AND CONTINGENCIES (Tables) false false R22.htm 00000022 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) Sheet http://abtbiomedical.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationDetails 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) false false R23.htm 00000023 - Disclosure - 2. PROPERTY AND EQUIPMENT (Details) Sheet http://abtbiomedical.com/role/PropertyAndEquipmentDetails 2. PROPERTY AND EQUIPMENT (Details) false false R24.htm 00000024 - Disclosure - 3. OTHER PAYABLES AND ACCRUED EXPENSES (Details) Sheet http://abtbiomedical.com/role/OtherPayablesAndAccruedExpensesDetails 3. OTHER PAYABLES AND ACCRUED EXPENSES (Details) false false R25.htm 00000025 - Disclosure - 4. RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://abtbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative 4. RELATED PARTY TRANSACTIONS (Details Narrative) false false R26.htm 00000026 - Disclosure - 5. STOCKHOLDERS EQUITY (Details Narrative) Sheet http://abtbiomedical.com/role/StockholdersEquityDetailsNarrative 5. STOCKHOLDERS EQUITY (Details Narrative) false false R27.htm 00000027 - Disclosure - 6. COMMITMENTS AND CONTINGENCIES (Details) Sheet http://abtbiomedical.com/role/CommitmentsAndContingenciesDetails 6. COMMITMENTS AND CONTINGENCIES (Details) false false R28.htm 00000028 - Disclosure - 7. INCOME TAX (Details Narrative) Sheet http://abtbiomedical.com/role/IncomeTaxDetailsNarrative 7. INCOME TAX (Details Narrative) false false R29.htm 00000029 - Disclosure - 8. CONCENTRATIONS AND RISKS (Details Narrative) Sheet http://abtbiomedical.com/role/ConcentrationsAndRisksDetailsNarrative 8. CONCENTRATIONS AND RISKS (Details Narrative) false false R30.htm 00000030 - Disclosure - 10. GOING CONCERN (Details Narrative) Sheet http://abtbiomedical.com/role/GoingConcernDetailsNarrative 10. GOING CONCERN (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Process Flow-Through: Removing column 'Oct. 31, 2012' Process Flow-Through: 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Process Flow-Through: 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Process Flow-Through: 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) abtbi-20141031.xml abtbi-20141031.xsd abtbi-20141031_cal.xml abtbi-20141031_def.xml abtbi-20141031_lab.xml abtbi-20141031_pre.xml true true XML 53 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

3. OTHER PAYABLES AND ACCRUED EXPENSES (Tables)
12 Months Ended

Oct. 31, 2014

Payables and Accruals [Abstract]

Other payables and accrued expenses

October 31,

2014 2013

Other payables $ 929 $ 790

Accrued expenses 104,842 58,447

$ 105,771 $ 59,237

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

4. RELATED PARTY TRANSACTIONS (Details Narrative) (CNY)	3 Months Ended		12 Months Ended
4. RELATED PARTY TRANSACTIONS (Details Narrative) (CNY)	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Imputed interest on advances from two directors	20,079	22,936
Interest expenses on advances from stockholder and related parties	181,393us-gaap_InterestExpenseRelatedParty	137,502us-gaap_InterestExpenseRelatedParty	181,393us-gaap_InterestExpenseRelatedParty	137,502us-gaap_InterestExpenseRelatedParty
Stockholder
Related party debt	459,131	349,911	459,131	349,911
Two Related Parties
Related party debt	2,988,738	2,266,916	2,988,738	2,266,916
Two Directors
Related party debt	402,510	455,574	402,510	455,574

8. CONCENTRATIONS AND RISKS (Details Narrative)	Oct. 31, 2014	Oct. 31, 2013
RMB
Percent of assets located in country	91.00%	96.00%
US
Percent of assets located in country	9.00%	4.00%

7. INCOME TAX (Details Narrative) (CNY)	12 Months Ended
7. INCOME TAX (Details Narrative) (CNY)	Oct. 31, 2014	Oct. 31, 2013
Income Tax Details Narrative
Net operating loss carry forwards	1,512,723us-gaap_OperatingLossCarryforwards	1,423,563us-gaap_OperatingLossCarryforwards
Deferred tax asset valuation allowance	514,326	484,011
Deferred tax asset	0us-gaap_DeferredTaxAssetsNet	0us-gaap_DeferredTaxAssetsNet
Net change in the valuation allowance	30,315

10. GOING CONCERN (Details Narrative) (USD $)	12 Months Ended
10. GOING CONCERN (Details Narrative) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Going Concern Details Narrative
Accumulated deficit	$ (5,400,107)	$ (4,572,351)
Net loss	$ (827,756)us-gaap_ProfitLoss	$ (890,343)us-gaap_ProfitLoss

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Oct. 31, 2014	Oct. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$ 74,354us-gaap_Cash	$ 48,380us-gaap_Cash
Other receivables and prepaid expenses	18,768us-gaap_PrepaidExpenseCurrent	21,105us-gaap_PrepaidExpenseCurrent
Total Current Assets	93,122us-gaap_AssetsCurrent	69,485us-gaap_AssetsCurrent
PROPERTY AND EQUIPMENT, NET	108,254us-gaap_PropertyPlantAndEquipmentNet	126,568us-gaap_PropertyPlantAndEquipmentNet
DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT	16,238	1,140
TOTAL ASSETS	217,614us-gaap_Assets	197,193us-gaap_Assets
CURRENT LIABILITIES
Other payables and accrued expenses	105,771us-gaap_OtherLiabilitiesCurrent	59,237us-gaap_OtherLiabilitiesCurrent
Due to directors	402,510abtbi_DueToDirectors	455,574abtbi_DueToDirectors
Due to a stockholder	459,131	349,911
Due to related parties	2,988,738us-gaap_DueToRelatedPartiesCurrent	2,266,916us-gaap_DueToRelatedPartiesCurrent
Total Current Liabilities	3,956,150us-gaap_LiabilitiesCurrent	3,131,638us-gaap_LiabilitiesCurrent
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Common stock, $0.00001 par value, 100,000,000 shares authorized, 56,874,850 shares issued and outstanding as of October 31, 2014 and October 31, 2013	569us-gaap_CommonStockValue	569us-gaap_CommonStockValue
Additional paid-in capital	1,927,968us-gaap_AdditionalPaidInCapital	1,907,889us-gaap_AdditionalPaidInCapital
Accumulated deficit	(5,400,107)	(4,572,351)
Accumulated other comprehensive loss	(266,966)	(270,552)
Total Deficit	(3,738,536)us-gaap_StockholdersEquity	(2,934,445)us-gaap_StockholdersEquity
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 217,614	$ 197,193

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (827,756)us-gaap_ProfitLoss	$ (890,343)us-gaap_ProfitLoss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	26,640abtbi_DepreciationCashflow	26,201abtbi_DepreciationCashflow
Stock issued for services	0abtbi_StockIssuedForServices	214,667abtbi_StockIssuedForServices
Imputed interest	20,079	22,936
Changes in operating assets and liabilities
Decrease in Other receivables and prepaid expenses	2,270	978
Increase in Other payables and accrued expenses	46,346	20,592
Net cash used in operating activities	(732,421)	(604,969)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(8,793)	(8,166)
(Increase) decrease in deposit for purchase of property and equipment	(15,009)	562
Net cash used in investing activities	(23,802)	(7,604)
CASH FLOWS FROM FINANCING ACTIVITIES
Due to a stockholder	109,253abtbi_IncreaseDecreaseDueToStockholder	82,142abtbi_IncreaseDecreaseDueToStockholder
Due to directors	(51,460)abtbi_IncreaseDecreaseDueToDirectors	(62,450)abtbi_IncreaseDecreaseDueToDirectors
Due to related parties	724,435	591,492
Net cash provided by financing activities	782,228	611,184
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(31)	677
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	25,974	(712)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	48,380	49,092
CASH AND CASH EQUIVALENTS AT END OF YEAR	$ 74,354	$ 48,380

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details)	Oct. 31, 2014	Oct. 31, 2013
US \| Rate For Balance sheet items
Exchange rate	1.0000	1.0000
US \| Rate For Transactions Occuring Throughout The Year
Exchange rate	1.0000	1.0000
HK \| Rate For Balance sheet items
Exchange rate	7.7551	7.7530
HK \| Rate For Transactions Occuring Throughout The Year
Exchange rate	7.7543	7.7561
RMB \| Rate For Balance sheet items
Exchange rate	6.1124	6.0943
RMB \| Rate For Transactions Occuring Throughout The Year
Exchange rate	6.1498	6.1717

3. OTHER PAYABLES AND ACCRUED EXPENSES (Details) (CNY)	Oct. 31, 2014	Oct. 31, 2013
Payables and Accruals [Abstract]
Other payables	929us-gaap_AccountsPayableOtherCurrent	790us-gaap_AccountsPayableOtherCurrent
Accrued expenses	104,842us-gaap_AccruedLiabilitiesCurrent	58,447us-gaap_AccruedLiabilitiesCurrent
Total	105,771abtbi_TotalOtherPayableAccruedExpenses	59,237abtbi_TotalOtherPayableAccruedExpenses

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Condensed Consolidated Balance Sheets Parenthetical
Common Stock Shares Par Value	$ 0.00001	$ 0.00001
Common Stock Shares Authorized	100,000,000us-gaap_CommonStockSharesAuthorized	100,000,000us-gaap_CommonStockSharesAuthorized
Common Stock Shares Issued	56,874,850us-gaap_CommonStockSharesIssued	56,874,850us-gaap_CommonStockSharesIssued
Common Stock Shares Outstanding	56,874,850us-gaap_CommonStockSharesOutstanding	56,874,850us-gaap_CommonStockSharesOutstanding

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Oct. 31, 2014	Jan. 29, 2015	Apr. 30, 2014
StockIssuedForServices
Entity Registrant Name	Advanced Biomedical Technologies Inc.
Entity Central Index Key	0001385799
Document Type	10-K
Document Period End Date	Oct. 31, 2014
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 8,436,210dei_EntityPublicFloat
Entity Common Stock, Shares Outstanding		56,874,850dei_EntityCommonStockSharesOutstanding
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
OPERATING EXPENSES
General and administrative expenses	$ 543,414us-gaap_GeneralAndAdministrativeExpense	$ 661,794us-gaap_GeneralAndAdministrativeExpense
Depreciation	26,640us-gaap_Depreciation	26,201us-gaap_Depreciation
Research and development	47,700us-gaap_ResearchAndDevelopmentExpense	30,749us-gaap_ResearchAndDevelopmentExpense
Total Operating Expenses	617,754us-gaap_OperatingExpenses	718,744us-gaap_OperatingExpenses
LOSS FROM OPERATIONS	(617,754)	(718,744)
OTHER EXPENSES
Interest income	137us-gaap_InvestmentIncomeInterest	70us-gaap_InvestmentIncomeInterest
Interest paid to a stockholder and related parties	(181,393)	(137,502)
Imputed interest	(20,079)abtbi_ImputedInterest	(22,936)abtbi_ImputedInterest
Others, net	(8,667)us-gaap_OtherNoncashIncomeExpense	(11,231)us-gaap_OtherNoncashIncomeExpense
Total Other Expenses, net	(210,002)us-gaap_OtherOperatingIncomeExpenseNet	(171,599)us-gaap_OtherOperatingIncomeExpenseNet
LOSS FROM OPERATIONS BEFORE TAXES	(827,756)	(890,343)
Income tax expense	0us-gaap_IncomeTaxExpenseBenefit	0us-gaap_IncomeTaxExpenseBenefit
NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	(827,756)us-gaap_NetIncomeLoss	(890,343)us-gaap_NetIncomeLoss
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation income/(loss)	3,586	(55,510)
COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	$ (824,170)us-gaap_ComprehensiveIncomeNetOfTax	$ (945,853)us-gaap_ComprehensiveIncomeNetOfTax
Net loss per share-basic and diluted	$ (0.01)us-gaap_EarningsPerShareBasicAndDiluted	$ (0.02)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average number of shares outstanding during the year - basic and diluted	56,874,850	56,578,138

2. PROPERTY AND EQUIPMENT (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Gross Value of property plant and equipment	$ 488,298us-gaap_PropertyPlantAndEquipmentGross	$ 480,840us-gaap_PropertyPlantAndEquipmentGross
Less: accumulated depreciation and amortization	380,044	354,272
Total property and equipment, net	108,254us-gaap_PropertyPlantAndEquipmentNet	126,568us-gaap_PropertyPlantAndEquipmentNet
Plant and machinery
Gross Value of property plant and equipment	272,214	266,931
Motor vehicles
Gross Value of property plant and equipment	45,105	45,239
Office equipment
Gross Value of property plant and equipment	34,523	31,824
Computer software
Gross Value of property plant and equipment	5,017	5,017
Office improvements
Gross Value of property plant and equipment	$ 131,439	$ 131,829

5. STOCKHOLDERS EQUITY (Details Narrative) (CNY)	12 Months Ended
5. STOCKHOLDERS EQUITY (Details Narrative) (CNY)	Oct. 31, 2014	Oct. 31, 2013
Consultancy fees	0abtbi_ConsultancyFees	214,667abtbi_ConsultancyFees
General and administrative \| Dr. John Lynch
Share based compensation	0	1,667

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (UNAUDITED) (USD $)	Common Stock	Additional Paid-In Capital	Deferred stock compensation	Accumulated deficit	Accumulated Other Comprehensive Loss	Total
Beginning Balance, Amount at Oct. 31, 2012	$ 566	$ 1,671,956	$ (1,667)	$ (3,682,008)	$ (215,042)	$ (2,226,195)us-gaap_StockholdersEquity
Beginning Balance, Shares at Oct. 31, 2012	56,574,850
Amortisation for stock issued for services			1,667			1,667
Stock issued for services, Shares	300,000
Stock issued for services, Amount	3	212,997				213,000
Imputed interest on advances from directors		22,936				22,936
Net loss for the year						(890,343)us-gaap_ProfitLoss
Foreign currency translation gain (loss)					(55,510)	(55,510)
Ending Balance, Amount at Oct. 31, 2013	569	1,907,889		(4,572,351)	(270,552)	(2,934,445)us-gaap_StockholdersEquity
Ending Balance, Shares at Oct. 31, 2013	56,874,850
Imputed interest on advances from directors		20,079				20,079
Net loss for the year						(827,756)us-gaap_ProfitLoss
Foreign currency translation gain (loss)					3,586	3,586
Ending Balance, Amount at Oct. 31, 2014	$ 569	$ 1,927,968		$ (5,400,107)	$ (266,966)	$ (3,738,536)us-gaap_StockholdersEquity
Ending Balance, Shares at Oct. 31, 2014	56,874,850

6. COMMITMENTS AND CONTINGENCIES (Details) (CNY)	Oct. 31, 2014
Commitments And Contingencies Details
2015	8,151
Total	8,151